# EDGAR Filing Document

**Accession Number:** 0001355064
**File Stem:** 0001580642-25-005935
**Filing Date:** 2025-9
**Character Count:** 580839
**Document Hash:** 5d8868ff5a152b2b142ff0365eaeabf4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001580642-25-005935.hdr.sgml**: 20250908

**ACCESSION NUMBER**: 0001580642-25-005935

**CONFORMED SUBMISSION TYPE**: N-CSR

**PUBLIC DOCUMENT COUNT**: 181

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250908

**DATE AS OF CHANGE**: 20250908

**EFFECTIVENESS DATE**: 20250908

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MUTUAL FUND SERIES TRUST
- **CENTRAL INDEX KEY:** 0001355064

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** OH
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** N-CSR
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-21872
- **FILM NUMBER:** 251299593

**BUSINESS ADDRESS:**
- **STREET 1:** C/O GEMINI FUND SERVICES LLC
- **STREET 2:** 4221 NORTH 203RD STREET, SUITE 100
- **CITY:** ELKHORN
- **STATE:** NE
- **ZIP:** 68022-3474
- **BUSINESS PHONE:** 631 549 1859

**MAIL ADDRESS:**
- **STREET 1:** C/O GEMINI FUND SERVICES LLC
- **STREET 2:** 4221 NORTH 203RD STREET, SUITE 100
- **CITY:** ELKHORN
- **STATE:** NE
- **ZIP:** 68022-3474

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATALYST FUNDS
- **DATE OF NAME CHANGE:** 20060303

## Series and Classes Contracts Data

### Eventide Gilead Fund (Series ID: S000022598)

| Class ID   | Class Name                   | Ticker Symbol   |
|:---|:---|:---|
| C000065340 | Eventide Gilead Fund Class N | ETGLX           |
| C000080457 | Eventide Gilead Fund Class A | ETAGX           |
| C000080458 | Eventide Gilead Fund Class C | ETCGX           |
| C000080459 | Eventide Gilead Fund Class I | ETILX           |

### Eventide Healthcare & Life Sciences Fund (Series ID: S000039514)

| Class ID   | Class Name                                              | Ticker Symbol   |
|:---|:---|:---|
| C000121707 | Eventide Healthcare & Life Sciences Fund Class A Shares | ETAHX           |
| C000121708 | Eventide Healthcare & Life Sciences Fund Class C Shares | ETCHX           |
| C000121709 | Eventide Healthcare & Life Sciences Fund Class N Shares | ETNHX           |
| C000121710 | Eventide Healthcare & Life Sciences Fund Class I Shares | ETIHX           |

### Eventide Balanced Fund (Series ID: S000049985)

| Class ID   | Class Name                     | Ticker Symbol   |
|:---|:---|:---|
| C000157835 | Eventide Balanced Fund Class A | ETAMX           |
| C000157836 | Eventide Balanced Fund Class C | ETCMX           |
| C000157837 | Eventide Balanced Fund Class I | ETIMX           |
| C000157838 | Eventide Balanced Fund Class N | ETNMX           |

### Eventide Dividend Growth Fund (Series ID: S000059102)

| Class ID   | Class Name                                   | Ticker Symbol   |
|:---|:---|:---|
| C000193764 | Eventide Dividend Growth Fund Class A Shares | ETADX           |
| C000193765 | Eventide Dividend Growth Fund Class C Shares | ETCDX           |
| C000193766 | Eventide Dividend Growth Fund Class I Shares | ETIDX           |
| C000193767 | Eventide Dividend Growth Fund Class N Shares | ETNDX           |

### Eventide Limited-Term Bond Fund (Series ID: S000062486)

| Class ID   | Class Name                              | Ticker Symbol   |
|:---|:---|:---|
| C000202730 | Eventide Limited-Term Bond Fund Class A | ETABX           |
| C000202731 | Eventide Limited-Term Bond Fund Class C | ETCBX           |
| C000202732 | Eventide Limited-Term Bond Fund Class I | ETIBX           |
| C000202733 | Eventide Limited-Term Bond Fund Class N | ETNBX           |

### Eventide Exponential Technologies Fund (Series ID: S000068813)

| Class ID   | Class Name                                           | Ticker Symbol   |
|:---|:---|:---|
| C000219891 | Eventide Exponential Technologies Fund Class N Share | ETNEX           |
| C000219892 | Eventide Exponential Technologies Fund Class A Share | ETAEX           |
| C000219893 | Eventide Exponential Technologies Fund Class C Share | ETCEX           |
| C000219894 | Eventide Exponential Technologies Fund Class I Share | ETIEX           |

### Eventide Core Bond Fund (Series ID: S000069085)

| Class ID   | Class Name                             | Ticker Symbol   |
|:---|:---|:---|
| C000220843 | Eventide Core Bond Fund Class N Shares | ETNRX           |
| C000220844 | Eventide Core Bond Fund Class A Shares | ETARX           |
| C000220845 | Eventide Core Bond Fund Class C Shares | ETCRX           |
| C000220846 | Eventide Core Bond Fund Class I Shares | ETIRX           |

### Eventide Large Cap Focus Fund (Series ID: S000076523)

| Class ID   | Class Name                            | Ticker Symbol   |
|:---|:---|:---|
| C000236479 | Eventide Large Cap Focus Fund Class N | ETLNX           |
| C000236480 | Eventide Large Cap Focus Fund Class A | ETLAX           |
| C000236481 | Eventide Large Cap Focus Fund Class C | ETLCX           |
| C000236482 | Eventide Large Cap Focus Fund Class I | ETLIX           |

?xml version='1.0' encoding='ASCII'?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

**FORM N-CSR**

**CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES**

Investment Company Act file number <u>811-21872</u>

<u>Mutual Fund Series Trust</u> <br> (Exact name of registrant as specified in charter)

<u>225 Pictoria Drive, Suite 450, Cincinnati, OH</u> <u>45246</u> <br> (Address of principal executive offices) (Zip code)

<u>CT CORPORATION SYSTEM</u> <br> <u>1300 EAST NINTH STREET, CLEVELAND, OH 44114</u> <br> (Name and address of agent for service)

Registrant's telephone number, including area code: <u>631-470-2600</u>

Date of fiscal year end: <u>6/30</u> <br>Date of reporting period: <u>6/30/2025</u>

**Item 1. Reports to Stockholders.** 

(a) Tailored Shareholder Report

#### Eventide Balanced Fund

#### Class A (ETAMX)

#### Annual Shareholder Report - June 30, 2025
![Image](id6306d916dbc97bc93d73a85.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Balanced Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $111 | 1.07% |

---

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i2706d8c1f0783716424b8bb2.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Balanced Fund - with load** | **Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index** | **Bloomberg U.S. Aggregate Bond Index** |
| **Jul-2015** | $9425 | $10000 | $10000 |
| **Jun-2016** | $9872 | $10210 | $10595 |
| **Jun-2017** | $10882 | $11074 | $10562 |
| **Jun-2018** | $10899 | $11757 | $10520 |
| **Jun-2019** | $11614 | $12668 | $11348 |
| **Jun-2020** | $12435 | $13172 | $12339 |
| **Jun-2021** | $15773 | $16127 | $12298 |
| **Jun-2022** | $14268 | $14324 | $11032 |
| **Jun-2023** | $15023 | $15344 | $10929 |
| **Jun-2024** | $16893 | $16590 | $11217 |
| **Jun-2025** | $18303 | $18264 | $11898 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund's equity positions and fixed income positions outperformed its broad based benchmark. The Fund's equity positions, which are focused on high-quality dividend growth companies, outperformed fixed income during the reporting period. The Fund's fixed income positions outperformed its benchmark also due to the strength of corporate bonds versus treasuries from an allocation and selection perspective. Our focus remains on resilient growth, strong financials, idiosyncratic risk, and the overarching theme of human flourishing. Our experience underpins our confidence that these high-quality dividend growth companies, within this balanced equity and fixed income strategy, will continue to serve their customers, stakeholders, and shareholders effectively. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **Since Inception (7/15/2015)** |
| Eventide Balanced Fund - Class A | Eventide Balanced Fund - Class A | Eventide Balanced Fund - Class A | Eventide Balanced Fund - Class A |
| Without Load | 8.27% | 8.04% | 6.89% |
| With Load | 2.06% | 6.77% | 6.26% |
| Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index | 10.09% | 6.76% | 6.23% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -0.73% | 1.76% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $387042435 |
| Number of Portfolio Holdings | 155 |
| Advisory Fee (net of waivers) | $2330394 |
| Portfolio Turnover | 55% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](iaea2f85dc5de26f9e38ba238.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 1.6% |
| Other Industries | 24.6% |
| Home Construction | 2.1% |
| Government Owned, No Guarantee | 2.5% |
| Government Sponsored | 2.6% |
| Retail - Discretionary | 2.6% |
| Institutional Financial Services | 2.8% |
| Single-Family Housing | 3.0% |
| Technology Services | 3.3% |
| Software | 4.1% |
| Banking | 4.1% |
| Semiconductors | 4.1% |
| REIT | 4.1% |
| Insurance | 4.5% |
| Electrical Equipment | 5.5% |
| Oil & Gas Producers | 6.9% |
| Electric Utilities | 7.9% |
| Agency Fixed Rate | 13.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i19256ffd10bc0b8dad9b4423.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 1.2% |
| Collateralized Mortgage Obligations | 0.5% |
| Common Stocks | 53.9% |
| Corporate Bonds | 21.3% |
| Money Market Funds | 0.0% |
| Municipal Bonds | 4.0% |
| U.S. Government & Agencies | 19.1% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 2.7% |
| Arthur J Gallagher & Company | 2.4% |
| Williams Companies, Inc. (The) | 1.9% |
| Nasdaq, Inc. | 1.7% |
| Roper Technologies, Inc. | 1.7% |
| nVent Electric PLC | 1.6% |
| STERIS PLC | 1.6% |
| Entergy Corporation | 1.6% |
| Pentair PLC | 1.5% |
| EastGroup Properties, Inc. | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i514d9d10763a0048f224c238.jpg)

#### Eventide Balanced Fund - Class A (ETAMX)

#### Annual Shareholder Report - June 30, 2025

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETAMX

#### Eventide Balanced Fund

#### Class C (ETCMX)

#### Annual Shareholder Report - June 30, 2025
![Image](i3e5824c70613a431ed5fc2ac.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Balanced Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $189 | 1.82% |

---

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i3bf87f24b59fcd6d33b99c16.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Balanced Fund** | **Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index** | **Bloomberg U.S. Aggregate Bond Index** |
| **Jul-2015** | $10000 | $10000 | $10000 |
| **Jun-2016** | $10408 | $10210 | $10595 |
| **Jun-2017** | $11375 | $11074 | $10562 |
| **Jun-2018** | $11319 | $11757 | $10520 |
| **Jun-2019** | $11968 | $12668 | $11348 |
| **Jun-2020** | $12714 | $13172 | $12339 |
| **Jun-2021** | $16000 | $16127 | $12298 |
| **Jun-2022** | $14346 | $14324 | $11032 |
| **Jun-2023** | $14997 | $15344 | $10929 |
| **Jun-2024** | $16733 | $16590 | $11217 |
| **Jun-2025** | $17992 | $18264 | $11898 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund's equity positions and fixed income positions outperformed its broad based benchmark. The Fund's equity positions, which are focused on high-quality dividend growth companies, outperformed fixed income during the reporting period. The Fund's fixed income positions outperformed its benchmark also due to the strength of corporate bonds versus treasuries from an allocation and selection perspective. Our focus remains on resilient growth, strong financials, idiosyncratic risk, and the overarching theme of human flourishing. Our experience underpins our confidence that these high-quality dividend growth companies, within this balanced equity and fixed income strategy, will continue to serve their customers, stakeholders, and shareholders effectively. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **Since Inception (7/15/2015)** |
| Eventide Balanced Fund - Class C | 7.52% | 7.19% | 6.07% |
| Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index | 10.09% | 6.76% | 6.23% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -0.73% | 1.76% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $387042435 |
| Number of Portfolio Holdings | 155 |
| Advisory Fee (net of waivers) | $2330394 |
| Portfolio Turnover | 55% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](ic1bbccd508b3191d1ec1fcf9.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 1.6% |
| Other Industries | 24.6% |
| Home Construction | 2.1% |
| Government Owned, No Guarantee | 2.5% |
| Government Sponsored | 2.6% |
| Retail - Discretionary | 2.6% |
| Institutional Financial Services | 2.8% |
| Single-Family Housing | 3.0% |
| Technology Services | 3.3% |
| Software | 4.1% |
| Banking | 4.1% |
| Semiconductors | 4.1% |
| REIT | 4.1% |
| Insurance | 4.5% |
| Electrical Equipment | 5.5% |
| Oil & Gas Producers | 6.9% |
| Electric Utilities | 7.9% |
| Agency Fixed Rate | 13.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](id6b1b69d00b199b28605732f.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 1.2% |
| Collateralized Mortgage Obligations | 0.5% |
| Common Stocks | 53.9% |
| Corporate Bonds | 21.3% |
| Money Market Funds | 0.0% |
| Municipal Bonds | 4.0% |
| U.S. Government & Agencies | 19.1% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 2.7% |
| Arthur J Gallagher & Company | 2.4% |
| Williams Companies, Inc. (The) | 1.9% |
| Nasdaq, Inc. | 1.7% |
| Roper Technologies, Inc. | 1.7% |
| nVent Electric PLC | 1.6% |
| STERIS PLC | 1.6% |
| Entergy Corporation | 1.6% |
| Pentair PLC | 1.5% |
| EastGroup Properties, Inc. | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i0821bec1f36452a6c2f669de.jpg)

#### Eventide Balanced Fund - Class C (ETCMX)

#### Annual Shareholder Report - June 30, 2025

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETCMX

#### Eventide Balanced Fund

#### Class I (ETIMX)

#### Annual Shareholder Report - June 30, 2025
![Image](iae93566d368db452e51100eb.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Balanced Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $86 | 0.82% |

---

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i53d98fef0c07a65260a8ac53.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Balanced Fund** | **Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index** | **Bloomberg U.S. Aggregate Bond Index** |
| **Jul-2015** | $10000 | $10000 | $10000 |
| **Jun-2016** | $10503 | $10210 | $10595 |
| **Jun-2017** | $11603 | $11074 | $10562 |
| **Jun-2018** | $11657 | $11757 | $10520 |
| **Jun-2019** | $12451 | $12668 | $11348 |
| **Jun-2020** | $13352 | $13172 | $12339 |
| **Jun-2021** | $16973 | $16127 | $12298 |
| **Jun-2022** | $15368 | $14324 | $11032 |
| **Jun-2023** | $16223 | $15344 | $10929 |
| **Jun-2024** | $18291 | $16590 | $11217 |
| **Jun-2025** | $19856 | $18264 | $11898 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund's equity positions and fixed income positions outperformed its broad based benchmark. The Fund's equity positions, which are focused on high-quality dividend growth companies, outperformed fixed income during the reporting period. The Fund's fixed income positions outperformed its benchmark also due to the strength of corporate bonds versus treasuries from an allocation and selection perspective. Our focus remains on resilient growth, strong financials, idiosyncratic risk, and the overarching theme of human flourishing. Our experience underpins our confidence that these high-quality dividend growth companies, within this balanced equity and fixed income strategy, will continue to serve their customers, stakeholders, and shareholders effectively. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **Since Inception (7/15/2015)** |
| Eventide Balanced Fund - Class I | 8.55% | 8.26% | 7.13% |
| Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index | 10.09% | 6.76% | 6.23% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -0.73% | 1.76% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $387042435 |
| Number of Portfolio Holdings | 155 |
| Advisory Fee (net of waivers) | $2330394 |
| Portfolio Turnover | 55% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i114ac87151e3f44c3da316ba.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 1.6% |
| Other Industries | 24.6% |
| Home Construction | 2.1% |
| Government Owned, No Guarantee | 2.5% |
| Government Sponsored | 2.6% |
| Retail - Discretionary | 2.6% |
| Institutional Financial Services | 2.8% |
| Single-Family Housing | 3.0% |
| Technology Services | 3.3% |
| Software | 4.1% |
| Banking | 4.1% |
| Semiconductors | 4.1% |
| REIT | 4.1% |
| Insurance | 4.5% |
| Electrical Equipment | 5.5% |
| Oil & Gas Producers | 6.9% |
| Electric Utilities | 7.9% |
| Agency Fixed Rate | 13.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i56fbbaedcce86833adbf42c3.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 1.2% |
| Collateralized Mortgage Obligations | 0.5% |
| Common Stocks | 53.9% |
| Corporate Bonds | 21.3% |
| Money Market Funds | 0.0% |
| Municipal Bonds | 4.0% |
| U.S. Government & Agencies | 19.1% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 2.7% |
| Arthur J Gallagher & Company | 2.4% |
| Williams Companies, Inc. (The) | 1.9% |
| Nasdaq, Inc. | 1.7% |
| Roper Technologies, Inc. | 1.7% |
| nVent Electric PLC | 1.6% |
| STERIS PLC | 1.6% |
| Entergy Corporation | 1.6% |
| Pentair PLC | 1.5% |
| EastGroup Properties, Inc. | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i832a496107495dd5cbc5aef3.jpg)

#### Eventide Balanced Fund - Class I (ETIMX)

#### Annual Shareholder Report - June 30, 2025

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETIMX

#### Eventide Balanced Fund

#### Class N (ETNMX)

#### Annual Shareholder Report - June 30, 2025
![Image](id3018077c8938450f3ea4819.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Balanced Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $106 | 1.02% |

---

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i8fe24e0811057ba24ce2442e.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Balanced Fund** | **Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index** | **Bloomberg U.S. Aggregate Bond Index** |
| **Jul-2015** | $10000 | $10000 | $10000 |
| **Jun-2016** | $10479 | $10210 | $10595 |
| **Jun-2017** | $11558 | $11074 | $10562 |
| **Jun-2018** | $11591 | $11757 | $10520 |
| **Jun-2019** | $12358 | $12668 | $11348 |
| **Jun-2020** | $13226 | $13172 | $12339 |
| **Jun-2021** | $16772 | $16127 | $12298 |
| **Jun-2022** | $15166 | $14324 | $11032 |
| **Jun-2023** | $15977 | $15344 | $10929 |
| **Jun-2024** | $17977 | $16590 | $11217 |
| **Jun-2025** | $19476 | $18264 | $11898 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund's equity positions and fixed income positions outperformed its broad based benchmark. The Fund's equity positions, which are focused on high-quality dividend growth companies, outperformed fixed income during the reporting period. The Fund's fixed income positions outperformed its benchmark also due to the strength of corporate bonds versus treasuries from an allocation and selection perspective. Our focus remains on resilient growth, strong financials, idiosyncratic risk, and the overarching theme of human flourishing. Our experience underpins our confidence that these high-quality dividend growth companies, within this balanced equity and fixed income strategy, will continue to serve their customers, stakeholders, and shareholders effectively. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **Since Inception (7/15/2015)** |
| Eventide Balanced Fund - Class N | 8.34% | 8.05% | 6.92% |
| Bloomberg Mid Cap/Intermediate US Aggregate 50/50 TR Index | 10.09% | 6.76% | 6.23% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -0.73% | 1.76% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $387042435 |
| Number of Portfolio Holdings | 155 |
| Advisory Fee (net of waivers) | $2330394 |
| Portfolio Turnover | 55% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i58b8ffdc395cee48617aabe0.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 1.6% |
| Other Industries | 24.6% |
| Home Construction | 2.1% |
| Government Owned, No Guarantee | 2.5% |
| Government Sponsored | 2.6% |
| Retail - Discretionary | 2.6% |
| Institutional Financial Services | 2.8% |
| Single-Family Housing | 3.0% |
| Technology Services | 3.3% |
| Software | 4.1% |
| Banking | 4.1% |
| Semiconductors | 4.1% |
| REIT | 4.1% |
| Insurance | 4.5% |
| Electrical Equipment | 5.5% |
| Oil & Gas Producers | 6.9% |
| Electric Utilities | 7.9% |
| Agency Fixed Rate | 13.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i09bedc689d90ca811e826dd9.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 1.2% |
| Collateralized Mortgage Obligations | 0.5% |
| Common Stocks | 53.9% |
| Corporate Bonds | 21.3% |
| Money Market Funds | 0.0% |
| Municipal Bonds | 4.0% |
| U.S. Government & Agencies | 19.1% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 2.7% |
| Arthur J Gallagher & Company | 2.4% |
| Williams Companies, Inc. (The) | 1.9% |
| Nasdaq, Inc. | 1.7% |
| Roper Technologies, Inc. | 1.7% |
| nVent Electric PLC | 1.6% |
| STERIS PLC | 1.6% |
| Entergy Corporation | 1.6% |
| Pentair PLC | 1.5% |
| EastGroup Properties, Inc. | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](idcd2e91947a4dab3aff69e17.jpg)

#### Eventide Balanced Fund - Class N (ETNMX)

#### Annual Shareholder Report - June 30, 2025

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETNMX

#### Eventide Core Bond Fund

#### Class A (ETARX)

#### Annual Shareholder Report - June 30, 2025
![Image](i10f6071808e6ad487e1128aa.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Core Bond Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $85 | 0.83% |

---

# How did the Fund perform during the reporting period?
The Fund's performance for the year ended June 30, 2025, was materially impacted by interest rate movements across the yield curve and the performance of corporate bonds relative to treasuries. The Fund's investments slightly underperformed its benchmark net of fees, but outperformed gross of fees during the period. The Fund benefited from an overweight to corporate bonds and a significant underweight to treasury bonds as corporate bonds outperformed treasuries. The Fund's investments in corporate bonds also outperformed the performance of corporate bond allocations within the benchmark. Visit https://www.eventidefunds.com for more recent performance information.

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i8446e2d3ccf7b7d17b7049d7.jpg)

---

| | | |
|:---|:---|:---|
| | **Eventide Core Bond Fund - with load** | **Bloomberg U.S. Aggregate Bond Index** |
| **Jul-2020** | $9425 | $10000 |
| **Jun-2021** | $9210 | $9820 |
| **Jun-2022** | $8113 | $8809 |
| **Jun-2023** | $8040 | $8727 |
| **Jun-2024** | $8234 | $8956 |
| **Jun-2025** | $8706 | $9500 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market.

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $148770697 |
| Number of Portfolio Holdings | 100 |
| Advisory Fee (net of waivers) | $361029 |
| Portfolio Turnover | 24% |

---

# Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (7/31/2020)** |
| Eventide Core Bond Fund - Class A | Eventide Core Bond Fund - Class A | Eventide Core Bond Fund - Class A |
| Without Load | 5.73% | -1.60% |
| With Load | -0.40% | -2.78% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -1.04% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](ia2d56066bc59cae58757830c.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Liabilities in Excess of Other Assets | -1.1% |
| Other Industries | 7.5% |
| Other ABS | 1.2% |
| Auto Loan | 1.3% |
| Technology Services | 1.4% |
| Insurance | 2.3% |
| Retail - Discretionary | 2.3% |
| Software | 2.5% |
| Semiconductors | 2.6% |
| Engineering & Construction | 3.4% |
| REIT | 4.1% |
| Single-Family Housing | 5.6% |
| Banking | 6.1% |
| Government Sponsored | 6.2% |
| Oil & Gas Producers | 6.7% |
| Government Owned, No Guarantee | 8.4% |
| Electric Utilities | 10.8% |
| Agency Fixed Rate | 28.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i9baf46b0991503b9058efa86.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.5% |
| Corporate Bonds | 46.9% |
| Municipal Bonds | 7.7% |
| U.S. Government & Agencies | 42.9% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32 | 1.9% |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.9% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.8% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.7% |
| Federal Farm Credit Banks Funding Corporation, 4.125%, due 08/1/29 | 1.6% |
| Freddie Mac Pool, 5.000%, due 01/1/53 | 1.5% |
| Federal National Mortgage Association, 5.625%, due 07/15/37 | 1.5% |
| Freddie Mac Pool, 4.500%, due 08/1/52 | 1.5% |
| Freddie Mac Pool, 4.000%, due 08/1/52 | 1.5% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](ie5fec8d5a2e8cfccb0846b5e.jpg)

#### Eventide Core Bond Fund - Class A (ETARX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETARX

#### Eventide Core Bond Fund

#### Class C (ETCRX)

#### Annual Shareholder Report - June 30, 2025
![Image](i34cecc93c225863dd5ff1c12.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Core Bond Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $162 | 1.58% |

---

# How did the Fund perform during the reporting period?
The Fund's performance for the year ended June 30, 2025, was materially impacted by interest rate movements across the yield curve and the performance of corporate bonds relative to treasuries. The Fund's investments slightly underperformed its benchmark net of fees, but outperformed gross of fees during the period. The Fund benefited from an overweight to corporate bonds and a significant underweight to treasury bonds as corporate bonds outperformed treasuries. The Fund's investments in corporate bonds also outperformed the performance of corporate bond allocations within the benchmark. Visit https://www.eventidefunds.com for more recent performance information.

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i1df0b5e8b9864fcad16dc4cf.jpg)

---

| | | |
|:---|:---|:---|
| | **Eventide Core Bond Fund** | **Bloomberg U.S. Aggregate Bond Index** |
| **Jul-2020** | $10000 | $10000 |
| **Jun-2021** | $9698 | $9820 |
| **Jun-2022** | $8499 | $8809 |
| **Jun-2023** | $8357 | $8727 |
| **Jun-2024** | $8485 | $8956 |
| **Jun-2025** | $8913 | $9500 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market.

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $148770697 |
| Number of Portfolio Holdings | 100 |
| Advisory Fee (net of waivers) | $361029 |
| Portfolio Turnover | 24% |

---

# Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (7/31/2020)** |
| Eventide Core Bond Fund - Class C | 5.04% | -2.32% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -1.04% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i3a37d8275fc730a5d71d1369.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Liabilities in Excess of Other Assets | -1.1% |
| Other Industries | 7.5% |
| Other ABS | 1.2% |
| Auto Loan | 1.3% |
| Technology Services | 1.4% |
| Insurance | 2.3% |
| Retail - Discretionary | 2.3% |
| Software | 2.5% |
| Semiconductors | 2.6% |
| Engineering & Construction | 3.4% |
| REIT | 4.1% |
| Single-Family Housing | 5.6% |
| Banking | 6.1% |
| Government Sponsored | 6.2% |
| Oil & Gas Producers | 6.7% |
| Government Owned, No Guarantee | 8.4% |
| Electric Utilities | 10.8% |
| Agency Fixed Rate | 28.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i8481d5b3fa40347d92fb7057.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.5% |
| Corporate Bonds | 46.9% |
| Municipal Bonds | 7.7% |
| U.S. Government & Agencies | 42.9% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32 | 1.9% |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.9% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.8% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.7% |
| Federal Farm Credit Banks Funding Corporation, 4.125%, due 08/1/29 | 1.6% |
| Freddie Mac Pool, 5.000%, due 01/1/53 | 1.5% |
| Federal National Mortgage Association, 5.625%, due 07/15/37 | 1.5% |
| Freddie Mac Pool, 4.500%, due 08/1/52 | 1.5% |
| Freddie Mac Pool, 4.000%, due 08/1/52 | 1.5% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i45e1ccc8211bc34c70061a02.jpg)

#### Eventide Core Bond Fund - Class C (ETCRX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETCRX

#### Eventide Core Bond Fund

#### Class I (ETIRX)

#### Annual Shareholder Report - June 30, 2025
![Image](i940321183b0b1769e8dcd13d.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Core Bond Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $60 | 0.58% |

---

# How did the Fund perform during the reporting period?
The Fund's performance for the year ended June 30, 2025, was materially impacted by interest rate movements across the yield curve and the performance of corporate bonds relative to treasuries. The Fund's investments outperformed its benchmark net and gross of fees. The Fund benefited from an overweight to corporate bonds and a significant underweight to treasury bonds as corporate bonds outperformed treasuries. The Fund's investments in corporate bonds also outperformed the performance of corporate bond allocations within the benchmark. Visit https://www.eventidefunds.com for more recent performance information.

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i9bd2517adbb21101e6ac9814.jpg)

---

| | | |
|:---|:---|:---|
| | **Eventide Core Bond Fund** | **Bloomberg U.S. Aggregate Bond Index** |
| **Jul-2020** | $10000 | $10000 |
| **Jun-2021** | $9776 | $9820 |
| **Jun-2022** | $8651 | $8809 |
| **Jun-2023** | $8593 | $8727 |
| **Jun-2024** | $8812 | $8956 |
| **Jun-2025** | $9353 | $9500 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market.

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $148770697 |
| Number of Portfolio Holdings | 100 |
| Advisory Fee (net of waivers) | $361029 |
| Portfolio Turnover | 24% |

---

# Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (7/31/2020)** |
| Eventide Core Bond Fund - Class I | 6.14% | -1.35% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -1.04% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i3f6da6ecb3548de8d6ee0c59.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Liabilities in Excess of Other Assets | -1.1% |
| Other Industries | 7.5% |
| Other ABS | 1.2% |
| Auto Loan | 1.3% |
| Technology Services | 1.4% |
| Insurance | 2.3% |
| Retail - Discretionary | 2.3% |
| Software | 2.5% |
| Semiconductors | 2.6% |
| Engineering & Construction | 3.4% |
| REIT | 4.1% |
| Single-Family Housing | 5.6% |
| Banking | 6.1% |
| Government Sponsored | 6.2% |
| Oil & Gas Producers | 6.7% |
| Government Owned, No Guarantee | 8.4% |
| Electric Utilities | 10.8% |
| Agency Fixed Rate | 28.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i9773d99b3ef2e57817e67f4e.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.5% |
| Corporate Bonds | 46.9% |
| Municipal Bonds | 7.7% |
| U.S. Government & Agencies | 42.9% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32 | 1.9% |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.9% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.8% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.7% |
| Federal Farm Credit Banks Funding Corporation, 4.125%, due 08/1/29 | 1.6% |
| Freddie Mac Pool, 5.000%, due 01/1/53 | 1.5% |
| Federal National Mortgage Association, 5.625%, due 07/15/37 | 1.5% |
| Freddie Mac Pool, 4.500%, due 08/1/52 | 1.5% |
| Freddie Mac Pool, 4.000%, due 08/1/52 | 1.5% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i728eabe4e26dad6af59f22b3.jpg)

#### Eventide Core Bond Fund - Class I (ETIRX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETIRX

#### Eventide Core Bond Fund

#### Class N (ETNRX)

#### Annual Shareholder Report - June 30, 2025
![Image](i440fc8bcfa65f31aaf4e54e1.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Core Bond Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $80 | 0.78% |

---

# How did the Fund perform during the reporting period?
The Fund's performance for the year ended June 30, 2025, was materially impacted by interest rate movements across the yield curve and the performance of corporate bonds relative to treasuries. The Fund's investments slightly underperformed its benchmark net of fees, but outperformed gross of fees during the period. The Fund benefited from an overweight to corporate bonds and a significant underweight to treasury bonds as corporate bonds outperformed treasuries. The Fund's investments in corporate bonds also outperformed the performance of corporate bond allocations within the benchmark. Visit https://www.eventidefunds.com for more recent performance information.

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](ie70ecd160359c8e33943687c.jpg)

---

| | | |
|:---|:---|:---|
| | **Eventide Core Bond Fund** | **Bloomberg U.S. Aggregate Bond Index** |
| **Jul-2020** | $10000 | $10000 |
| **Jun-2021** | $9761 | $9820 |
| **Jun-2022** | $8620 | $8809 |
| **Jun-2023** | $8543 | $8727 |
| **Jun-2024** | $8743 | $8956 |
| **Jun-2025** | $9262 | $9500 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market.

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $148770697 |
| Number of Portfolio Holdings | 100 |
| Advisory Fee (net of waivers) | $361029 |
| Portfolio Turnover | 24% |

---

# Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (7/31/2020)** |
| Eventide Core Bond Fund - Class N | 5.93% | -1.55% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -1.04% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](ic43a7365cfc37d3c86bef75c.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Liabilities in Excess of Other Assets | -1.1% |
| Other Industries | 7.5% |
| Other ABS | 1.2% |
| Auto Loan | 1.3% |
| Technology Services | 1.4% |
| Insurance | 2.3% |
| Retail - Discretionary | 2.3% |
| Software | 2.5% |
| Semiconductors | 2.6% |
| Engineering & Construction | 3.4% |
| REIT | 4.1% |
| Single-Family Housing | 5.6% |
| Banking | 6.1% |
| Government Sponsored | 6.2% |
| Oil & Gas Producers | 6.7% |
| Government Owned, No Guarantee | 8.4% |
| Electric Utilities | 10.8% |
| Agency Fixed Rate | 28.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ic91b514ea34eb73702b541e3.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.5% |
| Corporate Bonds | 46.9% |
| Municipal Bonds | 7.7% |
| U.S. Government & Agencies | 42.9% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Federal Home Loan Mortgage Corporation, 6.250%, due 07/15/32 | 1.9% |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.9% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.8% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.7% |
| Federal Farm Credit Banks Funding Corporation, 4.125%, due 08/1/29 | 1.6% |
| Freddie Mac Pool, 5.000%, due 01/1/53 | 1.5% |
| Federal National Mortgage Association, 5.625%, due 07/15/37 | 1.5% |
| Freddie Mac Pool, 4.500%, due 08/1/52 | 1.5% |
| Freddie Mac Pool, 4.000%, due 08/1/52 | 1.5% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i6cbd825593c20636eabd6bd4.jpg)

#### Eventide Core Bond Fund - Class N (ETNRX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETNRX

# Eventide Dividend Growth Fund

# Class A (ETADX)

#### Annual Shareholder Report - June 30, 2025
![Image](iea2a4be0bec63c5add38caf5.jpg)

## Fund Overview
This annual shareholder report contains important information about Eventide Dividend Growth Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

## What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $126 | 1.20% |

---

## How has the Fund performed since inception?

### Total Return Based on $10,000 Investment
![Chart showing performance over last 10 years or since inception](i25b12ecc797b0b91a2240f3f.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Dividend Growth Fund - with load** | **Bloomberg US Mid Cap Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Sep-2017** | $9425 | $10000 | $10000 |
| **Jun-2018** | $9236 | $10897 | $11146 |
| **Jun-2019** | $10081 | $11723 | $10713 |
| **Jun-2020** | $10742 | $11654 | $10166 |
| **Jun-2021** | $15814 | $17332 | $17109 |
| **Jun-2022** | $13778 | $14753 | $12770 |
| **Jun-2023** | $15250 | $16886 | $14093 |
| **Jun-2024** | $18505 | $18980 | $15045 |
| **Jun-2025** | $20362 | $21448 | $16516 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

## How did the Fund perform during the reporting period?
The Fund slightly outperformed the broad based benchmark for the year. Strong performance and stock selection in energy, healthcare, utilities, consumer discretionary, and industrials was offset by underperformance in technology, real estate, and communications services. The high-quality, dividend growth focus of the Fund and strong positioning in areas such as natural gas infrastructure, independent power producers, HVAC, electric power generation, auto dealerships helped offset underperformance versus the benchmark in areas such as technology software, hardware, and communications equipment. Our focus remains on resilient growth, strong financials, idiosyncratic risk, and the overarching theme of human flourishing. Our experience underpins our confidence that these high-quality dividend growth companies will continue to serve their customers, stakeholders, and shareholders effectively. Visit https://www.eventidefunds.com for more recent performance information.

## Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **Since Inception (9/29/2017)** |
| Eventide Dividend Growth Fund - Class A | Eventide Dividend Growth Fund - Class A | Eventide Dividend Growth Fund - Class A | Eventide Dividend Growth Fund - Class A |
| Without Load | 10.03% | 13.64% | 10.45% |
| With Load | 3.72% | 12.31% | 9.61% |
| Bloomberg US Mid Cap Total Return Index | 13.00% | 12.98% | 10.35% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 6.69% |

---

## **Fund Statistics** 
* Net Assets$1,202,686,483

* Number of Portfolio Holdings53

* Advisory Fee $7,740,213

* Portfolio Turnover58%

## What did the Fund invest in?

## Industry Weighting (% of net assets)
![Group By Sector Chart](ib9881cc085e2945d589ec2d6.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 2.1% |
| Other Industries | 12.8% |
| Technology Hardware | 2.1% |
| Transportation & Logistics | 2.2% |
| Commercial Support Services | 2.4% |
| Diversified Industrials | 2.6% |
| Chemicals | 3.9% |
| Medical Equipment & Devices | 4.6% |
| Semiconductors | 4.7% |
| Insurance | 4.9% |
| Technology Services | 5.4% |
| Institutional Financial Services | 5.6% |
| REIT | 6.2% |
| Software | 6.4% |
| Retail - Discretionary | 6.7% |
| Electric Utilities | 8.6% |
| Oil & Gas Producers | 8.9% |
| Electrical Equipment | 9.9% |

---

## **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ia6c8eb95eb2aafc77ffb3b35.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.7% |
| Corporate Bonds | 0.3% |
| Money Market Funds | 0.0% |

---

## Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 5.2% |
| Arthur J Gallagher & Company | 4.3% |
| Williams Companies, Inc. (The) | 3.5% |
| Nasdaq, Inc. | 3.2% |
| Roper Technologies, Inc. | 3.0% |
| Entergy Corporation | 2.8% |
| STERIS PLC | 2.7% |
| EastGroup Properties, Inc. | 2.7% |
| Pentair PLC | 2.6% |
| Lam Research Corporation | 2.6% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). The Fund's name changed from "Eventide Dividend Opportunities Fund" to "Eventide Dividend Growth Fund" on November 1, 2024. That same day, the Fund adopted a policy to invest at least 80% of its assets in securities of companies the Adviser believes have the ability to increase dividends over the long term and updated its investment objective to dividend growth and long-term capital appreciation with a secondary objective of dividend income. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i0605bb917a0af5db4dcdd8b7.jpg)

# Eventide Dividend Growth Fund - Class A (ETADX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

## Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETADX

# Eventide Dividend Growth Fund

# Class C (ETCDX)

#### Annual Shareholder Report - June 30, 2025
![Image](i6edfba5cf6c6a737f21ff7cf.jpg)

## Fund Overview
This annual shareholder report contains important information about Eventide Dividend Growth Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

## What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $204 | 1.95% |

---

## How has the Fund performed since inception?

### Total Return Based on $10,000 Investment
![Chart showing performance over last 10 years or since inception](i85698dace6d5c8dfbf823004.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Dividend Growth Fund** | **Bloomberg US Mid Cap Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Sep-2017** | $10000 | $10000 | $10000 |
| **Jun-2018** | $9763 | $10897 | $11146 |
| **Jun-2019** | $10577 | $11723 | $10713 |
| **Jun-2020** | $11188 | $11654 | $10166 |
| **Jun-2021** | $16326 | $17332 | $17109 |
| **Jun-2022** | $14110 | $14753 | $12770 |
| **Jun-2023** | $15490 | $16886 | $14093 |
| **Jun-2024** | $18665 | $18980 | $15045 |
| **Jun-2025** | $20380 | $21448 | $16516 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

## How did the Fund perform during the reporting period?
The Fund slightly underperformed the broad based benchmark for the year. Strong performance and stock selection in energy, healthcare, utilities, consumer discretionary, and industrials was offset by underperformance in technology, real estate, and communications services. The high-quality, dividend growth focus of the Fund and strong positioning in areas such as natural gas infrastructure, independent power producers, HVAC, electric power generation, auto dealerships helped offset underperformance versus the benchmark in areas such as technology software, hardware, and communications equipment. Our focus remains on resilient growth, strong financials, idiosyncratic risk, and the overarching theme of human flourishing. Our experience underpins our confidence that these high-quality dividend growth companies will continue to serve their customers, stakeholders, and shareholders effectively. Visit https://www.eventidefunds.com for more recent performance information.

## Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **Since Inception (9/29/2017)** |
| Eventide Dividend Growth Fund - Class C | 9.19% | 12.74% | 9.62% |
| Bloomberg US Mid Cap Total Return Index | 13.00% | 12.98% | 10.35% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 6.69% |

---

## **Fund Statistics** 
* Net Assets$1,202,686,483

* Number of Portfolio Holdings53

* Advisory Fee $7,740,213

* Portfolio Turnover58%

## What did the Fund invest in?

## Industry Weighting (% of net assets)
![Group By Sector Chart](i70c294d51310f79f81ec9df8.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 2.1% |
| Other Industries | 12.8% |
| Technology Hardware | 2.1% |
| Transportation & Logistics | 2.2% |
| Commercial Support Services | 2.4% |
| Diversified Industrials | 2.6% |
| Chemicals | 3.9% |
| Medical Equipment & Devices | 4.6% |
| Semiconductors | 4.7% |
| Insurance | 4.9% |
| Technology Services | 5.4% |
| Institutional Financial Services | 5.6% |
| REIT | 6.2% |
| Software | 6.4% |
| Retail - Discretionary | 6.7% |
| Electric Utilities | 8.6% |
| Oil & Gas Producers | 8.9% |
| Electrical Equipment | 9.9% |

---

## **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i8d84edf2ba042823c3a39a6b.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.7% |
| Corporate Bonds | 0.3% |
| Money Market Funds | 0.0% |

---

## Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 5.2% |
| Arthur J Gallagher & Company | 4.3% |
| Williams Companies, Inc. (The) | 3.5% |
| Nasdaq, Inc. | 3.2% |
| Roper Technologies, Inc. | 3.0% |
| Entergy Corporation | 2.8% |
| STERIS PLC | 2.7% |
| EastGroup Properties, Inc. | 2.7% |
| Pentair PLC | 2.6% |
| Lam Research Corporation | 2.6% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). The Fund's name changed from "Eventide Dividend Opportunities Fund" to "Eventide Dividend Growth Fund" on November 1, 2024. That same day, the Fund adopted a policy to invest at least 80% of its assets in securities of companies the Adviser believes have the ability to increase dividends over the long term and updated its investment objective to dividend growth and long-term capital appreciation with a secondary objective of dividend income. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i450cc98da8983f0fe9d54643.jpg)

# Eventide Dividend Growth Fund - Class C (ETCDX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

## Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETCDX

# Eventide Dividend Growth Fund

# Class I (ETIDX)

#### Annual Shareholder Report - June 30, 2025
![Image](i00b0094bc304586868839ffb.jpg)

## Fund Overview
This annual shareholder report contains important information about Eventide Dividend Growth Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

## What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $100 | 0.95% |

---

## How has the Fund performed since inception?

### Total Return Based on $10,000 Investment
![Chart showing performance over last 10 years or since inception](iff2238f12fe3b7fc2e95af7a.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Dividend Growth Fund** | **Bloomberg US Mid Cap Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Sep-2017** | $10000 | $10000 | $10000 |
| **Jun-2018** | $9832 | $10897 | $11146 |
| **Jun-2019** | $10756 | $11723 | $10713 |
| **Jun-2020** | $11487 | $11654 | $10166 |
| **Jun-2021** | $16942 | $17332 | $17109 |
| **Jun-2022** | $14787 | $14753 | $12770 |
| **Jun-2023** | $16395 | $16886 | $14093 |
| **Jun-2024** | $19952 | $18980 | $15045 |
| **Jun-2025** | $22006 | $21448 | $16516 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

## How did the Fund perform during the reporting period?
The Fund slightly outperformed the broad based benchmark for the year. Strong performance and stock selection in energy, healthcare, utilities, consumer discretionary, and industrials was offset by underperformance in technology, real estate, and communications services. The high-quality, dividend growth focus of the Fund and strong positioning in areas such as natural gas infrastructure, independent power producers, HVAC, electric power generation, auto dealerships helped offset underperformance versus the benchmark in areas such as technology software, hardware, and communications equipment. Our focus remains on resilient growth, strong financials, idiosyncratic risk, and the overarching theme of human flourishing. Our experience underpins our confidence that these high-quality dividend growth companies will continue to serve their customers, stakeholders, and shareholders effectively. Visit https://www.eventidefunds.com for more recent performance information.

## Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **Since Inception (9/29/2017)** |
| Eventide Dividend Growth Fund - Class I | 10.30% | 13.89% | 10.71% |
| Bloomberg US Mid Cap Total Return Index | 13.00% | 12.98% | 10.35% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 6.69% |

---

## **Fund Statistics** 
* Net Assets$1,202,686,483

* Number of Portfolio Holdings53

* Advisory Fee $7,740,213

* Portfolio Turnover58%

## What did the Fund invest in?

## Industry Weighting (% of net assets)
![Group By Sector Chart](ia71d67600c5833f2838b54dd.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 2.1% |
| Other Industries | 12.8% |
| Technology Hardware | 2.1% |
| Transportation & Logistics | 2.2% |
| Commercial Support Services | 2.4% |
| Diversified Industrials | 2.6% |
| Chemicals | 3.9% |
| Medical Equipment & Devices | 4.6% |
| Semiconductors | 4.7% |
| Insurance | 4.9% |
| Technology Services | 5.4% |
| Institutional Financial Services | 5.6% |
| REIT | 6.2% |
| Software | 6.4% |
| Retail - Discretionary | 6.7% |
| Electric Utilities | 8.6% |
| Oil & Gas Producers | 8.9% |
| Electrical Equipment | 9.9% |

---

## **Asset Weighting (% of total investments)**![Group By Asset Type Chart](id5fba69e8d1ee0f4ec585232.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.7% |
| Corporate Bonds | 0.3% |
| Money Market Funds | 0.0% |

---

## Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 5.2% |
| Arthur J Gallagher & Company | 4.3% |
| Williams Companies, Inc. (The) | 3.5% |
| Nasdaq, Inc. | 3.2% |
| Roper Technologies, Inc. | 3.0% |
| Entergy Corporation | 2.8% |
| STERIS PLC | 2.7% |
| EastGroup Properties, Inc. | 2.7% |
| Pentair PLC | 2.6% |
| Lam Research Corporation | 2.6% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). The Fund's name changed from "Eventide Dividend Opportunities Fund" to "Eventide Dividend Growth Fund" on November 1, 2024. That same day, the Fund adopted a policy to invest at least 80% of its assets in securities of companies the Adviser believes have the ability to increase dividends over the long term and updated its investment objective to dividend growth and long-term capital appreciation with a secondary objective of dividend income. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](ie5811d7f1432fac85794583e.jpg)

# Eventide Dividend Growth Fund - Class I (ETIDX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

## Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETIDX

# Eventide Dividend Growth Fund

# Class N (ETNDX)

#### Annual Shareholder Report - June 30, 2025
![Image](ia4ee9f36e6a2b78f83383b43.jpg)

## Fund Overview
This annual shareholder report contains important information about Eventide Dividend Growth Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

## What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $121 | 1.15% |

---

## How has the Fund performed since inception?

### Total Return Based on $10,000 Investment
![Chart showing performance over last 10 years or since inception](i5c0b73279e08321e9cc2fe22.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Dividend Growth Fund** | **Bloomberg US Mid Cap Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Sep-2017** | $10000 | $10000 | $10000 |
| **Jun-2018** | $9813 | $10897 | $11146 |
| **Jun-2019** | $10716 | $11723 | $10713 |
| **Jun-2020** | $11424 | $11654 | $10166 |
| **Jun-2021** | $16817 | $17332 | $17109 |
| **Jun-2022** | $14647 | $14753 | $12770 |
| **Jun-2023** | $16209 | $16886 | $14093 |
| **Jun-2024** | $19678 | $18980 | $15045 |
| **Jun-2025** | $21662 | $21448 | $16516 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

## How did the Fund perform during the reporting period?
The Fund slightly outperformed the broad based benchmark for the year. Strong performance and stock selection in energy, healthcare, utilities, consumer discretionary, and industrials was offset by underperformance in technology, real estate, and communications services. The high-quality, dividend growth focus of the Fund and strong positioning in areas such as natural gas infrastructure, independent power producers, HVAC, electric power generation, auto dealerships helped offset underperformance versus the benchmark in areas such as technology software, hardware, and communications equipment. Our focus remains on resilient growth, strong financials, idiosyncratic risk, and the overarching theme of human flourishing. Our experience underpins our confidence that these high-quality dividend growth companies will continue to serve their customers, stakeholders, and shareholders effectively. Visit https://www.eventidefunds.com for more recent performance information.

## Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **Since Inception (9/29/2017)** |
| Eventide Dividend Growth Fund - Class N | 10.08% | 13.65% | 10.49% |
| Bloomberg US Mid Cap Total Return Index | 13.00% | 12.98% | 10.35% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 6.69% |

---

## **Fund Statistics** 
* Net Assets$1,202,686,483

* Number of Portfolio Holdings53

* Advisory Fee $7,740,213

* Portfolio Turnover58%

## What did the Fund invest in?

## Industry Weighting (% of net assets)
![Group By Sector Chart](i0deeae38abb067decb745b9b.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 2.1% |
| Other Industries | 12.8% |
| Technology Hardware | 2.1% |
| Transportation & Logistics | 2.2% |
| Commercial Support Services | 2.4% |
| Diversified Industrials | 2.6% |
| Chemicals | 3.9% |
| Medical Equipment & Devices | 4.6% |
| Semiconductors | 4.7% |
| Insurance | 4.9% |
| Technology Services | 5.4% |
| Institutional Financial Services | 5.6% |
| REIT | 6.2% |
| Software | 6.4% |
| Retail - Discretionary | 6.7% |
| Electric Utilities | 8.6% |
| Oil & Gas Producers | 8.9% |
| Electrical Equipment | 9.9% |

---

## **Asset Weighting (% of total investments)**![Group By Asset Type Chart](iaa93c4199e81c6e4d9cf2f4f.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.7% |
| Corporate Bonds | 0.3% |
| Money Market Funds | 0.0% |

---

## Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Trane Technologies PLC | 5.2% |
| Arthur J Gallagher & Company | 4.3% |
| Williams Companies, Inc. (The) | 3.5% |
| Nasdaq, Inc. | 3.2% |
| Roper Technologies, Inc. | 3.0% |
| Entergy Corporation | 2.8% |
| STERIS PLC | 2.7% |
| EastGroup Properties, Inc. | 2.7% |
| Pentair PLC | 2.6% |
| Lam Research Corporation | 2.6% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). The Fund's name changed from "Eventide Dividend Opportunities Fund" to "Eventide Dividend Growth Fund" on November 1, 2024. That same day, the Fund adopted a policy to invest at least 80% of its assets in securities of companies the Adviser believes have the ability to increase dividends over the long term and updated its investment objective to dividend growth and long-term capital appreciation with a secondary objective of dividend income. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i93d91ad54bcedf0051f56e80.jpg)

# Eventide Dividend Growth Fund - Class N (ETNDX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

## Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETNDX

#### Eventide Exponential Technologies Fund

#### Class A (ETAEX)

#### Annual Shareholder Report - June 30, 2025
![Image](i43859acbadafb29190e6806b.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Exponential Technologies Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $179 | 1.68% |

---

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](ibf29828fc8029e0f6083719a.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Exponential Technologies Fund - with load** | **Bloomberg US 2500 Technology Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2020** | $9425 | $10000 | $10000 |
| **Jun-2021** | $18002 | $15123 | $16831 |
| **Jun-2022** | $10451 | $10750 | $12562 |
| **Jun-2023** | $11474 | $12666 | $13864 |
| **Jun-2024** | $11436 | $13833 | $14800 |
| **Jun-2025** | $12870 | $15995 | $16247 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares**. In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US 2500 Technology Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund slightly outperformed the benchmark during the period. This was due primarily to outperformance in the Industrial and IT sectors which overcame a drag from the Communication Services and Consumer Discretionary Sectors. The fiscal year exhibited many of the same trends that have persisted over the past two years--the most important being how large the Artificial Intelligence ("AI") opportunity is and the most likely beneficiaries over time. While the Fund's core fundamental philosophy is relatively unchanged and there is still value in smaller companies, it has become more evident that larger companies will have a significant role to play in AI innovation (e.g. the so-called Mag7). Moreover, the chasm between the likely winners or innovators and the potentially disrupted seems to be widening every year. We believe that a disciplined approach to positioning is well-suited to deliver long- term value across market cycles, while still enabling participation in themes of technological innovation driving human progress. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (6/30/2020)** |
| Eventide Exponential Technologies Fund - Class A | Eventide Exponential Technologies Fund - Class A | Eventide Exponential Technologies Fund - Class A |
| Without Load | 12.54% | 6.43% |
| With Load | 6.07% | 5.18% |
| Bloomberg US 2500 Technology Total Return Index | 15.63% | 9.85% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $97287288 |
| Number of Portfolio Holdings | 61 |
| Advisory Fee (net of waivers) | $1066908 |
| Portfolio Turnover | 126% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i764fba1180b1b758ea91e0cf.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 0.1% |
| E-Commerce Discretionary | 0.5% |
| Asset Management | 0.8% |
| Institutional Financial Services | 1.2% |
| Electrical Equipment | 1.4% |
| Leisure Products | 2.2% |
| Biotech & Pharma | 3.7% |
| Industrial Intermediate Prod | 4.1% |
| Technology Hardware | 10.8% |
| Semiconductors | 11.6% |
| Technology Services | 12.7% |
| Software | 50.9% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i43276e5be6a8564390359c86.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.2% |
| Corporate Bonds | 0.8% |
| Money Market Funds | 0.0% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Nutanix, Inc. - Class A | 4.7% |
| Toast, Inc. - Class A | 4.5% |
| Xometry, Inc. - Class A | 4.1% |
| Constellation Software, Inc. | 4.0% |
| CyberArk Software Ltd. | 4.0% |
| Monday.com Ltd. | 3.6% |
| Flex Ltd. | 3.3% |
| NVIDIA Corporation | 3.1% |
| Adyen N.V. - ADR | 3.0% |
| Guidewire Software, Inc. | 2.7% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). Dr. Finny Kuruvilla, Co-Chief Investment Officer and Senior Portfolio Manager of Eventide Asset Management, LLC began serving as a portfolio manager of the Fund on July 16, 2024. Dr. Kuruvilla joined Anant Goel as portfolio manager of the Fund. As of November 1, 2024, Anant Goel is no longer a portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](ie6798ab666a36b380faa46fb.jpg)

#### Eventide Exponential Technologies Fund - Class A (ETAEX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETAEX

#### Eventide Exponential Technologies Fund

#### Class C (ETCEX)

#### Annual Shareholder Report - June 30, 2025
![Image](id35c956b7de56c6ce2267220.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Exponential Technologies Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $257 | 2.43% |

---

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](ie64c6d7a2404dc195ad3833d.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Exponential Technologies Fund** | **Bloomberg US 2500 Technology Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2020** | $10000 | $10000 | $10000 |
| **Jun-2021** | $18980 | $15123 | $16831 |
| **Jun-2022** | $10928 | $10750 | $12562 |
| **Jun-2023** | $11912 | $12666 | $13864 |
| **Jun-2024** | $11780 | $13833 | $14800 |
| **Jun-2025** | $13150 | $15995 | $16247 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares**. In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US 2500 Technology Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund slightly outperformed the benchmark during the period. This was due primarily to outperformance in the Industrial and IT sectors which overcame a drag from the Communication Services and Consumer Discretionary Sectors. The fiscal year exhibited many of the same trends that have persisted over the past two years--the most important being how large the Artificial Intelligence ("AI") opportunity is and the most likely beneficiaries over time. While the Fund's core fundamental philosophy is relatively unchanged and there is still value in smaller companies, it has become more evident that larger companies will have a significant role to play in AI innovation (e.g. the so-called Mag7). Moreover, the chasm between the likely winners or innovators and the potentially disrupted seems to be widening every year. We believe that a disciplined approach to positioning is well-suited to deliver long- term value across market cycles, while still enabling participation in themes of technological innovation driving human progress. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (6/30/2020)** |
| Eventide Exponential Technologies Fund - Class C | 11.63% | 5.63% |
| Bloomberg US 2500 Technology Total Return Index | 15.63% | 9.85% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $97287288 |
| Number of Portfolio Holdings | 61 |
| Advisory Fee (net of waivers) | $1066908 |
| Portfolio Turnover | 126% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i1892a1e5ca1803859a84e459.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 0.1% |
| E-Commerce Discretionary | 0.5% |
| Asset Management | 0.8% |
| Institutional Financial Services | 1.2% |
| Electrical Equipment | 1.4% |
| Leisure Products | 2.2% |
| Biotech & Pharma | 3.7% |
| Industrial Intermediate Prod | 4.1% |
| Technology Hardware | 10.8% |
| Semiconductors | 11.6% |
| Technology Services | 12.7% |
| Software | 50.9% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ieec449a3bd2d416d9621dd31.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.2% |
| Corporate Bonds | 0.8% |
| Money Market Funds | 0.0% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Nutanix, Inc. - Class A | 4.7% |
| Toast, Inc. - Class A | 4.5% |
| Xometry, Inc. - Class A | 4.1% |
| Constellation Software, Inc. | 4.0% |
| CyberArk Software Ltd. | 4.0% |
| Monday.com Ltd. | 3.6% |
| Flex Ltd. | 3.3% |
| NVIDIA Corporation | 3.1% |
| Adyen N.V. - ADR | 3.0% |
| Guidewire Software, Inc. | 2.7% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). Dr. Finny Kuruvilla, Co-Chief Investment Officer and Senior Portfolio Manager of Eventide Asset Management, LLC began serving as a portfolio manager of the Fund on July 16, 2024. Dr. Kuruvilla joined Anant Goel as portfolio manager of the Fund. As of November 1, 2024, Anant Goel is no longer a portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i075c401fa0ede93aefaa6818.jpg)

#### Eventide Exponential Technologies Fund - Class C (ETCEX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETCEX

#### Eventide Exponential Technologies Fund

#### Class I (ETIEX)

#### Annual Shareholder Report - June 30, 2025
![Image](ie0326459d6afa2859efaf08e.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Exponential Technologies Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $152 | 1.43% |

---

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](idf4a37f7fe39b502603e803f.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Exponential Technologies Fund** | **Bloomberg US 2500 Technology Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2020** | $10000 | $10000 | $10000 |
| **Jun-2021** | $19140 | $15123 | $16831 |
| **Jun-2022** | $11128 | $10750 | $12562 |
| **Jun-2023** | $12254 | $12666 | $13864 |
| **Jun-2024** | $12244 | $13833 | $14800 |
| **Jun-2025** | $13817 | $15995 | $16247 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares**. In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US 2500 Technology Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund slightly outperformed the benchmark during the period. This was due primarily to outperformance in the Industrial and IT sectors which overcame a drag from the Communication Services and Consumer Discretionary Sectors. The fiscal year exhibited many of the same trends that have persisted over the past two years--the most important being how large the Artificial Intelligence ("AI") opportunity is and the most likely beneficiaries over time. While the Fund's core fundamental philosophy is relatively unchanged and there is still value in smaller companies, it has become more evident that larger companies will have a significant role to play in AI innovation (e.g. the so-called Mag7). Moreover, the chasm between the likely winners or innovators and the potentially disrupted seems to be widening every year. We believe that a disciplined approach to positioning is well-suited to deliver long- term value across market cycles, while still enabling participation in themes of technological innovation driving human progress. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (6/30/2020)** |
| Eventide Exponential Technologies Fund - Class I | 12.84% | 6.68% |
| Bloomberg US 2500 Technology Total Return Index | 15.63% | 9.85% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $97287288 |
| Number of Portfolio Holdings | 61 |
| Advisory Fee (net of waivers) | $1066908 |
| Portfolio Turnover | 126% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i88f1fabc7ab193081268c200.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 0.1% |
| E-Commerce Discretionary | 0.5% |
| Asset Management | 0.8% |
| Institutional Financial Services | 1.2% |
| Electrical Equipment | 1.4% |
| Leisure Products | 2.2% |
| Biotech & Pharma | 3.7% |
| Industrial Intermediate Prod | 4.1% |
| Technology Hardware | 10.8% |
| Semiconductors | 11.6% |
| Technology Services | 12.7% |
| Software | 50.9% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i0fda38698686fc4f860bebcd.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.2% |
| Corporate Bonds | 0.8% |
| Money Market Funds | 0.0% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Nutanix, Inc. - Class A | 4.7% |
| Toast, Inc. - Class A | 4.5% |
| Xometry, Inc. - Class A | 4.1% |
| Constellation Software, Inc. | 4.0% |
| CyberArk Software Ltd. | 4.0% |
| Monday.com Ltd. | 3.6% |
| Flex Ltd. | 3.3% |
| NVIDIA Corporation | 3.1% |
| Adyen N.V. - ADR | 3.0% |
| Guidewire Software, Inc. | 2.7% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). Dr. Finny Kuruvilla, Co-Chief Investment Officer and Senior Portfolio Manager of Eventide Asset Management, LLC began serving as a portfolio manager of the Fund on July 16, 2024. Dr. Kuruvilla joined Anant Goel as portfolio manager of the Fund. As of November 1, 2024, Anant Goel is no longer a portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i1fa5a13de6c37318127d1617.jpg)

#### Eventide Exponential Technologies Fund - Class I (ETIEX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETIEX

#### Eventide Exponential Technologies Fund

#### Class N (ETNEX)

#### Annual Shareholder Report - June 30, 2025
![Image](ie8d956cebc41f91700380d34.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Exponential Technologies Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $173 | 1.63% |

---

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i602af847ee13eec592d44d3b.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Exponential Technologies Fund** | **Bloomberg US 2500 Technology Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2020** | $10000 | $10000 | $10000 |
| **Jun-2021** | $19100 | $15123 | $16831 |
| **Jun-2022** | $11078 | $10750 | $12562 |
| **Jun-2023** | $12174 | $12666 | $13864 |
| **Jun-2024** | $12143 | $13833 | $14800 |
| **Jun-2025** | $13665 | $15995 | $16247 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares**. In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US 2500 Technology Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund slightly outperformed the benchmark during the period. This was due primarily to outperformance in the Industrial and IT sectors which overcame a drag from the Communication Services and Consumer Discretionary Sectors. The fiscal year exhibited many of the same trends that have persisted over the past two years--the most important being how large the Artificial Intelligence ("AI") opportunity is and the most likely beneficiaries over time. While the Fund's core fundamental philosophy is relatively unchanged and there is still value in smaller companies, it has become more evident that larger companies will have a significant role to play in AI innovation (e.g. the so-called Mag7). Moreover, the chasm between the likely winners or innovators and the potentially disrupted seems to be widening every year. We believe that a disciplined approach to positioning is well-suited to deliver long- term value across market cycles, while still enabling participation in themes of technological innovation driving human progress. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (6/30/2020)** |
| Eventide Exponential Technologies Fund - Class N | 12.63% | 6.44% |
| Bloomberg US 2500 Technology Total Return Index | 15.63% | 9.85% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $97287288 |
| Number of Portfolio Holdings | 61 |
| Advisory Fee (net of waivers) | $1066908 |
| Portfolio Turnover | 126% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i3d878b97c5aa7939b82b2283.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 0.1% |
| E-Commerce Discretionary | 0.5% |
| Asset Management | 0.8% |
| Institutional Financial Services | 1.2% |
| Electrical Equipment | 1.4% |
| Leisure Products | 2.2% |
| Biotech & Pharma | 3.7% |
| Industrial Intermediate Prod | 4.1% |
| Technology Hardware | 10.8% |
| Semiconductors | 11.6% |
| Technology Services | 12.7% |
| Software | 50.9% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i61cda6bba8553f845b1507d7.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 99.2% |
| Corporate Bonds | 0.8% |
| Money Market Funds | 0.0% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Nutanix, Inc. - Class A | 4.7% |
| Toast, Inc. - Class A | 4.5% |
| Xometry, Inc. - Class A | 4.1% |
| Constellation Software, Inc. | 4.0% |
| CyberArk Software Ltd. | 4.0% |
| Monday.com Ltd. | 3.6% |
| Flex Ltd. | 3.3% |
| NVIDIA Corporation | 3.1% |
| Adyen N.V. - ADR | 3.0% |
| Guidewire Software, Inc. | 2.7% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). Dr. Finny Kuruvilla, Co-Chief Investment Officer and Senior Portfolio Manager of Eventide Asset Management, LLC began serving as a portfolio manager of the Fund on July 16, 2024. Dr. Kuruvilla joined Anant Goel as portfolio manager of the Fund. As of November 1, 2024, Anant Goel is no longer a portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](ic5c0916f418c54f4b2ba7bd3.jpg)

#### Eventide Exponential Technologies Fund - Class N (ETNEX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETNEX

#### Eventide Gilead Fund

#### Class A (ETAGX)

#### Annual Shareholder Report - June 30, 2025
![Image](ieaddc0bfff93942ec5eee06c.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Gilead Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $153 | 1.43% |

---

# How did the Fund perform during the reporting period?
While a flurry of persistent macro news (e.g. election, tariffs, Artificial Intelligence ("AI") innovation) drove markets over the past year, the fiscal year came to a close on a constructive note. Despite strong returns for the Fund's broad based benchmark, the portfolio outperformed on a relative basis due to both stock selection and sector allocation. As we turned the page on the presidential election and investors acclimated to tariff uncertainty, we saw alpha generation in the Fund's focus sectors during the second half of the fiscal year. The Fund's investment strategy remains anchored in the belief that companies with sustainable competitive advantages in attractive industries run by great management teams that focus on value creation for their stakeholders generate superior long-term risk-adjusted returns. Visit https://www.eventidefunds.com for more recent performance information.

# How has the Fund performed over the last ten years?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i9cf81e97017a02524abf9836.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Gilead Fund - with load** | **Bloomberg US Mid Cap Growth Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2015** | $9424 | $10000 | $10000 |
| **Jun-2016** | $7631 | $9917 | $9350 |
| **Jun-2017** | $9781 | $11406 | $11661 |
| **Jun-2018** | $12323 | $13199 | $13706 |
| **Jun-2019** | $14339 | $14848 | $13173 |
| **Jun-2020** | $16717 | $16228 | $12500 |
| **Jun-2021** | $24973 | $23424 | $21039 |
| **Jun-2022** | $16814 | $18205 | $15703 |
| **Jun-2023** | $19459 | $21389 | $17330 |
| **Jun-2024** | $19329 | $23928 | $18500 |
| **Jun-2025** | $21950 | $27851 | $20309 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Growth Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **10 Years** |
| Eventide Gilead Fund - Class A | Eventide Gilead Fund - Class A | Eventide Gilead Fund - Class A | Eventide Gilead Fund - Class A |
| Without Load | 13.56% | 5.60% | 8.82% |
| With Load | 7.02% | 4.36% | 8.18% |
| Bloomberg US Mid Cap Growth Total Return Index | 16.40% | 11.41% | 10.79% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 7.34% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $2790232380 |
| Number of Portfolio Holdings | 70 |
| Advisory Fee | $29160455 |
| Portfolio Turnover | 60% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](ibe4f79f7514fc7af0f021a16.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 0.1% |
| Other Industries | 6.3% |
| E-Commerce Discretionary | 1.6% |
| Leisure Products | 1.9% |
| Engineering & Construction | 1.9% |
| Commercial Support Services | 2.1% |
| Transportation & Logistics | 2.3% |
| Electric Utilities | 2.3% |
| Oil & Gas Producers | 2.7% |
| Retail - Discretionary | 3.4% |
| Industrial Intermediate Prod | 3.6% |
| Industrial Support Services | 5.2% |
| Electrical Equipment | 5.8% |
| Medical Equipment & Devices | 6.3% |
| Semiconductors | 7.6% |
| Technology Services | 8.6% |
| Software | 12.6% |
| Biotech & Pharma | 25.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i563589c427a25e44366ed90e.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 98.5% |
| Contingent Value Rights | 0.2% |
| Corporate Bonds | 1.1% |
| Money Market Funds | 0.2% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Verona Pharma PLC - ADR | 6.4% |
| Guardant Health, Inc. | 4.3% |
| Toast, Inc. - Class A | 3.7% |
| Xometry, Inc. - Class A | 3.6% |
| Trane Technologies PLC | 3.0% |
| Mirum Pharmaceuticals, Inc. | 2.6% |
| iRhythm Technologies, Inc. | 2.6% |
| Vistra Corporation | 2.3% |
| Old Dominion Freight Line, Inc. | 2.3% |
| GE Vernova, Inc. | 2.3% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). As of July 2024, Anant Goel is no longer a portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i055bbb9d7d81079404288e74.jpg)

#### Eventide Gilead Fund - Class A (ETAGX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETAGX

#### Eventide Gilead Fund

#### Class C (ETCGX)

#### Annual Shareholder Report - June 30, 2025
![Image](i8a807f59de4ac7c90a60dd29.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Gilead Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $232 | 2.18% |

---

# How did the Fund perform during the reporting period?
While a flurry of persistent macro news (e.g. election, tariffs, Artificial Intelligence ("AI") innovation) drove markets over the past year, the fiscal year came to a close on a constructive note. Despite strong returns for the Fund's broad based benchmark, the portfolio outperformed on a relative basis due to both stock selection and sector allocation. As we turned the page on the presidential election and investors acclimated to tariff uncertainty, we saw alpha generation in the Fund's focus sectors during the second half of the fiscal year. The Fund's investment strategy remains anchored in the belief that companies with sustainable competitive advantages in attractive industries run by great management teams that focus on value creation for their stakeholders generate superior long-term risk-adjusted returns. Visit https://www.eventidefunds.com for more recent performance information.

# How has the Fund performed over the last ten years?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i66db9b32adeb7ce1b1c553ba.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Gilead Fund** | **Bloomberg US Mid Cap Growth Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2015** | $10000 | $10000 | $10000 |
| **Jun-2016** | $8037 | $9917 | $9350 |
| **Jun-2017** | $10226 | $11406 | $11661 |
| **Jun-2018** | $12786 | $13199 | $13706 |
| **Jun-2019** | $14769 | $14848 | $13173 |
| **Jun-2020** | $17088 | $16228 | $12500 |
| **Jun-2021** | $25329 | $23424 | $21039 |
| **Jun-2022** | $16918 | $18205 | $15703 |
| **Jun-2023** | $19434 | $21389 | $17330 |
| **Jun-2024** | $19163 | $23928 | $18500 |
| **Jun-2025** | $21597 | $27851 | $20309 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Growth Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **10 Years** |
| Eventide Gilead Fund - Class C | 12.73% | 4.79% | 8.00% |
| Bloomberg US Mid Cap Growth Total Return Index | 16.40% | 11.41% | 10.79% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 7.34% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $2790232380 |
| Number of Portfolio Holdings | 70 |
| Advisory Fee | $29160455 |
| Portfolio Turnover | 60% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i2e026aee075d6c94c43831a0.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 0.1% |
| Other Industries | 6.3% |
| E-Commerce Discretionary | 1.6% |
| Leisure Products | 1.9% |
| Engineering & Construction | 1.9% |
| Commercial Support Services | 2.1% |
| Transportation & Logistics | 2.3% |
| Electric Utilities | 2.3% |
| Oil & Gas Producers | 2.7% |
| Retail - Discretionary | 3.4% |
| Industrial Intermediate Prod | 3.6% |
| Industrial Support Services | 5.2% |
| Electrical Equipment | 5.8% |
| Medical Equipment & Devices | 6.3% |
| Semiconductors | 7.6% |
| Technology Services | 8.6% |
| Software | 12.6% |
| Biotech & Pharma | 25.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ida528be1b80df1a5615e6340.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 98.5% |
| Contingent Value Rights | 0.2% |
| Corporate Bonds | 1.1% |
| Money Market Funds | 0.2% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Verona Pharma PLC - ADR | 6.4% |
| Guardant Health, Inc. | 4.3% |
| Toast, Inc. - Class A | 3.7% |
| Xometry, Inc. - Class A | 3.6% |
| Trane Technologies PLC | 3.0% |
| Mirum Pharmaceuticals, Inc. | 2.6% |
| iRhythm Technologies, Inc. | 2.6% |
| Vistra Corporation | 2.3% |
| Old Dominion Freight Line, Inc. | 2.3% |
| GE Vernova, Inc. | 2.3% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). As of July 2024, Anant Goel is no longer a portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i9c2b825228f91dc6261b1dfb.jpg)

#### Eventide Gilead Fund - Class C (ETCGX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETCGX

#### Eventide Gilead Fund

#### Class I (ETILX)

#### Annual Shareholder Report - June 30, 2025
![Image](i5cde287ab9b50e59bf72899b.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Gilead Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $126 | 1.18% |

---

# How did the Fund perform during the reporting period?
While a flurry of persistent macro news (e.g. election, tariffs, Artificial Intelligence ("AI") innovation) drove markets over the past year, the fiscal year came to a close on a constructive note. Despite strong returns for the Fund's broad based benchmark, the portfolio outperformed on a relative basis due to both stock selection and sector allocation. As we turned the page on the presidential election and investors acclimated to tariff uncertainty, we saw alpha generation in the Fund's focus sectors during the second half of the fiscal year. The Fund's investment strategy remains anchored in the belief that companies with sustainable competitive advantages in attractive industries run by great management teams that focus on value creation for their stakeholders generate superior long-term risk-adjusted returns. Visit https://www.eventidefunds.com for more recent performance information.

# How has the Fund performed over the last ten years?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i34cc8f544d28e1a96f9c93ea.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Gilead Fund** | **Bloomberg US Mid Cap Growth Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2015** | $10000 | $10000 | $10000 |
| **Jun-2016** | $8118 | $9917 | $9350 |
| **Jun-2017** | $10432 | $11406 | $11661 |
| **Jun-2018** | $13178 | $13199 | $13706 |
| **Jun-2019** | $15373 | $14848 | $13173 |
| **Jun-2020** | $17963 | $16228 | $12500 |
| **Jun-2021** | $26901 | $23424 | $21039 |
| **Jun-2022** | $18151 | $18205 | $15703 |
| **Jun-2023** | $21056 | $21389 | $17330 |
| **Jun-2024** | $20971 | $23928 | $18500 |
| **Jun-2025** | $23873 | $27851 | $20309 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Growth Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **10 Years** |
| Eventide Gilead Fund - Class I | 13.86% | 5.85% | 9.09% |
| Bloomberg US Mid Cap Growth Total Return Index | 16.40% | 11.41% | 10.79% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 7.34% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $2790232380 |
| Number of Portfolio Holdings | 70 |
| Advisory Fee | $29160455 |
| Portfolio Turnover | 60% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i3ba8fca313e38646e6c1ebd4.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 0.1% |
| Other Industries | 6.3% |
| E-Commerce Discretionary | 1.6% |
| Leisure Products | 1.9% |
| Engineering & Construction | 1.9% |
| Commercial Support Services | 2.1% |
| Transportation & Logistics | 2.3% |
| Electric Utilities | 2.3% |
| Oil & Gas Producers | 2.7% |
| Retail - Discretionary | 3.4% |
| Industrial Intermediate Prod | 3.6% |
| Industrial Support Services | 5.2% |
| Electrical Equipment | 5.8% |
| Medical Equipment & Devices | 6.3% |
| Semiconductors | 7.6% |
| Technology Services | 8.6% |
| Software | 12.6% |
| Biotech & Pharma | 25.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](idd1c9f770ab4cd1e0e77e1c3.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 98.5% |
| Contingent Value Rights | 0.2% |
| Corporate Bonds | 1.1% |
| Money Market Funds | 0.2% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Verona Pharma PLC - ADR | 6.4% |
| Guardant Health, Inc. | 4.3% |
| Toast, Inc. - Class A | 3.7% |
| Xometry, Inc. - Class A | 3.6% |
| Trane Technologies PLC | 3.0% |
| Mirum Pharmaceuticals, Inc. | 2.6% |
| iRhythm Technologies, Inc. | 2.6% |
| Vistra Corporation | 2.3% |
| Old Dominion Freight Line, Inc. | 2.3% |
| GE Vernova, Inc. | 2.3% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). As of July 2024, Anant Goel is no longer a portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i84ac98f65399b8734b61745f.jpg)

#### Eventide Gilead Fund - Class I (ETILX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETILX

#### Eventide Gilead Fund

#### Class N (ETGLX)

#### Annual Shareholder Report - June 30, 2025
![Image](ib9fd2ef62e46217c0097a044.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Gilead Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $147 | 1.38% |

---

# How did the Fund perform during the reporting period?
While a flurry of persistent macro news (e.g. election, tariffs, Artificial Intelligence ("AI") innovation) drove markets over the past year, the fiscal year came to a close on a constructive note. Despite strong returns for the Fund's broad based benchmark, the portfolio outperformed on a relative basis due to both stock selection and sector allocation. As we turned the page on the presidential election and investors acclimated to tariff uncertainty, we saw alpha generation in the Fund's focus sectors during the second half of the fiscal year. The Fund's investment strategy remains anchored in the belief that companies with sustainable competitive advantages in attractive industries run by great management teams that focus on value creation for their stakeholders generate superior long-term risk-adjusted returns. Visit https://www.eventidefunds.com for more recent performance information.

# How has the Fund performed over the last ten years?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i76effb2855d856388db69f86.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Gilead Fund** | **Bloomberg US Mid Cap Growth Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2015** | $10000 | $10000 | $10000 |
| **Jun-2016** | $8101 | $9917 | $9350 |
| **Jun-2017** | $10391 | $11406 | $11661 |
| **Jun-2018** | $13098 | $13199 | $13706 |
| **Jun-2019** | $15246 | $14848 | $13173 |
| **Jun-2020** | $17786 | $16228 | $12500 |
| **Jun-2021** | $26578 | $23424 | $21039 |
| **Jun-2022** | $17900 | $18205 | $15703 |
| **Jun-2023** | $20723 | $21389 | $17330 |
| **Jun-2024** | $20594 | $23928 | $18500 |
| **Jun-2025** | $23401 | $27851 | $20309 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, Bloomberg US Mid Cap Growth Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **10 Years** |
| Eventide Gilead Fund - Class N | 13.63% | 5.64% | 8.87% |
| Bloomberg US Mid Cap Growth Total Return Index | 16.40% | 11.41% | 10.79% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 7.34% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $2790232380 |
| Number of Portfolio Holdings | 70 |
| Advisory Fee | $29160455 |
| Portfolio Turnover | 60% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i631b9c1786d53ec3de392f14.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 0.1% |
| Other Industries | 6.3% |
| E-Commerce Discretionary | 1.6% |
| Leisure Products | 1.9% |
| Engineering & Construction | 1.9% |
| Commercial Support Services | 2.1% |
| Transportation & Logistics | 2.3% |
| Electric Utilities | 2.3% |
| Oil & Gas Producers | 2.7% |
| Retail - Discretionary | 3.4% |
| Industrial Intermediate Prod | 3.6% |
| Industrial Support Services | 5.2% |
| Electrical Equipment | 5.8% |
| Medical Equipment & Devices | 6.3% |
| Semiconductors | 7.6% |
| Technology Services | 8.6% |
| Software | 12.6% |
| Biotech & Pharma | 25.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i3b6c658ac73cfadc6a47d05d.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 98.5% |
| Contingent Value Rights | 0.2% |
| Corporate Bonds | 1.1% |
| Money Market Funds | 0.2% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Verona Pharma PLC - ADR | 6.4% |
| Guardant Health, Inc. | 4.3% |
| Toast, Inc. - Class A | 3.7% |
| Xometry, Inc. - Class A | 3.6% |
| Trane Technologies PLC | 3.0% |
| Mirum Pharmaceuticals, Inc. | 2.6% |
| iRhythm Technologies, Inc. | 2.6% |
| Vistra Corporation | 2.3% |
| Old Dominion Freight Line, Inc. | 2.3% |
| GE Vernova, Inc. | 2.3% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). As of July 2024, Anant Goel is no longer a portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i588275783123a46fd1f65a03.jpg)

#### Eventide Gilead Fund - Class N (ETGLX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETGLX

#### Eventide Healthcare & Life Sciences Fund

#### Class A (ETAHX)

#### Annual Shareholder Report - June 30, 2025
![Image](ia4e6e7bbc0093c1abb9be28a.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $156 | 1.56% |

---

# How has the Fund performed over the last ten years?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i8cbfaff037c7195800edbbd3.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Healthcare & Life Sciences Fund - with load** | **S&P Biotechnology Select Industry Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2015** | $9426 | $10000 | $10000 |
| **Jun-2016** | $6821 | $6443 | $9350 |
| **Jun-2017** | $8532 | $9214 | $11661 |
| **Jun-2018** | $12698 | $11389 | $13706 |
| **Jun-2019** | $14047 | $10515 | $13173 |
| **Jun-2020** | $17512 | $13429 | $12500 |
| **Jun-2021** | $19312 | $16274 | $21039 |
| **Jun-2022** | $12385 | $8928 | $15703 |
| **Jun-2023** | $17179 | $10011 | $17330 |
| **Jun-2024** | $15500 | $11206 | $18500 |
| **Jun-2025** | $15448 | $10045 | $20309 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
During the fiscal year, the SMID-cap healthcare sector underperformed the broader market due to the implications of "higher for longer" interest rates, and faced further headwind from regulatory and policy uncertainties, particularly potential impacts related to the higher tariffs and major personnel changes at the U.S. Food and Drug Administration and U.S. Department of Health and Human Services. Although the portfolio performance trailed against the broader market during this period, we saw a strong outperformance of the Fund against the healthcare benchmark and broader market in the second half of the fiscal year. We are confident in the Fund's investment philosophy and the healthcare sector's remarkable innovations in respiratory, rare and immunological diseases. The Fund has been overweight the medtech and diagnostic subsectors, as well as in biotech companies in later development and commercial stages. We believe the Fund is strategically aligned to leverage the innovation in healthcare to address important unmet needs. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **10 Years** |
| Eventide Healthcare & Life Sciences Fund - Class A | Eventide Healthcare & Life Sciences Fund - Class A | Eventide Healthcare & Life Sciences Fund - Class A | Eventide Healthcare & Life Sciences Fund - Class A |
| Without Load | -0.33% | -2.48% | 5.06% |
| With Load | -6.08% | -3.63% | 4.44% |
| S&P Biotechnology Select Industry Total Return Index | -10.36% | -5.64% | 0.04% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 7.34% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1145869567 |
| Number of Portfolio Holdings | 69 |
| Advisory Fee | $14591841 |
| Portfolio Turnover | 41% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i719edaa87c8a470a78d773d2.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 2.6% |
| Money Market Funds | 0.3% |
| Software | 3.5% |
| Medical Equipment & Devices | 21.6% |
| Biotech & Pharma | 72.0% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i793b726c72e13e1a709d92d8.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 96.0% |
| Contingent Value Rights | 0.2% |
| Convertible Bonds | 0.0% |
| Money Market Funds | 0.3% |
| Private Investments | 3.5% |
| Warrant | 0.0% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Insmed, Inc. | 6.8% |
| Verona Pharma PLC - ADR | 6.7% |
| Mirum Pharmaceuticals, Inc. | 5.3% |
| Guardant Health, Inc. | 4.9% |
| Scholar Rock Holding Corporation | 4.4% |
| Alnylam Pharmaceuticals, Inc. | 3.6% |
| Blueprint Medicines Corporation | 3.4% |
| Axsome Therapeutics, Inc. | 3.3% |
| Collegium Pharmaceutical, Inc. | 3.3% |
| TG Therapeutics, Inc. | 3.0% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). Dr. I-hung Shih, Portfolio Manager of Eventide Asset Management, LLC began serving as a portfolio manager of the Fund on September 1, 2024. Dr. Shih joined Dr. Kuruvilla as portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i08c0d2987beccd246bc8d2e0.jpg)

#### Eventide Healthcare & Life Sciences Fund - Class A (ETAHX)

#### Annual Shareholder Report - June 30, 2025

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETAHX

#### Eventide Healthcare & Life Sciences Fund

#### Class C (ETCHX)

#### Annual Shareholder Report - June 30, 2025
![Image](ifba8aa7c5827afd9e82ef143.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $230 | 2.31% |

---

# How has the Fund performed over the last ten years?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i50fb8381d48a2b8e67e08b84.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Healthcare & Life Sciences Fund** | **S&P Biotechnology Select Industry Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2015** | $10000 | $10000 | $10000 |
| **Jun-2016** | $7185 | $6443 | $9350 |
| **Jun-2017** | $8920 | $9214 | $11661 |
| **Jun-2018** | $13174 | $11389 | $13706 |
| **Jun-2019** | $14469 | $10515 | $13173 |
| **Jun-2020** | $17903 | $13429 | $12500 |
| **Jun-2021** | $19595 | $16274 | $21039 |
| **Jun-2022** | $12466 | $8928 | $15703 |
| **Jun-2023** | $17167 | $10011 | $17330 |
| **Jun-2024** | $15375 | $11206 | $18500 |
| **Jun-2025** | $15207 | $10045 | $20309 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
During the fiscal year, the SMID-cap healthcare sector underperformed the broader market due to the implications of "higher for longer" interest rates, and faced further headwind from regulatory and policy uncertainties, particularly potential impacts related to the higher tariffs and major personnel changes at the U.S. Food and Drug Administration and U.S. Department of Health and Human Services. Although the portfolio performance trailed against the broader market during this period, we saw a strong outperformance of the Fund against the healthcare benchmark and broader market in the second half of the fiscal year. We are confident in the Fund's investment philosophy and the healthcare sector's remarkable innovations in respiratory, rare and immunological diseases. The Fund has been overweight the medtech and diagnostic subsectors, as well as in biotech companies in later development and commercial stages. We believe the Fund is strategically aligned to leverage the innovation in healthcare to address important unmet needs. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **10 Years** |
| Eventide Healthcare & Life Sciences Fund - Class C | -1.06% | -3.21% | 4.28% |
| S&P Biotechnology Select Industry Total Return Index | -10.36% | -5.64% | 0.04% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 7.34% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1145869567 |
| Number of Portfolio Holdings | 69 |
| Advisory Fee | $14591841 |
| Portfolio Turnover | 41% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i785f2909d4174b9b4b1294e2.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 2.6% |
| Money Market Funds | 0.3% |
| Software | 3.5% |
| Medical Equipment & Devices | 21.6% |
| Biotech & Pharma | 72.0% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i392ee3a734c2aba8348768c2.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 96.0% |
| Contingent Value Rights | 0.2% |
| Convertible Bonds | 0.0% |
| Money Market Funds | 0.3% |
| Private Investments | 3.5% |
| Warrant | 0.0% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Insmed, Inc. | 6.8% |
| Verona Pharma PLC - ADR | 6.7% |
| Mirum Pharmaceuticals, Inc. | 5.3% |
| Guardant Health, Inc. | 4.9% |
| Scholar Rock Holding Corporation | 4.4% |
| Alnylam Pharmaceuticals, Inc. | 3.6% |
| Blueprint Medicines Corporation | 3.4% |
| Axsome Therapeutics, Inc. | 3.3% |
| Collegium Pharmaceutical, Inc. | 3.3% |
| TG Therapeutics, Inc. | 3.0% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). Dr. I-hung Shih, Portfolio Manager of Eventide Asset Management, LLC began serving as a portfolio manager of the Fund on September 1, 2024. Dr. Shih joined Dr. Kuruvilla as portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i5cc2c29f3ec35e2942d901d3.jpg)

#### Eventide Healthcare & Life Sciences Fund - Class C (ETCHX)

#### Annual Shareholder Report - June 30, 2025

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETCHX

#### Eventide Healthcare & Life Sciences Fund

#### Class I (ETIHX)

#### Annual Shareholder Report - June 30, 2025
![Image](i806774469646c1708489ac5c.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $131 | 1.31% |

---

# How has the Fund performed over the last ten years?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i9e830fca2433f5153391bc8d.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Healthcare & Life Sciences Fund** | **S&P Biotechnology Select Industry Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2015** | $10000 | $10000 | $10000 |
| **Jun-2016** | $7254 | $6443 | $9350 |
| **Jun-2017** | $9097 | $9214 | $11661 |
| **Jun-2018** | $13609 | $11389 | $13706 |
| **Jun-2019** | $15069 | $10515 | $13173 |
| **Jun-2020** | $18832 | $13429 | $12500 |
| **Jun-2021** | $20818 | $16274 | $21039 |
| **Jun-2022** | $13379 | $8928 | $15703 |
| **Jun-2023** | $18612 | $10011 | $17330 |
| **Jun-2024** | $16830 | $11206 | $18500 |
| **Jun-2025** | $16815 | $10045 | $20309 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
During the fiscal year, the SMID-cap healthcare sector underperformed the broader market due to the implications of "higher for longer" interest rates, and faced further headwind from regulatory and policy uncertainties, particularly potential impacts related to the higher tariffs and major personnel changes at the U.S. Food and Drug Administration and U.S. Department of Health and Human Services. Although the portfolio performance trailed against the broader market during this period, we saw a strong outperformance of the Fund against the healthcare benchmark and broader market in the second half of the fiscal year. We are confident in the Fund's investment philosophy and the healthcare sector's remarkable innovations in respiratory, rare and immunological diseases. The Fund has been overweight the medtech and diagnostic subsectors, as well as in biotech companies in later development and commercial stages. We believe the Fund is strategically aligned to leverage the innovation in healthcare to address important unmet needs. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **10 Years** |
| Eventide Healthcare & Life Sciences Fund - Class I | -0.09% | -2.24% | 5.33% |
| S&P Biotechnology Select Industry Total Return Index | -10.36% | -5.64% | 0.04% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 7.34% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1145869567 |
| Number of Portfolio Holdings | 69 |
| Advisory Fee | $14591841 |
| Portfolio Turnover | 41% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i109da799cf5be32ff9e88a2b.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 2.6% |
| Money Market Funds | 0.3% |
| Software | 3.5% |
| Medical Equipment & Devices | 21.6% |
| Biotech & Pharma | 72.0% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](iba8b5b72aef6a60c9e4b45c9.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 96.0% |
| Contingent Value Rights | 0.2% |
| Convertible Bonds | 0.0% |
| Money Market Funds | 0.3% |
| Private Investments | 3.5% |
| Warrant | 0.0% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Insmed, Inc. | 6.8% |
| Verona Pharma PLC - ADR | 6.7% |
| Mirum Pharmaceuticals, Inc. | 5.3% |
| Guardant Health, Inc. | 4.9% |
| Scholar Rock Holding Corporation | 4.4% |
| Alnylam Pharmaceuticals, Inc. | 3.6% |
| Blueprint Medicines Corporation | 3.4% |
| Axsome Therapeutics, Inc. | 3.3% |
| Collegium Pharmaceutical, Inc. | 3.3% |
| TG Therapeutics, Inc. | 3.0% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). Dr. I-hung Shih, Portfolio Manager of Eventide Asset Management, LLC began serving as a portfolio manager of the Fund on September 1, 2024. Dr. Shih joined Dr. Kuruvilla as portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](idf72f010ed26f5c0ef4171eb.jpg)

#### Eventide Healthcare & Life Sciences Fund - Class I (ETIHX)

#### Annual Shareholder Report - June 30, 2025

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETIHX

#### Eventide Healthcare & Life Sciences Fund

#### Class N (ETNHX)

#### Annual Shareholder Report - June 30, 2025
![Image](ib12af762d30a62723fc73d51.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $151 | 1.51% |

---

# How has the Fund performed over the last ten years?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i1a0ff51c843205497f489532.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Healthcare & Life Sciences Fund** | **S&P Biotechnology Select Industry Total Return Index** | **Bloomberg US 3000 Equal Weight Total Return Index** |
| **Jun-2015** | $10000 | $10000 | $10000 |
| **Jun-2016** | $7236 | $6443 | $9350 |
| **Jun-2017** | $9059 | $9214 | $11661 |
| **Jun-2018** | $13523 | $11389 | $13706 |
| **Jun-2019** | $14944 | $10515 | $13173 |
| **Jun-2020** | $18632 | $13429 | $12500 |
| **Jun-2021** | $20559 | $16274 | $21039 |
| **Jun-2022** | $13188 | $8928 | $15703 |
| **Jun-2023** | $18309 | $10011 | $17330 |
| **Jun-2024** | $16523 | $11206 | $18500 |
| **Jun-2025** | $16478 | $10045 | $20309 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
During the fiscal year, the SMID-cap healthcare sector underperformed the broader market due to the implications of "higher for longer" interest rates, and faced further headwind from regulatory and policy uncertainties, particularly potential impacts related to the higher tariffs and major personnel changes at the U.S. Food and Drug Administration and U.S. Department of Health and Human Services. Although the portfolio performance trailed against the broader market during this period, we saw a strong outperformance of the Fund against the healthcare benchmark and broader market in the second half of the fiscal year. We are confident in the Fund's investment philosophy and the healthcare sector's remarkable innovations in respiratory, rare and immunological diseases. The Fund has been overweight the medtech and diagnostic subsectors, as well as in biotech companies in later development and commercial stages. We believe the Fund is strategically aligned to leverage the innovation in healthcare to address important unmet needs. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **10 Years** |
| Eventide Healthcare & Life Sciences Fund - Class N | -0.27% | -2.43% | 5.12% |
| S&P Biotechnology Select Industry Total Return Index | -10.36% | -5.64% | 0.04% |
| Bloomberg US 3000 Equal Weight Total Return Index | 9.78% | 10.19% | 7.34% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $1145869567 |
| Number of Portfolio Holdings | 69 |
| Advisory Fee | $14591841 |
| Portfolio Turnover | 41% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i0e40338ff03d3e13e1bd8a52.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 2.6% |
| Money Market Funds | 0.3% |
| Software | 3.5% |
| Medical Equipment & Devices | 21.6% |
| Biotech & Pharma | 72.0% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](id11deb356a085d1578503e94.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Common Stocks | 96.0% |
| Contingent Value Rights | 0.2% |
| Convertible Bonds | 0.0% |
| Money Market Funds | 0.3% |
| Private Investments | 3.5% |
| Warrant | 0.0% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| Insmed, Inc. | 6.8% |
| Verona Pharma PLC - ADR | 6.7% |
| Mirum Pharmaceuticals, Inc. | 5.3% |
| Guardant Health, Inc. | 4.9% |
| Scholar Rock Holding Corporation | 4.4% |
| Alnylam Pharmaceuticals, Inc. | 3.6% |
| Blueprint Medicines Corporation | 3.4% |
| Axsome Therapeutics, Inc. | 3.3% |
| Collegium Pharmaceutical, Inc. | 3.3% |
| TG Therapeutics, Inc. | 3.0% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). Dr. I-hung Shih, Portfolio Manager of Eventide Asset Management, LLC began serving as a portfolio manager of the Fund on September 1, 2024. Dr. Shih joined Dr. Kuruvilla as portfolio manager of the Fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i93efaa8db76dfab5122c7cf5.jpg)

#### Eventide Healthcare & Life Sciences Fund - Class N (ETNHX)

#### Annual Shareholder Report - June 30, 2025

# Where can I find additional information about the Fund?
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETNHX

# Eventide Large Cap Focus Fund

## Class A (ETLAX)

#### Annual Shareholder Report - June 30, 2025
![Image](i9666bbfccb7283fcd0185ae5.jpg)

## Fund Overview
This annual shareholder report contains important information about Eventide Large Cap Focus Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

## What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $126 | 1.19% |

---

## How did the Fund perform during the reporting period?
The Fund's underperformance in Information Technology, Communication Services, Financials, and Real Estate was partly offset by outperformance in Energy, Healthcare, Industrials, Utilities, and Consumer Discretionary. The Fund outperformed in the first half of calendar 2025 due to strong stock selection, particularly within Industrials and Healthcare, and the market's winners broadened beyond the megacap technology companies. We remain focused on the Fund owning companies that create significant economic and societal value through innovation, while also trading at attractive valuations. Visit https://www.eventidefunds.com for more recent performance information.

## How has the Fund performed since inception?

### Total Return Based on $10,000 Investment
![Growth of 10K Chart](i8c67a338f133a15694e96a7b.jpg)

---

| | | |
|:---|:---|:---|
| | **Eventide Large Cap Focus Fund - with load** | **S&P 500<sup>®</sup> Index** |
| **Jun-2022** | $9425 | $10000 |
| **Jun-2023** | $10769 | $11959 |
| **Jun-2024** | $13183 | $14896 |
| **Jun-2025** | $14768 | $17155 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, S&P 500 Total Return Index, which represents the overall domestic equity market.

## **Fund Statistics** 
* Net Assets$163,393,024

* Number of Portfolio Holdings44

* Advisory Fee $817,762

* Portfolio Turnover50%

## Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (6/30/2022)** |
| Eventide Large Cap Focus Fund - Class A | Eventide Large Cap Focus Fund - Class A | Eventide Large Cap Focus Fund - Class A |
| Without Load | 11.94% | 16.15% |
| With Load | 5.53% | 13.88% |
| S&P 500<sup>®</sup> Index | 15.16% | 19.71% |

---

## What did the Fund invest in?

## Industry Weighting (% of net assets)
![Group By Sector Chart](i2728db30e950afbde28edefb.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 1.0% |
| Other Industries | 2.9% |
| Banking | 1.5% |
| Insurance | 1.8% |
| Home Construction | 1.9% |
| Technology Hardware | 2.7% |
| Medical Equipment & Devices | 3.2% |
| Transportation & Logistics | 3.2% |
| Oil & Gas Producers | 3.5% |
| Specialty Finance | 4.6% |
| Biotech & Pharma | 4.8% |
| Technology Services | 5.8% |
| Retail - Discretionary | 7.8% |
| Electric Utilities | 8.3% |
| Electrical Equipment | 8.5% |
| Chemicals | 8.5% |
| Semiconductors | 13.5% |
| Software | 16.5% |

---

## Market Cap Weighting
![Group By Asset Type Chart](idd10b076166b92d7dd45e281.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Large Cap | 75.5% |
| Mid Cap | 23.5% |
| Cash/Other | 1.0% |
| Small Cap | 0.0% |

---

## Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| NVIDIA Corporation | 6.4% |
| S&P Global, Inc. | 5.1% |
| Linde PLC | 4.9% |
| American Express Company | 4.6% |
| Trane Technologies PLC | 4.3% |
| GE Vernova, Inc. | 4.3% |
| Broadcom, Inc. | 4.1% |
| Roper Technologies, Inc. | 3.8% |
| Intuit, Inc. | 3.6% |
| O'Reilly Automotive, Inc. | 3.6% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). As of July 2024, Anant Goel is no longer a portfolio manager of the Fund. As of November 1, 2024, the Fund changed its status as a non-diversified fund to a diversified fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i7cf832a4bb215e65eb7bf40c.jpg)

## Eventide Large Cap Focus Fund - Class A (ETLAX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

## Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETLAX

# Eventide Large Cap Focus Fund

## Class C (ETLCX)

#### Annual Shareholder Report - June 30, 2025
![Image](icaa47c452c1176e511991dd5.jpg)

## Fund Overview
This annual shareholder report contains important information about Eventide Large Cap Focus Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

## What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $205 | 1.94% |

---

## How did the Fund perform during the reporting period?
The Fund's underperformance in Information Technology, Communication Services, Financials, and Real Estate was partly offset by outperformance in Energy, Healthcare, Industrials, Utilities, and Consumer Discretionary. The Fund outperformed in the first half of calendar 2025 due to strong stock selection, particularly within Industrials and Healthcare, and the market's winners broadened beyond the megacap technology companies. We remain focused on the Fund owning companies that create significant economic and societal value through innovation, while also trading at attractive valuations. Visit https://www.eventidefunds.com for more recent performance information.

## How has the Fund performed since inception?

### Total Return Based on $10,000 Investment
![Growth of 10K Chart](i0b0abe528bfacd1b817f4a1c.jpg)

---

| | | |
|:---|:---|:---|
| | **Eventide Large Cap Focus Fund** | **S&P 500<sup>®</sup> Index** |
| **Jun-2022** | $10000 | $10000 |
| **Jun-2023** | $11360 | $11959 |
| **Jun-2024** | $13790 | $14896 |
| **Jun-2025** | $15340 | $17155 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, S&P 500 Total Return Index, which represents the overall domestic equity market.

## **Fund Statistics** 
* Net Assets$163,393,024

* Number of Portfolio Holdings44

* Advisory Fee $817,762

* Portfolio Turnover50%

## Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (6/30/2022)** |
| Eventide Large Cap Focus Fund - Class C | 11.24% | 15.33% |
| S&P 500<sup>®</sup> Index | 15.16% | 19.71% |

---

## What did the Fund invest in?

## Industry Weighting (% of net assets)
![Group By Sector Chart](ic1649bb8a9dd65d11bf4733a.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 1.0% |
| Other Industries | 2.9% |
| Banking | 1.5% |
| Insurance | 1.8% |
| Home Construction | 1.9% |
| Technology Hardware | 2.7% |
| Medical Equipment & Devices | 3.2% |
| Transportation & Logistics | 3.2% |
| Oil & Gas Producers | 3.5% |
| Specialty Finance | 4.6% |
| Biotech & Pharma | 4.8% |
| Technology Services | 5.8% |
| Retail - Discretionary | 7.8% |
| Electric Utilities | 8.3% |
| Electrical Equipment | 8.5% |
| Chemicals | 8.5% |
| Semiconductors | 13.5% |
| Software | 16.5% |

---

## Market Cap Weighting
![Group By Asset Type Chart](ic202987f3ffe5d509ec357bd.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Large Cap | 75.5% |
| Mid Cap | 23.5% |
| Cash/Other | 1.0% |
| Small Cap | 0.0% |

---

## Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| NVIDIA Corporation | 6.4% |
| S&P Global, Inc. | 5.1% |
| Linde PLC | 4.9% |
| American Express Company | 4.6% |
| Trane Technologies PLC | 4.3% |
| GE Vernova, Inc. | 4.3% |
| Broadcom, Inc. | 4.1% |
| Roper Technologies, Inc. | 3.8% |
| Intuit, Inc. | 3.6% |
| O'Reilly Automotive, Inc. | 3.6% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). As of July 2024, Anant Goel is no longer a portfolio manager of the Fund. As of November 1, 2024, the Fund changed its status as a non-diversified fund to a diversified fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](ifce4c50d4a10f41c7791306b.jpg)

## Eventide Large Cap Focus Fund - Class C (ETLCX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

## Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETLCX

# Eventide Large Cap Focus Fund

## Class I (ETLIX)

#### Annual Shareholder Report - June 30, 2025
![Image](i8684b175f27ec67b530a0a99.jpg)

## Fund Overview
This annual shareholder report contains important information about Eventide Large Cap Focus Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

## What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $100 | 0.94% |

---

## How did the Fund perform during the reporting period?
The Fund's underperformance in Information Technology, Communication Services, Financials, and Real Estate was partly offset by outperformance in Energy, Healthcare, Industrials, Utilities, and Consumer Discretionary. The Fund outperformed in the first half of calendar 2025 due to strong stock selection, particularly within Industrials and Healthcare, and the market's winners broadened beyond the megacap technology companies. We remain focused on the Fund owning companies that create significant economic and societal value through innovation, while also trading at attractive valuations. Visit https://www.eventidefunds.com for more recent performance information.

## How has the Fund performed since inception?

### Total Return Based on $10,000 Investment
![Growth of 10K Chart](ica835a916a7bffa6edbc3a13.jpg)

---

| | | |
|:---|:---|:---|
| | **Eventide Large Cap Focus Fund** | **S&P 500<sup>®</sup> Index** |
| **Jun-2022** | $10000 | $10000 |
| **Jun-2023** | $11455 | $11959 |
| **Jun-2024** | $14058 | $14896 |
| **Jun-2025** | $15789 | $17155 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, S&P 500 Total Return Index, which represents the overall domestic equity market.

## **Fund Statistics** 
* Net Assets$163,393,024

* Number of Portfolio Holdings44

* Advisory Fee $817,762

* Portfolio Turnover50%

## Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (6/30/2022)** |
| Eventide Large Cap Focus Fund - Class I | 12.32% | 16.44% |
| S&P 500<sup>®</sup> Index | 15.16% | 19.71% |

---

## What did the Fund invest in?

## Industry Weighting (% of net assets)
![Group By Sector Chart](i65ee1c5997423f3f5f5ff3b2.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 1.0% |
| Other Industries | 2.9% |
| Banking | 1.5% |
| Insurance | 1.8% |
| Home Construction | 1.9% |
| Technology Hardware | 2.7% |
| Medical Equipment & Devices | 3.2% |
| Transportation & Logistics | 3.2% |
| Oil & Gas Producers | 3.5% |
| Specialty Finance | 4.6% |
| Biotech & Pharma | 4.8% |
| Technology Services | 5.8% |
| Retail - Discretionary | 7.8% |
| Electric Utilities | 8.3% |
| Electrical Equipment | 8.5% |
| Chemicals | 8.5% |
| Semiconductors | 13.5% |
| Software | 16.5% |

---

## Market Cap Weighting
![Group By Asset Type Chart](idd4dc58b79e3970309bedabb.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Large Cap | 75.5% |
| Mid Cap | 23.5% |
| Cash/Other | 1.0% |
| Small Cap | 0.0% |

---

## Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| NVIDIA Corporation | 6.4% |
| S&P Global, Inc. | 5.1% |
| Linde PLC | 4.9% |
| American Express Company | 4.6% |
| Trane Technologies PLC | 4.3% |
| GE Vernova, Inc. | 4.3% |
| Broadcom, Inc. | 4.1% |
| Roper Technologies, Inc. | 3.8% |
| Intuit, Inc. | 3.6% |
| O'Reilly Automotive, Inc. | 3.6% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). As of July 2024, Anant Goel is no longer a portfolio manager of the Fund. As of November 1, 2024, the Fund changed its status as a non-diversified fund to a diversified fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i85b78e815634c49bf9f2c914.jpg)

## Eventide Large Cap Focus Fund - Class I (ETLIX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

## Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETLIX

# Eventide Large Cap Focus Fund

## Class N (ETLNX)

#### Annual Shareholder Report - June 30, 2025
![Image](i199de314126d810ad0fd1024.jpg)

## Fund Overview
This annual shareholder report contains important information about Eventide Large Cap Focus Fund for the period of July 1, 2024 to June 30, 2025. **You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836. This report describes changes to the Fund that occurred during the reporting period.**

## What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $121 | 1.14% |

---

## How did the Fund perform during the reporting period?
The Fund's underperformance in Information Technology, Communication Services, Financials, and Real Estate was partly offset by outperformance in Energy, Healthcare, Industrials, Utilities, and Consumer Discretionary. The Fund outperformed in the first half of calendar 2025 due to strong stock selection, particularly within Industrials and Healthcare, and the market's winners broadened beyond the megacap technology companies. We remain focused on the Fund owning companies that create significant economic and societal value through innovation, while also trading at attractive valuations. Visit https://www.eventidefunds.com for more recent performance information.

## How has the Fund performed since inception?

### Total Return Based on $10,000 Investment
![Growth of 10K Chart](i495125d2b29a35c163d5ced3.jpg)

---

| | | |
|:---|:---|:---|
| | **Eventide Large Cap Focus Fund** | **S&P 500<sup>®</sup> Index** |
| **Jun-2022** | $10000 | $10000 |
| **Jun-2023** | $11443 | $11959 |
| **Jun-2024** | $14014 | $14896 |
| **Jun-2025** | $15708 | $17155 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, S&P 500 Total Return Index, which represents the overall domestic equity market.

## **Fund Statistics** 
* Net Assets$163,393,024

* Number of Portfolio Holdings44

* Advisory Fee $817,762

* Portfolio Turnover50%

## Average Annual Total Returns

---

| | | |
|:---|:---|:---|
| | **1 Year** | **Since Inception (6/30/2022)** |
| Eventide Large Cap Focus Fund - Class N | 12.09% | 16.24% |
| S&P 500<sup>®</sup> Index | 15.16% | 19.71% |

---

## What did the Fund invest in?

## Industry Weighting (% of net assets)
![Group By Sector Chart](ic099c49c827a78f324d8e18b.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 1.0% |
| Other Industries | 2.9% |
| Banking | 1.5% |
| Insurance | 1.8% |
| Home Construction | 1.9% |
| Technology Hardware | 2.7% |
| Medical Equipment & Devices | 3.2% |
| Transportation & Logistics | 3.2% |
| Oil & Gas Producers | 3.5% |
| Specialty Finance | 4.6% |
| Biotech & Pharma | 4.8% |
| Technology Services | 5.8% |
| Retail - Discretionary | 7.8% |
| Electric Utilities | 8.3% |
| Electrical Equipment | 8.5% |
| Chemicals | 8.5% |
| Semiconductors | 13.5% |
| Software | 16.5% |

---

## Market Cap Weighting
![Group By Asset Type Chart](i829ca938ba063c687469e332.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Large Cap | 75.5% |
| Mid Cap | 23.5% |
| Cash/Other | 1.0% |
| Small Cap | 0.0% |

---

## Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| NVIDIA Corporation | 6.4% |
| S&P Global, Inc. | 5.1% |
| Linde PLC | 4.9% |
| American Express Company | 4.6% |
| Trane Technologies PLC | 4.3% |
| GE Vernova, Inc. | 4.3% |
| Broadcom, Inc. | 4.1% |
| Roper Technologies, Inc. | 3.8% |
| Intuit, Inc. | 3.6% |
| O'Reilly Automotive, Inc. | 3.6% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). As of July 2024, Anant Goel is no longer a portfolio manager of the Fund. As of November 1, 2024, the Fund changed its status as a non-diversified fund to a diversified fund. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i31e036194ac7833e837bacc8.jpg)

## Eventide Large Cap Focus Fund - Class N (ETLNX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

## Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETLNX

#### Eventide Limited-Term Bond Fund

#### Class A (ETABX)

#### Annual Shareholder Report - June 30, 2025
![Image](ia7e6d6ebb25385edd8bc348c.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Limited-Term Bond Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class A | $82 | 0.80% |

---

# How has the Fund performed over the last ten years?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i6657eb891ae9b15ba6ceecf8.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Limited-Term Bond Fund - with load** | **Bloomberg U.S. 1-5 Year Government/Credit Index** | **Bloomberg U.S. Aggregate Bond Index** |
| **Jun-2015** | $9422 | $10000 | $10000 |
| **Jun-2016** | $9735 | $10263 | $10600 |
| **Jun-2017** | $9787 | $10275 | $10567 |
| **Jun-2018** | $9738 | $10254 | $10525 |
| **Jun-2019** | $10188 | $10802 | $11353 |
| **Jun-2020** | $10626 | $11388 | $12345 |
| **Jun-2021** | $10673 | $11433 | $12304 |
| **Jun-2022** | $10011 | $10839 | $11038 |
| **Jun-2023** | $10125 | $10860 | $10934 |
| **Jun-2024** | $10641 | $11366 | $11222 |
| **Jun-2025** | $11262 | $12095 | $11904 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg 1-5 Year Gov/Credit Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund's performance for the year ended June 30, 2025, was materially impacted by interest rate movements across the yield curve and the performance of corporate bonds relative to treasuries. The Fund's investments slightly underperformed its benchmark net of fees, but outperformed gross of fees during the period. The Fund benefited from an overweight to corporate bonds and a significant underweight to treasury bonds as corporate bonds outperformed treasuries. The Fund's investments in corporate bonds also outperformed the performance of corporate bond allocations within the benchmark. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **10 Years** |
| Eventide Limited-Term Bond Fund - Class A | Eventide Limited-Term Bond Fund - Class A | Eventide Limited-Term Bond Fund - Class A | Eventide Limited-Term Bond Fund - Class A |
| Without Load | 5.84% | 1.17% | 1.80% |
| With Load | -0.20% | -0.02% | 1.20% |
| Bloomberg U.S. 1-5 Year Government/Credit Index | 6.42% | 1.21% | 1.92% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -0.73% | 1.76% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $169206975 |
| Number of Portfolio Holdings | 98 |
| Advisory Fee (net of waivers) | $402987 |
| Portfolio Turnover | 7% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i8b3916623fbfe692c94eb93a.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 3.5% |
| Other Industries | 16.5% |
| Construction Materials | 1.8% |
| Home Construction | 1.9% |
| Machinery | 2.2% |
| Software | 2.5% |
| Single-Family Housing | 2.8% |
| Semiconductors | 3.2% |
| Engineering & Construction | 3.3% |
| Retail - Discretionary | 3.9% |
| Insurance | 4.6% |
| Oil & Gas Producers | 5.1% |
| REIT | 6.0% |
| Banking | 7.4% |
| Government Owned, No Guarantee | 7.8% |
| Government Sponsored | 8.0% |
| Agency Fixed Rate | 8.8% |
| Electric Utilities | 10.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i6232e1e2c57d057eaca1d8e4.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.5% |
| Corporate Bonds | 66.3% |
| Municipal Bonds | 5.7% |
| U.S. Government & Agencies | 25.5% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.8% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.7% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.7% |
| Fannie Mae Pool, 4.500%, due 01/1/40 | 1.6% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.6% |
| Aflac, Inc., 1.125%, due 03/15/26 | 1.6% |
| Royal Bank of Canada, 1.150%, due 07/14/26 | 1.6% |
| Roper Technologies, Inc., 4.200%, due 09/15/28 | 1.6% |
| MidAmerican Energy Company, 3.100%, due 05/1/27 | 1.5% |
| Nasdaq, Inc., 5.350%, due 06/28/28 | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i1c62e41a83db9d67f2601157.jpg)

#### Eventide Limited-Term Bond Fund - Class A (ETABX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETABX

#### Eventide Limited-Term Bond Fund

#### Class C (ETCBX)

#### Annual Shareholder Report - June 30, 2025
![Image](iaf7d8233ee7bcd02a55e7485.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Limited-Term Bond Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class C | $159 | 1.55% |

---

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](ib584dd01b69da83e68f482f7.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Limited-Term Bond Fund** | **Bloomberg U.S. 1-5 Year Government/Credit Index** | **Bloomberg U.S. Aggregate Bond Index** |
| **Dec-2018** | $10000 | $10000 | $10000 |
| **Jun-2019** | $10424 | $10427 | $10708 |
| **Jun-2020** | $10789 | $10993 | $11644 |
| **Jun-2021** | $10749 | $11037 | $11605 |
| **Jun-2022** | $10003 | $10463 | $10411 |
| **Jun-2023** | $10052 | $10483 | $10313 |
| **Jun-2024** | $10481 | $10971 | $10585 |
| **Jun-2025** | $11015 | $11676 | $11228 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg 1-5 Year Gov/Credit Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund's performance for the year ended June 30, 2025, was materially impacted by interest rate movements across the yield curve and the performance of corporate bonds relative to treasuries. The Fund's investments slightly underperformed its benchmark net of fees, but outperformed gross of fees during the period. The Fund benefited from an overweight to corporate bonds and a significant underweight to treasury bonds as corporate bonds outperformed treasuries. The Fund's investments in corporate bonds also outperformed the performance of corporate bond allocations within the benchmark. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **Since Inception (12/14/2018)** |
| Eventide Limited-Term Bond Fund - Class C | 5.10% | 0.41% | 1.49% |
| Bloomberg U.S. 1-5 Year Government/Credit Index | 6.42% | 1.21% | 2.40% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -0.73% | 1.79% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $169206975 |
| Number of Portfolio Holdings | 98 |
| Advisory Fee (net of waivers) | $402987 |
| Portfolio Turnover | 7% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i95c5bbbe6207eb98b6536595.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 3.5% |
| Other Industries | 16.5% |
| Construction Materials | 1.8% |
| Home Construction | 1.9% |
| Machinery | 2.2% |
| Software | 2.5% |
| Single-Family Housing | 2.8% |
| Semiconductors | 3.2% |
| Engineering & Construction | 3.3% |
| Retail - Discretionary | 3.9% |
| Insurance | 4.6% |
| Oil & Gas Producers | 5.1% |
| REIT | 6.0% |
| Banking | 7.4% |
| Government Owned, No Guarantee | 7.8% |
| Government Sponsored | 8.0% |
| Agency Fixed Rate | 8.8% |
| Electric Utilities | 10.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i97e369448074a38f17c235f4.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.5% |
| Corporate Bonds | 66.3% |
| Municipal Bonds | 5.7% |
| U.S. Government & Agencies | 25.5% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.8% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.7% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.7% |
| Fannie Mae Pool, 4.500%, due 01/1/40 | 1.6% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.6% |
| Aflac, Inc., 1.125%, due 03/15/26 | 1.6% |
| Royal Bank of Canada, 1.150%, due 07/14/26 | 1.6% |
| Roper Technologies, Inc., 4.200%, due 09/15/28 | 1.6% |
| MidAmerican Energy Company, 3.100%, due 05/1/27 | 1.5% |
| Nasdaq, Inc., 5.350%, due 06/28/28 | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i279c43e443f831d847cac0cb.jpg)

#### Eventide Limited-Term Bond Fund - Class C (ETCBX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETCBX

#### Eventide Limited-Term Bond Fund

#### Class I (ETIBX)

#### Annual Shareholder Report - June 30, 2025
![Image](i3b9a9ce555b909ffdfc74084.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Limited-Term Bond Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class I | $57 | 0.55% |

---

# How has the Fund performed over the last ten years?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i8fe1585faf8d04d84c771efd.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Limited-Term Bond Fund** | **Bloomberg U.S. 1-5 Year Government/Credit Index** | **Bloomberg U.S. Aggregate Bond Index** |
| **Jun-2015** | $10000 | $10000 | $10000 |
| **Jun-2016** | $10266 | $10263 | $10600 |
| **Jun-2017** | $10253 | $10275 | $10567 |
| **Jun-2018** | $10225 | $10254 | $10525 |
| **Jun-2019** | $10728 | $10802 | $11353 |
| **Jun-2020** | $11219 | $11388 | $12345 |
| **Jun-2021** | $11292 | $11433 | $12304 |
| **Jun-2022** | $10612 | $10839 | $11038 |
| **Jun-2023** | $10767 | $10860 | $10934 |
| **Jun-2024** | $11343 | $11366 | $11222 |
| **Jun-2025** | $12031 | $12095 | $11904 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg 1-5 Year Gov/Credit Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund's performance for the year ended June 30, 2025, was materially impacted by interest rate movements across the yield curve and the performance of corporate bonds relative to treasuries. The Fund's investments slightly underperformed its benchmark net of fees, but outperformed gross of fees during the period. The Fund benefited from an overweight to corporate bonds and a significant underweight to treasury bonds as corporate bonds outperformed treasuries. The Fund's investments in corporate bonds also outperformed the performance of corporate bond allocations within the benchmark. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **10 Years** |
| Eventide Limited-Term Bond Fund - Class I | 6.06% | 1.41% | 1.87% |
| Bloomberg U.S. 1-5 Year Government/Credit Index | 6.42% | 1.21% | 1.92% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -0.73% | 1.76% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $169206975 |
| Number of Portfolio Holdings | 98 |
| Advisory Fee (net of waivers) | $402987 |
| Portfolio Turnover | 7% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i9de26919236f4b89cbb89ba9.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 3.5% |
| Other Industries | 16.5% |
| Construction Materials | 1.8% |
| Home Construction | 1.9% |
| Machinery | 2.2% |
| Software | 2.5% |
| Single-Family Housing | 2.8% |
| Semiconductors | 3.2% |
| Engineering & Construction | 3.3% |
| Retail - Discretionary | 3.9% |
| Insurance | 4.6% |
| Oil & Gas Producers | 5.1% |
| REIT | 6.0% |
| Banking | 7.4% |
| Government Owned, No Guarantee | 7.8% |
| Government Sponsored | 8.0% |
| Agency Fixed Rate | 8.8% |
| Electric Utilities | 10.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](i5963030d364501d1b8096e10.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.5% |
| Corporate Bonds | 66.3% |
| Municipal Bonds | 5.7% |
| U.S. Government & Agencies | 25.5% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.8% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.7% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.7% |
| Fannie Mae Pool, 4.500%, due 01/1/40 | 1.6% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.6% |
| Aflac, Inc., 1.125%, due 03/15/26 | 1.6% |
| Royal Bank of Canada, 1.150%, due 07/14/26 | 1.6% |
| Roper Technologies, Inc., 4.200%, due 09/15/28 | 1.6% |
| MidAmerican Energy Company, 3.100%, due 05/1/27 | 1.5% |
| Nasdaq, Inc., 5.350%, due 06/28/28 | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](icb640db3233ba9d3b846306b.jpg)

#### Eventide Limited-Term Bond Fund - Class I (ETIBX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETIBX

#### Eventide Limited-Term Bond Fund

#### Class N (ETNBX)

#### Annual Shareholder Report - June 30, 2025
![Image](iacaf038569829bd8ba37ac45.jpg)

# Fund Overview
This annual shareholder report contains important information about Eventide Limited-Term Bond Fund for the period of July 1, 2024 to June 30, 2025. You can find additional information about the Fund at **https://www.eventidefunds.com**. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

# What were the Fund's costs for the last year?
(based on a hypothetical $10,000 investment)

---

| | | |
|:---|:---|:---|
| **Class Name** | **Costs of a $10,000 investment** | **Costs paid as a percentage of a $10,000 investment** |
| Class N | $77 | 0.75% |

---

# How has the Fund performed since inception?

# Total Return Based on $10,000 Investment
![Growth of 10K Chart](i91bfb423d0b0dd8d9c85e8fa.jpg)

---

| | | | |
|:---|:---|:---|:---|
| | **Eventide Limited-Term Bond Fund** | **Bloomberg U.S. 1-5 Year Government/Credit Index** | **Bloomberg U.S. Aggregate Bond Index** |
| **Dec-2018** | $10000 | $10000 | $10000 |
| **Jun-2019** | $10464 | $10427 | $10708 |
| **Jun-2020** | $10921 | $10993 | $11644 |
| **Jun-2021** | $10974 | $11037 | $11605 |
| **Jun-2022** | $10287 | $10463 | $10411 |
| **Jun-2023** | $10419 | $10483 | $10313 |
| **Jun-2024** | $10959 | $10971 | $10585 |
| **Jun-2025** | $11595 | $11676 | $11228 |

---

**The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares.** In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US Aggregate Index, which represents the overall domestic bond market. In addition, the strategy benchmark, Bloomberg 1-5 Year Gov/Credit Index, is included as the adviser believes it is more representative of the fund's investment universe.

# How did the Fund perform during the reporting period?
The Fund's performance for the year ended June 30, 2025, was materially impacted by interest rate movements across the yield curve and the performance of corporate bonds relative to treasuries. The Fund's investments slightly underperformed its benchmark net of fees, but outperformed gross of fees during the period. The Fund benefited from an overweight to corporate bonds and a significant underweight to treasury bonds as corporate bonds outperformed treasuries. The Fund's investments in corporate bonds also outperformed the performance of corporate bond allocations within the benchmark. Visit https://www.eventidefunds.com for more recent performance information.

# Average Annual Total Returns

---

| | | | |
|:---|:---|:---|:---|
| | **1 Year** | **5 Years** | **Since Inception (12/14/2018)** |
| Eventide Limited-Term Bond Fund - Class N | 5.80% | 1.20% | 2.29% |
| Bloomberg U.S. 1-5 Year Government/Credit Index | 6.42% | 1.21% | 2.40% |
| Bloomberg U.S. Aggregate Bond Index | 6.08% | -0.73% | 1.79% |

---

# **Fund Statistics** 

---

| | |
|:---|:---|
| Net Assets | $169206975 |
| Number of Portfolio Holdings | 98 |
| Advisory Fee (net of waivers) | $402987 |
| Portfolio Turnover | 7% |

---

# What did the Fund invest in?

# Industry Weighting (% of net assets)
![Group By Sector Chart](i45ada4652e8cdfaa1292baed.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Other Assets in Excess of Liabilities | 3.5% |
| Other Industries | 16.5% |
| Construction Materials | 1.8% |
| Home Construction | 1.9% |
| Machinery | 2.2% |
| Software | 2.5% |
| Single-Family Housing | 2.8% |
| Semiconductors | 3.2% |
| Engineering & Construction | 3.3% |
| Retail - Discretionary | 3.9% |
| Insurance | 4.6% |
| Oil & Gas Producers | 5.1% |
| REIT | 6.0% |
| Banking | 7.4% |
| Government Owned, No Guarantee | 7.8% |
| Government Sponsored | 8.0% |
| Agency Fixed Rate | 8.8% |
| Electric Utilities | 10.7% |

---

# **Asset Weighting (% of total investments)**![Group By Asset Type Chart](ieec8d4d873fd2e4a5e929132.jpg)

---

| | |
|:---|:---|
| **Value** | **Value** |
| Asset Backed Securities | 2.5% |
| Corporate Bonds | 66.3% |
| Municipal Bonds | 5.7% |
| U.S. Government & Agencies | 25.5% |

---

# Top 10 Holdings\* (% of net assets)

---

| | |
|:---|:---|
| Holding Name | % of Net Assets |
| JPMorgan Chase & Company, 6.070%, due 10/22/27 | 1.8% |
| Federal National Mortgage Association, 7.125%, due 01/15/30 | 1.7% |
| Federal National Mortgage Association, 6.625%, due 11/15/30 | 1.7% |
| Fannie Mae Pool, 4.500%, due 01/1/40 | 1.6% |
| Federal National Mortgage Association, 6.250%, due 05/15/29 | 1.6% |
| Aflac, Inc., 1.125%, due 03/15/26 | 1.6% |
| Royal Bank of Canada, 1.150%, due 07/14/26 | 1.6% |
| Roper Technologies, Inc., 4.200%, due 09/15/28 | 1.6% |
| MidAmerican Energy Company, 3.100%, due 05/1/27 | 1.5% |
| Nasdaq, Inc., 5.350%, due 06/28/28 | 1.5% |

---

# \* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

# Material Fund Changes
This is a summary of certain changes to the Fund since July 1, 2024. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2025 at https://www.eventidefunds.com/prospectus or upon request at 1-877-771 EVEN (3836). A new sub-advisory agreement between Eventide Asset Management, LLC and Boyd Watterson Asset Management, LLC was entered on August 30, 2024 as a result of a change of control of Boyd Watterson Asset Management, LLC. There was no increase in fees paid by the Fund as a result of this new agreement. Thomas Hamel is Vice-President of the Trust as of November 18, 2024.

![Image](i7d4ebb3fe7a8068e8403f053.jpg)

#### Eventide Limited-Term Bond Fund - Class N (ETNBX)

#### Annual Shareholder Report - June 30, 2025
![An image of a QR code that, when scanned, navigates the user to the following URL: https://www.eventidefunds.com/](ib9d926eb94ff927d87e56645.jpg)

# Where can I find additional information about the Fund?
Additional information is available on the Fund's website (**https://www.eventidefunds.com**), including its:

* Prospectus

* Financial information

* Holdings

* Proxy voting information

TSR-AR 063025-ETNBX

(b) Not applicable

**Item 2. Code of Ethics.** 

(a) The
 registrant has, as of the end of the period covered by this report, adopted a code of ethics that applies to the registrant's principal
 executive officer, principal financial officer, and principal accounting officer or controller, or persons performing similar functions,
 regardless of whether these individuals are employed by the registrant or a third party.

(b) N/A

(c) During
 the period covered by this report, there were no amendments to any provision of the code of ethics.

(d) During
 the period covered by this report, there were no waivers or implicit waivers of a provision of the code of ethics.

(e) N/A

(f) See
 Item 19(a)(1)

**Item 3. Audit Committee Financial Expert.** 

(a)(1) The registrant's Board of Trustees has determined that it does not have an audit committee financial expert serving on its audit committee. At this time, the registrant believes that the experience provided by each member of the audit committee together offer the registrant adequate oversight for the registrant's level of financial complexity.<br>(a)(2) Not applicable.<br>(a)(3) Not applicable.<br>

**Item 4. Principal Accountant Fees and Services.** 

(a) Audit
 Fees. The aggregate fees billed for each of the last two fiscal years for professional services rendered by the registrant's principal
 accountant for the audit of the registrant's annual financial statements or services that are normally provided by the accountant
 in connection with statutory and regulatory filings or engagements for those fiscal years are as follows:

---

| | | |
|:---|:---|:---|
| Trust Series | 2025 | 2024 |
| Eventide Gilead Fund | 66582 | 76445 |
| Eventide Dividend Growth Fund | 25966 | 17544 |
| Eventide Healthcare & Life Sciences Fund | 31952 | 35578 |
| Eventide Limited Term Bond Fund | 7266 | 6708 |
| Eventide Balanced Fund | 12170 | 10889 |
| Eventide Core Bond Fund | 7131 | 6090 |
| Eventide Exponential Technologies Fund | 6259 | 6373 |
| Eventide Large Cap Focus Fund | 7174 | 4874 |

---

(b) Audit-Related
 Fees. There were no fees billed in each of the last two fiscal years for assurances and related services by the principal accountant that
 are reasonably related to the performance of the audit of the registrant's financial statements and are not reported under paragraph
 (a) of this Item.

(c) Tax
 Fees. The aggregate fees billed in each of the last two fiscal years for professional services rendered by the principal accountant for
 tax compliance are as follows:

---

| | | |
|:---|:---|:---|
| Trust Series | 2025 | 2024 |
| Eventide Gilead Fund | 3062 | 3062 |
| Eventide Dividend Growth Fund | 3062 | 3062 |
| Eventide Healthcare & Life Sciences Fund | 3062 | 3062 |
| Eventide Limited Term Bond Fund | 3062 | 3062 |
| Eventide Balanced Fund | 3062 | 3062 |
| Eventide Core Bond Fund | 3062 | 3062 |
| Eventide Exponential Technologies Fund | 3062 | 3062 |
| Eventide Large Cap Focus Fund | 3062 | 3062 |

---

Preparation of Federal & State income tax returns, assistance with calculation of required income, capital gain and excise distributions and preparation of Federal excise tax returns.

---

| | |
|:---|:---|
| (d) | All Other Fees. The aggregate fees billed in each of the last two fiscal years for products and services provided by the registrant's principal accountant, other than the services reported in paragraphs (a) through (c) of this item were $0 and $0 for the fiscal years ended June 30, 2025 and 2024 respectively. |
| (e)(1) | The audit committee does not have pre-approval policies and procedures. Instead, the audit committee or audit committee chairman approves on a case-by-case basis each audit or non-audit service before the principal accountant is engaged by the registrant. |
| (e)(2) | There were no services described in each of paragraphs (b) through (d) of this Item that were approved by the audit committee pursuant to paragraph (c)(7)(i)(C) of Rule 2-01 of Regulation S-X. |
| (f) | Not applicable. |
| (g) | All non-audit fees billed by the registrant's principal accountant for services rendered to the registrant for the fiscal years ended June 30, 2025 and 2024 respectively are disclosed in (b)-(d) above. There were no audit or non-audit services performed by the registrant's principal accountant for the registrant's adviser. |
| (h) | Not applicable. |
| (i) | Not applicable. |
| (j) | Not applicable. |

---

**Item 5. Audit Committee of Listed Registrants.** 

Not applicable

**Item 6. Investments.** 

The Registrant's schedule of investments in unaffiliated issuers is included in the Financial Statements under Item 7 of this form.

**Item 7. Financial Statements and Financial Highlights for Open-End Management Investment Companies.**

(a)&nbsp;&nbsp;&nbsp;&nbsp;

![(EVENTIDE LOGO)](ev001_v1.jpg)

**ANNUAL**

**FINANCIAL STATEMENTS AND**

**ADDITIONAL INFORMATION**

**Eventide Balanced Fund**

**Eventide Core Bond Fund**

**Eventide Dividend Growth Fund**

**Eventide Exponential Technologies Fund**

**Eventide Gilead Fund**

**Eventide Healthcare & Life Sciences Fund**

**Eventide Large Cap Focus Fund**

**Eventide Limited-Term Bond Fund**

**June 30, 2025**

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 53.0%** |  |
|  | **BANKING - 1.5%** |  |
| 252179 | Huntington Bancshares, Inc. | $4226520 |
| 61206 | Regions Financial Corporation | 1439565 |
|  |  | 5666085 |
|  | **BIOTECH & PHARMA - 1.5%** |  |
| 156165 | Royalty Pharma plc, Class A | 5626625 |
|  | **CHEMICALS - 2.0%** |  |
| 155054 | Element Solutions, Inc. | 3511973 |
| 12656 | Sherwin-Williams Company (The) | 4345565 |
|  |  | 7857538 |
|  | **COMMERCIAL SUPPORT SERVICES - 1.3%** |  |
| 90319 | Rollins, Inc. | 5095798 |
|  | **CONTAINERS & PACKAGING - 1.1%** |  |
| 92239 | International Paper Company | 4319552 |
|  | **DIVERSIFIED INDUSTRIALS - 1.5%** |  |
| 57238 | Pentair PLC | 5876053 |
|  | **ELECTRIC UTILITIES - 4.8%** |  |
| 6987 | Constellation Energy Corporation | 2255124 |
| 74066 | Entergy Corporation | 6156367 |
| 21724 | Public Service Enterprise Group, Inc. | 1828726 |
| 34615 | Southern Company (The) | 3178695 |
| 4170 | Talen Energy Corporation<sup>(a)</sup> | 1212511 |
| 19819 | Vistra Corporation | 3841120 |
|  |  | 18472543 |
|  | **ELECTRICAL EQUIPMENT - 5.5%** |  |
| 8186 | GE Vernova, LLC | 4331622 |
| 84769 | nVent Electric PLC | 6209329 |
| 24016 | Trane Technologies PLC | 10504838 |
|  |  | 21045789 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 53.0% (Continued)** |  |
|  | **FOOD - 0.5%** |  |
| 25539 | McCormick & Company, Inc. | $1936367 |
|  | **GAS & WATER UTILITIES - 0.8%** |  |
| 80131 | NiSource, Inc. | 3232485 |
|  | **HOME CONSTRUCTION - 1.2%** |  |
| 35755 | DR Horton, Inc. | 4609535 |
|  | **INDUSTRIAL REIT - 2.0%** |  |
| 34668 | EastGroup Properties, Inc. | 5793716 |
| 19072 | Prologis, Inc. | 2004849 |
|  |  | 7798565 |
|  | **INDUSTRIAL SUPPORT SERVICES - 1.7%** |  |
| 20779 | Applied Industrial Technologies, Inc. | 4830078 |
| 39120 | Fastenal Company | 1643040 |
|  |  | 6473118 |
|  | **INSTITUTIONAL FINANCIAL SERVICES - 2.8%** |  |
| 24088 | Houlihan Lokey, Inc. | 4334636 |
| 74122 | Nasdaq, Inc. | 6627989 |
|  |  | 10962625 |
|  | **INSURANCE - 2.6%** |  |
| 28806 | Arthur J Gallagher & Company | 9221377 |
| 3827 | Progressive Corporation (The) | 1021273 |
|  |  | 10242650 |
|  | **MACHINERY - 0.6%** |  |
| 14053 | IDEX Corporation | 2467285 |
|  | **MEDICAL EQUIPMENT & DEVICES - 1.6%** |  |
| 25747 | STERIS plc | 6184944 |
|  | **OIL & GAS PRODUCERS - 4.9%** |  |
| 26866 | DT Midstream, Inc. | 2952842 |
| 67378 | EQT Corporation | 3929485 |
| 36035 | Range Resources Corporation | 1465543 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 53.0% (Continued)** |  |
|  | **OIL & GAS PRODUCERS - 4.9% (Continued)** |  |
| 18094 | Targa Resources Corporation | $3149804 |
| 118680 | Williams Companies, Inc. (The) | 7454291 |
|  |  | 18951965 |
|  | **RESIDENTIAL REIT - 1.0%** |  |
| 9748 | AvalonBay Communities, Inc. | 1983718 |
| 29551 | Equity Residential | 1994397 |
|  |  | 3978115 |
|  | **RETAIL - DISCRETIONARY - 1.7%** |  |
| 17210 | Ferguson Enterprises, Inc. | 3747477 |
| 8977 | Lithia Motors, Inc. | 3032610 |
|  |  | 6780087 |
|  | **SEMICONDUCTORS - 2.6%** |  |
| 5060 | KLA Corporation | 4532444 |
| 56674 | Lam Research Corporation | 5516648 |
|  |  | 10049092 |
|  | **SOFTWARE - 3.5%** |  |
| 11603 | Roper Technologies, Inc. | 6577044 |
| 4522 | Tyler Technologies, Inc.<sup>(a)</sup> | 2680822 |
| 17250 | Workday, Inc., Class A<sup>(a)</sup> | 4140000 |
|  |  | 13397866 |
|  | **TECHNOLOGY HARDWARE - 1.9%** |  |
| 15077 | Garmin Ltd. | 3146871 |
| 9969 | Motorola Solutions, Inc. | 4191566 |
|  |  | 7338437 |
|  | **TECHNOLOGY SERVICES - 3.0%** |  |
| 23666 | CDW Corporation | 4226511 |
| 4241 | MSCI, Inc. | 2445954 |
| 15665 | Verisk Analytics, Inc. | 4879648 |
|  |  | 11552113 |
|  | **TRANSPORTATION & LOGISTICS - 0.9%** |  |
| 22153 | Old Dominion Freight Line, Inc. | 3595432 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Shares** |  |  |  |  | **Fair Value** |
|  | **COMMON STOCKS — 53.0% (Continued)** |  |  |  |  |
|  | **WHOLESALE - DISCRETIONARY - 0.5%** |  |  |  |  |
| 5991 | Pool Corporation |  |  |  | $1746257 |
|  | **TOTAL COMMON STOCKS (Cost $159,584,829)** |  |  |  | 205256921 |
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **ASSET BACKED SECURITIES — 1.2%** |  |  |  |  |
|  | **AUTO LOAN — 0.6%** |  |  |  |  |
| 2230000 | CarMax Auto Owner Trust Series 2024-2 D |  | 6.4200 | &nbsp;&nbsp;10/15/30 | 2305759 |
|  | **OTHER ABS — 0.6%** |  |  |  |  |
| 2250000 | PFS Financing Corporation Series C A<sup>(b),(c)</sup> | SOFR30A + 0.800% | 5.1040 | &nbsp;&nbsp;04/17/28 | 2255266 |
|  | **TOTAL ASSET BACKED SECURITIES (Cost $4,544,431)** |  |  |  | 4561025 |
| **Principal<br> Amount ($)** |  |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **COLLATERALIZED MORTGAGE OBLIGATIONS — 0.5%** |  |  |  |  |
|  | **CMBS — 0.5%** |  |  |  |  |
| 1000000 | Freddie Mac Multifamily Structured Pass Through Series KG01 A10 |  | 2.9390 | &nbsp;&nbsp;04/25/29 | 957699 |
| 1000000 | Freddie Mac Multifamily Structured Pass Through Series KG02 A2 |  | 2.4120 | &nbsp;&nbsp;08/25/29 | 937374 |
|  |  |  |  |  | 1895073 |
|  | **TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $2,025,864)** |  |  |  | 1895073 |
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 20.9%** |  |  |  |  |
|  | **BANKING — 2.6%** |  |  |  |  |
| 2300000 | First Horizon Corporation<sup>(c)</sup> | SOFRRATE + 1.766% | 5.5140 | &nbsp;&nbsp;03/07/31 | 2334746 |
| 2225000 | Huntington Bancshares, Inc.<sup>(c)</sup> | SOFRINDX + 1.870% | 5.7090 | &nbsp;&nbsp;02/02/35 | 2275027 |
| 3200000 | JPMorgan Chase & Company<sup>(c)</sup> | SOFRRATE + 1.330% | 6.0700 | &nbsp;&nbsp;10/22/27 | 3270123 |
| 2250000 | M&T Bank Corporation<sup>(c)</sup> | SOFRRATE + 0.930% | 4.8330 | &nbsp;&nbsp;01/16/29 | 2268531 |
|  |  |  |  |  | 10148427 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 20.9% (Continued)** |  |  |  |  |
|  | **COMMERCIAL SUPPORT SERVICES — 0.5%** |  |  |  |  |
| 1790000 | Waste Management, Inc. |  | 4.9500 | &nbsp;&nbsp;07/03/31 | $1838149 |
|  | **CONSTRUCTION MATERIALS — 0.7%** |  |  |  |  |
| 1300000 | Advanced Drainage Systems, Inc.<sup>(b)</sup> |  | 5.0000 | &nbsp;&nbsp;09/30/27 | 1288732 |
| 1250000 | Quikrete Holdings, Inc.<sup>(b)</sup> |  | 6.3750 | &nbsp;&nbsp;03/01/32 | 1288065 |
|  |  |  |  |  | 2576797 |
|  | **CONTAINERS & PACKAGING — 0.2%** |  |  |  |  |
| 1000000 | TriMas Corporation<sup>(b)</sup> |  | 4.1250 | &nbsp;&nbsp;04/15/29 | 950167 |
|  | **ELEC & GAS MARKETING & TRADING — 0.3%** |  |  |  |  |
| 1000000 | Southern Power Company |  | 0.9000 | &nbsp;&nbsp;01/15/26 | 979652 |
|  | **ELECTRIC UTILITIES — 3.1%** |  |  |  |  |
| 1235000 | AES Corporation (The) |  | 1.3750 | &nbsp;&nbsp;01/15/26 | 1211579 |
| 1750000 | Constellation Energy Generation, LLC |  | 6.1250 | &nbsp;&nbsp;01/15/34 | 1886484 |
| 1000000 | Duke Energy Florida, LLC |  | 2.5000 | &nbsp;&nbsp;12/01/29 | 929316 |
| 1000000 | MidAmerican Energy Company |  | 3.1000 | &nbsp;&nbsp;05/01/27 | 984016 |
| 3475000 | National Rural Utilities Cooperative Finance Corporation |  | 1.3500 | &nbsp;&nbsp;03/15/31 | 2926479 |
| 3600000 | NextEra Energy Capital Holdings, Inc. |  | 1.9000 | &nbsp;&nbsp;06/15/28 | 3364379 |
| 1000000 | Wisconsin Power and Light Company |  | 1.9500 | &nbsp;&nbsp;09/16/31 | 858645 |
|  |  |  |  |  | 12160898 |
|  | **ENGINEERING & CONSTRUCTION — 1.4%** |  |  |  |  |
| 1435000 | Installed Building Products, Inc.<sup>(b)</sup> |  | 5.7500 | &nbsp;&nbsp;02/01/28 | 1436426 |
| 2000000 | MasTec, Inc.<sup>(b)</sup> |  | 4.5000 | &nbsp;&nbsp;08/15/28 | 1973438 |
| 2000000 | Quanta Services, Inc. |  | 2.9000 | &nbsp;&nbsp;10/01/30 | 1844180 |
|  |  |  |  |  | 5254044 |
|  | **FORESTRY, PAPER & WOOD PRODUCTS — 0.4%** |  |  |  |  |
| 1775000 | Louisiana-Pacific Corporation<sup>(b)</sup> |  | 3.6250 | &nbsp;&nbsp;03/15/29 | 1687461 |
|  | **HOME & OFFICE PRODUCTS — 0.5%** |  |  |  |  |
| 1910000 | Somnigroup International, Inc.<sup>(b)</sup> |  | 4.0000 | &nbsp;&nbsp;04/15/29 | 1828615 |
|  | **HOME CONSTRUCTION — 0.9%** |  |  |  |  |
| 1850000 | M/I Homes, Inc. |  | 3.9500 | &nbsp;&nbsp;02/15/30 | 1735511 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 20.9% (Continued)** |  |  |  |  |
|  | **HOME CONSTRUCTION — 0.9% (Continued)** |  |  |  |  |
| 1800000 | Patrick Industries, Inc.<sup>(b)</sup> |  | 4.7500 | &nbsp;&nbsp;05/01/29 | $1749114 |
|  |  |  |  |  | 3484625 |
|  | **INDUSTRIAL SUPPORT SERVICES — 0.4%** |  |  |  |  |
| 1700000 | United Rentals North America, Inc. |  | 4.8750 | &nbsp;&nbsp;01/15/28 | 1694108 |
|  | **INSURANCE — 1.9%** |  |  |  |  |
| 1015000 | Aflac, Inc. |  | 1.1250 | &nbsp;&nbsp;03/15/26 | 991622 |
| 2150000 | Assurant, Inc. |  | 3.7000 | &nbsp;&nbsp;02/22/30 | 2046103 |
| 2250000 | Brown & Brown, Inc. |  | 4.5000 | &nbsp;&nbsp;03/15/29 | 2249662 |
| 2000000 | Pacific Life Global Funding II<sup>(b)</sup> |  | 1.3750 | &nbsp;&nbsp;04/14/26 | 1955474 |
|  |  |  |  |  | 7242861 |
|  | **MACHINERY — 0.9%** |  |  |  |  |
| 1900000 | Mueller Water Products, Inc.<sup>(b)</sup> |  | 4.0000 | &nbsp;&nbsp;06/15/29 | 1830319 |
| 1875000 | Xylem, Inc. |  | 1.9500 | &nbsp;&nbsp;01/30/28 | 1774229 |
|  |  |  |  |  | 3604548 |
|  | **OIL & GAS PRODUCERS — 2.0%** |  |  |  |  |
| 2575000 | Cheniere Energy Partners, L.P. |  | 4.5000 | &nbsp;&nbsp;10/01/29 | 2547837 |
| 500000 | ConocoPhillips Company |  | 5.0000 | &nbsp;&nbsp;01/15/35 | 499970 |
| 1750000 | Diamondback Energy, Inc. |  | 3.5000 | &nbsp;&nbsp;12/01/29 | 1674305 |
| 500000 | Diamondback Energy, Inc. |  | 5.1500 | &nbsp;&nbsp;01/30/30 | 511482 |
| 2500000 | Plains All American Pipeline, L.P. / PAA Finance |  | 3.5500 | &nbsp;&nbsp;12/15/29 | 2389670 |
|  |  |  |  |  | 7623264 |
|  | **REAL ESTATE INVESTMENT TRUSTS — 1.1%** |  |  |  |  |
| 1000000 | AvalonBay Communities, Inc. |  | 2.0500 | &nbsp;&nbsp;01/15/32 | 863870 |
| 480000 | HAT Holdings I, LLC / HAT Holdings II, LLC<sup>(b)</sup> |  | 8.0000 | &nbsp;&nbsp;06/15/27 | 500691 |
| 1700000 | Iron Mountain, Inc.<sup>(b)</sup> |  | 6.2500 | &nbsp;&nbsp;01/15/33 | 1749115 |
| 1500000 | Welltower OP, LLC |  | 2.7000 | &nbsp;&nbsp;02/15/27 | 1466445 |
|  |  |  |  |  | 4580121 |
|  | **RETAIL - DISCRETIONARY — 0.9%** |  |  |  |  |
| 1750000 | Asbury Automotive Group, Inc. |  | 4.5000 | &nbsp;&nbsp;03/01/28 | 1727293 |
| 1950000 | Builders FirstSource, Inc.<sup>(b)</sup> |  | 4.2500 | &nbsp;&nbsp;02/01/32 | 1807992 |
|  |  |  |  |  | 3535285 |
|  | **SEMICONDUCTORS — 1.5%** |  |  |  |  |
| 1185000 | Amkor Technology, Inc.<sup>(b)</sup> |  | 6.6250 | &nbsp;&nbsp;09/15/27 | 1188912 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 20.9% (Continued)** |  |  |  |  |
|  | **SEMICONDUCTORS — 1.5% (Continued)** |  |  |  |  |
| 1000000 | Broadcom, Inc. |  | 4.1100 | &nbsp;&nbsp;09/15/28 | $996143 |
| 2800000 | NXP BV / NXP FUNDING, LLC / NXP USA, INC. |  | 2.5000 | &nbsp;&nbsp;05/11/31 | 2473514 |
| 1200000 | Synaptics, Inc.<sup>(b)</sup> |  | 4.0000 | &nbsp;&nbsp;06/15/29 | 1139952 |
|  |  |  |  |  | 5798521 |
|  | **SOFTWARE — 0.6%** |  |  |  |  |
| 2350000 | Roper Technologies, Inc. |  | 4.2000 | &nbsp;&nbsp;09/15/28 | 2341944 |
|  | **TECHNOLOGY SERVICES — 0.3%** |  |  |  |  |
| 1000000 | Verisk Analytics, Inc. |  | 5.7500 | &nbsp;&nbsp;04/01/33 | 1052116 |
|  | **WHOLESALE - CONSUMER STAPLES — 0.7%** |  |  |  |  |
| 2775000 | Sysco Corporation |  | 2.4000 | &nbsp;&nbsp;02/15/30 | 2539153 |
|  | **TOTAL CORPORATE BONDS (Cost $82,367,517)** |  |  |  | 80920756 |
| **Principal<br> Amount ($)** |  |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **MUNICIPAL BONDS — 4.0%** |  |  |  |  |
|  | **COMBINED UTILITIES — 0.4%** |  |  |  |  |
| 1475000 | City of Tacoma, WA Electric System Revenue |  | 5.6410 | &nbsp;&nbsp;01/01/27 | 1495028 |
|  | **COUNTY** — **0.0%<sup>(d)</sup>** |  |  |  |  |
| 150000 | City & County of Honolulu, HI |  | 2.5180 | &nbsp;&nbsp;10/01/26 | 147378 |
|  | **RESOURCE RECOVERY** — **0.0%<sup>(d)</sup>** |  |  |  |  |
| 100000 | City of Napa, CA Solid Waste Revenue |  | 2.3300 | &nbsp;&nbsp;08/01/25 | 99845 |
|  | **SINGLE-FAMILY HOUSING — 3.0%** |  |  |  |  |
| 1685000 | Florida Housing Finance Corporation |  | 5.5610 | &nbsp;&nbsp;07/01/49 | 1615602 |
| 500000 | Illinois Housing Development Authority |  | 5.2440 | &nbsp;&nbsp;04/01/31 | 516125 |
| 500000 | Illinois Housing Development Authority |  | 5.2940 | &nbsp;&nbsp;10/01/31 | 516025 |
| 1255000 | Maryland Department of Housing & Community |  | 5.4630 | &nbsp;&nbsp;03/01/34 | 1281110 |
| 2325000 | Massachusetts Housing Finance Agency |  | 5.8360 | &nbsp;&nbsp;12/01/42 | 2330502 |
| 2245000 | Minnesota Housing Finance Agency |  | 5.5880 | &nbsp;&nbsp;07/01/39 | 2241390 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **MUNICIPAL BONDS — 4.0% (Continued)** |  |  |  |
|  | **SINGLE-FAMILY HOUSING — 3.0% (Continued)** |  |  |  |
| 1715000 | Virginia Housing Development Authority | 4.9140 | &nbsp;&nbsp;04/01/30 | $1755486 |
| 1000000 | Virginia Housing Development Authority | 5.6620 | &nbsp;&nbsp;10/01/39 | 1001255 |
|  |  |  |  | 11257495 |
|  | **STATE — 0.1%** |  |  |  |
| 500000 | State of Oregon | 1.3150 | &nbsp;&nbsp;05/01/27 | 477742 |
|  | **WATER AND SEWER — 0.5%** |  |  |  |
| 2000000 | City of Aurora, CO Water Revenue | 2.0980 | &nbsp;&nbsp;08/01/34 | 1623515 |
| 200000 | City of Los Angeles, CA Wastewater System Revenue | 3.6940 | &nbsp;&nbsp;06/01/32 | 190996 |
|  |  |  |  | 1814511 |
|  | **TOTAL MUNICIPAL BONDS (Cost $15,781,988)** |  |  | 15291999 |
| **Principal<br> Amount ($)** |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 18.8%** |  |  |  |
|  | **AGENCY FIXED RATE — 13.7%** |  |  |  |
| 70385 | Fannie Mae Pool MA2915 | 3.0000 | &nbsp;&nbsp;02/01/27 | 69553 |
| 317972 | Fannie Mae Pool BM5976 | 3.0000 | &nbsp;&nbsp;02/01/47 | 287472 |
| 1221006 | Fannie Mae Pool MA4120 | 2.5000 | &nbsp;&nbsp;09/01/50 | 1024357 |
| 2266864 | Fannie Mae Pool CB2661 | 3.0000 | &nbsp;&nbsp;01/01/52 | 1979890 |
| 2978625 | Fannie Mae Pool MA4600 | 3.5000 | &nbsp;&nbsp;05/01/52 | 2689469 |
| 2271952 | Fannie Mae Pool MA4625 | 3.5000 | &nbsp;&nbsp;06/01/52 | 2051402 |
| 3097078 | Fannie Mae Pool MA4655 | 4.0000 | &nbsp;&nbsp;07/01/52 | 2887233 |
| 2924741 | Fannie Mae Pool MA4805 | 4.5000 | &nbsp;&nbsp;11/01/52 | 2804116 |
| 2756505 | Fannie Mae Pool MA4869 | 5.5000 | &nbsp;&nbsp;01/01/53 | 2766110 |
| 3178183 | Fannie Mae Pool MA4916 | 4.0000 | &nbsp;&nbsp;02/01/53 | 2958412 |
| 1393028 | Fannie Mae Pool FS7751 | 4.0000 | &nbsp;&nbsp;03/01/53 | 1296484 |
| 2301346 | Fannie Mae Pool MA5072 | 5.5000 | &nbsp;&nbsp;06/01/53 | 2305808 |
| 914146 | Fannie Mae Pool FS7279 | 5.0000 | &nbsp;&nbsp;10/01/53 | 899233 |
| 2336477 | Fannie Mae Pool MA5165 | 5.5000 | &nbsp;&nbsp;10/01/53 | 2340406 |
| 2829654 | Fannie Mae Pool CB7331 | 5.5000 | &nbsp;&nbsp;10/01/53 | 2840682 |
| 3020992 | Fannie Mae Pool FS9447 | 6.0000 | &nbsp;&nbsp;12/01/53 | 3082945 |
| 522796 | Freddie Mac Pool ZS9163 | 3.0000 | &nbsp;&nbsp;09/01/33 | 504001 |
| 2360860 | Freddie Mac Pool SB8347 | 4.0000 | &nbsp;&nbsp;01/01/40 | 2309929 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 18.8% (Continued)** |  |  |  |
|  | **AGENCY FIXED RATE — 13.7% (Continued)** |  |  |  |
| 1653889 | Freddie Mac Pool RA5696 | 2.5000 | &nbsp;&nbsp;08/01/51 | $1380930 |
| 2637967 | Freddie Mac Pool SD8214 | 3.5000 | &nbsp;&nbsp;05/01/52 | 2381884 |
| 843912 | Freddie Mac Pool SD8237 | 4.0000 | &nbsp;&nbsp;08/01/52 | 786688 |
| 2933199 | Freddie Mac Pool SD8238 | 4.5000 | &nbsp;&nbsp;08/01/52 | 2811912 |
| 3001092 | Freddie Mac Pool SD8288 | 5.0000 | &nbsp;&nbsp;01/01/53 | 2957111 |
| 3041942 | Freddie Mac Pool SD8329 | 5.0000 | &nbsp;&nbsp;06/01/53 | 2989515 |
| 1665484 | Freddie Mac Pool SD3026 | 5.0000 | &nbsp;&nbsp;06/01/53 | 1639192 |
| 2737614 | Freddie Mac Pool SD8332 | 6.0000 | &nbsp;&nbsp;06/01/53 | 2789684 |
| 287296 | Ginnie Mae II Pool MA3375 | 3.0000 | &nbsp;&nbsp;01/20/46 | 258052 |
|  |  |  |  | 53092470 |
|  | **GOVERNMENT OWNED, NO GUARANTEE — 2.5%** |  |  |  |
| 2750000 | Federal National Mortgage Association | 6.2500 | &nbsp;&nbsp;05/15/29 | 2995591 |
| 1600000 | Federal National Mortgage Association | 7.1250 | &nbsp;&nbsp;01/15/30 | 1820075 |
| 2900000 | Federal National Mortgage Association | 6.6250 | &nbsp;&nbsp;11/15/30 | 3282204 |
| 1500000 | Federal National Mortgage Association | 5.6250 | &nbsp;&nbsp;07/15/37 | 1645966 |
|  |  |  |  | 9743836 |
|  | **GOVERNMENT SPONSORED — 2.6%** |  |  |  |
| 1500000 | Federal Farm Credit Banks Funding Corporation | 4.2800 | &nbsp;&nbsp;12/17/26 | 1496392 |
| 2000000 | Federal Farm Credit Banks Funding Corporation | 4.6700 | &nbsp;&nbsp;12/02/27 | 1999958 |
| 1000000 | Federal Farm Credit Banks Funding Corporation | 4.3750 | &nbsp;&nbsp;02/28/28 | 1016338 |
| 1500000 | Federal Farm Credit Banks Funding Corporation | 4.6250 | &nbsp;&nbsp;04/05/29 | 1545410 |
| 2000000 | Federal Farm Credit Banks Funding Corporation | 4.0000 | &nbsp;&nbsp;04/01/30 | 2015440 |
| 1750000 | Federal Farm Credit Banks Funding Corporation | 4.0000 | &nbsp;&nbsp;01/13/31 | 1757805 |
|  |  |  |  | 9831343 |
|  | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $73,919,367)** |  |  | 72667649 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE BALANCED FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **SHORT-TERM INVESTMENTS — 0.0%<sup>(d)</sup>** |  |
|  | **MONEY MARKET FUNDS - 0.0% <sup>(d)</sup>** |  |
| 116557 | Fidelity Money Market Government Portfolio Class I, 4.18% (Cost $116,557)<sup>(e)</sup> | $116557 |
|  | **TOTAL INVESTMENTS - 98.4% (Cost $338,340,553)** | $380709980 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES- 1.6%** | 6332455 |
|  | **NET ASSETS - 100.0%** | $387042435 |

---

---

| | |
|:---|:---|
| ABS | - Asset Backed Security |
| CMBS | - Collaterized Mortgage Backed Security |
| LLC | - Limited Liability Company |
| L.P. | - Limited Partnership |
| MSCI | - Morgan Stanley Capital International |
| PLC | - Public Limited Company |
| REIT | - Real Estate Investment Trust |
| SOFR30A | United States 30 Day Average SOFR Secured Overnight Financing Rate |
| SOFRINDX | United States SOFR Index |
| SOFRRATE | United States SOFR Secured Overnight Financing Rate |

---

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of June 30, 2025 the total market value of 144A securities is $24,629,739 or 6.4% of net assets.

<sup>(c)</sup> Variable or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying pool of assets.

<sup>(d)</sup> Percentage rounds to less than 0.1%.

<sup>(e)</sup> Rate disclosed is the seven day effective yield as of June 30, 2025.

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE CORE BOND FUND** |
| **SCHEDULE OF INVESTMENTS** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **ASSET BACKED SECURITIES — 2.5%** |  |  |  |  |
|  | **AUTO LOAN — 1.3%** |  |  |  |  |
| 1925000 | CarMax Auto Owner Trust Series 2024-2 D |  | 6.4200 | &nbsp;&nbsp;10/15/30 | $1990397 |
|  | **OTHER ABS — 1.2%** |  |  |  |  |
| 1775000 | PFS Financing Corporation Series C A<sup>(a),(b)</sup> | SOFR30A + 0.800% | 5.1040 | &nbsp;&nbsp;04/17/28 | 1779154 |
|  | **TOTAL ASSET BACKED SECURITIES (Cost $3,755,482)** |  |  |  | 3769551 |
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 47.5%** |  |  |  |  |
|  | **ASSET MANAGEMENT — 0.5%** |  |  |  |  |
| 750000 | Hope Global Investments <sup>(c),(d),(e)</sup> |  | 4.6000 | &nbsp;&nbsp;10/10/28 | 726255 |
|  | **BANKING — 6.1%** |  |  |  |  |
| 1975000 | First Horizon Corporation<sup>(b)</sup> | SOFRRATE + 1.766% | 5.5140 | &nbsp;&nbsp;03/07/31 | 2004836 |
| 1000000 | Huntington Bancshares, Inc. |  | 2.5500 | &nbsp;&nbsp;02/04/30 | 914497 |
| 1400000 | Huntington Bancshares, Inc.<sup>(b)</sup> | SOFRINDX + 1.870% | 5.7090 | &nbsp;&nbsp;02/02/35 | 1431478 |
| 2750000 | JPMorgan Chase & Company<sup>(b)</sup> | SOFRRATE + 1.330% | 6.0700 | &nbsp;&nbsp;10/22/27 | 2810262 |
| 2000000 | M&T Bank Corporation<sup>(b)</sup> | SOFRRATE + 0.930% | 4.8330 | &nbsp;&nbsp;01/16/29 | 2016472 |
|  |  |  |  |  | 9177545 |
|  | **COMMERCIAL SUPPORT SERVICES — 0.7%** |  |  |  |  |
| 1000000 | Waste Management, Inc. |  | 4.9500 | &nbsp;&nbsp;07/03/31 | 1026899 |
|  | **CONSTRUCTION MATERIALS — 0.3%** |  |  |  |  |
| 500000 | Quikrete Holdings, Inc.<sup>(a)</sup> |  | 6.3750 | &nbsp;&nbsp;03/01/32 | 515226 |
|  | **ELECTRIC UTILITIES — 10.8%** |  |  |  |  |
| 1600000 | AES Corporation (The) |  | 5.4500 | &nbsp;&nbsp;06/01/28 | 1633684 |
| 2000000 | Ameren Illinois Company |  | 5.9000 | &nbsp;&nbsp;12/01/52 | 2070086 |
| 1900000 | Constellation Energy Generation, LLC |  | 5.7500 | &nbsp;&nbsp;03/15/54 | 1866144 |
| 2150000 | DTE Electric Company |  | 3.9500 | &nbsp;&nbsp;03/01/49 | 1697077 |
| 2000000 | Duke Energy Florida, LLC |  | 2.5000 | &nbsp;&nbsp;12/01/29 | 1858632 |
| 1000000 | MidAmerican Energy Company |  | 4.2500 | &nbsp;&nbsp;07/15/49 | 815570 |
| 2400000 | National Rural Utilities Cooperative Finance Corporation |  | 1.3500 | &nbsp;&nbsp;03/15/31 | 2021165 |
| 500000 | NextEra Energy Capital Holdings, Inc. |  | 5.0500 | &nbsp;&nbsp;02/28/33 | 504549 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE CORE BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 47.5% (Continued)** |  |  |  |  |
|  | **ELECTRIC UTILITIES — 10.8% (Continued)** |  |  |  |  |
| 1500000 | NextEra Energy Capital Holdings, Inc.<sup>(b)</sup> | US0003M + 2.409% | 4.8000 | &nbsp;&nbsp;12/01/77 | $1440057 |
| 1600000 | Public Service Company of Oklahoma |  | 3.1500 | &nbsp;&nbsp;08/15/51 | 1006715 |
| 1700000 | Wisconsin Public Service Corporation |  | 2.8500 | &nbsp;&nbsp;12/01/51 | 1041241 |
|  |  |  |  |  | 15954920 |
|  | **ENGINEERING & CONSTRUCTION — 3.4%** |  |  |  |  |
| 1000000 | Installed Building Products, Inc.<sup>(a)</sup> |  | 5.7500 | &nbsp;&nbsp;02/01/28 | 1000994 |
| 2000000 | MasTec, Inc.<sup>(a)</sup> |  | 4.5000 | &nbsp;&nbsp;08/15/28 | 1973437 |
| 2275000 | Quanta Services, Inc. |  | 2.9000 | &nbsp;&nbsp;10/01/30 | 2097755 |
|  |  |  |  |  | 5072186 |
|  | **HOME CONSTRUCTION — 0.8%** |  |  |  |  |
| 1275000 | M/I Homes, Inc. |  | 3.9500 | &nbsp;&nbsp;02/15/30 | 1196096 |
|  | **INSTITUTIONAL FINANCIAL SERVICES — 0.8%** |  |  |  |  |
| 1700000 | Nasdaq, Inc. |  | 3.2500 | &nbsp;&nbsp;04/28/50 | 1147136 |
|  | **INSURANCE — 2.3%** |  |  |  |  |
| 1600000 | Assurant, Inc. |  | 3.7000 | &nbsp;&nbsp;02/22/30 | 1522681 |
| 2175000 | Brown & Brown, Inc. |  | 4.9500 | &nbsp;&nbsp;03/17/52 | 1892086 |
|  |  |  |  |  | 3414767 |
|  | **MACHINERY — 1.0%** |  |  |  |  |
| 500000 | Mueller Water Products, Inc.<sup>(a)</sup> |  | 4.0000 | &nbsp;&nbsp;06/15/29 | 481663 |
| 1000000 | Xylem, Inc. |  | 1.9500 | &nbsp;&nbsp;01/30/28 | 946255 |
|  |  |  |  |  | 1427918 |
|  | **OIL & GAS PRODUCERS — 6.7%** |  |  |  |  |
| 2025000 | Cheniere Energy Partners, L.P. |  | 4.5000 | &nbsp;&nbsp;10/01/29 | 2003639 |
| 1000000 | ConocoPhillips Company |  | 5.0000 | &nbsp;&nbsp;01/15/35 | 999940 |
| 2250000 | Diamondback Energy, Inc. |  | 3.5000 | &nbsp;&nbsp;12/01/29 | 2152678 |
| 1000000 | EQT Corporation |  | 5.7500 | &nbsp;&nbsp;02/01/34 | 1034385 |
| 2000000 | Exxon Mobil Corporation |  | 4.1140 | &nbsp;&nbsp;03/01/46 | 1645648 |
| 2250000 | Plains All American Pipeline, L.P. / PAA Finance |  | 3.5500 | &nbsp;&nbsp;12/15/29 | 2150703 |
|  |  |  |  |  | 9986993 |
|  | **REAL ESTATE INVESTMENT TRUSTS — 4.1%** |  |  |  |  |
| 2100000 | American Tower Corporation |  | 4.0500 | &nbsp;&nbsp;03/15/32 | 2010014 |
| 2000000 | Equinix, Inc. |  | 3.9000 | &nbsp;&nbsp;04/15/32 | 1895329 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE CORE BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 47.5% (Continued)** |  |  |  |  |
|  | **REAL ESTATE INVESTMENT TRUSTS — 4.1% (Continued)** |  |  |  |  |
| 358000 | HAT Holdings I, LLC / HAT Holdings II, LLC<sup>(a)</sup> |  | 8.0000 | &nbsp;&nbsp;06/15/27 | $373432 |
| 2000000 | Welltower OP, LLC |  | 3.8500 | &nbsp;&nbsp;06/15/32 | 1899771 |
|  |  |  |  |  | 6178546 |
|  | **RETAIL - DISCRETIONARY — 2.3%** |  |  |  |  |
| 800000 | Asbury Automotive Group, Inc. |  | 4.7500 | &nbsp;&nbsp;03/01/30 | 775068 |
| 1250000 | AutoZone, Inc. |  | 5.1000 | &nbsp;&nbsp;07/15/29 | 1281327 |
| 1500000 | Builders FirstSource, Inc.<sup>(a)</sup> |  | 4.2500 | &nbsp;&nbsp;02/01/32 | 1390763 |
|  |  |  |  |  | 3447158 |
|  | **SEMICONDUCTORS — 2.6%** |  |  |  |  |
| 1175000 | Broadcom, Inc. |  | 4.1100 | &nbsp;&nbsp;09/15/28 | 1170469 |
| 2200000 | NXP BV / NXP Funding, LLC / NXP USA, Inc. |  | 2.5000 | &nbsp;&nbsp;05/11/31 | 1943475 |
| 800000 | Synaptics, Inc.<sup>(a)</sup> |  | 4.0000 | &nbsp;&nbsp;06/15/29 | 759968 |
|  |  |  |  |  | 3873912 |
|  | **SOFTWARE — 2.5%** |  |  |  |  |
| 2000000 | Roper Technologies, Inc. |  | 4.2000 | &nbsp;&nbsp;09/15/28 | 1993144 |
| 1750000 | Workday, Inc. |  | 3.7000 | &nbsp;&nbsp;04/01/29 | 1709660 |
|  |  |  |  |  | 3702804 |
|  | **TECHNOLOGY SERVICES — 1.4%** |  |  |  |  |
| 1950000 | Verisk Analytics, Inc. |  | 5.7500 | &nbsp;&nbsp;04/01/33 | 2051626 |
|  | **WHOLESALE - CONSUMER STAPLES — 1.2%** |  |  |  |  |
| 1875000 | Sysco Corporation |  | 2.4000 | &nbsp;&nbsp;02/15/30 | 1715644 |
|  | **TOTAL CORPORATE BONDS (Cost $71,129,020)** |  |  |  | 70615631 |
| **Principal<br> Amount ($)** |  |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **MUNICIPAL BONDS — 7.8%** |  |  |  |  |
|  | **COMBINED UTILITIES — 0.7%** |  |  |  |  |
| 1000000 | City of Tacoma, WA Electric System Revenue |  | 5.6410 | &nbsp;&nbsp;01/01/27 | 1013578 |
|  | **MULTI-FAMILY HOUSING — 0.1%** |  |  |  |  |
| 100000 | New York State Housing Finance Agency |  | 0.7000 | &nbsp;&nbsp;11/01/25 | 98740 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE CORE BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **MUNICIPAL BONDS — 7.8% (Continued)** |  |  |  |
|  | **SINGLE-FAMILY HOUSING — 5.6%** |  |  |  |
| 1785000 | Florida Housing Finance Corporation | 5.5610 | &nbsp;&nbsp;07/01/49 | $1711483 |
| 1000000 | Illinois Housing Development Authority | 5.6140 | &nbsp;&nbsp;10/01/39 | 1001533 |
| 1825000 | Massachusetts Housing Finance Agency | 5.8360 | &nbsp;&nbsp;12/01/42 | 1829319 |
| 1490000 | Minnesota Housing Finance Agency | 5.9000 | &nbsp;&nbsp;01/01/49 | 1490803 |
| 362508 | Minnesota Housing Finance Agency | 1.5800 | &nbsp;&nbsp;02/01/51 | 265576 |
| 2000000 | Virginia Housing Development Authority | 5.6620 | &nbsp;&nbsp;10/01/39 | 2002510 |
|  |  |  |  | 8301224 |
|  | **STATE — 0.7%** |  |  |  |
| 1250000 | State of Oregon | 2.3370 | &nbsp;&nbsp;11/01/33 | 1067549 |
|  | **WATER AND SEWER — 0.7%** |  |  |  |
| 1500000 | City of Aurora, CO Water Revenue | 2.6260 | &nbsp;&nbsp;08/01/41 | 1095016 |
|  | **TOTAL MUNICIPAL BONDS (Cost $12,423,703)** |  |  | 11576107 |
| **Principal<br> Amount ($)** |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 43.3%** |  |  |  |
|  | **AGENCY FIXED RATE — 28.7%** |  |  |  |
| 738384 | Fannie Mae Pool BO9355 | 3.0000 | &nbsp;&nbsp;03/01/50 | 646727 |
| 1679616 | Fannie Mae Pool MA4120 | 2.5000 | &nbsp;&nbsp;09/01/50 | 1409105 |
| 637127 | Fannie Mae Pool FM4720 | 3.0000 | &nbsp;&nbsp;10/01/50 | 559746 |
| 1689179 | Fannie Mae Pool CA8256 | 2.5000 | &nbsp;&nbsp;12/01/50 | 1404354 |
| 1809630 | Fannie Mae Pool CB0199 | 3.0000 | &nbsp;&nbsp;04/01/51 | 1576063 |
| 1915925 | Fannie Mae Pool MA4379 | 2.5000 | &nbsp;&nbsp;07/01/51 | 1598840 |
| 1207551 | Fannie Mae Pool MA4600 | 3.5000 | &nbsp;&nbsp;05/01/52 | 1090325 |
| 2169508 | Fannie Mae Pool MA4625 | 3.5000 | &nbsp;&nbsp;06/01/52 | 1958903 |
| 1150002 | Fannie Mae Pool MA4700 | 4.0000 | &nbsp;&nbsp;08/01/52 | 1072022 |
| 844073 | Fannie Mae Pool MA4783 | 4.0000 | &nbsp;&nbsp;10/01/52 | 785530 |
| 2104130 | Fannie Mae Pool MA4805 | 4.5000 | &nbsp;&nbsp;11/01/52 | 2017350 |
| 2028000 | Fannie Mae Pool MA4869 | 5.5000 | &nbsp;&nbsp;01/01/53 | 2035068 |
| 1472976 | Fannie Mae Pool MA4916 | 4.0000 | &nbsp;&nbsp;02/01/53 | 1371120 |
| 2092132 | Fannie Mae Pool MA5072 | 5.5000 | &nbsp;&nbsp;06/01/53 | 2096189 |
| 1347454 | Fannie Mae Pool CB7331 | 5.5000 | &nbsp;&nbsp;10/01/53 | 1352705 |
| 1999186 | Fannie Mae Pool FS9447 | 6.0000 | &nbsp;&nbsp;12/01/53 | 2040185 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE CORE BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 43.3% (Continued)** |  |  |  |
|  | **AGENCY FIXED RATE — 28.7% (Continued)** |  |  |  |
| 1160619 | Fannie Mae Pool MA5470 | 5.5000 | &nbsp;&nbsp;09/01/54 | $1161524 |
| 1415299 | Freddie Mac Pool SD8090 | 2.0000 | &nbsp;&nbsp;09/01/50 | 1130567 |
| 1188805 | Freddie Mac Pool SD8122 | 2.5000 | &nbsp;&nbsp;01/01/51 | 995538 |
| 1846319 | Freddie Mac Pool SD8128 | 2.0000 | &nbsp;&nbsp;02/01/51 | 1471423 |
| 947734 | Freddie Mac Pool RA5696 | 2.5000 | &nbsp;&nbsp;08/01/51 | 791320 |
| 1829219 | Freddie Mac Pool SD8206 | 3.0000 | &nbsp;&nbsp;04/01/52 | 1584677 |
| 2079769 | Freddie Mac Pool RA7587 | 3.5000 | &nbsp;&nbsp;06/01/52 | 1882928 |
| 2338025 | Freddie Mac Pool SD8237 | 4.0000 | &nbsp;&nbsp;08/01/52 | 2179488 |
| 2342485 | Freddie Mac Pool SD8238 | 4.5000 | &nbsp;&nbsp;08/01/52 | 2245625 |
| 2329519 | Freddie Mac Pool SD8288 | 5.0000 | &nbsp;&nbsp;01/01/53 | 2295380 |
| 1998990 | Freddie Mac Pool SD8329 | 5.0000 | &nbsp;&nbsp;06/01/53 | 1964538 |
| 999291 | Freddie Mac Pool SD3026 | 5.0000 | &nbsp;&nbsp;06/01/53 | 983515 |
| 977719 | Freddie Mac Pool SD8332 | 6.0000 | &nbsp;&nbsp;06/01/53 | 996316 |
|  |  |  |  | 42697071 |
|  | **GOVERNMENT OWNED, NO GUARANTEE — 8.4%** |  |  |  |
| 2500000 | Federal Home Loan Mortgage Corporation | 6.2500 | &nbsp;&nbsp;07/15/32 | 2837870 |
| 2000000 | Federal National Mortgage Association | 6.2500 | &nbsp;&nbsp;05/15/29 | 2178612 |
| 2250000 | Federal National Mortgage Association | 7.1250 | &nbsp;&nbsp;01/15/30 | 2559481 |
| 2400000 | Federal National Mortgage Association | 6.6250 | &nbsp;&nbsp;11/15/30 | 2716307 |
| 2050000 | Federal National Mortgage Association | 5.6250 | &nbsp;&nbsp;07/15/37 | 2249486 |
|  |  |  |  | 12541756 |
|  | **GOVERNMENT SPONSORED — 6.2%** |  |  |  |
| 1425000 | Federal Farm Credit Banks Funding Corporation | 4.5000 | &nbsp;&nbsp;03/09/29 | 1454364 |
| 2350000 | Federal Farm Credit Banks Funding Corporation | 4.1250 | &nbsp;&nbsp;08/01/29 | 2368570 |
| 1000000 | Federal Farm Credit Banks Funding Corporation | 4.3750 | &nbsp;&nbsp;10/24/29 | 1017615 |
| 1750000 | Federal Farm Credit Banks Funding Corporation | 4.0000 | &nbsp;&nbsp;01/13/31 | 1757805 |
| 1750000 | Federal Farm Credit Banks Funding Corporation | 2.9400 | &nbsp;&nbsp;02/23/32 | 1609062 |
| 1000000 | Federal Farm Credit Banks Funding Corporation | 4.5000 | &nbsp;&nbsp;08/08/33 | 1011170 |
|  |  |  |  | 9218586 |
|  | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $65,112,867)** |  |  | 64457413 |
|  | **TOTAL INVESTMENTS - 101.1% (Cost $152,421,072)** |  |  | $150418702 |
|  | **LIABILITIES IN EXCESS OF OTHER ASSETS - (1.1)%** |  |  | (1648005) |
|  | **NET ASSETS - 100.0%** |  |  | $148770697 |

---

---

| | |
|:---|:---|
| ABS | - Asset Backed Security |
| LLC | - Limited Liability Company |
| L.P. | - Limited Partnership |
| SOFR30A | United States 30 Day Average SOFR Secured Overnight Financing Rate |
| SOFRINDX | United States SOFR Index |
| SOFRRATE | United States SOFR Secured Overnight Financing Rate |
| US0003M | ICE LIBOR USD 3 Month |

---

 <sup>(a)</sup> Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of June 30, 2025, the total market value of 144A securities is $8,274,637 or 5.6% of net assets.

<sup>(b)</sup> Variable or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying pool of assets.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of June 30, 2025, was $726,255, representing 0.5% of net assets.

<sup>(d)</sup> Restricted security. See Note 6 for additional details.

<sup>(e)</sup> Private investment.

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE DIVIDEND GROWTH FUND** |
| **SCHEDULE OF INVESTMENTS** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 97.6%** |  |
|  | **BANKING - 1.5%** |  |
| 1069692 | Huntington Bancshares, Inc. | $17928038 |
|  | **BIOTECH & PHARMA - 1.5%** |  |
| 498527 | Royalty Pharma plc, Class A | 17961928 |
|  | **CHEMICALS - 3.9%** |  |
| 876042 | Element Solutions, Inc. | 19842351 |
| 75894 | Sherwin-Williams Company (The) | 26058964 |
|  |  | 45901315 |
|  | **COMMERCIAL SUPPORT SERVICES - 2.4%** |  |
| 509542 | Rollins, Inc. | 28748360 |
|  | **CONTAINERS & PACKAGING - 1.7%** |  |
| 449411 | International Paper Company | 21045917 |
|  | **DIVERSIFIED INDUSTRIALS - 2.6%** |  |
| 309398 | Pentair PLC | 31762799 |
|  | **ELECTRIC UTILITIES - 8.6%** |  |
| 37206 | Constellation Energy Corporation | 12008609 |
| 409558 | Entergy Corporation | 34042460 |
| 138071 | Public Service Enterprise Group, Inc. | 11622817 |
| 192448 | Southern Company (The) | 17672500 |
| 23872 | Talen Energy Corporation<sup>(a)</sup> | 6941261 |
| 110565 | Vistra Corporation | 21428603 |
|  |  | 103716250 |
|  | **ELECTRICAL EQUIPMENT - 9.9%** |  |
| 47729 | GE Vernova, LLC | 25255800 |
| 423825 | nVent Electric PLC | 31045181 |
| 142596 | Trane Technologies PLC | 62372917 |
|  |  | 118673898 |
|  | **FOOD - 0.9%** |  |
| 135477 | McCormick & Company, Inc. | 10271866 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE DIVIDEND GROWTH FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 97.6% (Continued)** |  |
|  | **GAS & WATER UTILITIES - 1.4%** |  |
| 419246 | NiSource, Inc. | $16912384 |
|  | **HOME CONSTRUCTION - 1.7%** |  |
| 161189 | DR Horton, Inc. | 20780486 |
|  | **INDUSTRIAL REIT - 3.6%** |  |
| 191774 | EastGroup Properties, Inc. | 32049271 |
| 108110 | Prologis, Inc. | 11364523 |
|  |  | 43413794 |
|  | **INDUSTRIAL SUPPORT SERVICES - 1.8%** |  |
| 91181 | Applied Industrial Technologies, Inc. | 21195023 |
|  | **INSTITUTIONAL FINANCIAL SERVICES - 5.6%** |  |
| 159284 | Houlihan Lokey, Inc. | 28663156 |
| 436700 | Nasdaq, Inc. | 39049714 |
|  |  | 67712870 |
|  | **INSURANCE - 4.9%** |  |
| 161368 | Arthur J Gallagher & Company | 51657124 |
| 105222 | RLI Corporation | 7599133 |
|  |  | 59256257 |
|  | **MACHINERY - 1.2%** |  |
| 82273 | IDEX Corporation | 14444671 |
|  | **MEDICAL EQUIPMENT & DEVICES - 4.6%** |  |
| 19974 | Mettler-Toledo International, Inc.<sup>(a)</sup> | 23463857 |
| 135049 | STERIS plc | 32441471 |
|  |  | 55905328 |
|  | **OIL & GAS PRODUCERS - 8.9%** |  |
| 142253 | DT Midstream, Inc. | 15635027 |
| 369337 | EQT Corporation | 21539734 |
| 207239 | Range Resources Corporation | 8428410 |
| 111889 | Targa Resources Corporation | 19477637 |
| 675261 | Williams Companies, Inc. (The) | 42413144 |
|  |  | 107493952 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE DIVIDEND GROWTH FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 97.6% (Continued)** |  |
|  | **RESIDENTIAL REIT - 2.6%** |  |
| 56106 | AvalonBay Communities, Inc. | $11417571 |
| 138476 | Equity LifeStyle Properties, Inc. | 8539815 |
| 169468 | Equity Residential | 11437395 |
|  |  | 31394781 |
|  | **RETAIL - DISCRETIONARY - 6.7%** |  |
| 112880 | Ferguson Enterprises, Inc. | 24579620 |
| 62350 | Group 1 Automotive, Inc. | 27228868 |
| 83570 | Lithia Motors, Inc., Class A | 28231617 |
|  |  | 80040105 |
|  | **SEMICONDUCTORS - 4.7%** |  |
| 28137 | KLA Corporation | 25203436 |
| 324805 | Lam Research Corporation | 31616519 |
|  |  | 56819955 |
|  | **SOFTWARE - 6.4%** |  |
| 64321 | Roper Technologies, Inc. | 36459716 |
| 30987 | Tyler Technologies, Inc.<sup>(a)</sup> | 18370333 |
| 93675 | Workday, Inc., Class A<sup>(a)</sup> | 22482000 |
|  |  | 77312049 |
|  | **TECHNOLOGY HARDWARE - 2.1%** |  |
| 58732 | Motorola Solutions, Inc. | 24694457 |
|  | **TECHNOLOGY SERVICES - 5.4%** |  |
| 131099 | CDW Corporation | 23412970 |
| 27002 | MSCI, Inc. | 15573133 |
| 83727 | Verisk Analytics, Inc. | 26080961 |
|  |  | 65067064 |
|  | **TRANSPORTATION & LOGISTICS - 2.2%** |  |
| 159831 | Old Dominion Freight Line, Inc. | 25940571 |
|  | **WHOLESALE - DISCRETIONARY - 0.8%** |  |
| 31211 | Pool Corporation | 9097382 |
|  | **TOTAL COMMON STOCKS (Cost $966,362,884)** | 1173491500 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE DIVIDEND GROWTH FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 0.3%** |  |  |  |
|  | **ASSET MANAGEMENT — 0.3%** |  |  |  |
| 3250000 | Vision Fund International<sup>(b),(c),(d)</sup> | 5.2600 | &nbsp;&nbsp;11/30/25 | $3248258 |
|  | **TOTAL CORPORATE BONDS (Cost $3,250,000)** |  |  | 3248258 |
| **Shares** |  |  |  | **Fair Value** |
|  | **SHORT-TERM INVESTMENTS — 0.0%<sup>(e)</sup>** |  |  |  |
|  | **MONEY MARKET FUNDS - 0.0% <sup>(e)</sup>** |  |  |  |
| 116934 | Fidelity Money Market Government Portfolio Class I, 4.18% (Cost $116,934)<sup>(f)</sup> |  |  | 116934 |
|  | **TOTAL INVESTMENTS - 97.9% (Cost $969,729,818)** |  |  | $1176856692 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES- 2.1%** |  |  | 25829791 |
|  | **NET ASSETS - 100.0%** |  |  | $1202686483 |

---

---

| | |
|:---|:---|
| LLC | - Limited Liability Company |
| MSCI | - Morgan Stanley Capital International |
| PLC | - Public Limited Company |
| REIT | - Real Estate Investment Trust |

---

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Private investment.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of June 30, 2025, was $3,248,258, representing 0.3% of net assets.

<sup>(d)</sup> Restricted security. See Note 6 for additional details.

<sup>(e)</sup> Percentage rounds to less than 0.1%.

<sup>(f)</sup> Rate disclosed is the seven day effective yield as of June 30, 2025.

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE EXPONENTIAL TECHNOLOGIES FUND** |
| **SCHEDULE OF INVESTMENTS** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 99.1%** |  |
|  | **BIOTECH & PHARMA - 3.7%** |  |
| 70363 | Beta Bionics, Inc.<sup>(a)</sup> | $1024485 |
| 49765 | Guardant Health, Inc.<sup>(a)</sup> | 2589771 |
|  |  | 3614256 |
|  | **E-COMMERCE DISCRETIONARY - 0.5%** |  |
| 11760 | Chewy, Inc., Class A<sup>(a)</sup> | 501211 |
|  | **ELECTRICAL EQUIPMENT - 1.4%** |  |
| 2548 | GE Vernova, LLC | 1348274 |
|  | **INDUSTRIAL INTERMEDIATE PROD - 4.1%** |  |
| 117653 | Xometry, Inc., Class A<sup>(a)</sup> | 3975495 |
|  | **INSTITUTIONAL FINANCIAL SERVICES - 1.2%** |  |
| 8268 | Tradeweb Markets, Inc., Class A | 1210435 |
|  | **LEISURE PRODUCTS - 2.2%** |  |
| 2572 | Axon Enterprise, Inc.<sup>(a)</sup> | 2129462 |
|  | **SEMICONDUCTORS - 11.6%** |  |
| 6918 | Astera Labs, Inc.<sup>(a)</sup> | 625526 |
| 4716 | Broadcom, Inc. | 1299965 |
| 12366 | Entegris, Inc. | 997318 |
| 2861 | Impinj, Inc.<sup>(a)</sup> | 317771 |
| 18511 | Lam Research Corporation | 1801861 |
| 2634 | Monolithic Power Systems, Inc. | 1926455 |
| 19332 | NVIDIA Corporation | 3054262 |
| 1797 | SiTime Corporation<sup>(a)</sup> | 382905 |
| 4044 | Taiwan Semiconductor Manufacturing Company Ltd. - ADR | 915926 |
|  |  | 11321989 |
|  | **SOFTWARE - 50.9%** |  |
| 195165 | Arteris, Inc.<sup>(a)</sup> | 1859922 |
| 44443 | AvePoint, Inc.<sup>(a)</sup> | 858194 |
| 5070 | CommVault Systems, Inc.<sup>(a)</sup> | 883853 |
| 43976 | Confluent, Inc., Class A<sup>(a)</sup> | 1096322 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE EXPONENTIAL TECHNOLOGIES FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 99.1% (Continued)** |  |
|  | **SOFTWARE - 50.9% (Continued)** |  |
| 1059 | Constellation Software, Inc. | $3886248 |
| 1634 | Crowdstrike Holdings, Inc., Class A<sup>(a)</sup> | 832213 |
| 9528 | CyberArk Software Ltd.<sup>(a)</sup> | 3876753 |
| 15964 | DocuSign, Inc.<sup>(a)</sup> | 1243436 |
| 24448 | Dynatrace, Inc.<sup>(a)</sup> | 1349774 |
| 15368 | Gen Digital, Inc. | 451819 |
| 8824 | Global-e Online Ltd.<sup>(a)</sup> | 295957 |
| 11043 | Guidewire Software, Inc.<sup>(a)</sup> | 2600074 |
| 2936 | HubSpot, Inc.<sup>(a)</sup> | 1634266 |
| 2979 | Intuit, Inc. | 2346350 |
| 18002 | Klaviyo, Inc.<sup>(a)</sup> | 604507 |
| 4931 | Manhattan Associates, Inc.<sup>(a)</sup> | 973725 |
| 11001 | Monday.com Ltd.<sup>(a)</sup> | 3459594 |
| 59821 | Nutanix, Inc., Class A<sup>(a)</sup> | 4572718 |
| 4524 | Palo Alto Networks, Inc.<sup>(a)</sup> | 925791 |
| 2688 | Paycom Software, Inc. | 622003 |
| 6406 | Paylocity Holding Corporation<sup>(a)</sup> | 1160703 |
| 84693 | Privia Health Group, Inc.<sup>(a)</sup> | 1947939 |
| 10329 | Procore Technologies, Inc.<sup>(a)</sup> | 706710 |
| 3154 | Roper Technologies, Inc. | 1787813 |
| 8791 | Rubrik, Inc., Class A<sup>(a)</sup> | 787586 |
| 35145 | Samsara, Inc., Class A<sup>(a)</sup> | 1398068 |
| 8332 | SAP S.E. - ADR | 2533761 |
| 462 | ServiceNow, Inc.<sup>(a)</sup> | 474973 |
| 9718 | Shopify, Inc., Class A<sup>(a)</sup> | 1120971 |
| 6984 | Snowflake, Inc., Class A<sup>(a)</sup> | 1562810 |
| 818 | Tyler Technologies, Inc.<sup>(a)</sup> | 484943 |
| 3910 | Zscaler, Inc.<sup>(a)</sup> | 1227505 |
|  |  | 49567301 |
|  | **TECHNOLOGY HARDWARE - 10.8%** |  |
| 25945 | Ciena Corporation<sup>(a)</sup> | 2110107 |
| 9826 | Credo Technology Group Holding Ltd.<sup>(a)</sup> | 909789 |
| 7723 | F5, Inc.<sup>(a)</sup> | 2273033 |
| 64589 | Flex Ltd.<sup>(a)</sup> | 3224283 |
| 7651 | Lumentum Holdings, Inc.<sup>(a)</sup> | 727304 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE EXPONENTIAL TECHNOLOGIES FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Shares** |  |  |  | **Fair Value** |
|  | **COMMON STOCKS — 99.1% (Continued)** |  |  |  |
|  | **TECHNOLOGY HARDWARE - 10.8% (Continued)** |  |  |  |
| 21491 | Pure Storage, Inc., Class A<sup>(a)</sup> |  |  | $1237452 |
|  |  |  |  | 10481968 |
|  | **TECHNOLOGY SERVICES - 12.7%** |  |  |  |
| 156895 | Adyen N.V. - ADR<sup>(a)</sup> |  |  | 2872747 |
| 41130 | ExlService Holdings, Inc.<sup>(a)</sup> |  |  | 1801083 |
| 28008 | Kyndryl Holdings, Inc.<sup>(a)</sup> |  |  | 1175216 |
| 110629 | Remitly Global, Inc.<sup>(a)</sup> |  |  | 2076506 |
| 99020 | Toast, Inc., Class A<sup>(a)</sup> |  |  | 4385596 |
|  |  |  |  | 12311148 |
|  | **TOTAL COMMON STOCKS (Cost $67,440,340)** |  |  | 96461539 |
| **Principal<br> Amount ($)** |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 0.8%** |  |  |  |
|  | **ASSET MANAGEMENT — 0.8%** |  |  |  |
| 750000 | Vision Fund International<sup>(b),(c),(d)</sup> | 5.2600 | &nbsp;&nbsp;11/30/25 | 749598 |
|  | **TOTAL CORPORATE BONDS (Cost $750,000)** |  |  | 749598 |
| **Shares** |  |  |  | **Fair Value** |
|  | **SHORT-TERM INVESTMENTS — 0.0%<sup>(e)</sup>** |  |  |  |
|  | **MONEY MARKET FUNDS - 0.0% <sup>(e)</sup>** |  |  |  |
| 13109 | Fidelity Money Market Government Portfolio, Class I, 4.18% (Cost $13,109)<sup>(f)</sup> |  |  | 13109 |
|  | **TOTAL INVESTMENTS - 99.9% (Cost $68,203,449)** |  |  | $97224246 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES- 0.1%** |  |  | 63042 |
|  | **NET ASSETS - 100.0%** |  |  | $97287288 |

---

---

| | |
|:---|:---|
| ADR | - American Depositary Receipt |
| LLC | - Limited Liability Company |
| LTD | - Limited Company |
| N.V. | - Naamioze Vennootschap |

---

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Private investment.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of June 30, 2025, was $749,598, representing 0.8% of net assets.

<sup>(d)</sup> Restricted security. See Note 6 for additional details.

<sup>(e)</sup> Percentage rounds to less than 0.1%.

<sup>(f)</sup> Rate disclosed is the seven day effective yield as of June 30, 2025.

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE GILEAD FUND** |
| **SCHEDULE OF INVESTMENTS** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 98.4%** |  |
|  | **ADVERTISING & MARKETING - 1.3%** |  |
| 509779 | Trade Desk, Inc. (The), Class A<sup>(a)</sup> | $36698990 |
|  | **BIOTECH & PHARMA - 25.5%** |  |
| 75482 | Argenx S.E. - ADR<sup>(a)</sup> | 41607188 |
| 355738 | Axsome Therapeutics, Inc.<sup>(a)</sup> | 37135490 |
| 425298 | Blueprint Medicines Corporation<sup>(a)</sup> | 54514698 |
| 1344376 | Collegium Pharmaceutical, Inc.<sup>(a)</sup> | 39753198 |
| 2299237 | Guardant Health, Inc.<sup>(a)</sup> | 119652292 |
| 422934 | Insmed, Inc.<sup>(a)</sup> | 42564078 |
| 1430349 | Mirum Pharmaceuticals, Inc.<sup>(a)</sup> | 72790461 |
| 1460906 | Scholar Rock Holding Corporation<sup>(a)</sup> | 51745291 |
| 460684 | TransMedics Group, Inc.<sup>(a)</sup> | 61736263 |
| 376068 | Vaxcyte, Inc.<sup>(a)</sup> | 12225971 |
| 1889627 | Verona Pharma plc - ADR<sup>(a)</sup> | 178720922 |
|  |  | 712445852 |
|  | **COMMERCIAL SUPPORT SERVICES - 2.1%** |  |
| 306479 | Waste Connections, Inc. | 57225759 |
|  | **CONSTRUCTION MATERIALS - 1.6%** |  |
| 166555 | Vulcan Materials Company | 43440875 |
|  | **E-COMMERCE DISCRETIONARY - 1.6%** |  |
| 1039756 | Chewy, Inc., Class A<sup>(a)</sup> | 44314401 |
|  | **ELECTRIC UTILITIES - 2.3%** |  |
| 333361 | Vistra Corporation | 64608695 |
|  | **ELECTRICAL EQUIPMENT - 5.8%** |  |
| 119355 | GE Vernova, LLC | 63156698 |
| 48962 | Rockwell Automation, Inc. | 16263708 |
| 189717 | Trane Technologies PLC | 82984112 |
|  |  | 162404518 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE GILEAD FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 98.4% (Continued)** |  |
|  | **ENGINEERING & CONSTRUCTION - 1.9%** |  |
| 479463 | Frontdoor, Inc.<sup>(a)</sup> | $28259549 |
| 67645 | Quanta Services, Inc. | 25575222 |
|  |  | 53834771 |
|  | **FOOD - 0.6%** |  |
| 460567 | Vital Farms, Inc.<sup>(a)</sup> | 17741041 |
|  | **HOME CONSTRUCTION - 1.0%** |  |
| 211004 | DR Horton, Inc. | 27202636 |
|  | **INDUSTRIAL INTERMEDIATE PROD - 3.6%** |  |
| 3013657 | Xometry, Inc., Class A<sup>(a)</sup> | 101831470 |
|  | **INDUSTRIAL SUPPORT SERVICES - 5.2%** |  |
| 690508 | Fastenal Company | 29001336 |
| 519570 | RB Global, Inc. | 55173138 |
| 79189 | United Rentals, Inc. | 59660993 |
|  |  | 143835467 |
|  | **LEISURE PRODUCTS - 1.9%** |  |
| 64205 | Axon Enterprise, Inc.<sup>(a)</sup> | 53157888 |
|  | **MACHINERY - 0.5%** |  |
| 108663 | Xylem, Inc. | 14056646 |
|  | **MEDICAL EQUIPMENT & DEVICES - 6.3%** |  |
| 2766154 | Beta Bionics, Inc.<sup>(a),(b),(c),(e)</sup> | 40275202 |
| 180000 | Beta Bionics, Inc.<sup>(a)</sup> | 2620800 |
| 57024 | Intuitive Surgical, Inc.<sup>(a)</sup> | 30987412 |
| 464252 | iRhythm Technologies, Inc.<sup>(a)</sup> | 71476238 |
| 25043 | Mettler-Toledo International, Inc.<sup>(a)</sup> | 29418513 |
|  |  | 174778165 |
|  | **OIL & GAS PRODUCERS - 2.7%** |  |
| 151035 | Cheniere Energy, Inc. | 36780043 |
| 214336 | Targa Resources Corporation | 37311611 |
|  |  | 74091654 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE GILEAD FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 98.4% (Continued)** |  |
|  | **RETAIL - DISCRETIONARY - 3.4%** |  |
| 86692 | Lithia Motors, Inc. | $29286291 |
| 121288 | Lowe's Companies, Inc. | 26910169 |
| 450495 | O'Reilly Automotive, Inc.<sup>(a)</sup> | 40603113 |
|  |  | 96799573 |
|  | **SEMICONDUCTORS - 7.6%** |  |
| 65539 | ASML Holding N.V. | 52522299 |
| 519244 | Lam Research Corporation | 50543211 |
| 586648 | Lattice Semiconductor Corporation<sup>(a)</sup> | 28739886 |
| 39318 | Monolithic Power Systems, Inc. | 28756399 |
| 110283 | NVIDIA Corporation | 17423611 |
| 151204 | SiTime Corporation<sup>(a)</sup> | 32218548 |
|  |  | 210203954 |
|  | **SOFTWARE - 12.6%** |  |
| 44414 | Crowdstrike Holdings, Inc., Class A<sup>(a)</sup> | 22620494 |
| 45656 | CyberArk Software Ltd.<sup>(a)</sup> | 18576513 |
| 342996 | Datadog, Inc., Class A<sup>(a)</sup> | 46074653 |
| 1979930 | Evolent Health, Inc., Class A<sup>(a)</sup> | 22294012 |
| 1205139 | Global-e Online Ltd.<sup>(a)</sup> | 40420362 |
| 80944 | HubSpot, Inc.<sup>(a)</sup> | 45055859 |
| 129906 | Monday.com Ltd.<sup>(a)</sup> | 40852839 |
| 564653 | Nutanix, Inc., Class A<sup>(a)</sup> | 43162075 |
| 121998 | Palo Alto Networks, Inc.<sup>(a)</sup> | 24965671 |
| 86425 | Roper Technologies, Inc. | 48989148 |
|  |  | 353011626 |
|  | **TECHNOLOGY SERVICES - 8.6%** |  |
| 33778 | Adyen N.V.<sup>(a)</sup> | 62001926 |
| 351008 | ExlService Holdings, Inc.<sup>(a)</sup> | 15370640 |
| 7718 | Fair Isaac Corporation<sup>(a)</sup> | 14108195 |
| 1317855 | Remitly Global, Inc.<sup>(a)</sup> | 24736138 |
| 2352452 | Toast, Inc., Class A<sup>(a)</sup> | 104190100 |
| 63720 | Verisk Analytics, Inc. | 19848780 |
|  |  | 240255779 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE GILEAD FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Shares** |  |  |  | **Fair Value** |
|  | **COMMON STOCKS — 98.4% (Continued)** |  |  |  |
|  | **TRANSPORTATION & LOGISTICS - 2.3%** |  |  |  |
| 390981 | Old Dominion Freight Line, Inc. |  |  | $63456216 |
|  | **TOTAL COMMON STOCKS (Cost $1,542,650,027)** |  |  | 2745395976 |
| **Shares** |  |  |  | **Fair Value** |
|  | **CONTINGENT VALUE RIGHTS — 0.2%** |  |  |  |
|  | **BIOTECH & PHARMA - 0.2%** |  |  |  |
| 3982940 | Peloton Therapeutics, Inc. - CVR<sup>(a),(c),(d),(e),(f)</sup> |  |  | 4493951 |
|  | **TOTAL CONTINGENT VALUE RIGHTS (Cost $–)** |  |  | 4493951 |
| **Principal<br> Amount ($)** |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 1.1%** |  |  |  |
|  | **ASSET MANAGEMENT — 1.1%** |  |  |  |
| 2000000 | Hope Global Investments<sup>(c),(d),(e)</sup> | 4.0000 | &nbsp;&nbsp;01/07/28 | 1930976 |
| 5000000 | Vision Fund International<sup>(c),(d),(e)</sup> | 5.9030 | &nbsp;&nbsp;09/19/25 | 5000000 |
| 9000000 | Vision Fund International<sup>(c),(d),(e)</sup> | 5.2600 | &nbsp;&nbsp;11/30/25 | 8995176 |
| 5000000 | Vision Fund International<sup>(c),(d),(e)</sup> | 3.1500 | &nbsp;&nbsp;12/15/25 | 4946960 |
| 5000000 | Vision Fund International<sup>(c),(d),(e)</sup> | 3.2230 | &nbsp;&nbsp;12/15/26 | 4848285 |
| 5000000 | Vision Fund International<sup>(c),(d),(e),(f)</sup> | 5.5000 | &nbsp;&nbsp;06/30/28 | 5000000 |
|  |  |  |  | 30721397 |
|  | **TOTAL CORPORATE BONDS (Cost $31,000,000)** |  |  | 30721397 |
| **Shares** |  |  |  | **Fair Value** |
|  | **SHORT-TERM INVESTMENTS — 0.2%** |  |  |  |
|  | **MONEY MARKET FUNDS - 0.2%** |  |  |  |
| 5443531 | Fidelity Money Market Government Portfolio, Class I, 4.18% (Cost $5,443,531)<sup>(g)</sup> | Fidelity Money Market Government Portfolio, Class I, 4.18% (Cost $5,443,531)<sup>(g)</sup> | Fidelity Money Market Government Portfolio, Class I, 4.18% (Cost $5,443,531)<sup>(g)</sup> | 5443531 |
|  | **TOTAL INVESTMENTS - 99.9% (Cost $1,579,093,558)** |  |  | $2786054855 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES- 0.1%** |  |  | 4177525 |
|  | **NET ASSETS - 100.0%** |  |  | $2790232380 |

---

---

| | |
|:---|:---|
| ADR | - American Depositary Receipt |
| CVR | - Contingent Value Rights |
| LLC | - Limited Liability Company |
| LTD | - Limited Company |
| N.V. | - Naamioze Vennootschap |
| PLC | - Public Limited Company |

---

 <sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Affiliated Company – Eventide Gilead Fund holds in excess of 5% of outstanding voting securities of this security.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of June 30, 2025 was $75,490,550, representing 2.7% of net assets.

<sup>(d)</sup> Private investment.

<sup>(e)</sup> Restricted security. See Note 6 for additional details.

<sup>(f)</sup> The value of this security has been determined using significant unobservable inputs in good faith under policies of the Board of Trustees.

<sup>(g)</sup> Rate disclosed is the seven day effective yield as of June 30, 2025.

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE HEALTHCARE & LIFE SCIENCES FUND** |
| **SCHEDULE OF INVESTMENTS** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 93.5%** |  |
|  | **BIOTECH & PHARMA - 69.3%** |  |
| 728437 | ACADIA Pharmaceuticals, Inc.<sup>(a)</sup> | $15712386 |
| 200000 | Akero Therapeutics, Inc.<sup>(a)</sup> | 10672000 |
| 124968 | Alnylam Pharmaceuticals, Inc.<sup>(a)</sup> | 40750815 |
| 49222 | Argenx S.E. - ADR<sup>(a)</sup> | 27132151 |
| 375924 | Avidity Biosciences, Inc.<sup>(a)</sup> | 10676242 |
| 366719 | Axsome Therapeutics, Inc.<sup>(a)</sup> | 38281796 |
| 300000 | Biohaven Ltd.<sup>(a)</sup> | 4233000 |
| 299790 | Blueprint Medicines Corporation<sup>(a)</sup> | 38427082 |
| 384231 | Bridgebio Pharma, Inc.<sup>(a)</sup> | 16591095 |
| 1356186 | Celldex Therapeutics, Inc.<sup>(a)</sup> | 27598385 |
| 1285217 | Collegium Pharmaceutical, Inc.<sup>(a)</sup> | 38003867 |
| 249500 | Cytokinetics, Inc.<sup>(a)</sup> | 8243480 |
| 308030 | Disc Medicine, Inc.<sup>(a)</sup> | 16313269 |
| 568310 | Edgewise Therapeutics, Inc.<sup>(a)</sup> | 7450544 |
| 1088200 | Guardant Health, Inc.<sup>(a)</sup> | 56629928 |
| 771844 | Ideaya Biosciences, Inc.<sup>(a)</sup> | 16224161 |
| 769846 | Insmed, Inc.<sup>(a)</sup> | 77477300 |
| 562990 | Kymera Therapeutics, Inc.<sup>(a)</sup> | 24568884 |
| 396160 | Metsera, Inc.<sup>(a)</sup> | 11270752 |
| 1194573 | Mirum Pharmaceuticals, Inc.<sup>(a)</sup> | 60791819 |
| 951433 | ORIC Pharmaceuticals, Inc.<sup>(a)</sup> | 9657045 |
| 372229 | REVOLUTION Medicines, Inc.<sup>(a)</sup> | 13694305 |
| 1439533 | Scholar Rock Holding Corporation<sup>(a)</sup> | 50988259 |
| 1414081 | Syndax Pharmaceuticals, Inc.<sup>(a)</sup> | 13242869 |
| 954531 | TG Therapeutics, Inc.<sup>(a)</sup> | 34353571 |
| 82628 | TransMedics Group, Inc.<sup>(a)</sup> | 11072978 |
| 1381324 | Trevi Therapeutics, Inc.<sup>(a)</sup> | 7555842 |
| 47241 | United Therapeutics Corporation<sup>(a)</sup> | 13574701 |
| 468780 | Vaxcyte, Inc.<sup>(a)</sup> | 15240038 |
| 809112 | Verona Pharma plc - ADR<sup>(a)</sup> | 76525813 |
|  |  | 792954377 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE HEALTHCARE & LIFE SCIENCES FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Shares** |  |  |  | **Fair Value** |
|  | **COMMON STOCKS — 93.5% (Continued)** |  |  |  |
|  | **MEDICAL EQUIPMENT & DEVICES - 20.7%** |  |  |  |
| 1768644 | Beta Bionics, Inc.<sup>(a),(b),(c),(f)</sup> |  |  | $25751457 |
| 120000 | Beta Bionics, Inc.<sup>(a)</sup> |  |  | 1747200 |
| 272323 | Bruker Corporation |  |  | 11219708 |
| 1389427 | Celcuity, Inc.<sup>(a)</sup> |  |  | 18548850 |
| 565546 | Exact Sciences Corporation<sup>(a)</sup> |  |  | 30053114 |
| 220740 | Glaukos Corporation<sup>(a)</sup> |  |  | 22800235 |
| 156658 | Inspire Medical Systems, Inc.<sup>(a)</sup> |  |  | 20329509 |
| 223127 | iRhythm Technologies, Inc.<sup>(a)</sup> |  |  | 34352633 |
| 693008 | Kestra Medical Technologies Inc<sup>(a),(c),(f)</sup> |  |  | 11490073 |
| 367549 | Kestra Medical Technologies, Inc.<sup>(a)</sup> |  |  | 6093962 |
| 468476 | PROCEPT BioRobotics Corporation<sup>(a)</sup> |  |  | 26984218 |
| 77711 | Repligen Corporation<sup>(a)</sup> |  |  | 9665694 |
| 684782 | Veracyte, Inc.<sup>(a)</sup> |  |  | 18509657 |
|  |  |  |  | 237546310 |
|  | **SOFTWARE - 3.5%** |  |  |  |
| 2070815 | Evolent Health, Inc., Class A<sup>(a)</sup> |  |  | 23317377 |
| 737694 | Privia Health Group, Inc.<sup>(a)</sup> |  |  | 16966962 |
|  |  |  |  | 40284339 |
|  | **TOTAL COMMON STOCKS (Cost $839,655,275)** |  |  | 1070785026 |
| **Shares** |  |  |  | **Fair Value** |
|  | **CONTINGENT VALUE RIGHTS — 0.2%** |  |  |  |
|  | **BIOTECH & PHARMA - 0.2%** |  |  |  |
| 1528871 | Peloton Therapeutics, Inc. - CVR<sup>(a),(c),(d),(e),(f)</sup> |  |  | 1725025 |
|  | **TOTAL CONTINGENT VALUE RIGHTS (Cost $–)** |  |  | 1725025 |
| **Shares** |  | **Coupon Rate** | **Maturity Date** | **Fair Value** |
|  | **PRIVATE INVESTMENTS — 3.4%** |  |  |  |
|  | **BIOTECH & PHARMA - 2.5%** |  |  |  |
| 20482289 | Avalyn Pharma Inc. Series C1 <sup>(a),(c),(d),(e),(f)</sup> | 8.00% |  | 16310046 |
| 4060259 | Avalyn Pharma Inc. Series D1<sup>(a),(c),(d),(e),(f)</sup> | 8.00% |  | 3233184 |
| 295276 | BioSplice Therapeutics, Inc. Series B-1<sup>(a),(c),(d),(e),(f)</sup> |  |  |  |
| 5000000 | Casma Therapeutics, Inc. Series B1<sup>(a),(b),(c),(d),(e),(f)</sup> |  |  | 349500 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE HEALTHCARE & LIFE SCIENCES FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Shares** |  | **Coupon Rate** | **Maturity Date** | **Fair Value** |
|  | **PRIVATE INVESTMENTS — 3.4% (Continued)** |  |  |  |
|  | **BIOTECH & PHARMA - 2.5% (Continued)** |  |  |  |
| 5000000 | Casma Therapeutics, Inc. Series B2<sup>(a),(b),(c),(d),(e),(f)</sup> |  |  | $349500 |
| 1820413 | Casma Therapeutics, Inc. Series C1<sup>(a),(b),(c),(d),(e),(f)</sup> |  |  | 127247 |
| 2479882 | Casma Therapeutics, Inc. Series C2<sup>(a),(b),(c),(d),(e),(f)</sup> |  |  | 173344 |
| 1017770 | Evida BioSciences, Inc. <sup>(a),(b),(c),(d),(e),(f)</sup> |  |  | 702261 |
| 1097561 | Flare Therapeutics, Inc. Series A<sup>(a),(c),(d),(e),(f)</sup> |  |  | 1503659 |
| 902439 | Flare Therapeutics, Inc. Series A2<sup>(a),(c),(d),(e),(f)</sup> |  |  | 1236341 |
| 1952962 | Flare Therapeutics, Inc. Series B<sup>(a),(c),(d),(e),(f)</sup> |  |  | 2870854 |
| 930436 | Freenome Holdings, Inc. Series D<sup>(a),(c),(d),(e),(f)</sup> | 6.00% |  | 769378 |
| 133941 | Freenome Holdings, Inc. Series F<sup>(a),(c),(d),(e),(f)</sup> | 6.00% |  | 110756 |
| 5000000 | Goldfinch Biopharma, Inc. Series A<sup>(a),(b),(c),(d),(e),(f)</sup> | $0.08 |  |  |
| 8474576 | Goldfinch Biopharma, Inc. Series B<sup>(a),(b),(c),(d),(e),(f)</sup> | $0.0944 |  |  |
| 4237288 | Goldfinch Biopharma, Inc. Series B2<sup>(a),(b),(c),(d),(e),(f)</sup> | $0.0944 |  |  |
| 763319 | Kojin Therapeutics, Inc. Series A-1<sup>(a),(c),(d),(e),(f)</sup> | 3.00% |  |  |
| 763319 | Kojin Therapeutics, Inc. Series A-2 <sup>(a),(c),(d),(e),(f)</sup> | 3.00% |  |  |
| 1489958 | Shoreline Biosciences Series B<sup>(a),(c),(d),(e),(f)</sup> | 8.00% |  | 1643813 |
|  |  |  |  | 29379883 |
|  | **MEDICAL EQUIPMENT & DEVICES - 0.9%** |  |  |  |
| 15450219 | Kardium Inc. Series D-8 <sup>(a),(c),(d),(e),(f)</sup> | 8.00% |  | 10000000 |
|  | **TOTAL PRIVATE INVESTMENTS (Cost $103,754,578)** |  |  | 39379883 |
| **Principal<br> Amount ($)** |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CONVERTIBLE BONDS — 0.0%<sup>(g)</sup>** |  |  |  |
|  | **BIOTECH & PHARMA** — **0.0%<sup>(g)</sup>** |  |  |  |
| 3500000 | Biosplice Therapeutics Inc. Series C PIK<sup>(c),(d),(e),(f)</sup> | 10.50 | &nbsp;&nbsp;03/12/26 | 242533 |
|  | **TOTAL CONVERTIBLE BONDS (Cost $3,500,000)** |  |  | 242533 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE HEALTHCARE & LIFE SCIENCES FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Shares** |  | **Expiration Date** | **Exercise Price** | **Exercise Price** | **Fair Value** |
|  | **WARRANT — 0.0%<sup>(g)</sup>** |  |  |  |  |
|  | **BIOTECH & PHARMA - 0.0% <sup>(g)</sup>** |  |  |  |  |
| 106490 | Biosplice Therapeutics, Inc. Series C Warrant<sup>(a),(c),(d),(e),(f)</sup> | 09/12/27 | $| 0.98 | $— |
|  | **TOTAL WARRANT (Cost $–)** |  |  |  |  |
| **Shares** |  |  |  |  | **Fair Value** |
|  | **SHORT-TERM INVESTMENTS — 0.3%** |  |  |  |  |
|  | **MONEY MARKET FUNDS - 0.3%** |  |  |  |  |
| 3554866 | Fidelity Money Market Government Portfolio, Class I, 4.18% (Cost $3,554,866)<sup>(h)</sup> | Fidelity Money Market Government Portfolio, Class I, 4.18% (Cost $3,554,866)<sup>(h)</sup> | Fidelity Money Market Government Portfolio, Class I, 4.18% (Cost $3,554,866)<sup>(h)</sup> | Fidelity Money Market Government Portfolio, Class I, 4.18% (Cost $3,554,866)<sup>(h)</sup> | 3554866 |
|  | **TOTAL INVESTMENTS - 97.4% (Cost $950,464,719)** |  |  |  | $1115687333 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES- 2.6%** |  |  |  | 30182234 |
|  | **NET ASSETS - 100.0%** |  |  |  | $1145869567 |

---

---

| | |
|:---|:---|
| ADR | - American Depositary Receipt |
| CVR | - Contingent Value Rights |
| LTD | - Limited Company |
| PIK | - Payment in Kind |
| PLC | - Public Limited Company |

---

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Affiliated company – Eventide Healthcare & Life Sciences Fund holds in excess of 5% of outstanding voting securities of this security.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of June 30, 2025, was $78,588,971, representing 6.9% of net assets.

<sup>(d)</sup> The value of this security has been determined using significant unobservable inputs in good faith under policies of the Board of Trustees.

<sup>(e)</sup> Private investment.

<sup>(f)</sup> Restricted security. See Note 6 for additional details.

<sup>(g)</sup> Percentage rounds to less than 0.1%.

<sup>(h)</sup> Rate disclosed is the seven day effective yield as of June 30, 2025.

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE LARGE CAP FOCUS FUND** |
| **SCHEDULE OF INVESTMENTS** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 99.0%** |  |
|  | **BANKING - 1.5%** |  |
| 142022 | Huntington Bancshares, Inc. | $2380289 |
|  | **BIOTECH & PHARMA - 4.8%** |  |
| 4261 | Amgen, Inc. | 1189714 |
| 2514 | Eli Lilly & Company | 1959738 |
| 131755 | Royalty Pharma plc, Class A | 4747133 |
|  |  | 7896585 |
|  | **CHEMICALS - 8.5%** |  |
| 5325 | Air Products and Chemicals, Inc. | 1501970 |
| 17030 | Linde PLC | 7990135 |
| 12924 | Sherwin-Williams Company (The) | 4437585 |
|  |  | 13929690 |
|  | **COMMERCIAL SUPPORT SERVICES - 1.2%** |  |
| 7786 | Republic Services, Inc. | 1920105 |
|  | **CONTAINERS & PACKAGING - 0.9%** |  |
| 30275 | International Paper Company | 1417778 |
|  | **ELECTRIC UTILITIES - 8.3%** |  |
| 12613 | Constellation Energy Corporation | 4070972 |
| 23151 | Entergy Corporation | 1924311 |
| 22889 | Public Service Enterprise Group, Inc. | 1926796 |
| 62290 | Southern Company (The) | 5720091 |
|  |  | 13642170 |
|  | **ELECTRICAL EQUIPMENT - 8.5%** |  |
| 13182 | GE Vernova, LLC | 6975255 |
| 15993 | Trane Technologies PLC | 6995499 |
|  |  | 13970754 |
|  | **HOME CONSTRUCTION - 1.9%** |  |
| 23622 | DR Horton, Inc. | 3045348 |
|  | **INDUSTRIAL REIT - 0.8%** |  |
| 12954 | Prologis, Inc. | 1361725 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE LARGE CAP FOCUS FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 99.0% (Continued)** |  |
|  | **INSURANCE - 1.8%** |  |
| 9291 | Arthur J Gallagher & Company | $2974235 |
|  | **MEDICAL EQUIPMENT & DEVICES - 3.2%** |  |
| 23226 | Boston Scientific Corporation<sup>(a)</sup> | 2494705 |
| 2315 | Mettler-Toledo International, Inc.<sup>(a)</sup> | 2719476 |
|  |  | 5214181 |
|  | **OIL & GAS PRODUCERS - 3.5%** |  |
| 91759 | Williams Companies, Inc. (The) | 5763383 |
|  | **RETAIL - DISCRETIONARY - 7.8%** |  |
| 8880 | Ferguson Enterprises, Inc. | 1933620 |
| 8655 | Home Depot, Inc. (The) | 3173269 |
| 8355 | Lowe's Companies, Inc. | 1853724 |
| 64816 | O'Reilly Automotive, Inc.<sup>(a)</sup> | 5841866 |
|  |  | 12802479 |
|  | **SEMICONDUCTORS - 13.5%** |  |
| 4180 | Advanced Micro Devices, Inc.<sup>(a)</sup> | 593142 |
| 1366 | ASML Holding N.V. | 1094699 |
| 24319 | Broadcom, Inc. | 6703532 |
| 2213 | KLA Corporation | 1982273 |
| 12765 | Lam Research Corporation | 1242545 |
| 65718 | NVIDIA Corporation | 10382787 |
|  |  | 21998978 |
|  | **SOFTWARE - 16.5%** |  |
| 11942 | Cadence Design Systems, Inc.<sup>(a)</sup> | 3679927 |
| 7458 | Intuit, Inc. | 5874145 |
| 10938 | Roper Technologies, Inc. | 6200095 |
| 7258 | SAP S.E. - ADR | 2207158 |
| 4425 | ServiceNow, Inc.<sup>(a)</sup> | 4549254 |
| 18399 | Workday, Inc., Class A<sup>(a)</sup> | 4415760 |
|  |  | 26926339 |
|  | **SPECIALTY FINANCE - 4.6%** |  |
| 23453 | American Express Company | 7481038 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE LARGE CAP FOCUS FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | |
|:---|:---|:---|
| **Shares** |  | **Fair Value** |
|  | **COMMON STOCKS — 99.0% (Continued)** |  |
|  | **TECHNOLOGY HARDWARE - 2.7%** |  |
| 10240 | Dell Technologies, Inc., Class C | $1255424 |
| 7409 | Motorola Solutions, Inc. | 3115188 |
|  |  | 4370612 |
|  | **TECHNOLOGY SERVICES - 5.8%** |  |
| 5929 | CDW Corporation | 1058860 |
| 15827 | S&P Global, Inc. | 8345419 |
|  |  | 9404279 |
|  | **TRANSPORTATION & LOGISTICS - 3.2%** |  |
| 12086 | Old Dominion Freight Line, Inc. | 1961558 |
| 14193 | Union Pacific Corporation | 3265525 |
|  |  | 5227083 |
|  | **TOTAL COMMON STOCKS (Cost $139,408,720)** | 161727051 |
|  | **TOTAL INVESTMENTS - 99.0% (Cost $139,408,720)** | $161727051 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES- 1.0%** | 1665973 |
|  | **NET ASSETS - 100.0%** | $163393024 |

---

---

| | |
|:---|:---|
| ADR | - American Depositary Receipt |
| LLC | - Limited Liability Company |
| N.V. | - Naamioze Vennootschap |
| PLC | - Public Limited Company |
| REIT | - Real Estate Investment Trust |

---

<sup>(a)</sup> Non-income producing security.

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **ASSET BACKED SECURITIES — 2.4%** |  |  |  |  |
|  | **AUTO LOAN — 1.2%** |  |  |  |  |
| 2070000 | CarMax Auto Owner Trust Series 2024-2 D |  | 6.4200 | &nbsp;&nbsp;10/15/30 | $2140323 |
|  | **OTHER ABS — 1.2%** |  |  |  |  |
| 1975000 | PFS Financing Corporation Series C A<sup>(a),(b)</sup> | SOFR30A + 0.800% | 5.1040 | &nbsp;&nbsp;04/17/28 | 1979622 |
|  | **TOTAL ASSET BACKED SECURITIES (Cost $4,104,715)** |  |  |  | 4119945 |
| **Principal Amount ($)** |  | **Spread** | **Coupon Rate (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 64.0%** |  |  |  |  |
|  | **ASSET MANAGEMENT — 0.4%** |  |  |  |  |
| 750000 | Hope Global Investments <sup>(c),(d),(e)</sup> |  | 4.6000 | &nbsp;&nbsp;10/10/28 | 726255 |
|  | **BANKING — 7.4%** |  |  |  |  |
| 2350000 | First Horizon Corporation<sup>(b)</sup> | SOFRRATE + 1.766% | 5.5140 | &nbsp;&nbsp;03/07/31 | 2385501 |
| 2750000 | Huntington Bancshares, Inc. |  | 2.5500 | &nbsp;&nbsp;02/04/30 | 2514866 |
| 2975000 | JPMorgan Chase & Company<sup>(b)</sup> | SOFRRATE + 1.330% | 6.0700 | &nbsp;&nbsp;10/22/27 | 3040193 |
| 2000000 | M&T Bank Corporation<sup>(b)</sup> | SOFRRATE + 0.930% | 4.8330 | &nbsp;&nbsp;01/16/29 | 2016472 |
| 2750000 | Royal Bank of Canada |  | 1.1500 | &nbsp;&nbsp;07/14/26 | 2666137 |
|  |  |  |  |  | 12623169 |
|  | **BIOTECH & PHARMA — 1.2%** |  |  |  |  |
| 2000000 | Zoetis, Inc. |  | 3.9000 | &nbsp;&nbsp;08/20/28 | 1986779 |
|  | **CHEMICALS — 1.3%** |  |  |  |  |
| 2100000 | Sherwin-Williams Company (The) |  | 4.5500 | &nbsp;&nbsp;03/01/28 | 2119901 |
|  | **COMMERCIAL SUPPORT SERVICES — 1.2%** |  |  |  |  |
| 2000000 | Waste Management, Inc. |  | 4.9500 | &nbsp;&nbsp;07/03/27 | 2034583 |
|  | **CONSTRUCTION MATERIALS — 1.8%** |  |  |  |  |
| 1475000 | Advanced Drainage Systems, Inc.<sup>(a)</sup> |  | 5.0000 | &nbsp;&nbsp;09/30/27 | 1462216 |
| 1600000 | Quikrete Holdings, Inc.<sup>(a)</sup> |  | 6.3750 | &nbsp;&nbsp;03/01/32 | 1648723 |
|  |  |  |  |  | 3110939 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 64.0% (Continued)** |  |  |  |  |
|  | **ELECTRIC UTILITIES — 10.7%** |  |  |  |  |
| 2000000 | AES Corporation (The) |  | 1.3750 | &nbsp;&nbsp;01/15/26 | $1962071 |
| 2325000 | Ameren Illinois Company |  | 3.8000 | &nbsp;&nbsp;05/15/28 | 2308185 |
| 2000000 | Constellation Energy Generation, LLC |  | 5.6000 | &nbsp;&nbsp;03/01/28 | 2069797 |
| 2500000 | Duke Energy Florida, LLC |  | 2.5000 | &nbsp;&nbsp;12/01/29 | 2323290 |
| 1525000 | Georgia Power Company Series 2016-A |  | 3.2500 | &nbsp;&nbsp;04/01/26 | 1512391 |
| 2650000 | MidAmerican Energy Company |  | 3.1000 | &nbsp;&nbsp;05/01/27 | 2607644 |
| 2500000 | National Rural Utilities Cooperative Finance |  | 4.8500 | &nbsp;&nbsp;02/07/29 | 2545900 |
| 1000000 | NextEra Energy Capital Holdings, Inc. |  | 4.9000 | &nbsp;&nbsp;02/28/28 | 1013774 |
| 1750000 | NextEra Energy Capital Holdings, Inc.<sup>(b)</sup> | US0003M + 2.409% | 4.8000 | &nbsp;&nbsp;12/01/77 | 1680066 |
|  |  |  |  |  | 18023118 |
|  | **ELECTRICAL EQUIPMENT — 1.4%** |  |  |  |  |
| 2350000 | Lennox International, Inc. |  | 5.5000 | &nbsp;&nbsp;09/15/28 | 2423854 |
|  | **ENGINEERING & CONSTRUCTION — 3.3%** |  |  |  |  |
| 1550000 | Installed Building Products, Inc.<sup>(a)</sup> |  | 5.7500 | &nbsp;&nbsp;02/01/28 | 1551540 |
| 2000000 | MasTec, Inc.<sup>(a)</sup> |  | 4.5000 | &nbsp;&nbsp;08/15/28 | 1973438 |
| 2000000 | Quanta Services, Inc. |  | 4.7500 | &nbsp;&nbsp;08/09/27 | 2017452 |
|  |  |  |  |  | 5542430 |
|  | **FORESTRY, PAPER & WOOD PRODUCTS — 0.9%** |  |  |  |  |
| 1575000 | Louisiana-Pacific Corporation<sup>(a)</sup> |  | 3.6250 | &nbsp;&nbsp;03/15/29 | 1497324 |
|  | **HOME & OFFICE PRODUCTS — 0.7%** |  |  |  |  |
| 1250000 | Somnigroup International, Inc.<sup>(a)</sup> |  | 4.0000 | &nbsp;&nbsp;04/15/29 | 1196737 |
|  | **HOME CONSTRUCTION — 1.9%** |  |  |  |  |
| 1600000 | M/I Homes, Inc. |  | 4.9500 | &nbsp;&nbsp;02/01/28 | 1591004 |
| 1600000 | Patrick Industries, Inc.<sup>(a)</sup> |  | 4.7500 | &nbsp;&nbsp;05/01/29 | 1554768 |
|  |  |  |  |  | 3145772 |
|  | **INDUSTRIAL SUPPORT SERVICES — 0.9%** |  |  |  |  |
| 1575000 | United Rentals North America, Inc. |  | 3.8750 | &nbsp;&nbsp;11/15/27 | 1543122 |
|  | **INSTITUTIONAL FINANCIAL SERVICES — 1.5%** |  |  |  |  |
| 2500000 | Nasdaq, Inc. |  | 5.3500 | &nbsp;&nbsp;06/28/28 | 2575107 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 64.0% (Continued)** |  |  |  |  |
|  | **INSURANCE — 4.6%** |  |  |  |  |
| 2750000 | Aflac, Inc. |  | 1.1250 | &nbsp;&nbsp;03/15/26 | $2686659 |
| 1750000 | Assurant, Inc. |  | 3.7000 | &nbsp;&nbsp;02/22/30 | 1665433 |
| 2100000 | Brown & Brown, Inc. |  | 4.5000 | &nbsp;&nbsp;03/15/29 | 2099684 |
| 1425000 | Pacific Life Global Funding II<sup>(a)</sup> |  | 1.3750 | &nbsp;&nbsp;04/14/26 | 1393276 |
|  |  |  |  |  | 7845052 |
|  | **MACHINERY — 2.2%** |  |  |  |  |
| 1700000 | Mueller Water Products, Inc.<sup>(a)</sup> |  | 4.0000 | &nbsp;&nbsp;06/15/29 | 1637654 |
| 2250000 | Xylem, Inc. |  | 1.9500 | &nbsp;&nbsp;01/30/28 | 2129075 |
|  |  |  |  |  | 3766729 |
|  | **OIL & GAS PRODUCERS — 5.1%** |  |  |  |  |
| 2200000 | Cheniere Energy Partners, L.P. |  | 4.5000 | &nbsp;&nbsp;10/01/29 | 2176793 |
| 1000000 | ConocoPhillips Company |  | 4.7000 | &nbsp;&nbsp;01/15/30 | 1014078 |
| 2100000 | Diamondback Energy, Inc. |  | 3.5000 | &nbsp;&nbsp;12/01/29 | 2009166 |
| 1400000 | EQT Corporation |  | 5.7000 | &nbsp;&nbsp;04/01/28 | 1440231 |
| 2000000 | Plains All American Pipeline, L.P. / PAA Finance |  | 3.5500 | &nbsp;&nbsp;12/15/29 | 1911736 |
|  |  |  |  |  | 8552004 |
|  | **REAL ESTATE INVESTMENT TRUSTS — 6.0%** |  |  |  |  |
| 1675000 | Alexandria Real Estate Equities, Inc. |  | 3.8000 | &nbsp;&nbsp;04/15/26 | 1663270 |
| 2000000 | American Tower Corporation |  | 5.2500 | &nbsp;&nbsp;07/15/28 | 2050601 |
| 2250000 | Equinix, Inc. |  | 1.5500 | &nbsp;&nbsp;03/15/28 | 2097854 |
| 412000 | HAT Holdings I, LLC / HAT Holdings II, LLC<sup>(a)</sup> |  | 8.0000 | &nbsp;&nbsp;06/15/27 | 429760 |
| 1500000 | Iron Mountain, Inc.<sup>(a)</sup> |  | 5.2500 | &nbsp;&nbsp;03/15/28 | 1494414 |
| 2500000 | Welltower OP, LLC |  | 2.7000 | &nbsp;&nbsp;02/15/27 | 2444074 |
|  |  |  |  |  | 10179973 |
|  | **RETAIL - DISCRETIONARY — 3.9%** |  |  |  |  |
| 1600000 | Asbury Automotive Group, Inc. |  | 4.5000 | &nbsp;&nbsp;03/01/28 | 1579240 |
| 2500000 | AutoZone, Inc. |  | 4.5000 | &nbsp;&nbsp;02/01/28 | 2520099 |
| 1500000 | Builders FirstSource, Inc.<sup>(a)</sup> |  | 5.0000 | &nbsp;&nbsp;03/01/30 | 1473605 |
| 1000000 | Home Depot, Inc. (The) |  | 4.8750 | &nbsp;&nbsp;06/25/27 | 1016095 |
|  |  |  |  |  | 6589039 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **CORPORATE BONDS — 64.0% (Continued)** |  |  |  |  |
|  | **SEMICONDUCTORS — 3.2%** |  |  |  |  |
| 2300000 | Broadcom, Inc. |  | 4.1100 | &nbsp;&nbsp;09/15/28 | $2291129 |
| 2025000 | NXP BV / NXP Funding, LLC / NXP USA, Inc. |  | 2.5000 | &nbsp;&nbsp;05/11/31 | 1788880 |
| 1325000 | Synaptics, Inc.<sup>(a)</sup> |  | 4.0000 | &nbsp;&nbsp;06/15/29 | 1258698 |
|  |  |  |  |  | 5338707 |
|  | **SOFTWARE — 2.5%** |  |  |  |  |
| 2675000 | Roper Technologies, Inc. |  | 4.2000 | &nbsp;&nbsp;09/15/28 | 2665830 |
| 1650000 | Workday, Inc. |  | 3.5000 | &nbsp;&nbsp;04/01/27 | 1628779 |
|  |  |  |  |  | 4294609 |
|  | **TECHNOLOGY SERVICES — 1.2%** |  |  |  |  |
| 2025000 | Verisk Analytics, Inc. |  | 4.1250 | &nbsp;&nbsp;03/15/29 | 2012722 |
|  | **WHOLESALE - CONSUMER STAPLES — 0.7%** |  |  |  |  |
| 1250000 | Sysco Corporation |  | 2.4000 | &nbsp;&nbsp;02/15/30 | 1143763 |
|  | **TOTAL CORPORATE BONDS (Cost $107,458,330)** |  |  |  | 108271688 |
| **Principal<br> Amount ($)** |  |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **MUNICIPAL BONDS — 5.5%** |  |  |  |  |
|  | **COMBINED UTILITIES — 0.9%** |  |  |  |  |
| 1525000 | City of Tacoma, WA Electric System Revenue |  | 5.6410 | &nbsp;&nbsp;01/01/27 | 1545707 |
|  | **COUNTY — 0.6%** |  |  |  |  |
| 1115000 | City & County of Honolulu, HI |  | 2.5180 | &nbsp;&nbsp;10/01/26 | 1095508 |
|  | **SINGLE-FAMILY HOUSING — 2.8%** |  |  |  |  |
| 305000 | Illinois Housing Development Authority |  | 5.0940 | &nbsp;&nbsp;04/01/30 | 312294 |
| 1000000 | Illinois Housing Development Authority |  | 5.2440 | &nbsp;&nbsp;04/01/31 | 1032251 |
| 525000 | Illinois Housing Development Authority |  | 5.0530 | &nbsp;&nbsp;04/01/32 | 533612 |
| 30000 | Maryland Community Development Administration |  | 3.2420 | &nbsp;&nbsp;09/01/48 | 29822 |
| 2150000 | Virginia Housing Development Authority |  | 4.8570 | &nbsp;&nbsp;10/01/29 | 2196858 |
| 500000 | Virginia Housing Development Authority |  | 4.9140 | &nbsp;&nbsp;04/01/30 | 511803 |
|  |  |  |  |  | 4616640 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  |  | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **MUNICIPAL BONDS — 5.5% (Continued)** |  |  |  |  |
|  | **WATER AND SEWER — 1.2%** |  |  |  |  |
| 2000000 | Boston Water & Sewer Commission |  | 0.9650 | &nbsp;&nbsp;11/01/25 | $1979461 |
|  | **TOTAL MUNICIPAL BONDS (Cost $9,254,572)** |  |  |  | 9237316 |
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 24.6%** |  |  |  |  |
|  | **AGENCY FIXED RATE — 8.8%** |  |  |  |  |
| 2774418 | Fannie Mae Pool MA5589 |  | 4.5000 | &nbsp;&nbsp;01/01/40 | 2757999 |
| 1882919 | Fannie Mae Pool MA5072 |  | 5.5000 | &nbsp;&nbsp;06/01/53 | 1886571 |
| 1796606 | Fannie Mae Pool CB7331 |  | 5.5000 | &nbsp;&nbsp;10/01/53 | 1803607 |
| 1486849 | Fannie Mae Pool MA5165 |  | 5.5000 | &nbsp;&nbsp;10/01/53 | 1489349 |
| 888527 | Fannie Mae Pool FS9447 |  | 6.0000 | &nbsp;&nbsp;12/01/53 | 906748 |
| 1735769 | Freddie Mac Pool SB8333 |  | 4.5000 | &nbsp;&nbsp;10/01/39 | 1726704 |
| 1888688 | Freddie Mac Pool SB8347 |  | 4.0000 | &nbsp;&nbsp;01/01/40 | 1847944 |
| 1614212 | Freddie Mac Pool SD8258 |  | 5.0000 | &nbsp;&nbsp;10/01/52 | 1590722 |
| 970183 | Ginnie Mae II Pool MA7107 |  | 2.5000 | &nbsp;&nbsp;01/20/36 | 908881 |
|  |  |  |  |  | 14918525 |
|  | **AGENCY HYBRID ARMS** — **0.0%<sup>(f)</sup>** |  |  |  |  |
| 5217 | Ginnie Mae II Pool 82903<sup>(b)</sup> | H15T1Y + 1.500% | 4.6250 | &nbsp;&nbsp;08/20/41 | 5313 |
|  | **ARMS** — **0.0%<sup>(f)</sup>** |  |  |  |  |
| 1315 | Fannie Mae Pool 791573<sup>(b)</sup> | H15T1Y + 2.170% | 7.2950 | &nbsp;&nbsp;08/01/34 | 1347 |
| 3 | Ginnie Mae II Pool 8660<sup>(b)</sup> | H15T1Y + 1.500% | 4.6250 | &nbsp;&nbsp;07/20/25 | 3 |
| 9261 | Ginnie Mae II Pool 80569<sup>(b)</sup> | H15T1Y + 1.500% | 5.6250 | &nbsp;&nbsp;01/20/32 | 9390 |
| 1098 | Ginnie Mae II Pool 80659<sup>(b)</sup> | H15T1Y + 1.500% | 4.7500 | &nbsp;&nbsp;12/20/32 | 1118 |
|  |  |  |  |  | 11858 |
|  | **GOVERNMENT OWNED, NO GUARANTEE — 7.8%** |  |  |  |  |
| 2000000 | Federal Home Loan Mortgage Corporation |  | 4.2500 | &nbsp;&nbsp;10/23/26 | 1997038 |
| 1000000 | Federal Home Loan Mortgage Corporation |  | 4.6000 | &nbsp;&nbsp;06/17/27 | 999947 |
| 2500000 | Federal National Mortgage Association |  | 6.2500 | &nbsp;&nbsp;05/15/29 | 2723265 |
| 2500000 | Federal National Mortgage Association |  | 7.1250 | &nbsp;&nbsp;01/15/30 | 2843868 |
| 1500000 | Federal National Mortgage Association |  | 7.2500 | &nbsp;&nbsp;05/15/30 | 1727982 |
| 2500000 | Federal National Mortgage Association |  | 6.6250 | &nbsp;&nbsp;11/15/30 | 2829486 |
|  |  |  |  |  | 13121586 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| **EVENTIDE LIMITED-TERM BOND FUND** |
| **SCHEDULE OF INVESTMENTS (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Principal<br> Amount ($)** |  | **Spread** | **Coupon Rate<br> (%)** | **Maturity** | **Fair Value** |
|  | **U.S. GOVERNMENT & AGENCIES — 24.6% (Continued)** |  |  |  |  |
|  | **GOVERNMENT SPONSORED — 8.0%** |  |  |  |  |
| 1250000 | Federal Farm Credit Banks Funding Corporation |  | 4.2800 | &nbsp;&nbsp;12/17/26 | $1246994 |
| 1250000 | Federal Farm Credit Banks Funding Corporation |  | 3.5000 | &nbsp;&nbsp;06/23/27 | 1241122 |
| 2000000 | Federal Farm Credit Banks Funding Corporation |  | 4.6700 | &nbsp;&nbsp;12/02/27 | 1999958 |
| 2250000 | Federal Farm Credit Banks Funding Corporation |  | 4.3750 | &nbsp;&nbsp;02/28/28 | 2286759 |
| 1500000 | Federal Farm Credit Banks Funding Corporation |  | 3.7800 | &nbsp;&nbsp;06/08/28 | 1489232 |
| 1750000 | Federal Farm Credit Banks Funding Corporation |  | 4.0000 | &nbsp;&nbsp;04/01/30 | 1763510 |
| 1200000 | Federal Farm Credit Banks Funding Corporation |  | 4.8400 | &nbsp;&nbsp;04/08/30 | 1199865 |
| 1500000 | Federal Farm Credit Banks Funding Corporation |  | 1.4500 | &nbsp;&nbsp;06/11/30 | 1333757 |
| 1000000 | Federal Farm Credit Banks Funding Corporation |  | 4.0000 | &nbsp;&nbsp;01/13/31 | 1004460 |
|  |  |  |  |  | 13565657 |
|  | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $41,486,511)** |  |  |  | 41622939 |
|  | **TOTAL INVESTMENTS – 96.5% (Cost $162,304,128)** |  |  |  | $163251888 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES- 3.5%** |  |  |  | 5955087 |
|  | **NET ASSETS - 100.0%** |  |  |  | $169206975 |

---

---

| | |
|:---|:---|
| ABS | Asset Backed Security |
| LLC | Limited Liability Company |
| LP | Limited Partnership |
| H15T1Y | US Treasury Yield Curve Rate T Note Constant Maturity 1 Year |
| SOFR30A | United States 30 Day Average SOFR Secured Overnight Financing Rate |
| SOFRRATE | United States SOFR Secured Overnight Financing Rate |
| US0003M | ICE LIBOR USD 3 Month |

---

<sup>(a)</sup> Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of June 30, 2025 the total market value of 144A securities is $20,551,775 or 12.1% of net assets.

<sup>(b)</sup> Variable or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying pool of assets.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of June 30, 2025 was $726,255, representing 0.4% of net assets.

<sup>(d)</sup> Restricted security. See Note 6 for additional details.

<sup>(e)</sup> Private investment.

<sup>(f)</sup> Percentage rounds to less than 0.1%.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF ASSETS AND LIABILITIES** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | <br>**Eventide**<br>**Balanced** | **Eventide**<br>**Core Bond**<br>**Fund** | **Eventide**<br>**Dividend**<br>**Growth Fund** | **Eventide**<br>**Exponential**<br>**Technologies Fund** | <br>**Eventide**<br>**Gilead Fund** |
| **ASSETS** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Investment securities: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments at cost | $338340553 | $152421072 | $969729818 | $68203449 | $1532306400 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments at cost |  |  |  |  | 46787158 |
| &nbsp;&nbsp;&nbsp;Total Investments at cost | 338340553 | 152421072 | 969729818 | 68203449 | 1579093558 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments at value | $380709980 | $150418702 | $1176856692 | $97224246 | $2745779653 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments at value |  |  |  |  | 40275202 |
| &nbsp;&nbsp;&nbsp;Total investments at value | 380709980 | 150418702 | 1176856692 | 97224246 | 2786054855 |
| &nbsp;&nbsp;&nbsp;Cash held at custodian | 4971527 | 3813160 | 24370607 | 511631 | 4741816 |
| &nbsp;&nbsp;&nbsp;Cash held at broker | 116211 |  | 112148 | 170539 | 181061 |
| &nbsp;&nbsp;&nbsp;Receivable for securities sold | 1484338 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Receivable for Fund shares sold | 199728 | 79771 | 1816765 | 37624 | 5987216 |
| &nbsp;&nbsp;&nbsp;Dividends and interest receivable | 1862345 | 1559177 | 1185564 | 21237 | 495495 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 50752 | 1765 | 134847 | 13950 | 138305 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL ASSETS** | 389394881 | 155872575 | 1204476623 | 97979227 | 2797598748 |
| **LIABILITIES** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Payable for investments purchased | 1593731 | 95163 |  |  |  |
| &nbsp;&nbsp;&nbsp;Payable for Fund shares redeemed | 304458 | 6879410 | 559915 | 490179 | 4111129 |
| &nbsp;&nbsp;&nbsp;Advisory fees payable | 193776 | 22743 | 838874 | 91467 | 2222216 |
| &nbsp;&nbsp;&nbsp;Distribution (12b-1) fees payable | 105111 | 13982 | 175603 | 25463 | 149236 |
| &nbsp;&nbsp;&nbsp;Payable to related parties | 66374 | 36230 | 117865 | 24467 | 241486 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | 88996 | 54350 | 97883 | 60363 | 642301 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL LIABILITIES** | 2352446 | 7101878 | 1790140 | 691939 | 7366368 |
| **NET ASSETS** | $**387042435** | $**148770697** | $**1202686483** | $**97287288** | $**2790232380** |
| **Composition of Net Assets:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Paid in capital | $332881764 | $165972532 | $972282974 | $116099129 | $1353461223 |
| &nbsp;&nbsp;&nbsp;Accumulated earnings (losses) | 54160671 | (17201835) | 230403509 | (18811841) | 1436771157 |
| **NET ASSETS** | $**387042435** | $**148770697** | $**1202686483** | $**97287288** | $**2790232380** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF ASSETS AND LIABILITIES (Continued)** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | <br>**Eventide**<br>**Balanced** | **Eventide**<br>**Core Bond**<br>**Fund** | **Eventide**<br>**Dividend**<br>**Growth Fund** | **Eventide**<br>**Exponential**<br>**Technologies Fund** | <br>**Eventide**<br>**Gilead Fund** |
| **Net Asset Value Per Share:** |  |  |  |  |  |
| Class N Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**18546714** | $**37596281** | $**77292598** | $**19462053** | $**288736177** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **1265179** | **4570278** | **3981887** | **1444336** | **5343021** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $**14.66** | $**8.23** | $**19.41** | $**13.47** | $**54.04** |
| Class A Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**37205086** | $**979293** | $**65648354** | $**8133436** | $**307538393** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **2532863** | **118515** | **3380167** | **604089** | **5736061** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding) and redemption price per share | $**14.69** | $**8.26** | $**19.42** | $**13.46** | $**53.61** |
| &nbsp;&nbsp;&nbsp;Maximum offering price per share (net asset value plus maximum sales charge of 5.75%) | $**15.59** | $**8.76** | $**20.60** | $**14.28** | $**56.88** |
| Class C Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**16869003** | $**644315** | $**27017788** | $**2147987** | $**139105483** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **1157312** | **78823** | **1413868** | **165687** | **3001146** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $**14.58** | $**8.17** | $**19.11** | $**12.96** | $**46.35** |
| Class I Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**314421632** | $**109550808** | $**1032727743** | $**67543812** | $**2054852327** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **21444579** | **13315593** | **53157127** | **4960104** | **36672300** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $**14.66** | $**8.23** | $**19.43** | $**13.62** | $**56.03** |

---

(a) Unlimited number of shares of beneficial
 interest authorized, no par value.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF ASSETS AND LIABILITIES (Continued)** |
| **June 30, 2025** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Eventide**<br>**Healthcare &**<br>**Life Sciences Fund** | **Eventide**<br>**Large Cap**<br>**Focus Fund** | **Eventide**<br>**Limited-Term**<br>**Bond Fund** |
| **ASSETS** |  |  |  |
| &nbsp;&nbsp;&nbsp;Investment securities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments at cost | $890026207 | $139408720 | $162304128 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments at cost | 60438512 |  |  |
| &nbsp;&nbsp;&nbsp;Investments at cost | 950464719 | 139408720 | 162304128 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments at value | $1088234024 | $161727051 | $163251888 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments at value | 27453309 |  |  |
| &nbsp;&nbsp;&nbsp;Total investments at value | 1115687333 | 161727051 | 163251888 |
| &nbsp;&nbsp;&nbsp;Cash held at custodian | 31784024 | 1569951 | 4551997 |
| &nbsp;&nbsp;&nbsp;Cash held at broker | 121122 |  |  |
| &nbsp;&nbsp;&nbsp;Receivable for securities sold |  | 1160761 |  |
| &nbsp;&nbsp;&nbsp;Receivable for Fund shares sold | 443463 | 66148 | 177015 |
| &nbsp;&nbsp;&nbsp;Dividends and interest receivable | 218526 | 49534 | 1666700 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 85821 | 57239 | 36739 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL ASSETS** | 1148340289 | 164630684 | 169684339 |
| **LIABILITIES** |  |  |  |
| &nbsp;&nbsp;&nbsp;Payable for investments purchased |  | 1166172 | 237908 |
| &nbsp;&nbsp;&nbsp;Payable for Fund shares redeemed | 937549 | 51964 | 123584 |
| &nbsp;&nbsp;&nbsp;Advisory fees payable | 1029786 | 4463 | 32089 |
| &nbsp;&nbsp;&nbsp;Distribution (12b-1) fees payable | 50226 |  | 6879 |
| &nbsp;&nbsp;&nbsp;Payable to related parties | 131800 | 15061 | 29419 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | 321361 |  | 47485 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL LIABILITIES** | 2470722 | 1237660 | 477364 |
| **NET ASSETS** | $**1145869567** | $**163393024** | $**169206975** |
| **Composition of Net Assets:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Paid in capital | $1133954839 | $141450451 | $177155167 |
| &nbsp;&nbsp;&nbsp;Accumulated earnings (losses) | 11914728 | 21942573 | (7948192) |
| **NET ASSETS** | $**1145869567** | $**163393024** | $**169206975** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF ASSETS AND LIABILITIES (Continued)** |
| **June 30, 2025** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Eventide**<br>**Healthcare &**<br>**Life Sciences Fund** | **Eventide**<br>**Large Cap**<br>**Focus Fund** | **Eventide**<br>**Limited-Term**<br>**Bond Fund** |
| **Net Asset Value Per Share:** |  |  |  |
| Class N Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**59747855** | $**9268233** | $**17358950** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **1799342** | **611123** | **1718141** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $**33.21** | $**15.17** | $**10.10** |
| Class A Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**97510031** | $**4428276** | $**4378082** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **2961148** | **292679** | **432186** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding) |  |  |  |
| &nbsp;&nbsp;&nbsp; and redemption price per share | $**32.93** | $**15.13** | $**10.13** |
| &nbsp;&nbsp;&nbsp;Maximum offering price per share |  |  |  |
| &nbsp;&nbsp;&nbsp;(net asset value plus maximum sales charge of 5.75%) | $**34.94** | $**16.05** | $**10.75** |
| Class C Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**37459646** | $**1018874** | $**1602882** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **1257513** | **68699** | **159384** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), |  |  |  |
| &nbsp;&nbsp;&nbsp; offering price, and redemption price per share | $**29.79** | $**14.83** | $**10.06** |
| Class I Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $**951152035** | $**148677641** | $**145867061** |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding (a) | **27923036** | **9771357** | **14050596** |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), |  |  |  |
| &nbsp;&nbsp;&nbsp; offering price, and redemption price per share | $**34.06** | $**15.22** | $**10.38** |

---

(a) Unlimited
 number of shares of beneficial interest authorized, no par value.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF OPERATIONS** |
| **For the Year Ended June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | <br>**Eventide**<br>**Balanced** | **Eventide**<br>**Core Bond**<br>**Fund** | **Eventide**<br>**Dividend**<br>**Growth Fund** | **Eventide**<br>**Exponential**<br>**Technologies Fund** | <br>**Eventide**<br>**Gilead Fund** |
| **INVESTMENT INCOME** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Dividend income | $3244649 | $— | $15425811 | $125924 | $8986982 |
| &nbsp;&nbsp;&nbsp;Interest | 7489663 | 7089290 | 1192452 | 255778 | 5038951 |
| &nbsp;&nbsp;&nbsp;Less: Foreign dividend withholding taxes |  |  |  | (5645) | (219473) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL INVESTMENT INCOME** | 10734312 | 7089290 | 16618263 | 376057 | 13806460 |
| **EXPENSES** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Investment advisory fees | 2330394 | 504777 | 7598747 | 1179143 | 29160455 |
| &nbsp;&nbsp;&nbsp;Distribution (12b-1) fees: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Class N | 38566 | 74079 | 161536 | 37545 | 709292 |
| &nbsp;&nbsp;&nbsp; Class A | 82748 | 1977 | 150352 | 20306 | 762961 |
| &nbsp;&nbsp;&nbsp; Class C | 166770 | 5834 | 240961 | 22937 | 1492371 |
| &nbsp;&nbsp;&nbsp;Shareholder servicing fees | 317348 | 199846 | 1014228 | 153336 | 3079575 |
| &nbsp;&nbsp;&nbsp;Financial administration/fund accounting fees | 161320 | 86087 | 309703 | 58868 | 843659 |
| &nbsp;&nbsp;&nbsp;Registration fees | 86075 | 42345 | 118625 | 71010 | 133000 |
| &nbsp;&nbsp;&nbsp;Legal administration/management services fees | 82497 | 31707 | 222474 | 22805 | 631818 |
| &nbsp;&nbsp;&nbsp;Transfer agent fees | 49700 | 24788 | 84824 | 32427 | 256746 |
| &nbsp;&nbsp;&nbsp;Legal fees | 26657 | 26185 | 36499 | 28551 | 27328 |
| &nbsp;&nbsp;&nbsp;Printing and postage expenses | 25562 | 33763 | 197778 | 40533 | 300938 |
| &nbsp;&nbsp;&nbsp;Custodian fees | 23743 | 9677 | 55054 | 14051 | 161914 |
| &nbsp;&nbsp;&nbsp;Compliance officer fees | 18613 | 12589 | 32739 | 9524 | 81643 |
| &nbsp;&nbsp;&nbsp;Trustees fees and expenses | 15922 | 15882 | 15909 | 15922 | 15822 |
| &nbsp;&nbsp;&nbsp;Insurance expense | 12775 | 3650 | 20075 | 3650 | 116800 |
| &nbsp;&nbsp;&nbsp;Audit fees | 9243 | 7785 | 33320 | 8689 | 129827 |
| &nbsp;&nbsp;&nbsp;Other expenses | 8940 | 6057 | 16326 | 5870 | 7177 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL EXPENSES** | 3456873 | 1087028 | 10309150 | 1725167 | 37911326 |
| &nbsp;&nbsp;&nbsp;Less: Fees waived/reimbursed by the Advisor |  | (143748) |  | (112235) |  |
| &nbsp;&nbsp;&nbsp;Plus: Recapture of fees previously waived |  |  | 141466 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET EXPENSES** | 3456873 | 943280 | 10450616 | 1612932 | 37911326 |
| **NET INVESTMENT INCOME (LOSS)** | 7277439 | 6146010 | 6167647 | (1236875) | (24104866) |
| **REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments | 23798429 | (1388720) | 56088289 | 10877977 | 465406101 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments (See Note 5) |  |  |  |  | (69428028) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities sold short |  |  |  | (107439) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency transactions |  |  |  |  | (39255) |
| &nbsp;&nbsp;&nbsp;**Net realized gain (loss):** | 23798429 | (1388720) | 56088289 | 10770538 | 395938818 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments | 273040 | 3590668 | 32216411 | 2805100 | (153831073) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments (See Note 5) |  |  |  |  | 158781235 |
| &nbsp;&nbsp;&nbsp;**Net change in unrealized appreciation:** | 273040 | 3590668 | 32216411 | 2805100 | 4950162 |
| **NET REALIZED AND UNREALIZED GAIN FROM INVESTMENTS** | 24071469 | 2201948 | 88304700 | 13575638 | 400888980 |
| **NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS** | $**31348908** | $**8347958** | $**94472347** | $**12338763** | $**376784114** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Funds*** |
| **STATEMENTS OF OPERATIONS (Continued)** |
| **For the Year Ended June 30, 2025** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Eventide**<br>**Healthcare &**<br>**Life Sciences Fund** | **Eventide**<br>**Large Cap**<br>**Focus Fund** | **Eventide**<br>**Limited-Term**<br>**Bond Fund** |
| **INVESTMENT INCOME** |  |  |  |
| &nbsp;&nbsp;&nbsp;Dividend income | $— | $1765593 | $— |
| &nbsp;&nbsp;&nbsp;Interest | 2774072 | 165561 | 6590013 |
| &nbsp;&nbsp;&nbsp;Less: Foreign dividend withholding taxes | (562) | (5334) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL INVESTMENT INCOME** | 2773510 | 1925820 | 6590013 |
| **EXPENSES** |  |  |  |
| &nbsp;&nbsp;&nbsp;Investment advisory fees | 14591841 | 1097776 | 479962 |
| &nbsp;&nbsp;&nbsp;Distribution (12b-1) fees: |  |  |  |
| &nbsp;&nbsp;&nbsp; Class N | 149347 | 29752 | 36207 |
| &nbsp;&nbsp;&nbsp; Class A | 278978 | 7325 | 11429 |
| &nbsp;&nbsp;&nbsp; Class C | 475291 | 5529 | 15792 |
| &nbsp;&nbsp;&nbsp;Shareholder servicing fees | 1406079 | 180681 | 151928 |
| &nbsp;&nbsp;&nbsp;Financial administration/fund accounting fees | 378662 | 63055 | 80990 |
| &nbsp;&nbsp;&nbsp;Legal administration/management services fees | 281921 | 32169 | 33086 |
| &nbsp;&nbsp;&nbsp;Printing and postage expenses | 197934 | 129544 | 15301 |
| &nbsp;&nbsp;&nbsp;Transfer agent fees | 181158 | 36861 | 24341 |
| &nbsp;&nbsp;&nbsp;Registration fees | 97350 | 68525 | 63000 |
| &nbsp;&nbsp;&nbsp;Custodian fees | 73661 | 12427 | 9186 |
| &nbsp;&nbsp;&nbsp;Audit fees | 53452 | 9562 | 8457 |
| &nbsp;&nbsp;&nbsp;Insurance expense | 52925 | 1103 | 5475 |
| &nbsp;&nbsp;&nbsp;Compliance officer fees | 40408 | 10566 | 12776 |
| &nbsp;&nbsp;&nbsp;Legal fees | 32671 | 30563 | 21956 |
| &nbsp;&nbsp;&nbsp;Trustees fees and expenses | 15917 | 15922 | 15922 |
| &nbsp;&nbsp;&nbsp;Other expenses | 21272 | 6296 | 6487 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL EXPENSES** | 18328867 | 1737656 | 992295 |
| &nbsp;&nbsp;&nbsp;Less: Fees waived/reimbursed by the Advisor |  | (280014) | (76975) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET EXPENSES** | 18328867 | 1457642 | 915320 |
| **NET INVESTMENT INCOME (LOSS)** | (15555357) | 468178 | 5674693 |
| **REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) from: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments | 14423207 | 1634873 | (411501) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments (See Note 5) | (117035593) |  |  |
| &nbsp;&nbsp;&nbsp;**Net realized gain (loss):** | (102612386) | 1634873 | (411501) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments | 30068410 | 14793770 | 3761607 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments (See Note 5) | 81992644 |  |  |
| &nbsp;&nbsp;&nbsp;**Net change in unrealized appreciation (depreciation):** | 112061054 | 14793770 | 3761607 |
| **NET REALIZED AND UNREALIZED GAIN FROM INVESTMENTS** | 9448668 | 16428643 | 3350106 |
| **NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS** | $**(6106689)** | $**16896821** | $**9024799** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $7277439 | $5685090 |
| &nbsp;&nbsp;&nbsp;Net realized gain | 23798429 | 3359942 |
| &nbsp;&nbsp;&nbsp;Distributions of long term capital gains from underlying investment companies |  | 2982 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation | 273040 | 32146544 |
| Net increase in net assets resulting from operations | 31348908 | 41194558 |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;From Accumulated Earnings |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (343693) | (422597) |
| &nbsp;&nbsp;&nbsp;Class A | (592586) | (408420) |
| &nbsp;&nbsp;&nbsp;Class C | (171720) | (129472) |
| &nbsp;&nbsp;&nbsp;Class I | (6417037) | (4928123) |
| Total distributions to shareholders | (7525036) | (5888612) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 5425454 | 9079352 |
| &nbsp;&nbsp;&nbsp;Class A | 10050801 | 7382970 |
| &nbsp;&nbsp;&nbsp;Class C | 3676253 | 2465144 |
| &nbsp;&nbsp;&nbsp;Class I | 79882967 | 99214636 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 320908 | 399727 |
| &nbsp;&nbsp;&nbsp;Class A | 541839 | 363434 |
| &nbsp;&nbsp;&nbsp;Class C | 161394 | 120546 |
| &nbsp;&nbsp;&nbsp;Class I | 5855202 | 4513376 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (10887263) | (20672373) |
| &nbsp;&nbsp;&nbsp;Class A | (5652475) | (5867639) |
| &nbsp;&nbsp;&nbsp;Class C | (4011035) | (4339723) |
| &nbsp;&nbsp;&nbsp;Class I | (101665264) | (81509861) |
| Net increase (decrease) in net assets from shares of beneficial interest | (16301219) | 11149589 |
| **TOTAL INCREASE IN NET ASSETS** | 7522653 | 46455535 |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Year | 379519782 | 333064247 |
| &nbsp;&nbsp;&nbsp;End of Year | $**387042435** | $**379519782** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 379280 | 702251 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 22262 | 30806 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (755446) | (1575339) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (353904) | (842282) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 703397 | 556790 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 37532 | 27746 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (393817) | (450768) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 347112 | 133768 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 256631 | 189180 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 11261 | 9284 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (279902) | (336562) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (12010) | (138098) |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 5556351 | 7563324 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 406334 | 345405 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (7087635) | (6292309) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (1124950) | 1616420 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $6146010 | $3858167 |
| &nbsp;&nbsp;&nbsp;Net realized loss | (1388720) | (2770122) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation | 3590668 | 2371706 |
| Net increase in net assets resulting from operations | 8347958 | 3459751 |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;From Accumulated Earnings |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (1457744) | (1109828) |
| &nbsp;&nbsp;&nbsp;Class A | (31197) | (14181) |
| &nbsp;&nbsp;&nbsp;Class C | (19228) | (7752) |
| &nbsp;&nbsp;&nbsp;Class I | (4645541) | (2637606) |
| Total distributions to shareholders | (6153710) | (3769367) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 6594772 | 7288166 |
| &nbsp;&nbsp;&nbsp;Class A | 364509 | 392447 |
| &nbsp;&nbsp;&nbsp;Class C | 186531 | 324177 |
| &nbsp;&nbsp;&nbsp;Class I | 57015246 | 96894042 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 1454517 | 1106587 |
| &nbsp;&nbsp;&nbsp;Class A | 31036 | 14053 |
| &nbsp;&nbsp;&nbsp;Class C | 18491 | 7478 |
| &nbsp;&nbsp;&nbsp;Class I | 3031515 | 1570467 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (6539391) | (10033040) |
| &nbsp;&nbsp;&nbsp;Class A | (38702) | (206432) |
| &nbsp;&nbsp;&nbsp;Class C | (61906) | (57303) |
| &nbsp;&nbsp;&nbsp;Class I | (52785061) | (37064233) |
| Net increase in net assets from shares of beneficial interest | 9271557 | 60236409 |
| **TOTAL INCREASE IN NET ASSETS** | 11465805 | 59926793 |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Year | 137304892 | 77378099 |
| &nbsp;&nbsp;&nbsp;End of Year | $**148770697** | $**137304892** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 801510 | 896472 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 177427 | 136943 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (796295) | (1241562) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 182642 | (208147) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 44589 | 47998 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 3768 | 1728 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (4718) | (25196) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 43639 | 24530 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 22941 | 40205 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 2273 | 929 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (7652) | (7073) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 17562 | 34061 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 6939005 | 12040793 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 369931 | 193765 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (6454977) | (4596461) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 853959 | 7638097 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $6167647 | $3693391 |
| &nbsp;&nbsp;&nbsp;Net realized gain | 56088289 | 14015615 |
| &nbsp;&nbsp;&nbsp;Distributions of long term capital gains from underlying investment companies |  | 68490 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation | 32216411 | 117234972 |
| Net increase in net assets resulting from operations | 94472347 | 135012468 |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;From Accumulated Earnings |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (395039) | (334756) |
| &nbsp;&nbsp;&nbsp;Class A | (282723) | (147401) |
| &nbsp;&nbsp;&nbsp;Class I | (6375869) | (3216856) |
| Total distributions to shareholders | (7053631) | (3699013) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 29707917 | 29519252 |
| &nbsp;&nbsp;&nbsp;Class A | 21230753 | 12265171 |
| &nbsp;&nbsp;&nbsp;Class C | 9391939 | 5169491 |
| &nbsp;&nbsp;&nbsp;Class I | 543513016 | 334215421 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 387623 | 324923 |
| &nbsp;&nbsp;&nbsp;Class A | 273316 | 141369 |
| &nbsp;&nbsp;&nbsp;Class I | 5640651 | 2894360 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (48828521) | (50762173) |
| &nbsp;&nbsp;&nbsp;Class A | (11453642) | (6831786) |
| &nbsp;&nbsp;&nbsp;Class C | (3918430) | (3551445) |
| &nbsp;&nbsp;&nbsp;Class I | (294590525) | (164593403) |
| Net increase in net assets from shares of beneficial interest | 251354097 | 158791180 |
| **TOTAL INCREASE IN NET ASSETS** | 338772813 | 290104635 |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Year | 863913670 | 573809035 |
| &nbsp;&nbsp;&nbsp;End of Year | $**1202686483** | $**863913670** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 1588817 | 1807676 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 20467 | 19929 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (2585707) | (3142435) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (976423) | (1314830) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 1121380 | 762040 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 14439 | 8574 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (606903) | (424470) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 528916 | 346144 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 506317 | 319457 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (209307) | (226340) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 297010 | 93117 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 28790641 | 20550743 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 298143 | 174089 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (15726135) | (10273314) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 13362649 | 10451518 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss | $(1236875) | $(1477820) |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) | 10770538 | (2174150) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation | 2805100 | 3599272 |
| Net increase (decrease) in net assets resulting from operations | 12338763 | (52698) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 3229416 | 6027041 |
| &nbsp;&nbsp;&nbsp;Class A | 842122 | 1869118 |
| &nbsp;&nbsp;&nbsp;Class C | 221228 | 542067 |
| &nbsp;&nbsp;&nbsp;Class I | 24547146 | 32629726 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (5292622) | (8987032) |
| &nbsp;&nbsp;&nbsp;Class A | (2056176) | (1673077) |
| &nbsp;&nbsp;&nbsp;Class C | (877078) | (611792) |
| &nbsp;&nbsp;&nbsp;Class I | (51152017) | (30069547) |
| Net decrease in net assets from shares of beneficial interest | (30537981) | (273496) |
| **TOTAL DECREASE IN NET ASSETS** | (18199218) | (326194) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Year | 115486506 | 115812700 |
| &nbsp;&nbsp;&nbsp;End of Year | $**97287288** | $**115486506** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 260846 | 488743 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (421353) | (732729) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (160507) | (243986) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 67380 | 152030 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (167294) | (135986) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (99914) | 16044 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 18259 | 45554 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (72221) | (50461) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (53962) | (4907) |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 1972841 | 2640341 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (4082214) | (2419872) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (2109373) | 220469 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss | $(24104866) | $(25487931) |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) | 395938818 | (13157494) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation | 4950162 | 27536900 |
| Net increase (decrease) in net assets resulting from operations | 376784114 | (11108525) |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (4820502) |  |
| &nbsp;&nbsp;&nbsp;Class A | (3949917) |  |
| &nbsp;&nbsp;&nbsp;Class C | (2226342) |  |
| &nbsp;&nbsp;&nbsp;Class I | (26484044) |  |
| Total distributions to shareholders | (37480805) |  |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 31028381 | 73774173 |
| &nbsp;&nbsp;&nbsp;Class A | 23458379 | 43406603 |
| &nbsp;&nbsp;&nbsp;Class C | 6120741 | 10231757 |
| &nbsp;&nbsp;&nbsp;Class I | 372043932 | 642713540 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 4569532 |  |
| &nbsp;&nbsp;&nbsp;Class A | 3671233 |  |
| &nbsp;&nbsp;&nbsp;Class C | 2175853 |  |
| &nbsp;&nbsp;&nbsp;Class I | 23101297 |  |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (214388138) | (172318771) |
| &nbsp;&nbsp;&nbsp;Class A | (75482610) | (73157162) |
| &nbsp;&nbsp;&nbsp;Class C | (50191326) | (60256585) |
| &nbsp;&nbsp;&nbsp;Class I | (1024515333) | (864585791) |
| Net decrease in net assets from shares of beneficial interest | (898408059) | (400192236) |
| **TOTAL DECREASE IN NET ASSETS** | (559104750) | (411300761) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Year | 3349337130 | 3760637891 |
| &nbsp;&nbsp;&nbsp;End of Year | $**2790232380** | $**3349337130** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 628223 | 1518597 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 88113 |  |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (4257788) | (3552489) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (3541452) | (2033892) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 475760 | 908469 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 71328 |  |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (1526527) | (1533665) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (979439) | (625196) |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 143311 | 243481 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 48699 |  |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (1174308) | (1439695) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (982298) | (1196214) |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 7269688 | 12826677 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 430032 |  |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (19909056) | (17409071) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (12209336) | (4582394) |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss | $(15555357) | $(17761829) |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) | (102612386) | 28786860 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized depreciation (depreciation) | 112061054 | (171706635) |
| Net decrease in net assets resulting from operations | (6106689) | (160681604) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 9067271 | 27610590 |
| &nbsp;&nbsp;&nbsp;Class A | 7849699 | 18327882 |
| &nbsp;&nbsp;&nbsp;Class C | 2315607 | 5931902 |
| &nbsp;&nbsp;&nbsp;Class I | 282230941 | 338891051 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (42738482) | (56522523) |
| &nbsp;&nbsp;&nbsp;Class A | (32541536) | (33663932) |
| &nbsp;&nbsp;&nbsp;Class C | (20154252) | (19891812) |
| &nbsp;&nbsp;&nbsp;Class I | (493968741) | (483248261) |
| Net decrease in net assets from shares of beneficial interest | (287939493) | (202565103) |
| **TOTAL DECREASE IN NET ASSETS** | (294046182) | (363246707) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Year | 1439915749 | 1803162456 |
| &nbsp;&nbsp;&nbsp;End of Year | $**1145869567** | $**1439915749** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 271626 | 808352 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (1266000) | (1645670) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (994374) | (837318) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 234866 | 533812 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (979214) | (1004391) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (744348) | (470579) |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 76653 | 189732 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (667547) | (643139) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (590894) | (453407) |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 8291869 | 9731634 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (14654078) | (13939231) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (6362209) | (4207597) |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **STATEMENT OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $468178 | $84834 |
| &nbsp;&nbsp;&nbsp;Net realized gain | 1634873 | 3919159 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation | 14793770 | 5840777 |
| Net increase in net assets resulting from operations | 16896821 | 9844770 |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;From Accumulated Earnings |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (588763) |  |
| &nbsp;&nbsp;&nbsp;Class A | (97241) |  |
| &nbsp;&nbsp;&nbsp;Class C | (15297) |  |
| &nbsp;&nbsp;&nbsp;Class I | (4748135) |  |
| Total distributions to shareholders | (5449436) |  |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 8576462 | 13208513 |
| &nbsp;&nbsp;&nbsp;Class A | 2398308 | 1618697 |
| &nbsp;&nbsp;&nbsp;Class C | 760700 | 250508 |
| &nbsp;&nbsp;&nbsp;Class I | 97554183 | 80767005 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 583567 |  |
| &nbsp;&nbsp;&nbsp;Class A | 96969 |  |
| &nbsp;&nbsp;&nbsp;Class C | 15209 |  |
| &nbsp;&nbsp;&nbsp;Class I | 4498959 |  |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (13716586) | (2227146) |
| &nbsp;&nbsp;&nbsp;Class A | (195278) | (129860) |
| &nbsp;&nbsp;&nbsp;Class C | (118297) | (2696) |
| &nbsp;&nbsp;&nbsp;Class I | (54691740) | (10501346) |
| Net increase in net assets from shares of beneficial interest | 45762456 | 82983675 |
| **TOTAL INCREASE IN NET ASSETS** | 57209841 | 92828445 |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Year | 106183183 | 13354738 |
| &nbsp;&nbsp;&nbsp;End of Year | $**163393024** | $**106183183** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **STATEMENT OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 594653 | 1073482 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 40471 |  |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (958678) | (167698) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (323554) | 905784 |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 168731 | 124512 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 6740 |  |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (14036) | (9870) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 161435 | 114642 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 54985 | 19051 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 1075 |  |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (8544) | (206) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 47516 | 18845 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 6782956 | 6219032 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 311160 |  |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (3799719) | (861446) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 3294397 | 5357586 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $5674693 | $4124196 |
| &nbsp;&nbsp;&nbsp;Net realized loss | (411501) | (995253) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation | 3761607 | 3826483 |
| Net increase in net assets resulting from operations | 9024799 | 6955426 |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;From Accumulated Earnings |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (641154) | (515651) |
| &nbsp;&nbsp;&nbsp;Class A | (159723) | (282483) |
| &nbsp;&nbsp;&nbsp;Class C | (43540) | (30364) |
| &nbsp;&nbsp;&nbsp;Class I | (4795342) | (3275627) |
| Total distributions to shareholders | (5639759) | (4104125) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 3245212 | 5325751 |
| &nbsp;&nbsp;&nbsp;Class A | 1423790 | 5593337 |
| &nbsp;&nbsp;&nbsp;Class C | 430944 | 517636 |
| &nbsp;&nbsp;&nbsp;Class I | 72438989 | 71435949 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 640240 | 514104 |
| &nbsp;&nbsp;&nbsp;Class A | 154867 | 278766 |
| &nbsp;&nbsp;&nbsp;Class C | 43461 | 30364 |
| &nbsp;&nbsp;&nbsp;Class I | 4502624 | 3066017 |
| &nbsp;&nbsp;&nbsp;Payments for shares redeemed: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (4852608) | (5935269) |
| &nbsp;&nbsp;&nbsp;Class A | (1907385) | (20858904) |
| &nbsp;&nbsp;&nbsp;Class C | (468802) | (632265) |
| &nbsp;&nbsp;&nbsp;Class I | (55654936) | (43733461) |
| Net increase in net assets from shares of beneficial interest | 19996396 | 15602025 |
| **TOTAL INCREASE IN NET ASSETS** | 23381436 | 18453326 |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Year | 145825539 | 127372213 |
| &nbsp;&nbsp;&nbsp;End of Year | $**169206975** | $**145825539** |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | **For the**<br>**Year Ended**<br>**June 30, 2025** | **For the**<br>**Year Ended**<br>**June 30, 2024** |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 323561 | 540489 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 63922 | 52457 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (484366) | (605720) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (96883) | (12774) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 141565 | 572186 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 15420 | 28422 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (190011) | (2133393) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (33026) | (1532785) |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 43235 | 52892 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 4359 | 3112 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (47069) | (64985) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 525 | (8981) |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 7038609 | 7107542 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 437711 | 304804 |
| &nbsp;&nbsp;&nbsp;Shares Redeemed | (5414576) | (4351992) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 2061744 | 3060354 |

---

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $13.78 | $12.44 | $12.12 | $14.21 | $11.38 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.25 | 0.19 | 0.16 | 0.10 | 0.08 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.89 | 1.35 | 0.47 | (1.35) | 2.95 |
| Total from investment operations | 1.14 | 1.54 | 0.63 | (1.25) | 3.03 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.26) | (0.20) | (0.15) | (0.21) | (0.18) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.12) | (0.63) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.04) |  |  |
| Total distributions | (0.26) | (0.20) | (0.31) | (0.84) | (0.20) |
| Net asset value, end of year | $14.66 | $13.78 | $12.44 | $12.12 | $14.21 |
| Total return (2) | 8.34% | 12.52% | 5.35% | (9.58)% | 26.81% |
| Net assets, at end of year (000s) | $18547 | $22308 | $30618 | $34856 | $39947 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.02% | 1.09% | 1.10% | 1.01% | 1.05% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.02% | 1.02% | 1.02% | 1.02% | 1.02% |
| Ratio of net investment income to average net assets (4)(5) | 1.74% | 1.51% | 1.34% | 0.69% | 0.59% |
| Portfolio Turnover Rate | 55% | 43% | 48% | 66% | 73% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's
 expenses in certain periods, total returns would have been lower.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $13.81 | $12.46 | $12.14 | $14.22 | $11.38 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.25 | 0.19 | 0.16 | 0.09 | 0.07 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.88 | 1.36 | 0.47 | (1.33) | 2.96 |
| Total from investment operations | 1.13 | 1.55 | 0.63 | (1.24) | 3.03 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.25) | (0.20) | (0.15) | (0.21) | (0.17) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.12) | (0.63) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.04) |  |  |
| Total distributions | (0.25) | (0.20) | (0.31) | (0.84) | (0.19) |
| Net asset value, end of year | $14.69 | $13.81 | $12.46 | $12.14 | $14.22 |
| Total return (2) | 8.27% | 12.53% (6) | 5.29% | (9.55)% | 26.84% |
| Net assets, at end of year (000s) | $37205 | $30175 | $25577 | $25744 | $23139 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.07% | 1.14% | 1.15% | 1.06% | 1.10% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.07% | 1.07% | 1.07% | 1.07% | 1.07% |
| Ratio of net investment income to average net assets (4)(5) | 1.72% | 1.47% | 1.32% | 0.65% | 0.55% |
| Portfolio Turnover Rate | 55% | 43% | 48% | 66% | 73% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges.
 Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(6) Includes
 adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset
 values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns
 for shareholder transactions.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $13.70 | $12.38 | $12.06 | $14.15 | $11.34 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | 0.14 | 0.09 | 0.07 | (0.01) | (0.03) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.89 | 1.34 | 0.47 | (1.35) | 2.95 |
| Total from investment operations | 1.03 | 1.43 | 0.54 | (1.36) | 2.92 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.15) | (0.11) | (0.06) | (0.10) | (0.09) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.12) | (0.63) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.04) |  |  |
| Total distributions | (0.15) | (0.11) | (0.22) | (0.73) | (0.11) |
| Net asset value, end of year | $14.58 | $13.70 | $12.38 | $12.06 | $14.15 |
| Total return (2) | 7.52% | 11.58% | 4.54% | (10.33)% | 25.85% |
| Net assets, at end of year (000s) | $16869 | $16020 | $16181 | $18146 | $18883 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.82% | 1.89% | 1.90% | 1.81% | 1.85% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.82% | 1.82% | 1.82% | 1.82% | 1.82% |
| Ratio of net investment income (loss) to average net assets (4)(5) | 0.96% | 0.72% | 0.56% | (0.10)% | (0.21)% |
| Portfolio Turnover Rate | 55% | 43% | 48% | 66% | 73% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's
 expenses in certain periods, total returns would have been lower.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income (loss) to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which
 the Fund invests.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Balanced Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $13.78 | $12.44 | $12.12 | $14.22 | $11.38 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.28 | 0.22 | 0.19 | 0.12 | 0.11 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.89 | 1.35 | 0.47 | (1.35) | 2.95 |
| Total from investment operations | 1.17 | 1.57 | 0.66 | (1.23) | 3.06 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.29) | (0.23) | (0.18) | (0.24) | (0.20) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.12) | (0.63) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.04) |  |  |
| Total distributions | (0.29) | (0.23) | (0.34) | (0.87) | (0.22) |
| Net asset value, end of year | $14.66 | $13.78 | $12.44 | $12.12 | $14.22 |
| Total return (2) | 8.55% | 12.75% | 5.57% | (9.46)% | 27.12% |
| Net assets, at end of year (000s) | $314422 | $311017 | $260688 | $269421 | $279142 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 0.82% | 0.89% | 0.90% | 0.81% | 0.85% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 0.82% | 0.82% | 0.82% | 0.82% | 0.82% |
| Ratio of net investment income to average net assets (4)(5) | 1.95% | 1.72% | 1.57% | 0.90% | 0.81% |
| Portfolio Turnover Rate | 55% | 43% | 48% | 66% | 73% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's
 expenses in certain periods, total returns would have been lower.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Period Ended**<br>**June 30, 2021 \*** |
| Net asset value, beginning of period/year | $8.08 | $8.15 | $8.41 | $9.66 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.33 | 0.28 | 0.17 | 0.08 | 0.05 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.14 | (0.09) | (0.25) | (1.20) | (0.29) |
| Total from investment operations | 0.47 | 0.19 | (0.08) | (1.12) | (0.24) |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.32) | (0.26) | (0.18) | (0.11) | (0.05) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.02) | (0.05) |
| Total distributions | (0.32) | (0.26) | (0.18) | (0.13) | (0.10) |
| Net asset value, end of period/year | $8.23 | $8.08 | $8.15 | $8.41 | $9.66 |
| Total return (2) | 5.93% | 2.34% | (0.89)% | (11.69)% | (2.39)% (6) |
| Net assets, at end of period/year (000s) | $37596 | $35467 | $37445 | $58166 | $56644 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.88% | 0.90% | 1.01% | 0.96% | 0.89% (7) |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.78% | 0.78% | 0.78% | 0.78% | 0.78% (7) |
| Ratio of net investment income to average net assets (4)(5) | 3.99% | 3.46% | 2.09% | 0.88% | 0.53% (7) |
| Portfolio Turnover Rate | 24% | 33% | 57% | 56% | 52% (6) |

---

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Period Ended**<br>**June 30, 2021 \*** |
| Net asset value, beginning of period/year | $8.12 | $8.18 | $8.44 | $9.71 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.33 | 0.28 | 0.18 | 0.07 | 0.05 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.13 | (0.09) | (0.26) | (1.22) | (0.27) |
| Total from investment operations | 0.46 | 0.19 | (0.08) | (1.15) | (0.22) |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.32) | (0.25) | (0.18) | (0.10) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.02) | (0.05) |
| Total distributions | (0.32) | (0.25) | (0.18) | (0.12) | (0.07) |
| Net asset value, end of period/year | $8.26 | $8.12 | $8.18 | $8.44 | $9.71 |
| Total return (2) | 5.73% | 2.42% | (0.90)% | (11.91)% | (2.28)% (6) |
| Net assets, at end of period/year (000s) | $979 | $608 | $412 | $197 | $384 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.93% | 0.95% | 1.06% | 1.01% | 0.94% (7) |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.83% | 0.83% | 0.83% | 0.83% | 0.83% (7) |
| Ratio of net investment income to average net assets (4)(5) | 3.94% | 3.47% | 2.19% | 0.78% | 0.51% (7) |
| Portfolio Turnover Rate | 24% | 33% | 57% | 56% | 52% (6) |

---

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Period Ended**<br>**June 30, 2021 \*** |
| Net asset value, beginning of period/year | $8.03 | $8.11 | $8.37 | $9.63 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | 0.26 | 0.22 | 0.11 | 0.01 | (0.02) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.14 | (0.09) | (0.25) | (1.20) | (0.28) |
| Total from investment operations | 0.40 | 0.13 | (0.14) | (1.19) | (0.30) |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.26) | (0.21) | (0.12) | (0.06) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.01) | (0.05) |
| Total distributions | (0.26) | (0.21) | (0.12) | (0.07) | (0.07) |
| Net asset value, end of period/year | $8.17 | $8.03 | $8.11 | $8.37 | $9.63 |
| Total return (2) | 5.04% | 1.53% | (1.67)% | (12.37)% | (3.02)% (6) |
| Net assets, at end of period/year (000s) | $644 | $492 | $221 | $224 | $163 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.68% | 1.70% | 1.81% | 1.76% | 1.69% (7) |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.58% | 1.58% | 1.58% | 1.58% | 1.58% (7) |
| Ratio of net investment income (loss) to average net assets (4)(5) | 3.19% | 2.74% | 1.35% | 0.09% | (0.20)% (7) |
| Portfolio Turnover Rate | 24% | 33% | 57% | 56% | 52% (6) |

---

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income/(loss) to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Core Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Period Ended**<br>**June 30, 2021 \*** |
| Net asset value, beginning of period/year | $8.08 | $8.15 | $8.41 | $9.66 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.35 | 0.30 | 0.20 | 0.09 | 0.07 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.14 | (0.10) | (0.26) | (1.19) | (0.29) |
| Total from investment operations | 0.49 | 0.20 | (0.06) | (1.10) | (0.22) |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.34) | (0.27) | (0.20) | (0.13) | (0.07) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.02) | (0.05) |
| Total distributions | (0.34) | (0.27) | (0.20) | (0.15) | (0.12) |
| Net asset value, end of period/year | $8.23 | $8.08 | $8.15 | $8.41 | $9.66 |
| Total return (2) | 6.14% | 2.54% | (0.67)% | (11.51)% | (2.24)% (6) |
| Net assets, at end of period/year (000s) | $109551 | $100738 | $39300 | $13877 | $64377 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.68% | 0.70% | 0.81% | 0.76% | 0.69% (7) |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.58% | 0.58% | 0.58% | 0.58% | 0.58% (7) |
| Ratio of net investment income to average net assets (4)(5) | 4.19% | 3.77% | 2.45% | 1.00% | 0.80% (7) |
| Portfolio Turnover Rate | 24% | 33% | 57% | 56% | 52% (6) |

---

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $17.72 | $14.65 | $13.43 | $15.86 | $10.88 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.08 | 0.06 | 0.11 | 0.05 | 0.04 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.70 | 3.07 | 1.31 | (2.01) | 5.08 |
| Total from investment operations | 1.78 | 3.13 | 1.42 | (1.96) | 5.12 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.09) | (0.06) | (0.10) | (0.18) | (0.14) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.09) | (0.29) |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.01) |  |  |
| Total distributions | (0.09) | (0.06) | (0.20) | (0.47) | (0.14) |
| Net asset value, end of year | $19.41 | $17.72 | $14.65 | $13.43 | $15.86 |
| Total return (2) | 10.08% | 21.40% | 10.66% | (12.90)% | 47.21% |
| Net assets, at end of year (000s) | $77293 | $87873 | $91912 | $74940 | $70566 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.14% | 1.16% | 1.23% | 1.14% | 1.19% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.15% | 1.15% | 1.15% | 1.15% | 1.15% |
| Ratio of net investment income to average net assets (4)(5) | 0.45% | 0.40% | 0.75% | 0.34% | 0.27% |
| Portfolio Turnover Rate | 58% | 38% | 50% | 50% | 35% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived or recaptured a portion
 of the Fund's expenses in certain periods, total returns would have been lower/higher.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $17.73 | $14.66 | $13.43 | $15.85 | $10.87 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.07 | 0.05 | 0.10 | 0.05 | 0.03 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.71 | 3.07 | 1.32 | (2.01) | 5.08 |
| Total from investment operations | 1.78 | 3.12 | 1.42 | (1.96) | 5.11 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.09) | (0.05) | (0.06) | (0.17) | (0.13) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.09) | (0.29) |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.04) |  |  |
| Total distributions | (0.09) | (0.05) | (0.19) | (0.46) | (0.13) |
| Net asset value, end of year | $19.42 | $17.73 | $14.66 | $13.43 | $15.85 |
| Total return (2) | 10.03% | 21.35% | 10.68% | (12.88)% | 47.22% |
| Net assets, at end of year (000s) | $65648 | $50563 | $36722 | $29243 | $17865 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.19% | 1.21% | 1.28% | 1.19% | 1.24% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.20% | 1.20% | 1.20% | 1.20% | 1.20% |
| Ratio of net investment income to average net assets (4)(5) | 0.40% | 0.34% | 0.69% | 0.31% | 0.22% |
| Portfolio Turnover Rate | 58% | 38% | 50% | 50% | 35% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges.
 Had the advisor not waived or recaptured a portion of the Fund's expenses in certain periods, total returns would have been lower/higher.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $17.52 | $14.54 | $13.34 | $15.77 | $10.86 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | (0.07) | (0.06) | (0.01) | (0.07) | (0.08) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.66 | 3.04 | 1.31 | (2.00) | 5.06 |
| Total from investment operations | 1.59 | 2.98 | 1.30 | (2.07) | 4.98 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  |  |  | (0.07) | (0.07) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.09) | (0.29) |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.01) |  |  |
| Total distributions |  |  | (0.10) | (0.36) | (0.07) |
| Net asset value, end of year | $19.11 | $17.52 | $14.54 | $13.34 | $15.77 |
| Total return (2) | 9.19 | 20.50 | 9.78% | (13.57)% | 45.93% |
| Net assets, at end of year (000s) | $27018 | $19564 | $14889 | $9975 | $4508 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 1.94 | 1.96 | 2.03% | 1.94% | 1.99% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 1.95 | 1.95 | 1.95% | 1.95% | 1.95% |
| Ratio of net investment income (loss) to average net assets (4)(5) | (0.36) | (0.40) | (0.05)% | (0.42)% | (0.53)% |
| Portfolio Turnover Rate | 58 | 38 | 50% | 50% | 35% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived or recaptured a portion
 of the Fund's expenses in certain periods, total returns would have been lower/higher.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income/(loss) to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which
 the Fund invests.

(6) As
 required by SEC standard per share data calculation methodology, this represents a balancing figure derived from the other amounts in
 the financial highlights tables that captures all other changes affecting net asset value per share. This per share loss amount does not
 correlate to the aggregate of the net investment income in the Statement of Operations for the fiscal year, primarily due to the timing
 of sales and repurchases of the Fund's shares in relation to underlying income.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Dividend Growth Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $17.74 | $14.66 | $13.44 | $15.87 | $10.88 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.12 | 0.09 | 0.13 | 0.09 | 0.07 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.70 | 3.08 | 1.32 | (2.02) | 5.07 |
| Total from investment operations | 1.82 | 3.17 | 1.45 | (1.93) | 5.14 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.13) | (0.09) | (0.11) | (0.21) | (0.15) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.09) | (0.29) |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.03) |  |  |
| Total distributions | (0.13) | (0.09) | (0.23) | (0.50) | (0.15) |
| Net asset value, end of year | $19.43 | $17.74 | $14.66 | $13.44 | $15.87 |
| Total return (2) | 10.30% | 21.70% | 10.87% | (12.72)% | 47.49% |
| Net assets, at end of year (000s) | $1032728 | $705913 | $430286 | $305801 | $237256 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4) | 0.94% | 0.96% | 1.03% | 0.94% | 0.99% |
| Ratio of net expenses to average net assets after expense reimbursement/recapture (4) | 0.95% | 0.95% | 0.95% | 0.95% | 0.95% |
| Ratio of net investment income to average net assets (4)(5) | 0.65% | 0.61% | 0.96% | 0.55% | 0.48% |
| Portfolio Turnover Rate | 58% | 38% | 50% | 50% | 35% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived or recaptured a portion
 of the Fund's expenses in certain periods, total returns would have been lower/higher.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021 \*** |
| Net asset value, beginning of year | $11.96 | $12.00 | $10.92 | $19.08 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.16) | (0.17) | (0.13) | (0.25) | (0.25) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.67 | 0.13 | 1.20 | (7.69) | 9.33 |
| Total from investment operations | 1.51 | (0.04) | 1.07 | (7.94) | 9.08 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  | (0.23) | (0.02) |
| Total distributions |  |  |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees (1) |  |  | 0.01 | 0.01 | 0.02 |
| Net asset value, end of year | $13.47 | $11.96 | $12.00 | $10.92 | $19.08 |
| Total return (2) | 12.63% | (0.33)% | 9.89% | (42.00)% | 91.00% |
| Net assets, at end of year (000s) | $19462 | $19201 | $22186 | $12479 | $15730 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.74% | 1.69% | 1.70% | 1.63% | 1.73% |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.63% | 1.63% | 1.63% | 1.63% | 1.63% |
| Ratio of net investment loss to average net assets (4)(5) | (1.28)% | (1.36)% | (1.23)% | (1.54)% | (1.50)% |
| Portfolio Turnover Rate | 126% | 70% | 80% | 69% | 60% |

---

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021 \*** |
| Net asset value, beginning of year | $11.96 | $12.00 | $10.93 | $19.08 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.17) | (0.17) | (0.14) | (0.25) | (0.26) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.67 | 0.13 | 1.20 | (7.68) | 9.34 |
| Total from investment operations | 1.50 | (0.04) | 1.06 | (7.93) | 9.08 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  | (0.23) | (0.02) |
| Total distributions |  |  |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees (1) |  |  | 0.01 | 0.01 | 0.02 |
| Net asset value, end of year | $13.46 | $11.96 | $12.00 | $10.93 | $19.08 |
| Total return (2) | 12.54% | (0.33)% | 9.79% | (41.95)% | 91.00% |
| Net assets, at end of year (000s) | $8133 | $8421 | $8257 | $7377 | $7662 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.79% | 1.74% | 1.75% | 1.68% | 1.78% |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.68% | 1.68% | 1.68% | 1.68% | 1.68% |
| Ratio of net investment loss to average net assets (4)(5) | (1.33)% | (1.41)% | (1.28)% | (1.58)% | (1.55)% |
| Portfolio Turnover Rate | 126% | 70% | 80% | 69% | 60% |

---

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021 \*** |
| Net asset value, beginning of year | $11.61 | $11.74 | $10.77 | $18.96 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.25) | (0.25) | (0.21) | (0.37) | (0.38) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.60 | 0.12 | 1.17 | (7.60) | 9.35 |
| Total from investment operations | 1.35 | (0.13) | 0.96 | (7.97) | 8.97 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  | (0.23) | (0.02) |
| Total distributions |  |  |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees (1) |  |  | 0.01 | 0.01 | 0.01 |
| Net asset value, end of year | $12.96 | $11.61 | $11.74 | $10.77 | $18.96 |
| Total return (2) | 11.63% | (1.11)% | 9.01% | (42.43)% | 89.80% |
| Net assets, at end of year (000s) | $2148 | $2550 | $2635 | $2422 | $2065 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 2.54% | 2.49% | 2.50% | 2.43% | 2.53% |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 2.43% | 2.43% | 2.43% | 2.43% | 2.43% |
| Ratio of net investment loss to average net assets (4)(5) | (2.08)% | (2.16)% | (2.03)% | (2.33)% | (2.30)% |
| Portfolio Turnover Rate | 126% | 70% | 80% | 69% | 60% |

---

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Exponential Technologies Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021 \*** |
| Net asset value, beginning of year | $12.07 | $12.08 | $10.97 | $19.12 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.14) | (0.14) | (0.11) | (0.22) | (0.22) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 1.69 | 0.13 | 1.21 | (7.71) | 9.34 |
| Total from investment operations | 1.55 | (0.01) | 1.10 | (7.93) | 9.12 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  | (0.23) | (0.02) |
| Total distributions |  |  |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees (1) |  |  | 0.01 | 0.01 | 0.02 |
| Net asset value, end of year | $13.62 | $12.07 | $12.08 | $10.97 | $19.12 |
| Total return (2) | 12.84% | (0.08)% | 10.12% | (41.86)% | 91.40% |
| Net assets, at end of year (000s) | $67544 | $85315 | $82735 | $72567 | $96821 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.54% | 1.49% | 1.50% | 1.43% | 1.53% |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.43% | 1.43% | 1.43% | 1.43% | 1.43% |
| Ratio of net investment loss to average net assets (4)(5) | (1.08)% | (1.16)% | (1.02)% | (1.33)% | (1.30)% |
| Portfolio Turnover Rate | 126% | 70% | 80% | 69% | 60% |

---

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $48.15 | $48.25 | $44.10 | $69.91 | $47.16 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.46) | (0.38) | (0.27) | (0.53) | (0.51) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 6.99 | 0.28 | 6.70 | (21.01) | 23.77 |
| Total from investment operations | 6.53 | (0.10) | 6.43 | (21.54) | 23.26 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Total distributions | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Net asset value, end of year | $54.04 | $48.15 | $48.25 | $44.10 | $69.91 |
| Total return (2) | 13.63% | (0.21)% (5) | 15.29% (5) | (32.65)% | 49.43% |
| Net assets, at end of year (000s) | $288736 | $427768 | $526825 | $529869 | $827811 |
| Ratio of net expenses to average net assets (3) | 1.38% | 1.36% | 1.38% | 1.31% | 1.31% |
| Ratio of net investment loss to average net assets (3)(4) | (0.91)% | (0.79)% | (0.59)% | (0.86)% | (0.85)% |
| Portfolio Turnover Rate | 60% | 36% | 34% | 27% | 19% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The
 ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment
 companies in which the Fund invests.

(4) Recognition
 of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(5) Includes
 adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset
 values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns
 for shareholder transactions.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $47.80 | $47.94 | $43.83 | $69.53 | $46.92 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.48) | (0.41) | (0.29) | (0.55) | (0.54) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 6.93 | 0.27 | 6.68 | (20.88) | 23.66 |
| Total from investment operations | 6.45 | (0.14) | 6.39 | (21.43) | 23.12 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Total distributions | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Net asset value, end of year | $53.61 | $47.80 | $47.94 | $43.83 | $69.53 |
| Total return (2) | 13.56% | (0.29)% (5) | 15.30% (5) | (32.67)% | 49.39% |
| Net assets, at end of year (000s) | $307538 | $320983 | $351924 | $302171 | $458726 |
| Ratio of net expenses to average net assets (3) | 1.43% | 1.41% | 1.43% | 1.36% | 1.36% |
| Ratio of net investment loss to average net assets (3)(4) | (0.96)% | (0.85)% | (0.65)% | (0.91)% | (0.91)% |
| Portfolio Turnover Rate | 60% | 36% | 34% | 27% | 19% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges.

(3) The
 ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment
 companies in which the Fund invests.

(4) Recognition
 of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(5) Includes
 adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset
 values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns
 for shareholder transactions.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $41.71 | $42.13 | $39.09 | $62.97 | $42.86 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.74) | (0.67) | (0.55) | (0.91) | (0.89) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 6.02 | 0.25 | 5.87 | (18.70) | 21.51 |
| Total from investment operations | 5.28 | (0.42) | 5.32 | (19.61) | 20.62 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Total distributions | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Net asset value, end of year | $46.35 | $41.71 | $42.13 | $39.09 | $62.97 |
| Total return (2) | 12.73% | (1.00)% (5) | 14.38% (5) | (33.21)% | 48.23% |
| Net assets, at end of year (000s) | $139105 | $166155 | $218201 | $235967 | $404272 |
| Ratio of net expenses to average net assets (3) | 2.18% | 2.16% | 2.18% | 2.11% | 2.11% |
| Ratio of net investment loss to average net assets (3)(4) | (1.71)% | (1.59)% | (1.40)% | (1.67)% | (1.65)% |
| Portfolio Turnover Rate | 60% | 36% | 34% | 27% | 19% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The
 ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment
 companies in which the Fund invests.

(4) Recognition
 of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(5) Includes
 adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset
 values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns
 for shareholder transactions.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Gilead Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $49.80 | $49.82 | $45.36 | $71.65 | $48.22 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.37) | (0.30) | (0.19) | (0.41) | (0.40) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 7.24 | 0.28 | 6.93 | (21.61) | 24.34 |
| Total from investment operations | 6.87 | (0.02) | 6.74 | (22.02) | 23.94 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Total distributions | (0.64) |  | (2.28) | (4.27) | (0.51) |
| Net asset value, end of year | $56.03 | $49.80 | $49.82 | $45.36 | $71.65 |
| Total return (2) | 13.86% | (0.04)% (5) | 15.56% (5) | (32.52)% | 49.76% |
| Net assets, at end of year (000s) | $2054852 | $2434432 | $2663688 | $2408991 | $3522353 |
| Ratio of net expenses to average net assets (3) | 1.18% | 1.16% | 1.18% | 1.11% | 1.11% |
| Ratio of net investment loss to average net assets (3)(4) | (0.71)% | (0.60)% | (0.40)% | (0.66)% | (0.65)% |
| Portfolio Turnover Rate | 60% | 36% | 34% | 27% | 19% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The
 ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment
 companies in which the Fund invests.

(4) Recognition
 of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(5) Includes
 adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset
 values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns
 for shareholder transactions.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $33.30 | $36.63 | $26.52 | $46.19 | $43.33 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.44) | (0.42) | (0.37) | (0.57) | (0.72) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.35 | (2.91) | 10.48 | (14.74) | 5.52 |
| Total from investment operations | (0.09) | (3.33) | 10.11 | (15.31) | 4.80 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  |  |  | (0.63) |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  | (3.73) | (1.94 |
| Total distributions |  |  |  | (4.36) | (1.94 |
| Paid-in-capital from redemption fees (1) |  |  |  |  | 0.00 |
| Net asset value, end of year | $33.21 | $33.30 | $36.63 | $26.52 | $46.19 |
| Total return (2) | (0.27)% | (9.09)% (6) | 38.12% (6) | (35.99)% (6) | 10.34 |
| Net assets, at end of year (000s) | $59748 | $93027 | $133006 | $115954 | $227441 |
| Ratio of net expenses to average net assets (3) | 1.51% | 1.52% | 1.50% | 1.50% | 1.48 |
| Ratio of net investment loss to average net assets (3)(4) | (1.31)% | (1.24)% | (1.14)% | (1.49)% | (1.47) |
| Portfolio Turnover Rate | 41% | 71% | 79% | 59% | 62 |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The
 ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment
 companies in which the Fund invests.

(4) Recognition
 of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(5) Amount
 represents less than $0.01 per share.

(6) Includes
 adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset
 values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns
 for shareholder transactions.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $33.04 | $36.37 | $26.34 | $45.91 | $43.10 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.45) | (0.44) | (0.38) | (0.58) | (0.74) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.34 | (2.89) | 10.41 | (14.64) | 5.49 |
| Total from investment operations | (0.11) | (3.33) | 10.03 | (15.22) | 4.75 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  |  |  | (0.62) |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  | (3.73) | (1.94 |
| Total distributions |  |  |  | (4.35) | (1.94 |
| Paid-in-capital from redemption fees (1) |  |  |  |  | 0.00 |
| Net asset value, end of year | $32.93 | $33.04 | $36.37 | $26.34 | $45.91 |
| Total return (2) | (0.33)% | (9.16)% (6) | 38.08% (6) | (36.02)% (6) | 10.28 |
| Net assets, at end of year (000s) | $97510 | $122423 | $151885 | $114642 | $191709 |
| Ratio of net expenses to average net assets (3) | 1.56% | 1.57% | 1.55% | 1.55% | 1.53 |
| Ratio of net investment loss to average net assets (3)(4) | (1.35)% | (1.29)% | (1.19)% | (1.54)% | (1.52) |
| Portfolio Turnover Rate | 41% | 71% | 79% | 59% | 62 |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges.

(3) The
 ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment
 companies in which the Fund invests.

(4) Recognition
 of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(5) Amount
 represents less than $0.01 per share.

(6) Includes
 adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset
 values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns
 for shareholder transactions.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $30.11 | $33.39 | $24.37 | $42.78 | $40.56 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.64) | (0.63) | (0.57) | (0.80) | (1.04) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.32 | (2.65) | 9.59 | (13.60) | 5.20 |
| Total from investment operations | (0.32) | (3.28) | 9.02 | (14.40) | 4.16 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  |  |  | (0.28) |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  | (3.73) | (1.94 |
| Total distributions |  |  |  | (4.01) | (1.94 |
| Paid-in-capital from redemption fees (1) |  |  |  |  | 0.00 |
| Net asset value, end of year | $29.79 | $30.11 | $33.39 | $24.37 | $42.78 |
| Total return (2) | (1.06)% | (9.82)% (6) | 37.01% (6) | (36.51)% (6) | 9.45 |
| Net assets, at end of year (000s) | $37460 | $55661 | $76849 | $66540 | $120351 |
| Ratio of net expenses to average net assets (3) | 2.31% | 2.32% | 2.30% | 2.30% | 2.28 |
| Ratio of net investment loss to average net assets (3)(4) | (2.10)% | (2.04)% | (1.94)% | (2.29)% | (2.27) |
| Portfolio Turnover Rate | 41% | 71% | 79% | 59% | 62 |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The
 ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment
 companies in which the Fund invests.

(4) Recognition
 of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(5) Amount
 represents less than $0.01 per share.

(6) Includes
 adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset
 values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns
 for shareholder transactions.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Healthcare & Life Sciences Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $34.09 | $37.45 | $27.05 | $47.04 | $44.02 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.38) | (0.37) | (0.31) | (0.49) | (0.64) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.35 | (2.99) | 10.71 | (15.03) | 5.60 |
| Total from investment operations | (0.03) | (3.36) | 10.40 | (15.52) | 4.96 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  |  |  | (0.74) |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  | (3.73) | (1.94 |
| Total distributions |  |  |  | (4.47) | (1.94 |
| Paid-in-capital from redemption fees (1) |  |  |  |  | 0.00 |
| Net asset value, end of year | $34.06 | $34.09 | $37.45 | $27.05 | $47.04 |
| Total return (2) | (0.09)% | (8.97)% (6) | 38.45% (6) | (35.85)% (6) | 10.54 |
| Net assets, at end of year (000s) | $951152 | $1168805 | $1441422 | $1024430 | $1573091 |
| Ratio of net expenses to average net assets (3) | 1.31% | 1.32% | 1.30% | 1.30% | 1.28 |
| Ratio of net investment loss to average net assets (3)(4) | (1.10)% | (1.04)% | (0.94)% | (1.29)% | (1.28) |
| Portfolio Turnover Rate | 41% | 71% | 79% | 59% | 62 |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The
 ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment
 companies in which the Fund invests.

(4) Recognition
 of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(5) Amount
 represents less than $0.01 per share.

(6) Includes
 adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset
 values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns
 for shareholder transactions.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023 \*** |
| Net asset value, beginning of year | $14.01 | $11.44 | $10.00 |
| Activity from investment operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | 0.02 | (0.00) | (0.01) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain on investments | 1.64 | 2.57 | 1.45 |
| Total from investment operations | 1.66 | 2.57 | 1.44 |
| Less distributions from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.02) |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.48) |  |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.00 |
| Total distributions | (0.50) |  | (0.00 |
| Net asset value, end of year | $15.17 | $14.01 | $11.44 |
| Total return (2) | 12.09% | 22.47 | 14.43 |
| Net assets, at end of year (000s) | $9268 | $13097 | $330 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.33% | 1.38 | 2.84 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.14% | 1.14 | 1.15 |
| Ratio of net investment loss to average net assets (4)(5) | 0.14% | (0.02) | (0.15) |
| Portfolio Turnover Rate | 50% | 101 | 48 |

---

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Amount represents less than $0.01 per share.

(7) As required by SEC standard per share data calculation methodology, this represents a balancing figure derived from the other amounts in the financial highlights tables that captures all other changes affecting net asset value per share. This per share loss amount does not correlate to the aggregate of the net investment income in the Statement of Operations for the fiscal year, primarily due to the timing of sales and repurchases of the Fund's shares in relation to underlying income.

(8) The ratio includes 0.01% for the year ended June 30, 2023 attributed to line of credit fees.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023 \*** |
| Net asset value, beginning of year | $13.99 | $11.42 | $10.00 |
| Activity from investment operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | 0.01 | (0.00) | (0.00) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain on investments | 1.63 | 2.57 | 1.43 |
| Total from investment operations | 1.64 | 2.57 | 1.43 |
| Less distributions from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.02) |  | 0.00 |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.48) |  |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.01 |
| Total distributions | (0.50) |  | (0.01 |
| Net asset value, end of year | $15.13 | $13.99 | $11.42 |
| Total return (2) | 11.94% | 22.50 | 14.26 |
| Net assets, at end of year (000s) | $4428 | $1836 | $190 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.38% | 1.43 | 2.89 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.19% | 1.19 | 1.20 |
| Ratio of net investment loss to average net assets (4)(5) | 0.09% | (0.03) | (0.25) |
| Portfolio Turnover Rate | 50% | 101 | 48 |

---

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Amount represents less than $0.01 per share.

(7) As required by SEC standard per share data calculation methodology, this represents a balancing figure derived from the other amounts in the financial highlights tables that captures all other changes affecting net asset value per share. This per share loss amount does not correlate to the aggregate of the net investment income in the Statement of Operations for the fiscal year, primarily due to the timing of sales and repurchases of the Fund's shares in relation to underlying income.

(8) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(9) The ratio includes 0.01% for the year ended June 30, 2023 attributed to line of credit fees.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023 \*** |
| Net asset value, beginning of year | $13.79 | $11.36 | $10.00 |
| Activity from investment operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss (1) | (0.09) | (0.09) | (0.09) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain on investments | 1.61 | 2.52 | 1.45 |
| Total from investment operations | 1.52 | 2.43 | 1.36 |
| Less distributions from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.48 |  |  |
| Total distributions | (0.48 |  |  |
| Net asset value, end of year | $14.83 | $13.79 | $11.36 |
| Total return (2) | 11.24 | 21.39 | 13.60% |
| Net assets, at end of year (000s) | $1019 | $292 | $27 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 2.13 | 2.18 | 3.64% (7) |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.94 | 1.94 | 1.95% (7) |
| Ratio of net investment loss to average net assets (4)(5) | (0.66) | (0.68) | (0.93)% |
| Portfolio Turnover Rate | 50 | 101 | 48% |

---

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) As required by SEC standard per share data calculation methodology, this represents a balancing figure derived from the other amounts in the financial highlights tables that captures all other changes affecting net asset value per share. This per share loss amount does not correlate to the aggregate of the net investment income in the Statement of Operations for the fiscal year, primarily due to the timing of sales and repurchases of the Fund's shares in relation to underlying income.

(7) The ratio includes 0.01% for the year ended June 30, 2023 attributed to line of credit fees.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Large Cap Focus Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** |  | **Year Ended**<br>**June 30, 2023 \*** |
| Net asset value, beginning of year | $14.04 | $11.44 |  | $10.00 |
| Activity from investment operations: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.04 | 0.03 |  | 0.01 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain on investments | 1.65 | 2.57 | (4) | 1.44 |
| Total from investment operations | 1.69 | 2.60 |  | 1.45 |
| Less distributions from: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.03) |  |  | (0.00) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.48) |  |  |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.01 |
| Total distributions | (0.51) |  |  | (0.01 |
| Net asset value, end of year | $15.22 | $14.04 |  | $11.44 |
| Total return (2) | 12.32% | 22.73 | % | 14.55 |
| Net assets, at end of year (000s) | $148678 | $90959 |  | $12808 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.13% | 1.18 | % | 2.64 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.94% | 0.94 | % | 0.95 |
| Ratio of net investment income (loss) to average net assets (4)(5) | 0.34% | 0.24 | % | 0.08 |
| Portfolio Turnover Rate | 50% | 101 | % | 48 |

---

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Amount represents less than $0.01 per share.

(7) The ratio includes 0.01% for the year ended June 30, 2023 attributed to line of credit fees.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class N** | **Class N** | **Class N** | **Class N** | **Class N** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $9.89 | $9.68 | $9.72 | $10.49 | $10.62 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.35 | 0.28 | 0.16 | 0.04 | 0.06 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.22 | 0.22 | (0.04 | (0.69) | (0.01) |
| Total from investment operations | 0.57 | 0.50 | 0.12 | (0.65) | 0.05 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.36) | (0.29) | (0.16) | (0.07) | (0.07) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (0.07) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.00 | (0.05) | (0.04) |
| Total distributions | (0.36) | (0.29) | (0.16 | (0.12) | (0.18) |
| Net asset value, end of year | $10.10 | $9.89 | $9.68 | $9.72 | $10.49 |
| Total return (2) | 5.80% | 5.18% | 1.29 | (6.26)% | 0.48% |
| Net assets, at end of year (000s) | $17359 | $17949 | $17698 | $5622 | $6906 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.80% | 0.89% | 0.91 | 0.84% | 0.86% |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.75% | 0.75% | 0.75 | 0.75% | 0.75% |
| Ratio of net investment income to average net assets (4)(5) | 3.50% | 2.87% | 1.66 | 0.42% | 0.54% |
| Portfolio Turnover Rate | 7% | 33% | 34 | 48% | 72% |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's
 expenses in certain periods, total returns would have been lower.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(6) Amount
 represents less than $0.01 per share.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class A** | **Class A** | **Class A** | **Class A** | **Class A** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $9.91 | $9.70 | $9.75 | $10.51 | $10.65 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.35 | 0.27 | 0.14 | 0.04 | 0.03 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealised gain (loss) on investments | 0.22 | 0.22 | (0.03 | (0.69) | 0.01 |
| Total from investment operations | 0.57 | 0.49 | 0.11 | (0.65) | 0.04 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.35) | (0.28) | (0.16) | (0.06) | (0.07) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (0.07) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.00 | (0.05) | (0.04 |
| Total distributions | (0.35) | (0.28) | (0.16 | (0.11) | (0.18 |
| Paid-in-capital from redemption fees (1) |  |  |  |  |  |
| Net asset value, end of year | $10.13 | $9.91 | $9.70 | $9.75 | $10.51 |
| Total return (2) | 5.84% | 5.09% | 1.14 | (6.20)% | 0.45 |
| Net assets, at end of year (000s) | $4378 | $4612 | $19390 | $22210 | $29596 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.85% | 0.94% | 0.96 | 0.89% | 0.91 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.80% | 0.80% | 0.80 | 0.80% | 0.80 |
| Ratio of net investment income to average net assets (4)(5) | 3.45% | 2.70% | 1.47 | 0.37% | 0.27 |
| Portfolio Turnover Rate | 7% | 33% | 34 | 48% | 72 |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges.
 Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(6) Due
 to the timing of shareholder transactions, and allocations of expenses among share classes, the per unit amounts presented may not coincide
 with the aggregate presentation on the Statements of Operations.

(7) Amount
 represents less than $0.01 per share.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class C** | **Class C** | **Class C** | **Class C** | **Class C** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $9.84 | $9.64 | $9.68 | $10.44 | $10.60 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) (1) | 0.27 | 0.20 | 0.07 | (0.04) | (0.05) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.22 | 0.21 | (0.02 | (0.68) | 0.01 |
| Total from investment operations | 0.49 | 0.41 | 0.05 | (0.72) | (0.04 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.27) | (0.21) | (0.09) | (0.02) | (0.01) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (0.07) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.00 | (0.02) | (0.04 |
| Total distributions | (0.27) | (0.21) | (0.09 | (0.04) | (0.12 |
| Net asset value, end of year | $10.06 | $9.84 | $9.64 | $9.68 | $10.44 |
| Total return (2) | 5.10% | 4.26% | 0.49 | (6.94)% | (0.38 |
| Net assets, at end of year (000s) | $1603 | $1564 | $1618 | $1678 | $1545 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 1.60% | 1.69% | 1.71 | 1.64% | 1.66 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 1.55% | 1.55% | 1.55 | 1.55% | 1.55 |
| Ratio of net investment income (loss) to average net assets (4)(5) | 2.70% | 2.05% | 0.74 | (0.37)% | (0.50) |
| Portfolio Turnover Rate | 7% | 33% | 34 | 48% | 72 |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's
 expenses in certain periods, total returns would have been lower.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which
 the Fund invests.

(6) Due
 to the timing of shareholder transactions, and allocations of expenses among share classes, the per unit amounts presented may not coincide
 with the aggregate presentation on the Statements of Operations.

(7) Amount
 represents less than $0.01 per share.

See accompanying notes to financial statements.

---

| |
|:---|
| ***Eventide Limited-Term Bond Fund*** |
| **FINANCIAL HIGHLIGHTS** |
| Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Class I** | **Class I** | **Class I** | **Class I** | **Class I** |
|  | **Year Ended**<br>**June 30, 2025** | **Year Ended**<br>**June 30, 2024** | **Year Ended**<br>**June 30, 2023** | **Year Ended**<br>**June 30, 2022** | **Year Ended**<br>**June 30, 2021** |
| Net asset value, beginning of year | $10.15 | $9.93 | $9.97 | $10.75 | $10.89 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (1) | 0.38 | 0.31 | 0.16 | 0.07 | 0.05 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.23 | 0.22 | (0.02 | (0.71) | 0.01 |
| Total from investment operations | 0.61 | 0.53 | 0.14 | (0.64) | 0.06 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.38) | (0.31) | (0.18) | (0.08) | (0.09) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  |  |  | (0.07) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  | (0.00 | (0.06) | (0.04 |
| Total distributions | (0.38) | (0.31) | (0.18 | (0.14) | (0.20 |
| Paid-in-capital from redemption fees (1) |  |  |  |  |  |
| Net asset value, end of year | $10.38 | $10.15 | $9.93 | $9.97 | $10.75 |
| Total return (2) | 6.06% | 5.35% | 1.46 | (6.02)% | 0.65 |
| Net assets, at end of year (000s) | $145867 | $121701 | $88666 | $152546 | $144089 |
| Ratio of gross expenses to average net assets before expense reimbursement (3)(4) | 0.60% | 0.69% | 0.71 | 0.64% | 0.66 |
| Ratio of net expenses to average net assets after expense reimbursement (4) | 0.55% | 0.55% | 0.55 | 0.55% | 0.55 |
| Ratio of net investment income to average net assets (4)(5) | 3.71% | 3.10% | 1.68 | 0.64% | 0.49 |
| Portfolio Turnover Rate | 7% | 33% | 34 | 48% | 72 |

---

(1) Per
 share amounts calculated using the average shares method.

(2) Total
 return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment
 in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's
 expenses in certain periods, total returns would have been lower.

(3) Represents
 the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The
 ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying
 investment companies in which the Fund invests.

(5) Recognition
 of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund
 invests.

(6) Due
 to the timing of shareholder transactions, and allocations of expenses among share classes, the per unit amounts presented may not coincide
 with the aggregate presentation on the Statements of Operations.

(7) Amount
 represents less than $0.01 per share.

See accompanying notes to financial statements.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS*** |
| **June 30, 2025** |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(1)** **ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES** 

Mutual Fund Series Trust (the "***Trust***"), was organized as an Ohio business trust on February 27, 2006. The Trust is registered as an open-end management investment company under the Investment Company Act of 1940, as amended ("***1940 Act***"). The Trust currently consists of thirty-five series. These financial statements include the following series: Eventide Balanced Fund, Eventide Core Bond Fund, Eventide Dividend Growth Fund (formerly Eventide Dividend Opportunities Fund), Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund and the Eventide Limited-Term Bond Fund (each a "***Fund***" or collectively the "***Funds***"). Each Fund except Eventide Exponential Technologies Fund is a diversified series of the Trust. Eventide Exponential Technologies Fund is a non-diversified series of the Trust. The Funds' investment advisor is Eventide Asset Management, LLC (the "***Advisor***").

Eventide Balanced Fund commenced operations on July 15, 2015. The Fund's investment objective is current income while maintaining the potential for capital appreciation.

Eventide Core Bond Fund commenced operations on July 31, 2020. The Fund's investment objective is total return consistent with income generation.

Eventide Dividend Growth Fund commenced operations on September 29, 2017. The Fund's investment objectives are dividend growth and long term capital appreciation. The Fund's secondary objective is dividend income.

Eventide Exponential Technologies Fund commenced operations on June 30, 2020. The Fund's investment objective is long-term capital appreciation.

Eventide Gilead Fund commenced operations on July 8, 2008. The Fund's investment objective is long-term capital appreciation.

Eventide Healthcare & Life Sciences Fund commenced operations on December 27, 2012. The Fund's investment objective is long-term capital appreciation.

Eventide Large Cap Focus Fund commenced operations on June 30, 2022. The Fund's investment objective is long-term capital appreciation.

Eventide Limited-Term Bond Fund (formerly Epiphany FFV Strategic Income Fund) Class A and Class I shares commenced operations on July 28, 2010. On March 29, 2017, the Board of Trustees of Epiphany Funds voted to reclassify all outstanding Class C Shares of the Epiphany FFV Strategic Income Fund to Class I shares to be effective on May 30, 2017 (the ***"Conversion Date"***). On the Conversion Date, each Class C share was reclassified as a Class I shares equal in value to the Class C shares owned by that shareholder. The Fund's investment objective is income.

Each Fund offers four classes of shares, Class N, Class A, Class C and Class I. Each class differs as to sales and redemption charges and ongoing fees.

**Operating Segments**- The Funds have adopted Financial Accounting Standards Board (***"FASB"***) Accounting Standards Update (***"ASU"***) 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. Adoption of the standard impacted financial statement disclosures only and did not affect each Fund's financial position or the results of its operations. An operating segment is defined in Topic 280 as a component of a public entity that engages in business activities from which it may recognize revenues and incur expenses, has operating results that are regularly reviewed by the public entity's chief operating decision maker (***"CODM"***) to make decisions about resources to be allocated to the segment and assess its performance, and has discrete financial information available. The CODM is comprised of the portfolio manager(s) of the Funds and the Chief Financial Officer of the Trust. Each Fund operates as a single operating segment. Each Fund's income, expenses, assets, changes in net assets resulting from operations and performance are regularly monitored and assessed as a whole by the CODM responsible for oversight functions of each Fund, using the information presented in the financial statements and financial highlights.

The following is a summary of significant accounting policies consistently followed by the Funds and are in accordance with generally accepted accounting principles in the United States of America (***"GAAP"***). The Funds are investment companies and accordingly follow the investment company accounting and reporting guidance of the FASB Accounting Standards Codification Topic 946 "Financial Services – Investment Companies" including ASU 2013-08.

a) Securities Valuation - Securities listed on an exchange are valued at the last reported sale price at the close of the regular trading session of the exchange on the business day the value is being determined, or in the case of securities listed on NASDAQ, at the NASDAQ Official Closing Price (***"NOCP"***). In the absence of a sale, such securities shall be valued at the last bid price on the day of valuation. Debt securities (other than short-term obligations) are valued each day by an independent pricing service approved by the Board of Trustees (the ***"Board"***) using methods which include current market quotations from a major market maker in the securities and based on methods which include the consideration of yields or prices of securities of comparable quality, coupon, maturity and type. The Funds may invest in portfolios of open-end or closed-end investment companies (the ***"underlying funds"***). Open-end investment companies are valued at their respective net asset values as reported by such investment companies. The underlying funds value securities in their portfolios for which market quotations are readily available at their market values (generally the last reported sale price) and all other securities and assets at their fair value by the methods

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

established by the boards of trustees of the underlying funds. The shares of many closed-end investment companies, after their initial public offering, frequently trade at a price per share, which is different than the net asset value per share. The difference represents a market premium or market discount of such shares. There can be no assurances that the market discount or market premium on shares of any -closed-end investment company purchased by the Funds will not-change. The independent pricing service does not distinguish between smaller sized bond positions known as "odd lots" and larger institutional sized bond positions known as "round lots". The Funds may fair value a particular bond if the Advisor does not believe that the round lot value provided by the independent pricing service reflects fair value of the Fund's holding. Short term debt obligations having 60 days or less remaining until maturity, at time of purchase, may be valued at amortized cost, provided each such valuations represent fair value. Options are valued at their closing price on the exchange they are traded on. When no closing price is available, options are valued at their mean price.

The Funds may hold investments, such as private investments, interests in commodity pools, other non-traded securities or temporarily illiquid securities, for which market quotations are not readily available or are determined to be unreliable. These securities are valued using the "fair value" procedures approved by the Board. The Board has designated the Advisor as its valuation designee (the "***Valuation Designee***") to execute these procedures. The Board may also enlist third party consultants such as a valuation specialist at a public accounting firm, valuation consultant or financial officer of a security issuer, on an as-needed basis to assist the Valuation Designee in determining a security -specific fair value. The Board is responsible for reviewing and approving fair value methodologies utilized by the Valuation Designee, approval of which shall be based upon whether the Valuation Designee followed the valuation procedures established by the Board.

The Funds utilize various methods to measure the fair value of most of their investments on a recurring basis. GAAP establishes a hierarchy that prioritizes inputs to valuation methods. The three levels of input are:

Level 1 – Unadjusted quoted prices in active markets for identical assets and liabilities that the Funds have the ability to access.

Level 2 – Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument in an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.

Level 3 – Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Funds' own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.

The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following tables summarize the inputs used as of June 30, 2025 for the Funds' assets measured at fair value:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Eventide Balanced Fund**<br>**Assets**<br>**Security Classifications** |<br>**Level 1** |<br>**Level 2** |<br>**Level 3** |<br>**Totals** |
| Common Stocks <sup>(a)</sup> | $205256921 | $— | $— | $205256921 |
| Asset Backed Securities <sup>(a)</sup> |  | 4561025 |  | 4561025 |
| Collateralized Mortgage Obligations <sup>(a)</sup> |  | 1895073 |  | 1895073 |
| Corporate Bonds <sup>(a)</sup> |  | 80920756 |  | 80920756 |
| Municipal Bonds <sup>(a)</sup> |  | 15291999 |  | 15291999 |
| U.S. Government & Agencies <sup>(a)</sup> |  | 72667649 |  | 72667649 |
| Short-Term Investments | 116557 |  |  | 116557 |
| &nbsp;&nbsp;&nbsp;**Total** | $205373478 | $175336502 | $— | $380709980 |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Eventide Core Bond Fund**<br>**Assets**<br>**Security Classifications** |<br>**Level 1** |<br>**Level 2** |<br>**Level 3** |<br>**Totals** |
| Asset Backed Securities <sup>(a)</sup> | $— | $3769551 | $— | $3769551 |
| Corporate Bonds <sup>(a)</sup> |  | 70615631 |  | 70615631 |
| Municipal Bonds <sup>(a)</sup> |  | 11576107 |  | 11576107 |
| U.S. Government & Agencies <sup>(a)</sup> |  | 64457413 |  | 64457413 |
| &nbsp;&nbsp;&nbsp;**Total** | $— | $150418702 | $— | $150418702 |
| **Eventide Dividend Growth Fund** |  |  |  |  |
| **Assets** |  |  |  |  |
| **Security Classifications** | **Level 1** | **Level 2** | **Level 3** | **Totals** |
| Common Stocks <sup>(a)</sup> | $1173491500 | $— | $— | $1173491500 |
| Corporate Bonds <sup>(a)</sup> |  | 3248258 |  | 3248258 |
| Short-Term Investments | 116934 |  |  | 116934 |
| &nbsp;&nbsp;&nbsp;**Total** | $1173608434 | $3248258 | $— | $1176856692 |
| **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** |
| **Assets** |  |  |  |  |
| **Security Classifications** | **Level 1** | **Level 2** | **Level 3** | **Totals** |
| Common Stocks <sup>(a)</sup> | $96461539 | $— | $— | $96461539 |
| Corporate Bonds <sup>(a)</sup> |  | 749598 |  | 749598 |
| Short-Term Investments | 13109 |  |  | 13109 |
| &nbsp;&nbsp;&nbsp;**Total** | $96474648 | $749598 | $— | $97224246 |
| **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** |
| **Assets** |  |  |  |  |
| **Security Classifications** | **Level 1** | **Level 2** | **Level 3** | **Totals** |
| Common Stocks <sup>(a)</sup> | $2745395976 | $— | $— | $2745395976 |
| Contingent Value Rights <sup>(a)</sup> |  |  | 4493951 | 4493951 |
| Corporate Bonds <sup>(a)</sup> |  | 25721397 | 5000000 | 30721397 |
| Short-Term Investments | 5443531 |  |  | 5443531 |
| &nbsp;&nbsp;&nbsp;**Total** | $2750839507 | $25721397 | $9493951 | $2786054855 |
| **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** |
| **Assets** |  |  |  |  |
| **Security Classifications** | **Level 1** | **Level 2** | **Level 3** | **Totals** |
| Common Stocks <sup>(a)</sup> | $1070785026 | $— | $— | $1070785026 |
| Contingent Value Rights <sup>(a)</sup> |  |  | 1725025 | 1725025 |
| Private Investments <sup>(a)</sup> |  |  | 39379883 | 39379883 |
| Convertible Bonds <sup>(a)</sup> |  |  | 242533 | 242533 |
| Warrant <sup>(a)</sup> |  |  |  |  |
| Short-Term Investments | 3554866 |  |  | 3554866 |
| &nbsp;&nbsp;&nbsp;**Total** | $1074339892 | $— | $41347441 | $1115687333 |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Eventide Large Cap Focus Fund** | **Eventide Large Cap Focus Fund** | **Eventide Large Cap Focus Fund** | **Eventide Large Cap Focus Fund** | **Eventide Large Cap Focus Fund** |
| **Assets** | | | | |
| **Security Classifications** | **Level 1** | **Level 2** | **Level 3** | **Totals** |
| Common Stocks <sup>(a)</sup> | $161727051 | $— | $— | $161727051 |
| &nbsp;&nbsp;&nbsp;**Total** | $161727051 | $— | $— | $161727051 |
| **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** | **Eventide Limited-Term Bond Fund** |
| **Assets** |  |  |  |  |
| **Security Classifications** | **Level 1** | **Level 2** | **Level 3** | **Totals** |
| Asset Backed Securities <sup>(a)</sup> | $— | $4119945 | $— | $4119945 |
| Corporate Bonds <sup>(a)</sup> |  | 108271688 |  | 108271688 |
| Municipal Bonds <sup>(a)</sup> |  | 9237316 |  | 9237316 |
| U.S. Government & Agencies <sup>(a)</sup> |  | 41622939 |  | 41622939 |
| &nbsp;&nbsp;&nbsp;**Total** | $— | $163251888 | $— | $163251888 |

---

(a) For a detailed break-out of investments
 by security classification, please refer to the Schedule of Investments.

The following is a reconciliation of assets in which level 3 inputs were used in determining value:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Contingent | Private | | | |
| **Eventide Gilead Fund** | Value Rights | Investments | Corporate Bonds | Warrant | Total |
| Beginning balance 6/30/2024 | $3365186 | $32891954 | $— | $5133496 | $41390636 |
| Total realized gain (loss) |  |  |  |  |  |
| Change in unrealized appreciation (depreciation) | 1128765 | 10507934 |  | (5133496) | 6503203 |
| Cost of purchases |  | 3387258 | 5000000 |  | 8387258 |
| Proceeds from sales |  |  |  |  |  |
| Corporate action |  | (46787146) |  |  | (46787146) |
| Net transfers in/out of level 3 |  |  |  |  |  |
| Ending balance 6/30/2025 | $4493951 | $— | $5000000 | $— | $9493951 |
|  | Contingent | Private | Convertible |  |  |
| **Eventide Healthcare & Life Sciences Fund** | Value Rights | Investments | Bonds | Warrants | Total |
| Beginning balance 6/30/2024 | $1291743 | $60005195 | $394520 | $3125031 | $64816489 |
| Total realized gain (loss) |  | (5790926) |  |  | (5790926) |
| Change in unrealized appreciation (depreciation) | 433282 | 93815 | (151987) | (3125031) | (2749921) |
| Cost of purchases |  | 23491354 |  |  | 23491354 |
| Proceeds from sales |  | (8161440) |  |  | (8161440) |
| Corporate action |  | (30258115) |  |  | (30258115) |
| Net transfers in/out of level 3 |  |  |  |  |  |
| Ending balance 6/30/2025 | $1725025 | $39379883 | $242533 | $— | $41347441 |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private investments were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Fund** | **Description** | **Valuation<br> Technique(s)** | **Unobservable<br> Input** | **Input** | **Impact to<br> Valuation from<br> an increase in<br> Input<sup>A</sup>** |
| Eventide Gilead Fund | Vision Fund International 5.5% 6/30/28 | Market Approach | Recent transaction price | $100.00 | Increase |
| Eventide Healthcare & Life Sciences Fund | Avalyn Pharma Inc. Series C1, Avalyn Pharma Inc. Series D1 | Market Approach | Recent transaction price | $0.80 | Increase |
| Eventide Healthcare & Life Sciences Fund | BioSplice Therapeutics, Inc. Series, B-1, BioSplice Therapeutics, Inc. Series C Warrant,BioSplice Therapeutics, Inc. Series C PIK | Cash Value | Cash | $8.1M | Increase |
| Eventide Healthcare & Life Sciences Fund | Casma Therapeutics, Inc. Series B1,<br> Casma Therapeutics, Inc. Series B2,<br> Casma Therapeutics, Inc. Series C1,<br> Casma Therapeutics, Inc. Series C2 | Discount | Discount,<br> Recent transaction price | 84.8%,<br> $0.46 | Decrease,<br> Increase |
| Eventide Healthcare & Life Sciences Fund | Flare Therapeutics, Inc. Series A,<br> Flare Therapeutics, Inc. Series A2,<br> Flare Therapeutics, Inc. Series B | Probability-Weighted Expected Return | Revenue, <br> Revenue multiple, Recovery multiple, Strategic sale, <br> IPO, <br> Downside, Dissolution | $1B,<br> 9x-12x,<br> 50%-75%,<br> 1.8%,<br> 1.8%,<br> 1.8%,<br> 94.7% | Increase,<br> Increase,<br> Increase,<br> Increase,<br> Increase,<br> Decrease,<br> Decrease |
| Eventide Healthcare & Life Sciences Fund | Freenome Holdings, Inc. Series D,<br> Freenome Holdings, Inc. Series F | Cash Value | Cash | $243M | Increase |
| Eventide Healthcare & Life Sciences Fund | Kardium, Inc. Series D-8 | Market Approach | Recent transaction price | $0.65 | Increase |
| Eventide Healthcare & Life Sciences Fund | Goldfinch Biopharma, Inc. Series A,<br> Goldfinch Biopharma, Inc. Series B,<br> Goldfinch Biopharma, Inc. Series B2 | Residual Value | Net assets | $0 | Increase |
| Eventide Healthcare & Life Sciences Fund | Kojin Therapeutics, Inc. Series A-1,<br> Kojin Therapeutics, Inc. Series A-2 | Residual Value | Net assets | $0 | Increase |
| Eventide Healthcare & Life Sciences Fund | Peloton Therapeutics, Inc. - CRV | Present Value | Discount rate, <br> Probability of success,<br> Milestone payments, <br> Time horizon | 10%,<br> 0%-100%,<br> $50M-$1.1B | Decrease,<br> Increase,<br> Increase,<br> Decrease |
| Eventide Healthcare & Life Sciences Fund | Evida BioSciences, Inc. | Market Approach | Recent transaction price | $0.69 | Increase |
| Eventide Healthcare & Life Sciences Fund | Shoreline Biosciences Series B | Adjusted Net Asset Value | Adjusted Net Assets | $59.1M | Increase |

---

<sup>A</sup> Represents the directional change in the fair value of the Level 3 investments that could have resulted from an increase in the corresponding input as of period end. A decrease to the unobservable input would have had the opposite effect. Significant changes in these inputs may have resulted in a significantly higher or lower fair value measurement at period end.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

The total change in unrealized appreciation or depreciation included in the Statements of Operations attributable to Level 3 investments still held at June 30, 2025, was $1,128,765 and $(13,393,464) for the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund, respectively.

b) Accounting for Options - When the Funds write an option, an amount equal to the premium received by the Funds is recorded as a liability and is subsequently adjusted to the current fair value of the option written. Premiums received from writing options that expire unexercised are treated by the Funds on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security or currency in determining whether the Funds have realized gains or losses. If a put option is exercised, the premium reduces the cost basis of the securities purchased by the Funds.

The Advisor may use options strategies, such as puts and covered calls on individual securities, as well as options on securities indices, to generate income, to reduce portfolio volatility, or to reduce downside risk when the portfolio manager believes adverse market, political or other conditions are likely. The Advisor may also utilize a combination of puts and/or calls regarding the same security (sometimes referred to as "straddles," "collars" or "spreads") or utilize puts and calls on related securities. The Funds may purchase a call option on a stock (including securities of exchange traded funds ("***ETFs***")) it may purchase at some point in the future. When the Funds purchase an option, the premium paid is recorded as an asset. Each day the option contract is valued in accordance with the procedures for security valuation discussed above. When an offsetting option is written (a closing transaction) or the option contract expires, the Funds realize a gain or loss and the asset representing such option contract is eliminated. When a put option is exercised, the Funds realize a gain or loss from the sale of the underlying security and the proceeds of the sale are decreased by the premiums originally paid. When a call option is exercised, the Funds purchase the underlying security and the cost basis of such purchase is increased by the premium originally paid.

The notional value of the derivative instruments outstanding as of June 30, 2025 as disclosed in the amounts realized and changes in unrealized gains and losses on derivative instruments during the period as disclosed above and within the Statements of Operations serve as indicators of the volume of derivative activity of the Funds.

The effect of derivative instruments on the Statements of Operations for the year ended June 30, 2025, was as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** | **Eventide Exponential Technologies Fund** |
|  |  |  | **Realized and** |
| **Derivatives Not** |  |  | **Unrealized Gain** |
| **Accounted for as** |  |  | **(Loss) on Asset** |
| **Hedging Instruments** |  | **Location of Gain (Loss) on Derivatives** | **Derivatives** |
| **under GAAP** | **Primary Risk Exposure** | **Recognized in Statements of Operations** | **Recognized in Income** |
| Options Purchased | Equity Risk | Net realized gain (loss) from unaffiliated investments | $(143936) |
| Options Purchased | Equity Risk | Net change in unrealized depreciation on unaffiliated investments | 139936 |
| Total |  |  | $4000 |

---

c) Short Sales - The Funds may sell securities short. A short sale is a transaction in which the Funds sell securities they do not own in anticipation of a decline in the market price of the securities. To deliver the securities to the buyer, the Funds must arrange through a broker to borrow the securities and, in so doing, the Funds become obligated to replace the securities borrowed at their market price at the time of replacement, whatever that price may be. The Funds will make a profit or incur a loss as a result of a short sale depending on whether the price of the securities decrease or increase between the date of the short sale and the date on which the Funds purchased the securities to replace the borrowed securities that have been sold.

d) Federal Income Tax - The Funds have qualified and intend to continue to qualify as regulated investment companies and to comply with the applicable provisions of the Internal Revenue Code of 1986, as amended, and to distribute substantially all of their taxable income to their shareholders. Therefore, no federal income or excise tax provisions are required.

As of and during the year ended June 30, 2025, the Funds did not have a liability for any unrecognized tax expense. The Funds recognize interest and penalties, if any, related to unrecognized tax expense as income tax expense in the Statements of Operations. As of June 30, 2025, the Funds did not incur any interest or penalties. The Trust's officers have analyzed the Funds' tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years ended June 30, 2022, to June 30, 2024, or expected to be taken in the Funds' June 30, 2025, year-end tax returns.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

e) Distributions to Shareholders - Distributions to shareholders, which are determined in accordance with income tax regulations and may differ from GAAP, are recorded on the ex-dividend date. Each Fund typically distributes substantially all its net investment income in the form of dividends, interest and taxable capital gains to its shareholders. These distributions are automatically reinvested in the Fund unless you request cash distributions on your application or through a written request to the Fund. Each Fund expects that its distributions will consist of both capital gains, interest and dividend income. Each Fund may make distributions (after any reductions for capital loss carry forwards) annually except for the Eventide Balanced Fund and Eventide Limited-Term Bond Fund, which are monthly, and the Eventide Dividend Growth Fund and Eventide Core Bond Fund, which are quarterly.

f) Multiple Class Allocations - Income, non-class specific expenses and realized/unrealized gains or losses are allocated to each class based on relative net assets. Distribution fees are charged to each respective share class in accordance with the distribution plan. Expenses of the Trust that are directly identifiable to a specific fund are charged to that fund. Expenses which are not readily identifiable to a specific fund, are allocated in such a manner as deemed equitable, taking into consideration the nature and type of expense and the relative sizes of the funds in the Trust.

g) Security Transactions and Investment Income - Investment and shareholder transactions are recorded on the trade date. The Funds determine the gain or loss realized from the investment transactions by comparing the specific identified cost of the security lot sold with the net sales proceeds. Dividend income is recognized on the ex-dividend date or as soon as information is available to the Funds and interest income is recognized on an accrual basis. Discounts and premiums on debt securities are amortized over their respective lives using the effective interest method, except certain callable debt securities that are held at premium and will be amortized to the earliest call date. Withholding taxes on foreign dividends have been provided for in accordance with the Funds' understanding of the applicable country's tax rules and rates. Distributions received from a Fund's investments in MLPs generally are comprised of income and return of capital. The Funds record these distributions as investment income and subsequently adjusts these distributions within the components of net assets based upon their tax treatment when the information becomes available. Distribution from REITs are initially recorded as dividend income and, to the extent such represent a return of capital or capital gain for tax purposes, are reclassified when such information becomes available.

h) Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

i) Indemnification – The Trust indemnifies its officers and Trustees for certain liabilities that may arise from the performance of their duties to the Trust. In the normal course of business, the Trust may enter into contracts that contain a variety of representations and warranties and provide general indemnifications. The Funds' maximum exposure under these arrangements is dependent on future claims that may be made against the Funds and, therefore, cannot be estimated; however, management considers the risk of loss from such claims to be remote.

j) Redemption Fees and Sales Charges (loads) - A $15 fee may be charged for redemptions made by wire. A maximum sales charge of 5.75% is imposed on Class A shares of the Funds. Effective November 1, 2024 through January 30, 2025, the maximum deferred sales charge on Class A shares, applied only to purchases of $1 million or more made without an initial sale charge and applied to shares sold within 18 months of purchase unless you purchased your Class A shares through Edward Jones. If you purchased Class A shares through Edward Jones, a maximum deferred sales charge on Class A shares applied to purchases of $250,000 or more and applied to shares sold within 18 months of purchase. Prior to November 1, 2024, the maximum deferred sales charge of 1.00% on Class A shares applied only to purchases of $1 million or more made without an initial sales charge and applied to shares sold within 18 months of purchase. The maximum deferred sales charge of 1.00% on Class C shares applies to shares sold within 12 months of purchase. The respective shareholders pay such CDSC charges, which are not an expense of the Funds. For the year ended June 30, 2025, there were the following redemption fees paid to the Funds and CDSC fees paid to the distributor:

---

| | | | |
|:---|:---|:---|:---|
| | | **CDSC Fees** | **CDSC Fees** |
| <br>**Fund** |<br>**Redemption Fees** | **Class A** | **Class C** |
| Eventide Balanced Fund | $— | $— | $1296 |
| Eventide Core Bond Fund |  |  | 184 |
| Eventide Dividend Growth Fund |  |  | 991 |
| Eventide Exponential Technologies Fund |  |  | 50 |
| Eventide Gilead Fund |  |  | 2116 |
| Eventide Healthcare & Life Sciences Fund |  |  | 467 |
| Eventide Large Cap Focus Fund |  |  | 56 |
| Eventide Limited-Term Bond Fund |  |  | 89 |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

k) Cash and cash equivalents - Cash and cash equivalents are held with a financial institution. Cash and cash equivalents of the Funds may be placed in deposit accounts at U.S. banks and such deposits generally exceed Federal Deposit Insurance Corporation ("***FDIC***") insurance limits. The FDIC insures deposit accounts up to $250,000 for each accountholder. The counterparty is generally a single bank rather than a group of financial institutions; thus there may be a greater counterparty credit risk. The Funds place deposits only with those counterparties which are believed to be creditworthy and there has been no history of loss.

&nbsp;&nbsp;&nbsp;&nbsp;**(2)** **INVESTMENT TRANSACTIONS** 

For the year ended June 30, 2025, aggregate purchases and proceeds from sales of investment securities (excluding short-term investments) for the Funds were as follows:

---

| | | |
|:---|:---|:---|
| <br>**Fund** |<br>**Purchases of Securities** | **Proceeds From Sales of**<br>**Securities** |
| Eventide Balanced Fund | $224862889 | $206759656 |
| Eventide Core Bond Fund | 63931693 | 34764708 |
| Eventide Dividend Growth Fund | 834076930 | 593997660 |
| Eventide Exponential Technologies Fund | 129399198 | 155943886 |
| Eventide Gilead Fund | 1753866906 | 2696363436 |
| Eventide Healthcare & Life Sciences Fund | 521816988 | 737580814 |
| Eventide Large Cap Focus Fund | 115973641 | 73462033 |
| Eventide Limited-Term Bond Fund | 70304542 | 10535694 |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(3)** **INVESTMENT ADVISORY AGREEMENT AND TRANSACTIONS WITH RELATED PARTIES** 

Eventide Asset Management, LLC acts as investment manager to the Funds pursuant to the terms of an investment advisory agreement between the Advisor and the Trust (the ***"Advisory Agreement"***). Boyd Watterson Asset Management, LLC serves as sub-adviser to the Eventide Limited-Term Bond Fund, the Eventide Core Bond Fund, and a portion of the Eventide Balanced Fund's portfolio. Under the terms of the Advisory Agreement, the Advisor manages the investment operations of the Funds in accordance with the Funds' investment policies and restrictions. The Advisor provides the Funds with investment advice and supervision and furnishes an investment program for the Funds. The fees paid by the Funds to the Advisor are described in greater detail below. The Advisor pays expenses incurred by it in connection with acting as investment advisor to the Funds other than costs (including taxes and brokerage commissions, borrowing costs, costs of investing in underlying funds and extraordinary expenses, if any) of securities purchased for the Funds and certain other expenses paid by the Funds (as detailed in the Advisory Agreement). The Advisor pays for all employees, office space and facilities required by it to provide services under the Advisory Agreement, with the exception of specific items of expense (as detailed in the Advisory Agreement). For the year ended June 30, 2025, advisory fees before the waivers and reimbursements described below.

---

| | |
|:---|:---|
| **Fund** | **Advisory Fees** |
| Eventide Balanced Fund | $2330394 |
| Eventide Core Bond Fund | 504777 |
| Eventide Dividend Growth Fund | 7598747 |
| Eventide Exponential Technologies Fund | 1179143 |
| Eventide Gilead Fund | 29160455 |
| Eventide Healthcare & Life Sciences Fund | 14591841 |
| Eventide Large Cap Focus Fund | 1097776 |
| Eventide Limited-Term Bond Fund | 479962 |

---

Each Fund is authorized to pay the Advisor an annual fee based on its average daily net assets. The advisory fee is paid monthly. The Advisor has contractually agreed to waive fees and/or reimburse expenses, but only to the extent necessary to maintain each Fund's total annual operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at a certain level through October 31, 2025. This agreement may be terminated by the Board only on 60 days' written notice to the Advisor and upon the termination of the Advisory Agreement between the Trust and the Advisor. Fee waivers and expense reimbursements are subject to possible recoupment by the Advisor from the Funds in future years on a rolling three-year basis (within the three years after the fees have been waived or reimbursed) if, after the recoupment is taken into account, such recoupment can be achieved within the lesser of the expense limitation in place at the time of waiver/reimbursement and the expense limitation in place at the time of recapture. Each waiver or reimbursement by the Advisor is subject to repayment by the Fund within the three years following the year in which that particular expense is incurred, if the Fund is able to make the repayment without exceeding the expense limitation in effect at that time and the repayment is approved by the Board.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

The following table lists the contractual advisory fee and the expense limitation for each Fund.

---

| | | | |
|:---|:---|:---|:---|
| Fund | Contractual Advisory Fee | Expense Limitation | Expense Limitation |
| Eventide Balanced Fund | 0.60% | Class N: | 1.02% |
|  |  | Class A: | 1.07% |
|  |  | Class C: | 1.82% |
|  |  | Class I: | 0.82% |
| Eventide Core Bond Fund | 0.34% | Class N: | 0.78% |
|  |  | Class A: | 0.83% |
|  |  | Class C: | 1.58% |
|  |  | Class I: | 0.58% |
| Eventide Dividend Growth Fund | 0.73% | Class N: | 1.15% |
|  |  | Class A: | 1.20% |
|  |  | Class C: | 1.95% |
|  |  | Class I: | 0.95% |
| Eventide Exponential Technologies Fund | 1.10% | Class N: | 1.63% |
|  |  | Class A: | 1.68% |
|  |  | Class C: | 2.43% |
|  |  | Class I: | 1.43% |
| Eventide Gilead Fund | 1.00% of the first $2 billion; | Class N: | 1.62% |
|  | 0.95% on the next $1 billion; | Class A: | 1.67% |
|  | 0.90% on the next $1 billion; | Class C: | 2.42% |
|  | and 0.85% thereafter | Class I: | 1.42% |
| Eventide Healthcare & Life Sciences Fund | 1.10% | Class N: | 1.63% |
|  |  | Class A: | 1.68% |
|  |  | Class C: | 2.43% |
|  |  | Class I: | 1.43% |
| Eventide Large Cap Focus Fund | 0.73% | Class N: | 1.14% |
|  |  | Class A: | 1.19% |
|  |  | Class C: | 1.94% |
|  |  | Class I: | 0.94% |
| Eventide Limited-Term Bond Fund | 0.31% | Class N: | 0.75% |
|  |  | Class A: | 0.80% |
|  |  | Class C: | 1.55% |
|  |  | Class I: | 0.55% |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

For the year ended June 30, 2025, the Advisor waived the following amounts.

---

| | |
|:---|:---|
| **Fund** | **Waived Amount** |
| Eventide Balanced Fund | $— |
| Eventide Core Bond Fund | 143748 |
| Eventide Dividend Growth Fund |  |
| Eventide Exponential Technologies Fund | 112235 |
| Eventide Gilead Fund |  |
| Eventide Healthcare & Life Sciences Fund |  |
| Eventide Large Cap Focus Fund | 280014 |
| Eventide Limited-Term Bond Fund | 76975 |

---

As of June 30, 2025, the Advisor has waived/reimbursed expenses that may be recovered no later than June 30 of the years indicated below:

---

| | | | |
|:---|:---|:---|:---|
| | 2026 | 2027 | 2028 |
| Eventide Balanced Fund | $276044 | $236729 | $— |
| Eventide Core Bond Fund | 164775 | 131361 | 143748 |
| Eventide Dividend Growth Fund | 249595 | 97498 |  |
| Eventide Exponential Technologies Fund | 69721 | 68862 | 112235 |
| Eventide Large Cap Focus Fund | 107732 | 101331 | 280014 |
| Eventide Limited-Term Bond Fund | 243710 | 202441 | 76975 |

---

The Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund do not have any expenses previously waived by the Advisor that are subject to recapture and did not waive any further expenses during the year ended June 30, 2025. Eventide Dividend Growth Fund recaptured $141,466 expenses during the year ended June 30, 2025.

Pursuant to the Management Services Agreement between the Trust and MFund Services, LLC *(**"MFund"***), MFund provides the Funds with management and legal administrative services (the ***"Management Services Agreement"***). For these services, the Funds pay MFund an annual asset-based fee in accordance with the following schedule applied at the Fund family level (i.e., all the Funds in the Trust advised by the Advisor): 0.10% of net assets up to $50 million; 0.07% of net assets from $50 million to $100 million; 0.05% of net assets from $100 million to $250 million; 0.04% of net assets from $250 million to $500 million; 0.03% of net assets from $500 million to $1 billion; 0.02% of net assets from $1 billion to $5 billion; and 0.01% of assets from $5 billion and above. In addition, the Funds reimburse MFund for any reasonable out-of-pocket expenses incurred in the performance of its duties under the Management Services Agreement. The amounts due to MFund for the Management Services Agreement are listed in the Statements of Assets and Liabilities under "Payable to related parties" and the amounts accrued for the year are shown in the Statements of Operations under "Legal administration fees/Management service fees."

Pursuant to the Compliance Services Agreement, MFund provides chief compliance officer services to the Funds. For these services, the Funds pay MFund $1,200 per month for the first fund in the fund family and $400 each additional fund; $400 for each advisor and sub-advisor; and .0025% of the assets of each Fund. In addition, the Funds reimburse MFund for any reasonable out-of-pocket expenses incurred in the performance of its duties under the Compliance Services Agreement.

There are no amounts due to MFund for chief compliance officer services as of June 30, 2025, and the amounts accrued for the period are shown in the Statements of Operations under "Compliance officer fees."

A trustee of the Trust is also the controlling member of MFund and the investment advisors to other series of the Trust and is not paid any fees directly by the Trust for serving in such capacities. Trustees who are not "interested persons" as that term is defined in the 1940 Act are paid a quarterly retainer and receive compensation for each special Board meeting and Risk and Compliance Committee meeting attended. The fees paid to the Independent Trustees for attendance at a meeting will be shared equally by the funds of the Trust in which the meeting relates. The Lead Independent Trustee of the Trust, the Chairman of the Trust's Audit Committee and the Chairman of the Risk and Compliance Committee receive an additional quarterly retainer. The "interested persons" of the Trust receive no compensation from the Funds. The Trust reimburses each Trustee and Officer for his or her travel and other expenses related to attendance at such meetings.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

Ultimus Fund Solutions, LLC (**"*UFS*"**), an affiliate of the distributor, provides administrative, fund accounting, and transfer agency services to the Funds pursuant to agreements with the Trust, for which it receives from each Fund: (i) basis points in decreasing amounts as assets reach certain breakpoints; and (ii) any related out-of-pocket expenses.

Blu Giant, LLC (***"Blu Giant"***), an affiliate of UFS and the distributor, provides EDGAR conversion and filing services as well as print management services for the Funds on an ad-hoc basis. For the provision of these services, Blu Giant receives customary fees from the Funds.

The Trust's officers are not paid any fees directly by the Trust for serving in such capacity except for the chief compliance officer.

The Trust has adopted a Master Distribution Plan Pursuant to Rule 12b-1 (the **"*Plan*"**) under the 1940 Act for each class of shares except Class I, that allows the Funds to pay distribution and shareholder servicing expenses of up to 0.25% per annum for the Class N shares, up to 0.50% per annum for the Class A shares and up to 1.00% for the Class C shares based on average daily net assets of each class. The Class N shares are currently paying 0.20% per annum of 12b-1 fees, Class A shares are currently paying 0.25% per annum of 12b-1 fees and Class C shares are currently paying 1.00% per annum of 12b-1 fees.

The 12b-1 fees may be used for a variety of purposes, including compensating dealers and other financial service organizations for eligible services provided by those parties to the Funds and their shareholders and to reimburse Northern Lights Distributors, LLC (the ***"Distributor"***) and the Advisor for distribution related expenses.

For the year ended June 30, 2025, the Distributor received the following in underwriter commissions from the sale of Class A and Class C shares.

---

| | |
|:---|:---|
| <br>**Fund** | **Underwriter**<br>**Commissions** |
| Eventide Balanced Fund | $38607 |
| Eventide Core Bond Fund | 1226 |
| Eventide Dividend Growth Fund | 70099 |
| Eventide Exponential Technologies Fund | 4147 |
| Eventide Gilead Fund | 86141 |
| Eventide Healthcare & Life Sciences Fund | 19111 |
| Eventide Large Cap Focus Fund | 10129 |
| Eventide Limited-Term Bond Fund | 1984 |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(4)** **DISTRIBUTIONS TO SHAREHOLDERS AND TAX COMPONENTS OF CAPITAL** 

The following table represents aggregate cost for federal tax purposes, including options written, for the Funds as of June 30, 2025 and differs from market value by net unrealized appreciation/depreciation which consisted of:

---

| | | | | |
|:---|:---|:---|:---|:---|
| <br>**Fund** | **Cost for**<br>**Federal Tax**<br>**purposes** |<br>**Unrealized**<br>**Appreciation** |<br>**Unrealized**<br>**Depreciation** | **Tax Net**<br>**Unrealized**<br>**App/Dep** |
| Eventide Balanced Fund | $339442386 | $49545808 | $(8278214) | $41267594 |
| Eventide Core Bond Fund | 152585737 | 1535468 | (3702503) | (2167035) |
| Eventide Dividend Growth Fund | 975107928 | 224622279 | (22873515) | 201748764 |
| Eventide Exponential Technologies Fund | 68447580 | 29048036 | (271370) | 28776666 |
| Eventide Gilead Fund | 1602107139 | 1227110675 | (43162959) | 1183947716 |
| Eventide Healthcare & Life Sciences Fund | 953214865 | 347955542 | (185483074) | 162472468 |
| Eventide Large Cap Focus Fund | 140559945 | 25363810 | (4196704) | 21167106 |
| Eventide Limited-Term Bond Fund | 162304128 | 1896043 | (948283) | 947760 |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

The tax character of fund distributions for the years ended June 30, 2025, and June 30, 2024, was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| ***<u>For the year ended June 30, 2025:</u>*** | ***<u>For the year ended June 30, 2025:</u>*** | ***<u>For the year ended June 30, 2025:</u>*** | ***<u>For the year ended June 30, 2025:</u>*** | ***<u>For the year ended June 30, 2025:</u>*** |
| <br>**Fund** | **Ordinary**<br>**Income** | **Long-Term**<br>**Capital Gains** | **Return of**<br>**Capital** |<br>**Total** |
| Eventide Balanced Fund | $7525036 | $— | $— | $7525036 |
| Eventide Core Bond Fund | 6153710 |  |  | 6153710 |
| Eventide Dividend Growth Fund | 6543574 | 510057 |  | 7053631 |
| Eventide Gilead Fund |  | 37480805 |  | 37480805 |
| Eventide Large Cap Focus Fund | 2551278 | 2898158 |  | 5449436 |
| Eventide Limited-Term Bond Fund | 5639759 |  |  | 5639759 |
| ***<u>For the year ended June 30, 2024:</u>*** | ***<u>For the year ended June 30, 2024:</u>*** | ***<u>For the year ended June 30, 2024:</u>*** | ***<u>For the year ended June 30, 2024:</u>*** | ***<u>For the year ended June 30, 2024:</u>*** |
|  | **Ordinary** | **Long-Term** | **Return of** |  |
| **Fund** | **Income** | **Capital Gains** | **Capital** | **Total** |
| Eventide Balanced Fund | $5888612 | $— | $— | $5888612 |
| Eventide Core Bond Fund | 3769367 |  |  | 3769367 |
| Eventide Dividend Growth Fund | 3699013 |  |  | 3699013 |
| Eventide Limited-Term Bond Fund | 4104125 |  |  | 4104125 |

---

As of June 30, 2025, the components of accumulated earnings/(losses) on a tax basis were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| <br>**Fund** | **Undistributed**<br>**Ordinary**<br>**Income** | **Undistributed**<br>**Long-Term**<br>**Capital Gains** | **Post October Loss**<br>**and**<br>**Late Year Loss** | **Capital Loss**<br>**Carry**<br>**Forwards** | **Other**<br>**Book/Tax**<br>**Differences** | **Unrealized**<br>**Appreciation/**<br>**(Depreciation)** | **Total**<br>**Accumulated**<br>**Earnings/(Losses)** |
| Eventide Balanced Fund | $15304 | $12877773 | $— | $— | $— | $41267594 | $54160671 |
| Eventide Core Bond Fund | 150222 |  |  | (15185022) |  | (2167035) | (17201835) |
| Eventide Dividend Growth Fund |  | 28654745 |  |  |  | 201748764 | 230403509 |
| Eventide Exponential Technologies Fund |  |  | (600378) | (46820367) | (167762) | 28776666 | (18811841) |
| Eventide Gilead Fund |  | 272348115 | (19524674) |  |  | 1183947716 | 1436771157 |
| Eventide Healthcare & Life Sciences Fund |  |  | (142795526) | (7762214) |  | 162472468 | 11914728 |
| Eventide Large Cap Focus Fund | 78231 | 697236 |  |  |  | 21167106 | 21942573 |
| Eventide Limited-Term Bond Fund | 94711 |  |  | (8990663) |  | 947760 | (7948192) |

---

The difference between book basis and tax basis undistributed net investment income/(loss), accumulated net realized gain/(loss), and unrealized appreciation/(depreciation) from investments is primarily attributable to the tax deferral of losses on wash sales, mark-to-market on passive foreign investment companies and adjustments for C-Corporation return of capital. In addition, the amounts listed under other book/tax differences are primarily attributable to the tax deferral of losses on straddles.

Late year losses incurred after December 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such late year losses as follows:

---

| | |
|:---|:---|
| <br>**Fund** | **Late Year**<br>**Losses** |
| Eventide Exponential Technologies Fund | $600378 |
| Eventide Gilead Fund | 19524674 |
| Eventide Healthcare & Life Sciences Fund | 22140674 |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

Capital losses incurred after October 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such capital losses as follows:

---

| | |
|:---|:---|
| <br>**Fund** | **Post October**<br>**Losses** |
| Eventide Healthcare & Life Sciences Fund | $120654852 |

---

At June 30, 2025, the Funds had capital loss carry forwards for federal income tax purposes available to offset future capital gains and utilized prior year capital loss carry forwards, as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Non-Expiring** | **Non-Expiring** | | |
| <br>**Fund** | **Short-Term** | **Long-Term** |<br>**Total** | **CLCF**<br>**Utilized** |
| Eventide Balanced Fund | $— | $— | $— | $10658695 |
| Eventide Core Bond Fund | 4395821 | 10789201 | 15185022 |  |
| Eventide Dividend Growth Fund |  |  |  | 29982579 |
| Eventide Exponential Technologies Fund | 46820367 |  | 46820367 | 7342357 |
| Eventide Gilead Fund |  |  |  | 37418371 |
| Eventide Healthcare & Life Sciences Fund | 7762214 |  | 7762214 | 20199862 |
| Eventide Large Cap Focus Fund |  |  |  |  |
| Eventide Limited-Term Bond Fund | 2137661 | 6853002 | 8990663 |  |

---

As of the fiscal year ended June 30, 2025, permanent book and tax differences resulted in reclassifications between Paid in Capital and Accumulated Earnings/(Losses) for certain Funds. These reclasses are primarily attributable to net operating losses, distributions in excess, and the use of tax equalization credits, which is applying earnings and profits credited to redeeming shareholders redemptions to the Funds Dividends Paid Deduction for income tax purposes. For the fiscal year ended June 30, 2025, the total reclassifications are as follows:

---

| | | |
|:---|:---|:---|
| <br>**Fund** |<br>**Paid In Capital** | **Accumulated**<br>**Earnings (Losses)** |
| Eventide Balanced Fund | $1028405 | $(1028405) |
| Eventide Core Bond Fund |  |  |
| Eventide Dividend Growth Fund | 1813634 | (1813634) |
| Eventide Exponential Technologies Fund | (1402242) | 1402242 |
| Eventide Gilead Fund | 17407033 | (17407033) |
| Eventide Healthcare & Life Sciences Fund |  |  |
| Eventide Large Cap Focus Fund | 370311 | (370311) |
| Eventide Limited-Term Bond Fund |  |  |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(5)** **INVESTMENTS IN AFFILIATED COMPANIES** 

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities. Companies which are affiliates of the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund at June 30, 2025 are noted in the Funds' Schedule of Investments. Transactions during the period with companies which are affiliates are as follows:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** |
| Description | Market Value at<br> June 30, 2024 | Share Balance<br> at June 30,<br> 2024 | Purchases | Sales Proceeds | Corporate Actions | Dividends<br> Credited to<br> Income | Net Increase/<br> Decrease in<br> Appreciation<br> (Depreciation) | Realized Gains<br> (Losses) | Market Value at<br> June 30, 2025 | Share Balance at<br> June 30, 2025 |
| Beta Bionics, Inc. | $— |  | $— | $— | $46787158 | $— | $(6512085) | $129 | $40275202 | 2766154 |
| Total | $— |  | $— | $— | $46787158 | $— | $(6512085) | $129 | $40275202 | 2766154 |
| *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* |
| Description | Market Value at<br> June 30, 2024 | Share Balance<br> at June 30,<br> 2024 | Purchases | Sales Proceeds | Corporate Actions | Dividends<br> Credited to<br> Income | Net Increase/<br> Decrease in<br> Appreciation<br> (Depreciation) | Realized Gains<br> (Losses) | Market Value at<br> June 30, 2025 | Share Balance at<br> June 30, 2025 |
| Beta Bionics, Inc. Series B \* | $14072281 | 1881321 | $— | $— | $(20000032) | $— | $5927741 | $9 | $(1) |  |
| Beta Bionics, Inc. Series B2 \* | 5064257 | 665474 |  |  | (7400000) |  | 2335741 | 2 |  |  |
| Beta Bionics, Inc. Series C \* | 7133985 | 964052 |  |  | (9999866) |  | 2865881 |  |  |  |
| Beta Bionics, Inc. Series D \* | 6621431 | 714286 |  |  | (6000002) |  | (621429) |  |  |  |
| Beta Bionics, Inc. Series E \* |  |  | 3387258 |  | (3387258) |  |  |  |  |  |
| Beta Bionics, Inc. Series C Warrants \* | 1783496 | 241013 |  |  |  |  | (1783496) |  |  |  |
| Beta Bionics, Inc. Series D Warrants \* | 3350000 | 500000 |  |  |  |  | (3350000) |  |  |  |
| Mirum Pharmaceuticals, Inc. PIPE | 7814877 | 228572 |  |  | (6000015) |  | (1814862) |  |  |  |
| Xometry, Inc. | 64367190 | 5568096 |  | (59621555) |  |  | 112950735 | (15864900) | 101831470 | 3013657 |
| Zentalis Pharmaceuticals, Inc. | 14659824 | 3584309 |  | (9879565) |  |  | 48783009 | (53563268) |  |  |
| Total | $124867341 | 14347123 | $3387258 | $(69501120) | $(52787173) | $— | $165293320 | $(69428157) | $101831469 | 3013657 |
|  | $124867341 | 14347123 | $3387258 | $(69501120) | $(6000015) | $— | $158781235 | $(69428028) | $142106671 | 5779811 |

---

\* Conversion

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** |
| Description | Market Value at<br> June 30, 2024 | Share Balance<br> at June 30,<br> 2024 | Purchases | Sales Proceeds | Corporate Actions | Dividends<br> Credited to<br> Income | Net Increase/<br> Decrease in<br> Appreciation<br> (Depreciation) | Realized Gains<br> (Losses) | Market Value at<br> June 30, 2025 | Share Balance at<br> June 30, 2025 |
| Beta Bionics, Inc. | $— |  | $— | $— | $30258115 | $— | $(4506772) | $114 | $25751457 | 1768644 |
| Casma Therapeutics, Inc. Series B1 | 1046500 | 5000000 |  |  |  |  | (697000) |  | 349500 | 5000000 |
| Casma Therapeutics, Inc. Series B2 | 1046500 | 5000000 |  |  |  |  | (697000) |  | 349500 | 5000000 |
| Casma Therapeutics, Inc. Series C1 | 381013 | 1820413 |  |  |  |  | (253766) |  | 127247 | 1820413 |
| Casma Therapeutics, Inc. Series C2 | 414389 | 1979882 | 230000 |  |  |  | (471045) |  | 173344 | 2479882 |
|  Evida BioSciences, Inc. | 702261 | 1017770 |  |  |  |  |  |  | 702261 | 1017770 |
| Goldfinch Biopharma, Inc. Series A |  | 5000000 |  |  |  |  |  |  |  | 5000000 |
| Goldfinch Biopharma, Inc. Series B |  | 8474576 |  |  |  |  |  |  |  | 8474576 |
| Goldfinch Biopharma, Inc. Series B2 |  | 4237288 |  |  |  |  |  |  |  | 4237288 |
| TOTAL | $3590663 | 32529929 | $230000 | $— | $30258115 | $— | $(6625583) | $114 | $27453309 | 34798573 |
| *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* | *Investments no longer affiliated as of June 30, 2025* |
| Description | Market Value at<br> June 30, 2024 | Share Balance<br> at June 30,<br> 2024 | Purchases | Sales Proceeds | Corporate Actions | Dividends<br> Credited to<br> Income | Net Increase/<br> Decrease in<br> Appreciation<br> (Depreciation) | Realized Gains<br> (Losses) | Market Value at<br> June 30, 2025 | Share Balance at<br> June 30, 2025 |
| Aura Biosciences, Inc. | $43868276 | 5802682 | $— | $(43843596) | $— | $— | $15636830 | $(15661510) | $— |  |
| Beta Bionics, Inc. Series B \* | 7036136 | 940660 |  |  | (10000016) |  | 2963870 | 10 |  |  |
| Beta Bionics, Inc. Series B2 \* | 6159230 | 809360 |  |  | (9000000) |  | 2840764 | 6 |  |  |
| Beta Bionics, Inc. Series C \* | 3566992 | 482026 |  |  | (4999933) |  | 1432941 |  |  |  |
| Beta Bionics, Inc. Series D \* | 4414281 | 476190 |  |  | (3999996) |  | (414285) |  |  |  |
| Beta Bionics, Inc. Series E \* |  |  | 2258170 |  | (2258170) |  |  |  |  |  |
| Beta Bionics, Inc. Series C Warrant \* | 891700 | 120500 |  |  |  |  | (891700) |  |  |  |
| Beta Bionics, Inc. Series D Warrants \* | 2233331 | 333333 |  |  |  |  | (2233331) |  |  |  |
| Inozyme Pharma, Inc. | 17555541 | 3936220 | 873253 | (8584766) |  |  | 867999 | (10712027) |  |  |
| Korro Bio, Inc. | 12501688 | 369108 |  |  | (20078868) |  | 7577180 |  |  |  |
| Lexeo Therapeutics, Inc. \* | 20657050 | 1287846 |  |  | (19999995) |  | (657055) |  |  |  |
| Lexeo Therapeutics, Inc. | 33384068 | 2081301 |  | (32076518) | 19999995 |  | (10275109) | (11032436) |  |  |
| Mirum Pharmaceuticals, Inc. PIPE | 5209906 | 152381 |  |  | (4000001) |  | (1209905) |  |  |  |
| Zentalis Pharmaceuticals, Inc. | 20239754 | 4948595 |  | (13589918) |  |  | 72979914 | (79629750) |  |  |
| Total | $177717953 | 21740202 | $3131423 | $(98094798) | $(54336984) | $— | $88618113 | $(117035707) | $— |  |
|  | $181308616 | 54270131 | $3361423 | $(98094798) | $(24078869) | $— | $81992530 | $(117035593) | $27453309 | 34798573 |

---

\* Conversion

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(6)** **INVESTMENT IN RESTRICTED SECURITIES** 

Restricted securities include securities that have not been registered under the Securities Act of 1933, as amended, and securities that are subject to restrictions on resale. Each Fund may invest in restricted securities that are consistent with the Fund's investment objectives and investment strategies. A Fund will not invest in a restricted security if, immediately after and as a result of the investment in such security, more than 15% of the Fund's net assets would be invested in illiquid securities. In some cases, the issuer of restricted securities has agreed to register such securities for resale, at the issuer's expense either upon demand by the Funds or in connection with another registered offering of the securities. Investments in restricted securities are valued at fair value as determined in good faith in accordance with procedures adopted by the Board. It is possible that the estimated value may differ significantly from the amount that might ultimately be realized in the near term, and the difference could be material.

As of June 30, 2025, the Eventide Core Bond Fund, Eventide Dividend Growth Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund and Eventide Limited-Term Bond Fund were invested in the following restricted securities:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Eventide Core Bond Fund**<br>&nbsp;&nbsp;&nbsp;&nbsp;**Security** | <br>**Initial**<br>**Acquisition**<br>**Date** |<br><br>**Shares** |<br><br>**Cost** |<br><br>**Value** | <br>**% of Net Assets** |
| Hope Global Investments, 4.6000%, 10/10/28 | 11/15/2024 | 750000 | $750000 | $726255 | 0.5% |
| **Eventide Dividend Growth Fund** |  |  |  |  |  |
|  | **Initial** |  |  |  |  |
|  | **Acquisition** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Security** | **Date** | **Shares** | **Cost** | **Value** | **% of Net Assets** |
| Vision Fund International, 5.2600%, 11/30/25 | 12/1/2023 | 3250000 | $3250000 | $3248258 | 0.3% |
| **Eventide Exponential Technologies Fund** |  |  |  |  |  |
|  | **Initial** |  |  |  |  |
|  | **Acquisition** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Security** | **Date** | **Shares** | **Cost** | **Value** | **% of Net Assets** |
| Vision Fund International, 5.2600%, 11/30/25 | 12/1/2023 | 750000 | $750000 | $749598 | 0.8% |
| **Eventide Gilead Fund** |  |  |  |  |  |
|  | **Initial** |  |  |  |  |
|  | **Acquisition** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Security** | **Date** | **Shares** | **Cost** | **Value** | **% of Net Assets** |
| Beta Bionics, Inc. | 8/31/2018 | 2766154 | $46787158 | $40275202 | 1.4% |
| Hope Global Investments, 4.0000%, 01/07/28 | 12/28/2023 | 2000000 | 2000000 | 1930976 | 0.1% |
| Peloton Therapeutics, Inc. - CVR | 2/14/2019 | 3982940 |  | 4493951 | 0.2% |
| Vision Fund International, 3.1500%, 12/15/25 | 12/16/2021 | 5000000 | 5000000 | 4946960 | 0.2% |
| Vision Fund International, 3.2230%, 12/15/26 | 12/16/2021 | 5000000 | 5000000 | 4848285 | 0.2% |
| Vision Fund International, 5.9030%, 09/19/25 | 9/21/2022 | 5000000 | 5000000 | 5000000 | 0.2% |
| Vision Fund International, 5.2600%, 11/30/25 | 12/1/2023 | 9000000 | 9000000 | 8995176 | 0.3% |
| Vision Fund International, 5.5000%, 06/30/28 | 6/30/2025 | 5000000 | 5000000 | 5000000 | 0.2% |

---

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Eventide Healthcare & Life Sciences Fund**<br>&nbsp;&nbsp;&nbsp;&nbsp;**Security** | <br>**Initial**<br>**Acquisition**<br>**Date** |<br><br>**Shares** |<br><br>**Cost** |<br><br>**Value** | <br>**% of Net Assets** |
| Avalyn Pharma Inc. Series C1 | 9/25/2023 | 20482289 | $15000000 | $16310046 | 1.4% |
| Avalyn Pharma Inc. Series D1 | 4/25/2025 | 4060259 | 3233184 | $3233184 | 0.3% |
| Beta Bionics, Inc. | 8/31/2018 | 1768644 | 30258115 | 25751457 | 2.2% |
| BioSplice Therapeutics, Inc. Series B-1 | 3/5/2021 | 295276 | 15000021 |  | 0.0% |
| BioSplice Therapeutics, Inc. Series C PIK, 1.5000%, 03/12/26 | 5/2/2023 | 3500000 | 3500000 | 242533 | 0.0% |
| Biosplice Therapeutics, Inc. Series C Warrant | 5/2/2023 | 106490 |  |  | 0.0% |
| Casma Therapeutics, Inc. Series B1 | 8/26/2020 | 5000000 | 3750000 | 349500 | 0.0% |
| Casma Therapeutics, Inc. Series B2 | 6/7/2021 | 5000000 | 3750000 | 349500 | 0.0% |
| Casma Therapeutics, Inc. Series C1 | 7/6/2022 | 1820413 | 837390 | 127247 | 0.0% |
| Casma Therapeutics, Inc. Series C2 | 1/31/2023 | 2479882 | 1140746 | 173344 | 0.0% |
| Evida BioSciences, Inc. | 12/31/2020 | 1017770 | 702262 | 702261 | 0.1% |
| Flare Therapeutics, Inc. Series A | 4/22/2021 | 1097561 | 1097561 | 1503659 | 0.1% |
| Flare Therapeutics, Inc. Series A2 | 5/31/2022 | 902439 | 902439 | 1236341 | 0.1% |
| Flare Therapeutics, Inc. Series B | 2/1/2023 | 1952962 | 2349999 | 2870854 | 0.3% |
| Freenome Holdings, Inc. Series D | 11/22/2021 | 930436 | 6999994 | 769378 | 0.1% |
| Freenome Holdings, Inc. Series F | 1/26/2024 | 133941 | 990984 | 110756 | 0.0% |
| Goldfinch Biopharma, Inc. Series A | 3/15/2019 | 5000000 | 5000000 |  | 0.0% |
| Goldfinch Biopharma, Inc. Series B | 6/29/2020 | 8474576 | 10000000 |  | 0.0% |
| Goldfinch Biopharma, Inc. Series B2 | 3/21/2022 | 4237288 | 5000000 |  | 0.0% |
| Kardium Inc. | 6/6/2025 | 15450219 | 10000000 | 10000000 | 0.9% |
| Kestra Medical Technologies Series D | 7/15/2024 | 693008 | 8000000 | 11490073 | 1.0% |
| Kojin Therapeutics, Inc. Series A-1 | 6/2/2021 | 763319 | 1499998 |  | 0.0% |
| Kojin Therapeutics, Inc. Series A-2 | 1/28/2022 | 763319 | 1499998 |  | 0.0% |
| Peloton Therapeutics, Inc. - CVR | 2/14/2019 | 1528871 |  | 1725025 | 0.2% |
| Shoreline Biosciences Series B | 10/28/2021 | 1489958 | 15000003 | 1643813 | 0.1% |
| **Eventide Limited-Term Bond Fund** |  |  |  |  |  |
|  | **Initial** |  |  |  |  |
|  | **Acquisition** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Security** | **Date** | **Shares** | **Cost** | **Value** | **% of Net Assets** |
| Hope Global Investments, 4.6000%, 10/10/28 | 11/15/2024 | 750000 | $750000 | $726255 | 0.4% |

---

&nbsp;&nbsp;&nbsp;&nbsp;**(7)** **SECTOR EXPOSURE RISK** 

The Eventide Exponential Technologies Fund invests primarily in equity and equity-related securities of companies that the Advisor believes are participating in and benefitting from technologies, innovations, technology themes, or technology trends. The types of companies represented in the Fund's portfolio include, but are not limited to, companies falling within the information technology, e-commerce discretionary, internet media and services, healthcare technology, healthcare devices, or transaction and payment processing services industries. Because of its focus on technology companies, the Eventide Exponential Technologies Fund's investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Exponential Technologies Fund's net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries.

---

| |
|:---|
| **Eventide Funds** |
| ***NOTES TO FINANCIAL STATEMENTS (Continued)*** |
| **June 30, 2025** |

---

The Eventide Healthcare & Life Sciences Fund invests primarily in equity and equity-related securities of companies in the healthcare and life sciences sectors that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. Because of its focus on healthcare and life science companies, the Eventide Healthcare & Life Sciences Fund's investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Healthcare & Life Sciences Fund's net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries.

&nbsp;&nbsp;&nbsp;&nbsp;**(8)** **OPTIONS RISK** 

There are risks associated with the sale and purchase of call and put options. The seller (writer) of a call option which is covered (e.g., the writer holds the underlying security) assumes the risk of a decline in the market price of an underlying security below the purchase price of an underlying security less the premium received, and gives up the opportunity for gain on the underlying security above the exercise price of the option. The seller of an uncovered call option assumes the risk of a theoretical unlimited increase in the market price of an underlying security above the exercise price of the option. The securities necessary to satisfy the exercise of the call option may be unavailable for purchase except at much higher prices. Purchasing securities to satisfy the exercise of the call option can itself cause the price of securities to rise further, sometimes by a significant amount, thereby exacerbating the loss. The buyer of a call option assumes the risk of losing its entire premium invested in the call option. The seller (writer) of a put option which is covered (e.g., the writer has a short position in the underlying security) assumes the risk of an increase in the market price of the underlying security above the sales price (in establishing the short position) of the underlying security plus the premium received, and gives up the opportunity for gain on the underlying security below the exercise price of the option. The seller of an uncovered put option assumes the risk of a decline in the market price of the underlying security below the exercise price of the option. The buyer of a put option assumes the risk of losing his entire premium invested in the put option.

&nbsp;&nbsp;&nbsp;&nbsp;**(9)** **MARKET RISK** 

Overall market risks may also affect the value of the Funds. The market values of securities or other investments owned by the Funds will go up or down, sometimes rapidly or unpredictably. Factors such as economic growth and market conditions, interest rate levels, exchange rates and political events affect the securities markets. Changes in market conditions and interest rates generally do not have the same impact on all types of securities and instruments. Unexpected local, regional or global events and their aftermath, such as war; acts of terrorism; financial, political or social disruptions; natural, environmental or man-made disasters; climate-change and climate-related events; the spread of infectious illnesses or other public health issues; recessions and depressions; tariffs and trade wars; or other tragedies, catastrophes and events could have a significant impact on the Funds and their investments and could result in increased premiums or discounts to a Fund's net asset value, and may impair market liquidity, thereby increasing liquidity risk. Such events can cause investor fear and panic, which can adversely affect the economies of many companies, sectors, nations, regions and the market in general, in ways that cannot necessarily be foreseen. The Funds could lose money over short periods due to short-term market movements and over longer periods during more prolonged market downturns. During a general market downturn, multiple asset classes may be negatively affected. In times of severe market disruptions you could lose your entire investment.

&nbsp;&nbsp;&nbsp;&nbsp;**(10)** **LINE OF CREDIT** 

Effective January 22, 2025, the Funds have a $150,000,000 uncommitted line of credit provided by U.S. Bank National Association (the ***"Bank"***) under an agreement (the ***"Uncommitted Line"***), that is set to expire on January 21, 2026. Borrowings under the Uncommitted Line bear an interest at Prime Rate minus 0% per month. Any advance under the Uncommitted Line is contemplated primarily for temporary or emergency purposes, including the meeting of redemption requests that otherwise might require the untimely disposition of securities. Interest on borrowings is payable on an annualized basis. The Uncommitted Line is not a "committed" line of credit, which is to say that the Bank is not obligated to lend money to the Funds. Accordingly, it is possible that Funds may wish to borrow money for a temporary or emergency purpose but may not be able to do so. During the year ended June 30, 2025, none of the Funds accessed the line of credit.

&nbsp;&nbsp;&nbsp;&nbsp;**(11)** **BENEFICIAL OWNERSHIP** 

The beneficial ownership, either directly or indirectly, of more than 25% of the voting securities of a fund creates a presumption of control of the fund, under Section 2(a)(9) of the 1940 Act. As of June 30, 2025, Charles Schwab & Co, Inc. Special Custody Account for the Exclusive Benefit of Customers held 41.04%, 41.43%, 25.11% and 28.22% of the Eventide Core Bond Fund, Eventide Exponential Technologies Fund, Eventide Large Cap Focus Fund and Eventide Limited-Term Bond Fund, respectively. As of June 30, 2025, National Financial Services LLC held 40.34% of the Eventide Core Bond Fund. As of June 30, 2025, American Enterprise Investment Services held 33.00% of the Eventide Limited-Term Bond Fund.

&nbsp;&nbsp;&nbsp;&nbsp;**(12)** **SUBSEQUENT EVENTS** 

Subsequent events after the date of the Statements of Assets and Liabilities have been evaluated through the date the financial statements were issued. Management has determined that no events or transactions occurred requiring adjustment or disclosure in the financial statements.

![(LOGO)](ev002_v1.jpg)

**<u>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>**

To the Shareholders of Eventide Balanced Fund, Eventide Core Bond Fund, Eventide Dividend Growth Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund, and Eventide Limited-Term Bond Fund and

Board of Trustees of Mutual Fund Series Trust

Opinion on the Financial Statements

We have audited the accompanying statements of assets and liabilities, including the schedules of investments, of Eventide Balanced Fund, Eventide Core Bond Fund, Eventide Dividend Growth Fund (formerly, Eventide Dividend Opportunities Fund), Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund, and Eventide Limited-Term Bond Fund (the "Funds"), each a series of Mutual Fund Series Trust, as of June 30, 2025, the related statements of operations for the year then ended, the statements of changes in net assets for each of the two years in the period then ended, the financial highlights for each of the three years in the period then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of each of the Funds as of June 30, 2025, the results of their operations for the year then ended, the changes in net assets for each of the two years in the period then ended, and the financial highlights for each of the three years in the period then ended, in conformity with accounting principles generally accepted in the United States of America.

The Funds' financial highlights for the years ended June 30, 2022, and prior, were audited by other auditors whose report dated August 29, 2022, expressed an unqualified opinion on those financial highlights.

Basis for Opinion

These financial statements are the responsibility of the Funds' management. Our responsibility is to express an opinion on the Funds' financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Funds in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our procedures included confirmation of securities owned as of June 30, 2025, by correspondence with the custodian, issuers, and brokers; when replies were not received from issuers and brokers, we performed other auditing procedures. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

We have served as the Funds' auditor since 2023.

![(SIGNATURE)](ev003_v1.jpg)

COHEN & COMPANY, LTD.

Greenwood Village, Colorado

August 29, 2025

---

| |
|:---|
| **COHEN & COMPANY, LTD.** |
| **Registered with the Public Company Accounting Oversight Board** |
| **800.229.1099** **I 866.818.4538 fax I cohenco.com** |

---

---

| |
|:---|
| **Eventide Funds** |
| ***Additional Information (Unaudited)*** |
| **June 30, 2025** |

---

**Changes in and Disagreements with Accountants**

There were no changes in or disagreements with accountants during the period covered by this report.

**Proxy Disclosures**

Not applicable.

**Remuneration Paid to Directors, Officers and Others**

Refer to the financial statements included herein.

**Statement Regarding Basis for Approval of Investment Advisory Agreement**

Consideration and Renewal of Management Agreement between Mutual Fund Series Trust and Eventide Asset Management, LLC with respect to Eventide Gilead Fund, Eventide Healthcare and Life Sciences Fund, Eventide Balanced, Eventide Dividend Growth Fund, Eventide Limited-Term Bond Fund, Eventide Exponential Technologies Fund, Eventide Core Bond Fund and Eventide Large Cap Focus Fund.

In connection with a meeting held on May 14, 15 and 28, 2025, the Board of Trustees (the "Board") of Mutual Fund Series Trust (the "Trust"), including a majority of the Trustees who are not "interested persons" as that term is defined in the Investment Company Act of 1940, as amended, discussed the renewal of the advisory agreement (the "Advisory Agreement") between the Trust and Eventide Asset Management, LLC ("Eventide") with respect to Eventide Gilead Fund ("Eventide Gilead"), Eventide Healthcare and Life Sciences Fund ("Eventide HLS"), Eventide Balanced Fund ("Balanced"), Eventide Dividend Growth Fund ("Eventide DG"), Eventide Limited-Term Bond Fund ("Eventide LTB"), Eventide Exponential Technologies Fund ("Eventide ET"), Eventide Core Bond Fund ("Eventide CB") and Eventide Large Cap Focus Fund ("Eventide LCF") (collectively, the "Eventide Funds")

The Board examined Eventide's responses to a series of questions regarding, among other things, its advisory services provided to the Eventide Funds, comparative fee and expense information, and profitability from managing the Eventide Funds. The Board was assisted by legal counsel throughout the review process and relied upon the advice of legal counsel and its own business judgment in determining the material factors to be considered in evaluating the Advisory Agreement and the weight to be given to each factor considered. The conclusions reached by the Board were based on a comprehensive evaluation of all of the information provided and were not the result of any one factor. Moreover, each Trustee may have afforded different weight to the various factors in reaching his conclusions with respect to the renewal of the Advisory Agreement.

*Nature, Extent and Quality of Services.* The Board reviewed the key personnel involved in servicing the Eventide Funds, noting that a number of individuals had received promotions and new titles since the last renewal of the Advisory Agreement. The Board acknowledged that Eventide was responsible for providing portfolio management services to the Eventide Funds, including research and analysis, making investment decisions, and security selection consistent with the values principals articulated in each Eventide Fund's prospectus. The Board noted that Eventide utilized internal research analysts and portfolio managers to provide fundamental security and sector research, as well as external research partners to provide sector and macro-economic data. The Board discussed that Eventide reviewed compliance reports related to each Eventide Fund's investment limitations and used software to review portfolio holdings to ensure compliance with these limitations. The Board recognized that Eventide provided continuous oversight and compliance services to the Eventide Funds that are sub-advised by Boyd Watterson. The Board noted that Eventide reported no material compliance issues since the last renewal. After further discussion, the Board concluded Eventide could continue to provide high quality service to each Eventide Fund and its shareholders.

*Performance.* The Board reviewed the performance of each Eventide Fund relative to its peer group and Morningstar category.

*<u>Eventide Gilead:</u>* The Board observed that Eventide Gilead underperformed the peer group average, Morningstar category, and benchmark index for the 1- and 3- year periods and slightly underperformed all three benchmarks for the 5- and 10-year periods. The Board noted that Eventide explained that the underperformance was due to general stock selection in the portfolio and the limited exposure to large cap equity securities in the Fund, unlike the benchmark index and peer group funds.

*<u>Eventide HLS:</u>* The Board noted that the Fund underperformed all benchmarks for the 1-year period. The Board noted that the Fund underperformed the peer group and Morningstar category but outperformed the S&P Biotechnology Select Industry TR for the 3- and 5-year periods and outperformed all benchmarks over the 10-year period. The Board noted that Eventide explained that the Morningstar category and peer group funds included less biotechnology securities with a focus on insurance companies which led to the differences in performance.

---

| |
|:---|
| **Eventide Funds** |
| ***Additional Information (Unaudited) (Continued)*** |
| **June 30, 2025** |

---

*<u>Balanced:</u>* The Board discussed that Balanced underperformed the peer group average for all time periods but outperformed the Bloomberg Mid Cap/Intermediate US Aggregate index for all time periods. The Board noted that the Fund underperformed the Morningstar category in the 1- and 3-year periods but outperformed the category in the 5- and 10- year periods. The Board acknowledged that Eventide noted that the peer group funds had higher equity exposure than Balanced which led to the consistent underperformance.

*<u>Eventide DG:</u>* The Board noted that Eventide DG outperformed all benchmarks for all time periods. The Board noted that Eventide attributed the overperformance to strong security selection in the Fund.

*<u>Eventide LTB:</u>* The Board observed that the Fund underperformed the peer group and US Fund Short Term Bond Morningstar category for all time periods. The Board noted that the Fund outperformed the Bloomberg US Govt/Credit 1-5 Yr TR Index for the 3-year period but underperformed for the 1-, 5-, and 10-year periods. The Board discussed that Eventide reported that corporate bonds contributed to Fund's performance and that the longer duration in the Fund's bonds compared to funds in the peer group led to the underperformance.

*<u>Eventide ET:</u>* The Board discussed that Eventide ET underperformed the peer group average, Morningstar category, and benchmark index for all time periods. The Board noted that Eventide attributed the underperformance to security selection in the portfolio and the lack of large cap information technology securities. The Board noted that Eventide recently replaced the portfolio manager for the Fund.

*<u>Eventide CB:</u>* The Board noted that Eventide CB slightly underperformed the peer group, US Fund Intermediate Core Bond, and Bloomberg US Aggregate Bond TR index for the 1-year, 3-year and since inception periods. The Board noted that Eventide attributed the underperformance primarily to the timing of the Fund's launch coinciding with the start of rising interest rates and the Fund's underweight allocation to treasury bonds.

*<u>Eventide LCF:</u>* The Board observed that Eventide LCF trailed all benchmarks for the 1-year and since inception periods. The Board discussed that Eventide attributed the underperformance compared to the S&P 500 benchmark index to the Fund's allocations in the Information Technology, Industrials, and Communication Services sectors and the underperformance compared to the Morningstar category to the Fund's allocations in the Financials, Communication Services, Health Care, Consumer Discretionary, Materials, and Real Estate sectors.

After further discussion, the Board concluded that the performance of each Eventide Fund was acceptable.

*Fees and Expenses.* The Board reviewed the advisory fees paid by each of the Eventide Funds in comparison to the fees charged to the peer group funds, and the funds in each of the Eventide Funds' Morningstar category Funds along with the indirect benefits of Rule 12b-1 fees received by Eventide with respect to the distribution of the Eventide Funds. The Board discussed the allocation of fees between Eventide and Boyd Watterson, based on the sub-advisory fees paid by the adviser for each of Balanced, Eventide CB and Eventide LTB, in comparison to the level of service provided. The Board noted that the agreement between Eventide and Boyd Watterson was the product of an arm's length negotiation.

*<u>Eventide Gilead:</u>* The Board noted that the advisory fee of 0.97% was above the median and average for the peer group and Morningstar category but was well within the range for both. The Board commented that the net expense ratio of 1.41% was above the peer group and Morningstar category median and average but within the range for each.

*<u>Eventide HLS:</u>* The Board discussed that the advisory fee for Eventide HLS was above the median and average for the peer group and Morningstar category but within the range. The Board noted that the net expense ratio was higher than the median and average for the peer group and Morningstar category but well below the high for each.

*<u>Balanced:</u>* The Board noted that the advisory fee of 0.60% (before waiver) was below the average and median for the peer group and slightly above the Morningstar category median and average but well below the high. The Board discussed that net expense ratio was in line with the median for the peer group and below the average and within the range for the Morningstar category.

---

| |
|:---|
| **Eventide Funds** |
| ***Additional Information (Unaudited) (Continued)*** |
| **June 30, 2025** |

---

*<u>Eventide DG:</u>* The Board discussed that the advisory fee for Eventide DG was below the median and average for the peer group and in line with the median for the Morningstar category but slightly above the average. The Board observed that the net expense ratio was below the median and average for the peer group and slightly above the Morningstar category median and average but far below the high.

*<u>Eventide LTB:</u>* The Board acknowledged that the advisory fee of 0.31% (before waiver) was below the median and average for both the peer group and Morningstar category. The Board noted that the net expense ratio was slightly above the median and average for the peer group and Morningstar category but was within the range for each.

*<u>Eventide ET:</u>* The Board discussed that the advisory fee was above the peer group and Morningstar category median and average but within the range for each. The Board noted that the net expense ratio was above the peer group and Morningstar category median and average but well below the highs for both

*<u>Eventide CB:</u>* The Board noted the advisory fee of 0.34% (before waiver) was below the median and average for the peer group and Morningstar category. The Board discussed that the net expense ratio was above the median and slightly above the average but well below the highs for the peer group and Morningstar category.

*<u>Eventide LCF</u>*: The Board discussed that the Fund's advisory fee was above the peer group and Morningstar category median and average but within the range for each. The Board noted that when taking the expense waiver into account, the fee was below the peer group and Morningstar category median and averages. The Board discussed that the net expense ratio was above the peer group and Morningstar category median and average but below the highs for each.

The Board concluded that based on the advisory services provided to each of the Eventide Funds by Eventide that the advisory fee paid by each of the Eventide Funds to Eventide was not unreasonable.

*Profitability.* The Board reviewed the financial information provided by Eventide and discussed Eventide's profitability from its services to each of the Eventide Funds. The Board recognized that some of Eventide's senior personnel received compensation in the form of ownership distributions that, if included as an operating expense in Eventide's calculations, would reduce the estimated profit levels. The Board observed that Eventide earned a reasonable profit from advising Eventide Gilead, Eventide HLS, Balanced, Eventide DG, and Eventide ET; earned a small profit from Eventide LTB; and did not earn a profit from advising Eventide LCF. The Board discussed the soft dollar benefits received by Eventide, and, after further discussion, the Board determined excess profitability on a Fund by Fund basis was not a concern at this time.

*Economies of Scale*. The Board discussed potential breakpoints for the Eventide Funds, but acknowledged that Eventide Fund's shareholders benefited from each Fund's expense cap. The Board discussed that Eventide also paid a sub-advisory fee for the Eventide Sub-Advised Funds. The Board noted that Eventide had also lowered its advisory fee in recent years. After further discussion, the Board determined breakpoints were not appropriate at this time, but that the Board would continue to discuss breakpoints in the future.

*Conclusion.* Having requested and received such information from Eventide as the Board believed to be reasonably necessary to evaluate the terms of the Advisory Agreement, and as assisted by the advice of counsel, the Board concluded that renewal of the advisory agreement was in the best interests of each Eventide Fund and its respective shareholders

**Fund Proxy Voting Policies, Procedures and Summaries**

Information regarding how the Funds voted proxies relating to portfolio securities for the most recent 12-month period ended June 30 as well as a description of the policies and procedures that the Funds use to determine how to vote proxies is available without charge, upon request, by calling 1-877-771-3836 or by referring to the Securities and Exchange Commission's ("SEC") website at http://www.sec.gov.

**Item 8. Changes in and Disagreements with Accountants for Open-End Management Investment Companies.** 

Not applicable

**Item 9. Proxy Disclosures for Open-End Management Investment Companies.** 

Not applicable

**Item 10. Remuneration Paid to Directors, Officers, and Others of Open-End Management Investment Companies.** 

Included under Item 7

**Item 11. Statement Regarding Basis for Approval of Investment Advisory Contract.** 

Included under Item 7

**Item 12. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.** 

Not applicable

**Item 13. Portfolio Managers of Closed-End Management Investment Companies.**

Not applicable

**Item 14. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.** 

Not applicable

**Item 15. Submission of Matters to a Vote of Security Holders.** 

None

**Item 16. Controls and Procedures** 

(a) The registrant's Principal Executive Officer and Principal Financial Officer have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Act) are effective in design and operation and are sufficient to form the basis of the certifications required by Rule 30a-(2) under the Act, based on their evaluation of these disclosure controls and procedures as of a date within 90 days of this report on Form N-CSR.

(b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

**Item 17. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.** 

Not applicable

**Item 18. Recovery of Erroneously Awarded Compensation.**

(a)&nbsp;&nbsp;&nbsp;&nbsp; Not applicable

(b)&nbsp;&nbsp;&nbsp;&nbsp; Not applicable

**Item 19. Exhibits.** 

[(a)(1) Code of Ethics for Principal Executive and Senior Financial Officers.](coe.htm)

(a)(2) Not applicable

[(a)(3) A separate certification for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a) under the Act (17 CFR 270.30a-2(a)): Attached hereto.](ex_99cert.htm)

(a)(4) Not applicable

[(b) Certifications required by Rule 30a-2(b) under the Act (17 CFR 270.30a-2(b)): Attached hereto.](ex_99-906cert.htm)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Mutual Fund Series Trust

---

| | |
|:---|:---|
| By | /s/ Michael Schoonover |

---

Michael Schoonover <br> Principal Executive Officer <br> Date: 9/2/2025

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

---

| | |
|:---|:---|
| By | /s/ Michael Schoonover |

---

Michael Schoonover <br> Principal Executive Officer <br> Date: 9/2/2025

---

| | |
|:---|:---|
| By | /s/ Erik Naviloff |

---

Erik Naviloff <br> Principal Financial Officer <br> Date: 9/2/2025

## Ex-99.Code

**CODE OF ETHICS**

**I.** **Statement of General Principles**

This Code of Ethics has been adopted by the Mutual Fund Series Trust (the "Trust") for the purpose of instructing all employees, officers and trustees of the Trust and Catalyst Capital Advisors, LLC, the adviser to the Trust (the "Adviser"), in their ethical obligations and to provide rules for their personal securities transactions. All such persons owe a fiduciary duty to the Trust and its shareholders. A fiduciary duty means a duty of loyalty, fairness and good faith towards the Trust and its shareholders, and the obligation to adhere not only to the specific provisions of this Code but to the general principles that guide the Code. These general principles are:

· The duty at all times to place the interests of the Trust and its shareholders first;

· The requirement that all personal securities transactions be conducted in a manner consistent with the Code of Ethics and in such a manner as to avoid any actual or potential conflict of interest or any abuse of any individual's position of trust and responsibility; and

· The fundamental standard that such employees, officers, directors and trustees should not take inappropriate advantage of their positions, or of their relationship with the Trust or its shareholders.

It is imperative that the personal trading activities of the employees, officers, directors and trustees of the Trust and the Adviser, respectively, be conducted with the highest regard for these general principles in order to avoid any possible conflict of interest, any appearance of a conflict, or activities that could lead to disciplinary action. This includes executing transactions through or for the benefit of a third party when the transaction is not in keeping with the general principles of this Code.

All personal securities transactions must also comply with the Securities & Exchange Commission's Rule 17j-1. Under this rule, no Employee may:

· employ any device, scheme or artifice to defraud the Trust or any of its shareholders;

· make to the Trust or any of its shareholders any untrue statement of a material fact or omit to state to such client a material fact necessary in order to make the statements made, in light of the circumstances under which they are made, not misleading;

· engage in any act, practice, or course of business which operates or would operate as a fraud or deceit upon the Trust or any of its shareholders; or

· engage in any manipulative practice with respect to the Trust or any of its shareholders.

**II.** **Definitions**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. <u>Advisory Employees</u>: Employees who, in connection with their regular functions or duties, make, participate in, or obtain information regarding the purchase or sale of securities by a Fund, or whose functions relate to the making of any recommendation with respect to purchases or sales. The Compliance Officer will maintain a current list of all Advisory Employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. <u>Beneficial Interest</u>: ownership or any benefits of ownership, including the opportunity to directly or indirectly profit or otherwise obtain financial benefits from any interest in a security.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. <u>Compliance Officer</u>: the Compliance Officer for the Adviser and the Trust is each company's duly named Chief Compliance Officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. <u>Disinterested Trustees</u>: trustees of the Trust whose affiliation with the Trust is solely by reason of being a trustee of the Trust.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E. <u>Employee Account</u>: each account in which an Employee or a member of his or her family has any direct or indirect Beneficial Interest or over which such person exercises control or influence, including, but not limited to, any joint account, partnership, corporation, trust or estate. An Employee's family members include the Employee's spouse, minor children, any person living in the home of the Employee and any relative of the Employee (including in-laws) to whose support an Employee directly or indirectly contributes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F. <u>Employees</u>: the employees, officers, and trustees of the Trust and the employees, officers and directors of the Adviser, including Advisory Employees. The Compliance Officer will maintain a current list of all Employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;G. <u>Exempt Transactions</u>: transactions which are 1) effected in an amount or in a manner over which the Employee has no direct or indirect influence or control, 2) pursuant to a systematic dividend reinvestment plan, systematic cash purchase plan or systematic withdrawal plan, 3) in connection with the exercise or sale of rights to purchase additional securities from an issuer and granted by such issuer pro-rata to all holders of a class of its securities, 4) in connection with the call by the issuer of a preferred stock or bond, 5) pursuant to the exercise by a second party of a put or call option, 6) closing transactions no more than five business days prior to the expiration of a related put or call option, 7) inconsequential to any Fund because the transaction is very unlikely to affect a highly liquid market or because the security is clearly not related economically to any securities that a Fund may purchase or sell, 8) involving shares of a security of a company with a market capitalization in excess of $500 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;H. <u>Funds</u>: any series of the Trust.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I. <u>Related Securities</u>: securities issued by the same issuer or issuer under common control, or when either security gives the holder any contractual rights with respect to the other security, including options, warrants or other convertible securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;J. <u>Securities</u>: any note, stock, treasury stock, bond, debenture, evidence of indebtedness, certificate of interest or participation in any profit-sharing agreement, collateral-trust certificate, pre-organization certificate or subscription, transferable share, investment contract, voting-trust certificate, certificate of deposit for a security, fractional undivided interest in oil, gas or other mineral rights, or, in general, any interest or instrument commonly known as a "security," or any certificate or interest or participation in temporary or interim certificate for, receipt for, guarantee of, or warrant or right to subscribe to or purchase (including options) any of the foregoing; except for the following: 1) securities issued by the government of the United States, 2) bankers' acceptances, 3) bank certificates of deposit, 4) commercial paper, and 5) shares of unaffiliated registered open-end investment companies (other than exchange traded funds)..

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;K. <u>Securities Transaction</u>: the purchase or sale, or any action to accomplish the purchase or sale, of a Security for an Employee Account. The term Securities Transaction does not include transactions executed by the Adviser for the benefit of unaffiliated persons, such as investment advisory and brokerage clients.

**III.** **Personal Investment Guidelines**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.**

**Personal Accounts** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Personal Investment Guidelines in this Section III do not apply to Exempt Transactions unless the transaction involves a private placement or initial public offering. Employees must remember that regardless of the transaction's status as exempt or not exempt, the Employee's fiduciary obligations remain unchanged.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. While trustees of the Trust are subject at all times to the fiduciary obligations described in this Code, the Personal Investment Guidelines and Compliance Procedures in Sections III and IV of this Code apply to Disinterested Trustees only if such person knew, or in the ordinary course of fulfilling the duties of that position, should have known, that during the fifteen days immediately preceding or after the date of the such person's transaction that the same Security or a Related Security was or was to be purchased or sold for a Fund or that such purchase or sale for a Fund was being considered, in which case such Sections apply only to such transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Employees may not execute a Securities Transaction on a day during which a purchase or sell order in that same Security or a Related Security is pending for a Fund unless the Securities Transaction is combined ("blocked") with the Fund's transaction. Securities Transactions executed in violation of this prohibition shall be unwound or, if not possible or practical, the Employee must disgorge to the Fund the value received by the Employee due to any favorable price differential received by the Employee. For example, if the Employee buys 100 shares at $10 per share, and the Fund buys 1000 shares at $11 per share, the Employee will pay $100 (100 shares x $1 differential) to the Fund.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Any Securities Transactions in a private placement must be authorized by the Compliance Officer, in writing, prior to the transaction. In connection with a private placement acquisition, the Compliance Officer will take into account, among other factors, whether the investment opportunity should be reserved for a Fund, and whether the opportunity is being offered to the Employee by virtue of the Employee's position with the Trust or the Adviser. If the private placement acquisition is authorized, the Compliance Officer shall retain a record of the authorization and the rationale supporting the authorization. Employees who have been authorized to acquire securities in a private placement will, in connection therewith, be required to disclose that investment if and when the Employee takes part in any subsequent investment in the same issuer. In such circumstances, the determination to purchase Securities of that issuer on behalf of a Fund will be subject to an independent review by personnel of the Adviser with no personal interest in the issuer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Employees are prohibited from acquiring any Securities in an initial public offering without the prior written approval of the Compliance Officer. This restriction is imposed in order to preclude any possibility of an Employee profiting improperly from the Employee's position with the Trust or the Adviser. If the initial public offering is authorized, the Compliance Officer shall retain a record of the authorization and the rationale supporting the authorization.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.**

**Other Restrictions**

Employees are prohibited from serving on the boards of directors of publicly traded companies, absent prior authorization by the Compliance Officer. The consideration of prior authorization will be based upon a determination that the board service will be consistent with the interests of the Trust and the Funds' shareholders. In the event that board service is authorized, Employees serving as directors will be isolated from other Employees making investment decisions with respect to the securities of the company in question.

**IV.** **Compliance Procedures**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.**

**Employee Disclosure**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Within ten (10) days of commencement of employment with the Trust or the Adviser, each Employee must certify that he or she has read and understands this Code and recognizes that he or she is subject to it, and must disclose the following information, which information must be current as of a date no more than 45 days prior to the date the person became an Employee: a) the title, number of shares and principal amount of each Security in which the Employee has a Beneficial Interest when the person became an Employee, b) the name of any broker/dealer with whom the Employee maintained an account when the person became an Employee, and c) the date the report is submitted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Annually, each Employee must certify that he or she has read and understands this Code and recognizes that he or she is subject to it, that he or she has complied with the requirements of this Code and has disclosed or reported all personal Securities Transactions required to be disclosed or reported pursuant to the requirements of this Code. In addition, each Employee shall annually provide the following information (as of a date no more than 30 days before the report is submitted): a) the title, number of shares and principal amount of each Security in which the Employee had any Beneficial Interest, b) the name of any broker, dealer or bank with whom the Employee maintains an account in which any Securities are held for the direct or indirect benefit of the Employee, and c) the date the report is submitted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.**

**Compliance**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. All Employees must provide copies of all periodic broker account statements to the Compliance Officer. Each Employee must report, no later than thirty (30) days after the close of each calendar quarter, on the Securities Transaction Report form provided by the Trust or the Adviser, all transactions in which the Employee acquired or sold any direct or indirect Beneficial Interest in a Security, including Exempt Transactions, and certify that he or she has reported all transactions required to be disclosed pursuant to the requirements of this Code. The report will also identify any trading account, in which the Employee has a direct or indirect Beneficial Interest, established during the quarter with a broker, dealer or bank. The Employee may exclude transactions effected pursuant to an automatic investment plan. An automatic investment plan is a program in which regular periodic purchases (or withdrawals) are made automatically in (or from) investment accounts in accordance with a predetermined schedule and allocation. An automatic investment plan includes a dividend reinvestment plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The Compliance Officer will, on a quarterly basis, check the trading account statements provided by brokers to verify that the Employee has not violated the Code. The Compliance Officer shall identify all Employees, inform those persons of their reporting obligations, and maintain a record of all current and former access persons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. If an Employee violates this Code, the Compliance Officer will report the violation to management personnel of the Trust and the Adviser for appropriate remedial action which, in addition to the actions specifically delineated in other sections of this Code, may include a reprimand of the Employee, or suspension or termination of the Employee's relationship with the Trust and/or the Adviser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The management personnel of the Trust will prepare an annual report to the Trust's board of trustees that summarizes existing procedures and any changes in the procedures made during the past year and certify to the Trust's Board of Trustees that the Adviser and the Trust have each adopted procedures reasonably necessary to prevent Employees from violating this Code. The report will describe any issues existing under this Code since the last report, including without limitation, information about any material violations of this Code, any significant remedial action during the past year and any recommended procedural or substantive changes to this Code based on management's experience under this Code, evolving industry practices or legal developments.

**Responsible Party/Compliance Process:** Chief Compliance Officer/Investment Adviser

**Approved**: <u>DFG</u> 

**Revised**: <u>02/01/2007</u> 

**ANNUAL EMPLOYEE SECURITIES REPORT**

This information is current as of _______________ (must be current as of a date no more than 45 days before the Report is submitted). Please list all Securities in which you have a Beneficial Interest, as defined in the Code of Ethics.

---

| | | |
|:---|:---|:---|
| <br>Security(name, type, CUSIP or ticker symbol) | **# of Shares and**<br> **Principal Amount** | <br>**Date Acquired** |

---

Please list all brokers, dealers and banks that maintain a brokerage account in which you have a Beneficial Interest, as defined in the Code of Ethics.

---

| | |
|:---|:---|
| **Name of Broker, Dealer or Bank** | **Account Name** |

---

I certify that I have read and understand the Code of Ethics and recognize that I am subject to it. I certify that this is a complete list of all Securities in which I have a Beneficial Interest, and that I have complied with the requirements of the Code of Ethics including disclosure of all Securities Transactions for which the Code of Ethics requires disclosure.

Printed Name:

Signature:

Date:

 **PRE-CLEARANCE OF SECURITY TRANSACTION**

&nbsp;&nbsp;&nbsp;&nbsp;To:

Compliance Officer

From:

__________________________________________

(Name of Employee)

Date:

__________________________________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1. I hereby seek approval for the □ purchase/□ sale of _________ shares or $__________ par value of _______________________ for the cash or margin account of _____________________.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. The price per share or contract is approximately $_________________.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3. The transaction □ is/□ is not in connection with a private placement or an initial public offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4. Said transaction was recommended to me by __________________________________.

I have no knowledge of any pending purchase or sell order for this Security or a Related Security.

I have read the Code of Ethics within the past year and recognize that I am subject to it.

After inquiry, I am satisfied that this transaction is consistent with the Code of Ethics and the Insider Trading Policy. If I become aware that the trade does not comply with this Code or that the statements made on the request are no longer true, I will immediately notify the Compliance Officer.

______________________________________

Signature of Employee

APPROVED: _________________________________

DATE: ______________________

**TRANSACTION COMPLETED:** Date ___________

No. of Shares _________

Price _______

TRANSACTION UNFILLED: ___________________

<u>COMMENTS/FOLLOW UP</u>:

(This authorization is valid until close of business on the second trading day following authorization.

**QUARTERLY SECURITIES TRANSACTIONS REPORT**

**Calendar Quarter/Year:**

Persons subject to the Code of Ethics must report **ALL** Securities Transactions (including Exempt Transactions and transactions involving affiliated mutual Funds) as defined in the Code of Ethics, executed during the reporting period. **DO NOT ATTACH BROKERAGE REPORTS**. The report must be returned to the Compliance Officer, regardless of whether any Securities Transactions occurred, before the 30th day after the close of the calendar quarter. Please note that this Report covers all Securities in which you have a Beneficial Interest.

<br> □

I have executed no Securities Transactions during the quarter. □

The following is a complete list of my Securities Transactions:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>**Security\*** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>**Transaction**<br> **Date** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>**Purchase, Sale,**<br> **or Other** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**# of Shares &**<br> **Principal Amount**<br> **of Security** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>**Price** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>**Executing Broker** |

---

\*Provide interest rate, maturity date, ticker symbol or CUSIP, if applicable

I have not opened a brokerage account during the quarter.

The following is a complete list of all brokerage accounts I opened during the quarter:

---

| | | |
|:---|:---|:---|
| **Name of Broker, Dealer or Bank:** | **Account Name:** | **Date Established:** |

---

I certify that I have read and understand the Code of Ethics and that I have complied with the requirements of the Code of Ethics, including disclosure of all Securities Transactions that require disclosure.

Printed Name:

Signature:

Filing Date:

THIS REPORT SHALL NOT BE CONSTRUED AS AN ADMISSION THAT THE REPORTING PERSON HAS ANY DIRECT OR INDIRECT BENEFICIAL OWNERSHIP IN ANY SECURITY TO WHICH THIS REPORT RELATES.

**NEW EMPLOYEE SECURITIES REPORT**

This information is current as of _______________ (must be current as of a date no more than 45 days before your commencing employment). *Return to Compliance Officer within 10 days of your commencing employment.*

Please list all Securities in which you have a Beneficial Interest, as defined in the Code of Ethics.

---

| | | |
|:---|:---|:---|
| <br>Security(name, type, CUSIP or ticker symbol) | **# of Shares or**<br> **Principal Amount** | <br>**Date Acquired** |

---

Please list all brokers, dealers and banks that maintain a brokerage account in which you have a Beneficial Interest, as defined in the Code of Ethics.

---

| | |
|:---|:---|
| **Name of Broker, Dealer or Bank** | **Account Name** |

---

I certify that I have read and understand the Code of Ethics and recognize that I am subject to it. I certify that this is a complete list of all Securities in which I have a Beneficial Interest, and that I have complied with the requirements of the Code of Ethics including disclosure of all Securities Transactions for which the Code of Ethics requires disclosure.

Printed Name:

Signature:

Date:

**ANNUAL ISSUES REPORT AND CERTIFICATION** 

**OF**

**CATALYST FUNDS**

For the period__________ to ______________

**A. Issues Report**. Rule 17j-1 under the 1940 Act requires that the Catalysts Funds (the "Trust") submit at least annually, for the Board of Trustees' consideration, a written report describing any issues arising under the Trust's Code of Ethics, including, but not limited to, information about material violations of the code and sanctions imposed in response to the material violations.

[Describe all issues relevant to the Board or state that there are no issues to report.]

No issues to report.

**B.** 

**Certification**. The undersigned authorized officer of the Trust hereby certifies to the Board that the Trust has adopted procedures reasonably necessary to prevent Access Persons (as defined in the Code) from violating the Code.

Date:___________________

_________________________________________

Authorized Officer

**ANNUAL ISSUES REPORT AND CERTIFICATION** 

**OF**

**Name of Adviser or Sub Adviser**

For the period _______________ to __________________

**A.** 

**Issues Report**. Rule 17j-1 under the 1940 Act requires that __________________ (the "Adviser"), adviser to the Mutual Fund Series Trust submit at least annually, for the Board of Trustees' consideration, a written report describing any issues arising under the Trust's Code of Ethics, including, but not limited to, information about material violations of the code and sanctions imposed in response to the material violations.

[Describe all issues relevant to the Board or state that there are no issues to report.]

No issues to report.

**B.** 

**Certification**. The undersigned authorized officer of the Adviser hereby certifies to the Board that the Trust has adopted procedures reasonably necessary to prevent Access Persons (as defined in the Code) from violating the Code.

Date:___________________

_________________________________________

Authorized Officer

**ANNUAL ISSUES REPORT AND CERTIFICATION** 

**OF**

**Matrix Capital Group, Inc.** 

For the period _______________ to __________________

**A.** 

**Issues Report**. Rule 17j-1 under the 1940 Act requires that Matrix Capital Group, Inc. principal underwriter of the Mutual Fund Series Trust (the "Underwriter") submit at least annually, for the Board of Trustees' consideration, a written report describing any issues arising under the Trust's Code of Ethics, including, but not limited to, information about material violations of the code and sanctions imposed in response to the material violations.

[Describe all issues relevant to the Board or state that there are no issues to report.]

No issues to report.

**B.** 

**Certification**. The undersigned authorized officer of the Underwriter hereby certifies to the Board that the Trust has adopted procedures reasonably necessary to prevent Access Persons (as defined in the Code) from violating the Code.

Date:___________________

_________________________________________

Authorized Officer

## Ex-99.Cert

**Certification** [Exhibit 99. CERT]

I, Michael Schoonover, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I
 have reviewed this report on Form N-CSR of Eventide Funds, a series of the Mutual Fund Series
 Trust ("registrant");

&nbsp;&nbsp;&nbsp;&nbsp;2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or
 omit to state a material fact necessary to make the statements made, in light of the circumstances
 under which such statements were made, not misleading with respect to the period covered
 by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based
 on my knowledge, the financial statements, and other financial information included in this
 report, fairly present in all material respects the financial condition, results of operations,
 changes in net assets, and cash flows (if the financial statements are required to include
 a statement of cash flows) of the registrant as of, and for, the periods presented in this
 report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The
 registrant's other certifying officer(s) and I are responsible for establishing and maintaining
 disclosure controls and procedures (as defined in rule 30a-3(c) under the Investment Company
 Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under
 the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures
 to be designed under our supervision, to ensure that material information relating to the
 registrant, including its consolidated subsidiaries, is made known to us by others within
 those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Designed
 such internal control over financial reporting, or caused such internal control over financial
 reporting to be designed under our supervision, to provide reasonable assurance regarding
 the reliability of financial reporting and the preparation of financial statements for external
 purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in
 this report our conclusions about the effectiveness of the disclosure controls and procedures,
 as of a date within 90 days prior to the filing date of this report based on such evaluation;
 and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed
 in this report any change in the registrant's internal control over financial reporting
 that occurred during the period covered by this report that has materially affected, or is
 reasonably likely to materially affect, the registrant's internal control over financial
 reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The
 registrant's other certifying officer(s) and I have disclosed to the registrant's auditors
 and the audit committee of the registrant's board of directors (or persons performing the
 equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All
 significant deficiencies and material weaknesses in the design or operation of internal control
 over financial reporting which are reasonably likely to adversely affect the registrant's
 ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Any
 fraud, whether or not material, that involves management or other employees who have a significant
 role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: 9/2/2025 | /s/ Michael Schoonover |
|  | Michael Schoonover |
|  | Principal Executive Officer |

---

**Certification** [Exhibit 99. CERT]

I, Erik Naviloff, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I
 have reviewed this report on Form N-CSR of Eventide Funds, a series of the Mutual Fund Series
 Trust ("registrant");

&nbsp;&nbsp;&nbsp;&nbsp;2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or
 omit to state a material fact necessary to make the statements made, in light of the circumstances
 under which such statements were made, not misleading with respect to the period covered
 by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based
 on my knowledge, the financial statements, and other financial information included in this
 report, fairly present in all material respects the financial condition, results of operations,
 changes in net assets, and cash flows (if the financial statements are required to include
 a statement of cash flows) of the registrant as of, and for, the periods presented in this
 report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The
 registrant's other certifying officer(s) and I are responsible for establishing and maintaining
 disclosure controls and procedures (as defined in rule 30a-3(c) under the Investment Company
 Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under
 the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures
 to be designed under our supervision, to ensure that material information relating to the
 registrant, including its consolidated subsidiaries, is made known to us by others within
 those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Designed
 such internal control over financial reporting, or caused such internal control over financial
 reporting to be designed under our supervision, to provide reasonable assurance regarding
 the reliability of financial reporting and the preparation of financial statements for external
 purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated
 the effectiveness of the registrant's disclosure controls and procedures and presented in
 this report our conclusions about the effectiveness of the disclosure controls and procedures,
 as of a date within 90 days prior to the filing date of this report based on such evaluation;
 and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed
 in this report any change in the registrant's internal control over financial reporting
 that occurred during the period covered by this report that has materially affected, or is
 reasonably likely to materially affect, the registrant's internal control over financial
 reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The
 registrant's other certifying officer(s) and I have disclosed to the registrant's auditors
 and the audit committee of the registrant's board of directors (or persons performing the
 equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All
 significant deficiencies and material weaknesses in the design or operation of internal control
 over financial reporting which are reasonably likely to adversely affect the registrant's
 ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Any
 fraud, whether or not material, that involves management or other employees who have a significant
 role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: 9/2/2025 | /s/ Erik Naviloff |
|  | Erik Naviloff |
|  | Principal Financial Officer |

---

## Exhibit 99.906

**CERTIFICATION** [Exhibit 99.906CERT]

Michael Schoonover, Principal Executive Officer, and Erik Naviloff, Principal Financial Officer of Mutual Fund Series Trust (the "Registrant"), each certify to the best of his/her knowledge that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Registrant's periodic report on Form N-CSR for the period ended June 30, 2025, (the "Form N-CSR") fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Form N-CSR fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

---

| | | | |
|:---|:---|:---|:---|
| Principal Executive Officer | Principal Executive Officer | Principal Financial Officer | Principal Financial Officer |
| Mutual Fund Series Trust | Mutual Fund Series Trust | Mutual Fund Series Trust | Mutual Fund Series Trust |
| /s/ Michael Schoonover | /s/ Michael Schoonover | /s/ Erik Naviloff | /s/ Erik Naviloff |
| Michael Schoonover | Michael Schoonover | Erik Naviloff | Erik Naviloff |
| Date: | 9/2/2025 | Date: | 9/2/2025 |

---

This certification is being furnished to the Commission solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Form N-CSR filed with the Commission.